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Pharmacy-led Medicines Information (MI) Services provide evidence-based 
advice to clinicians, with high levels of user satisfaction.  However, satisfaction 
does not necessarily reflect improved patient care or patient outcome.  This 
has led to MI research concentrating on the effect MI advice has on patients, 
despite a lack of agreed definitions of effectiveness and the construction of 
inappropriate outcome measures. Although the majority of prescribing 
happens in primary care, most MI research has focused on secondary care.  
The aim of this qualitative study was to better understand how primary care 
clinicians used MI advice in shaping their prescribing decision-making and 
subsequent patient care.   
Taking an interpretive, idealist perspective and using a generic qualitative, 
exploratory methodological approach, this study tried to understand how 
prescribers use MI advice in decision-making and patient care.  Prescribers 
(general practitioners and dentists) across England who contacted MI Services 
with a medicine-related question, were interviewed by telephone.  To expand 
on findings from these interviews, additional prescribers in North West 
England were interviewed face-to-face.  All interviews (n=55) were analysed 
inductively using constant comparison to identify themes.  
Key findings of this study were clinicians describing using MI advice as a safety 
net to shape, support, or do their difficult research and make prescribing 
decisions, especially for complex or high risk cases.  New knowledge was 
incorporated into their ‘mindlines’ and shared with their ‘community of 
practice’, for future decision-making.  They valued advice provided by a 
trusted, expert ‘help desk’, which empowered them to make prescribing 
changes for their patients confidently and safely, and was also quicker than, 
and avoided, patient referrals.   
To conclude, this is the first study to describe the direct influence MI advice 
has on clinician decision-making and prescribing.  In light of this work there is 
a need to revisit currently used definitions describing impact and outcome, 
with MI services working alongside health library services to achieve this goal. 
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List of definitions 
Clinician: any health care professional involved in patient care, such as a 
doctor, dentist, nurse or pharmacist. 
 
Coding: tagging and organising empirical data to analyse them. Codes 
describe a part of a theme or the boundaries of a theme. 
 
Constant comparison: analytical process where data are repeatedly 
compared for new codes and themes until saturation is reached. 
  
Constructivist: see interpretivist. 
 
Deductive: an analytical approach where pre-defined ideas and hypotheses 
are used to code and analyse data. 
 
Epistemology: the nature and status of knowledge. How we know reality. 
 
Field notes: researcher notes recording incidents, observations and 
contextual information. 
 
Grounded theory: a systematic, inductive qualitative methodology which 
aims to generate theory ‘grounded’ in the data. 
 
Inductive: this is an analytical approach which is the opposite of the 
deductive approach, where the results are grounded in or derived from 
empirical data. 
 
Interpretivist: also called constructivist.  This paradigm assumes there are 
multiple interpretations of reality. Researchers try to understand how 
individuals construct their own reality within their social context. 
 
Methodology: describes how you go about finding what reality is. 
 
Medicines information advice: also described as an MI answer or 
information but described throughout this thesis as MI advice. 
 
Medicines optimisation: helping people get the best from their medicines by 
listening to their needs and jointly deciding on the best medicine and the best 
way forward with their health, their care and their medicines. 
 
Meta-theme: also called ‘uber-themes’ or unifying themes usually consist of 
two or more data-driven themes which correspond to content codes. 
 
Node: the terminology used for a code in NVivo software.  
 
NVivo: Computer assisted qualitative data analysis software produced by a 
company called QSR International. 
 
Ontology: The philosophical study of the nature of being or existence, ‘the 





Paradigm: the philosophical view of research.  A conceptual model or 
framework for how we look at reality.i.e. a “set of common beliefs and 
agreements shared between scientists about how problems should be 
understood and addressed”.  
 
Phenomenology: a philosophy and methodology which focusses on the 
perceptions, feelings and lived experiences of participants. 
 
Polypharmacy: is a term that refers to either the prescribing or taking many 
medicines. For many years it referred to the prescription or use of more than a 
certain number of medicines, at least four or five or more medicines per day.  
More recently it has been used in the context of prescribing or taking more 
medicines that are clinically required. 
 
Positivism: a research model which considers data or social facts as existing 
independently from the effects of participants and researchers. 
 
Primary care: the first point of medical contact for patients delivered by a 
range of clinicians, including GPs, dentists, pharmacists and optometrists. 
 
Purposive sampling: a method used by researchers to select participants 
considered most appropriate for a research study. 
 
Reflexivity: refers to critical awareness, acknowledgement and questioning of 
the ways the researcher’s attitudes, beliefs and role influence data collection, 
analysis and interpretation. 
 
Reliability: also called ‘dependability’ in qualitative research. This involves 
the steps taken to ensure the research process is consistent.  
 
Rigour: steps taken to ensure validity (credibility) and reliability 
(dependability) of the research. 
 
Saturation: the point when coding and interpretation of data reveals no new 
categories or themes and addition of new participants is unlikely to produce 
new ideas. 
 
Secondary care: the care provided by staff working in the hospital sector. 
 
Shared care guideline: these are local policies which are put in place to 
enable clinicians to pick up the prescribing and monitoring of 
medicines/treatments in primary care in agreement with the initiating 
specialist.  
 
Theme: ideas, phrases and/or concepts that identify or define what a 
statement is about or the core meaning of a statement or expression. 
 
Thematic analysis: an iterative (changing) analytical approach used to 





Triangulation: comparison of different data sources, methods and/or 
analytical frameworks to support the research findings of a single study. 
 
Validity: Also called ‘credibility’, steps taken to ensure the qualitative data 
collected, analysed and interpreted are meaningful and truthful i.e. accurately 








Chapter 1 Introduction to this thesis  
The aim of my research was to better understand how primary care clinicians 
use Medicines Information (MI) advice. The objectives were to explore how MI 
advice influences prescribing clinicians in their decision-making, and how they 
think MI advice subsequently affects patient care.  In this chapter, I introduce 
this thesis by briefly explaining the background and my reasons for doing this 
qualitative study, plus the methodology and methods I used.  Then I describe 
the structure and content of this thesis. 
In the UK, the MI Service is National Health Service (NHS) funded, mostly 
based in hospitals and consists of a network of centres with local and regional 
responsibilities.  Primary care clinicians have access to this pharmacist-led 
medicines advice service to help them answer their medicines-related 
questions (MRQ) and make prescribing decisions about their patients. 
However, awareness of this service by primary clinicians is low.  In this thesis, 
I use the term clinician for any health care professional involved in patient 
care, such as a doctor, dentist, nurse or pharmacist.  If a referenced study 
includes clinicians with prescribing responsibility, I describe them as 
‘prescribers’ and if a study only includes one clinician type I describe them as 
such.  
Prescribing medicines is the most common intervention in the NHS, yet 
clinicians sometimes struggle to keep up to date and to find answers to MRQs 
which occur during patient consultations and interrupt the prescribing process.  
This is complicated by the increasing numbers of patients requiring long-term 
medical treatment, often managed with polypharmacy.  Various resources are 
available to help clinicians with their MRQs and the MI Service is one of these 
resources. 
Previous studies have attempted to find out the effect (impact) of MI answers 
(an MI answer is defined here as information and/or advice and then referred 
to throughout this thesis as ‘advice’) on clinicians and patients by asking the 
opinion of clinicians, using surveys or structured interviews.  However, most of 
these studies yielded questionable results as they utilised pre-determined 
survey options and non-validated biased impact rating scales.  Despite these 




as I explain in Chapter 2, there are many reasons why determining MI effect is 
difficult to do.  For instance, the originator of the enquiry may only see the 
patient for that snapshot in time e.g. at an outpatient appointment or as a 
locum, so they are no longer directly involved in the patient’s care to the point 
of knowing the outcome. Due to such difficulties in establishing effect on 
patients, we can really only gather data on the influence of MI advice on 
clinicians who use the service and get their opinion about the effects of MI 
advice when used in patient care, and this is the focus of this thesis. 
As an experienced MI pharmacist working at a regional MI centre in North 
West England, I knew that it was becoming increasingly important to try to 
better understand how MI advice influences clinicians and the care of their 
patients.  By gaining this understanding, I could then use the findings to 
describe to commissioners, service providers and the wider NHS, how MI 
advice is utilised by clinicians working in primary care.  Ultimately to illustrate 
the contribution the MI advice service makes to the NHS, its service users and 
their patients. 
Initially, I was motivated to do research, as I held a regional research role for 
MI and was an active member of the UK Medicines Information (UKMI) 
research working group.  Also, I wanted to do more research because I had 
completed an MSc research project about service users and non-users in 
primary care, and been involved in several undergraduate and other 
postgraduate MI studies.  In addition, because of my role in MI, I knew there 
was very little understanding around how clinicians use MI advice in their 
decision-making and patient care.  Finally, my husband who is a Professor of 
Pharmacy Practice, encouraged me to undertake further MI-related research 
and has undoubtedly been a considerable source of encouragement.  All these 
were motivating factors for doing this study.  
At this point, I would also like to explain my reasons for using personal 
pronouns throughout this thesis.  Since this is primarily a qualitative study, 
writing in such a way shows my involvement as the researcher and is 





For my study I adopted an interpretive, idealist position and used a generic, 
qualitative exploratory approach (Green, 1998; Porter, 2000; Caelli, Ray and 
Mill, 2003; Given, 2008; Kahlke, 2014; Auta, Strickland-Hodge and Maz, 
2017), conducting interviews with prescribing clinicians in England by 
telephone to ask them about their use of MI advice.  Further in-depth 
interviews were done face-to-face with clinicians in the North West region to 
expand on my findings.  My analysis was inductive and I used constant 
comparative analysis to identify themes in the data (Green, 1998; Guest, 
MacQueen and Namey, 2012). 
This thesis is organised into a further four chapters which encompass the 
background, methodology, findings, discussion and conclusions of my 
research.  In this first chapter, I have introduced the study with my reasons 
for doing this research, briefly describing the aim and objectives, methodology 
and methods used.  Chapter 2 discusses the background and reasons for doing 
this qualitative research, including a review of the literature which is relevant 
to the research question, with particular reference to MI studies.  In Chapter 
3, I describe the approach taken and justify the methodology and methods 
used for this study.  In Chapter 4, I discuss my findings with illustrative quotes 
and integrated discussion, analysing and synthesising the findings supported 
by selected literature and research across all the interviews.  Chapter 5 
includes further critical discussion of my findings, which I relate to existing 
theories and models about decision-making and prescribing.  Finally, I provide 
my overall discussion and conclusions, with recommendations for practice and 






Chapter 2 The background and reasons for this research  
Introduction to this chapter 
In this chapter, I underpin the need for my research by discussing the key 
areas relevant to the aim and objectives of my research.  As the aim and 
objectives of this study were to better understand how primary care clinicians 
use MI advice in their prescribing decision-making and subsequent patient 
care, I considered the following questions: 
• What are the problems faced by prescribing clinicians in primary care? 
• How do clinicians make prescribing decisions? 
• How do primary care clinicians answer questions about medicines that 
arise during the consultation? 
• Who provides medicines information and advice to clinicians? 
• Why do we need to know about the effects of MI advice on clinicians and 
patients? 
• What has already been done to evaluate the effects of MI advice on 
clinicians and patients, and what are the limitations? 
• What have similar services done to evaluate the effects of their service on 
clinicians and patients, and what are the limitations? 
• What do we need to do next? 
I have taken each of the questions above and structured this chapter to 
address each of these in turn.  Firstly, I describe the increasing pressures on 
clinicians and the problems they face when prescribing.  I then present an 
overview of studies conducted to help understand prescribing, this includes the 
processes and influencing factors involved in prescriber decision-making and 
some of the associated theories and models that have been published in this 
field.  I also describe what clinicians do when they have a MRQ and the range 
of digital and human resources available for them to use.  Following on from 
this, I review the published studies which have tried to evaluate the effects of 
MI Service advice, their findings and limitations.  I also consider Health Library 
Information Services (LIS), as they too are NHS funded providers of 
information to clinicians, and their attempts to evaluate service effect in terms 
of impact and value.  Finally, I explain why we need to better understand the 
effects of MI advice and why there was a need for this study.  The purpose of 
the next section is to put into context the problems faced by primary care 




The problems faced by prescribing clinicians in primary care 
There are numerous factors that contribute to the complexity of prescribing for 
clinicians.  Particularly, the ageing population, polypharmacy, the sheer 
number of medicines, the increased availability of information, provision of 
person-centred evidence-based care versus guideline driven care, and keeping 
up to date.  
As there are more patients who are ageing, it is predicted that in the UK the 
number of people over the age of 85 who live with multiple morbidities and 
polypharmacy will double to 3.4 million by 2040.  This means their 
management is more challenging for prescribers with greater numbers of 
medicines available, with consequently burgeoning amounts of digital 
information via intranets and the internet.  Further adding to the difficulties 
faced by clinicians is the easy access patients, their families and carers have 
to digital health and medicines information, allowing them to research their 
condition online before asking a health professional (Pohjanoksa-Mantyla et 
al., 2011; Bowes et al., 2012; Wang et al., 2012; Carter et al., 2013).  Thus 
the public are more aware of available treatments and are potentially more 
informed (Edwards et al., 2012). Although some of this may be misinformation 
due to the availability of many unregulated sources of health and medicines 
information; which has the potential to complicate the consultation further.  
When patients present information to their General Practitioner (GP) or 
another clinician, ask for additional advice or even a particular treatment 
(Ahluwalia et al., 2010; Bowes et al., 2012; Townsend et al., 2015) the 
consultation may become awkward if the clinician is ‘put on the spot’ because 
they do not know the answer.  The clinician may then need to find information 
to answer the question asked. 
Current UK NHS priority is to deliver high quality care to all patients, ensuring 
that they have a positive experience and access to the right treatment when 
they need it (Department of Health, 2016), although this is becoming 
increasingly difficult to do as advances in medical treatment mean people are 
now living for longer and surviving conditions that would have killed them 
forty years ago (Public Health England, 2016).  As a consequence, more 




disease, diabetes, arthritis and dementia.  These multiple morbidities mean 
patients are managed using an array of medicines, with the potential for 
adverse effects, interactions and patient concordance problems (Smith, O'Kelly 
and O'Dowd, 2010; NICE, 2016; European Association of Hospital Pharmacists, 
2016). This cocktail of prescribed medicines may be further complicated by 
government self-care policies encouraging patients to self-medicate for minor 
ailments (Paudyal et al., 2011).  The use of complementary medicines further 
contributes to the complexity of treatment and dilemmas about treatment 
choices for both patients and clinicians.   
The development of new medicines by the pharmaceutical industry has 
undoubtedly helped manage and cure people with once life-threatening 
conditions. Consequently, over the last 70 years the range of medicines 
available to prescribers has increased substantially.  In just 2017 alone the 
European Medicines Agency (EMA) approved 92 medicines, 35 of which were 
new active substances (European Medicines Agency, 2018), and the British 
National Formulary (BNF) now contains around 1500 medicines (Joint 
Formulary Committee, 2018).  As well as the sheer number of medicines, the 
mechanisms by which these new substances help treat medical conditions tend 
to be complex, in terms of their action and how they target specific sites in the 
body, creating further difficulties when making treatment decisions.  To 
compound this, although most medicines are licensed, some are unlicensed or 
used in an unlicensed way.  For example, amitriptyline is licensed for 
depression but is also used ‘off licence’ for neuropathic pain.  This can cause 
more prescriber, and patient, uncertainty because manufacturer product 
information only refers to licensed indications.   
Prescribing is not easy, as it is not just about choosing a medicine to treat a 
condition, but is about patient-centred care, now recently called person-
centred care, and is an NHS goal.  In fact, it is the vision of Health Education 
England and the NHS Library and Knowledge Services that ‘NHS bodies, their 
staff, learners, patients and the public use the right knowledge and evidence, 
at the right time, in the right place, enabling high quality decision-making, 
learning, research and innovation to achieve excellent health care and health 




person-centred care, involves medicines optimisation and shared decision-
making (SDM).   
Although the aim is for all clinicians to practise person-centred, Evidenced-
Based Medicine (EBM), it can be difficult to interpret and use evidence 
appropriately and to adapt EBM to the individual patient situation (McCartney 
et al., 2016).  With more patients being treated closer to home, patient 
medications need to be optimised in primary care (NICE, 2015).  This is 
difficult for clinicians to do amid all the uncertainty surrounding guideline 
driven care, with the increasing number and complexity of medicines 
(McCartney et al., 2016), poor communication regarding specialist prescribing 
in hospital (NHS England, 2017), and the increasing availability of information 
to clinicians, patients and the public.   
Even though evidence-based guidelines e.g. National Institute for Health and 
Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), All 
Wales Medicines Strategy Group (AWMSG) are available in the UK to inform 
clinicians about clinical management, they tend to be related to a specific 
clinical condition, making it difficult to manage a patient who has multiple 
medical conditions.  As clinical guidelines are produced based on the EBM 
paradigm and tend to focus on a single disease or condition, they do not 
consider that the patient is a person, and increasingly older with multiple 
conditions.  Thus, there needs to be a balance between evidence-based 
decision-making and person-centred care (NICE, 2018).  
Arms' length bodies and those commissioning or influencing health care 
services have a responsibility to promote and monitor the use of evidence-
based decision-making (Marshall, M. and Bibby, 2011; RPS, 2013).  The 
Chartered Institute of Library and Information Professionals (CILIP) and Health 
Education England are campaigning for decisions in the health care sector to 
be fully evidence-based; calling on everyone involved in policy making and 
care delivery to make use of the skills of librarians and knowledge specialists.  
As stated by Professor Ian Cumming OBE, Chief Executive, Health Education 
England, when the Million Decisions Campaign was launched in 2017, ‘Every 
day across the health care sector more than a million decisions are made 




and cost of health care services’.  This campaign aims to highlight 
improvements in quality of care, patient experience and cost effectiveness 
when health care providers and their teams work closely with health librarians 
and knowledge specialists (Health Education England, 2017).    
However, in order to prescribe safely and appropriately all clinicians are 
required to keep up to date and to provide effective treatments based on the 
best available evidence (General Medical Council, 2014).  The General Medical 
Council (GMC) states that UK doctors need to recognise and work within the 
limits of their competence and keep their knowledge and skills up to date 
(General Medical Council, 2014).  Similarly for dentists in the UK, the General 
Dental Council (GDC) Standards for the Dental Team, says they need to work 
within their knowledge, skills, professional competence and abilities and 
provide good quality care based on current evidence and authoritative 
guidance (General Dental Council, 2013).  Yet, keeping up to date about all 
the medicines they prescribe or that are prescribed by others is demanding for 
clinicians, particularly those in primary care.  GPs, who prescribe 98% of 
medicines in primary care, receive little formal training in prescribing, have 
limited time to assess the large amount of information available.  Many GPs 
lack time or confidence to search for, or appraise, evidence-based information 
(Davidoff et al., 1995; Iqbal and Glenny, 2002; Bourne, 2007; Bernard et al., 
2012; Zwolsman, 2012; Clarke et al., 2013).   
An older study by Davidoff et al reported that GPs needed to read 17 articles 
each day to keep up with the medical literature (1995).  Given the expansion 
in medicine availability, this figure is likely to be higher today, although it may 
now be easier to keep up to date with use of the internet and articles being 
more readily accessible online.  However, this wealth of digital information can 
be difficult to access, filter and use, causing not just information overload but 
information confusion and chaos (Beasley et al., 2011).  This high volume of 
constantly changing information about medicines means it can be problematic 
for clinicians to keep up to date (Clarke et al., 2013).  It is therefore 
practically impossible for a general clinician to keep abreast of all new 




interactions with other medicines, cautions, adverse effects, contraindications 
and warnings (Del Fiol, Workman and Gorman, 2014).   
Compounding these issues, primary care clinicians, from time-to-time, may be 
asked by a specialist clinician e.g. consultant rheumatologist, to prescribe an 
unfamiliar medicine e.g. denosumab injection for post-menopausal 
osteoporosis.  Yet, they too need to know about its safety and efficacy in 
practice, as even though these medicines should be prescribed via a shared 
care guideline (SCG), where specialists are obliged to provide relevant 
information to primary care, this may not always happen (General Medical 
Council, 2014).  Either way, the primary care clinician must ensure they know 
enough about the medicine they are prescribing.  
In summary, there are growing numbers of patients with multiple conditions, 
managed predominantly through medicines, by generalist clinicians in primary 
care.  This means clinicians need to know more about prescribing medicines 
for complex patients, but difficulties in keeping up to date amidst the mass of 
accessible information mean they may need to seek help from others, such as 
MI Services. 
Clinicians, prescribing and decision-making 
Given people are living longer, often with one or more LTC, it is not surprising 
that prescribing rates continue to rise.  In fact, prescribing represents the 
most common therapeutic intervention, with most LTCs managed through 
medication, which helps prevent further complications or serious events, such 
as stroke and heart attack.  In 2016, 1.1 billion prescription items were 
dispensed by community pharmacies in England; a 47% increase in the last 10 
years (Prescribing and Medicines Team, 2017).  The complexity of patients 
and medicines means that prescribing is also becoming more challenging.  It 
has been suggested that to facilitate prescribing decision-making for clinically 
complex people with polypharmacy, a more co-ordinated collaboration 
between health care professionals is required (Sinnige et al., 2016). 
In this section, I present an overview of studies conducted to help understand 
prescribing, this includes the processes and influencing factors involved in 




that have been published in this field.  I am discussing these now as they are 
relevant to my research aim and objectives, I align some of these influencing 
factors, theories and models to my chosen study and to my findings in Chapter 
4 Findings and discussion, and finally discuss them in Chapter 5 Overall 
discussion and conclusions. 
Prescribing is a complex decision-making process, and as such it is not 
sufficiently understood (Jackson, Mangoni and Batty, 2004; Thistlethwaite, 
Ajjawi and Aslani, 2010; Grant, Sullivan and Dowell, 2013), even though some 
theories and models have been developed, which I discuss later in this section.  
Although we know little about prescribing decision-making, some studies have 
been undertaken to help us understand prescribing in general practice 
(Bradley, 1992; Armstrong, Reyburn and Jones, 1996; Grant, Sullivan and 
Dowell, 2013).  Two older UK studies explored the GP experience of making 
uncomfortable prescribing decisions and reasons for changes in prescribing 
behaviour (Bradley, 1992; Armstrong, Reyburn and Jones, 1996).  While a 
more recent ethnographic study explored prescribing decisions and influencing 
factors in three GP practices in Scotland (Grant, Sullivan and Dowell, 2013).  A 
further European study specifically evaluated prescribing behaviour relating to 
complex cases, i.e. older people with multiple morbidity and polypharmacy 
(Sinnige et al., 2016).  The latter study used pre-defined themes which 
included patient complexity, and treatment goals/strategies considered to be 
influencing factors for GP management of patients based on other studies 
(Luijks, H. D. et al., 2012; Sinnott et al., 2015).  I briefly discuss the findings 
of these studies later in this section. 
There is a wealth of published literature available on the wider subject of 
clinical decision-making (CDM) (Croskerry and Nimmo, 2011) and to review it 
fully, is beyond the scope of this thesis.  Instead, I have focussed on the 
literature specifically around prescribing and decision-making, and I briefly 
discuss the main components of CDM as they are of relevance to my research. 
It is thought that clinicians make prescribing decisions using the ‘dual process’ 
theory of decision-making (Bate et al., 2012).  Although, originally developed 
for diagnostic decision-making, it is a decision-making theory that has also 




2012).  Usually clinicians use the System 1 process of decision-making, which 
is based on their existing ‘tacit knowledge’ and ‘shortcuts’, only switching to 
System 2 decision-making when they override their System 1 thinking (Bate 
et al., 2012; Wieringa and Greenhalgh, 2015; Gabbay and le May, 2016).  
Using System 2 takes time and requires the clinician to research the problem 
so that they can then make an informed decision (Bate et al., 2012).  In 
comparison, System 1 processing is quick and intuitive and enables them to 
make a person-centred diagnostic or treatment decision without needing to 
consult more widely.  Shortcuts used to aid CDM have been described by 
psychologists as ‘scripts’, ‘heuristics’, ‘rules of thumb’ and ‘mindlines’ (Andre 
et al., 2002; Gabbay and le May, 2004; Bate et al., 2012).  I specifically 
discuss clinician use of ‘mindlines’ in the findings of my research, rather than 
the other shortcuts clinicians use.   
Studies have found that clinicians refer to ‘mindlines’, as well as ‘rules of 
thumb’, and ‘heuristics’, for scenarios they are familiar with (Gabbay and le 
May, 2004; Wieringa and Greenhalgh, 2015), and as such, when they cannot 
use these, e.g. for questions about new or unfamiliar medicines, they seek 
information elsewhere (Gabbay and le May, 2004; Grant, Sullivan and Dowell, 
2013; Wieringa and Greenhalgh, 2015; Gabbay and le May, 2016).  ‘Mindlines’ 
have been described as the clinician’s personal formulary or ‘knowledge-in-
practice-in-context’.  They consist of ‘tacit’ knowledge, which is accumulated 
over years as a result of seeking specialist advice and discussion with others, 
such as practice pharmacists and GP colleagues (Gabbay and le May, 2004; 
Grant, Sullivan and Dowell, 2013; Gabbay and le May, 2016).  To be able to 
rely on their ‘mindlines’ and make appropriate prescribing decisions, clinicians 
need to keep up to date via continuing professional development (CPD), 
discussions with specialist colleagues and reading updated clinical guidelines 
(Gabbay and le May, 2004; Gabbay and le May, 2016).  However, as I have 
already mentioned, keeping up to date is difficult to do.  
Clinicians are thought to use their wider ‘community of practice’ to help keep 
themselves up to date (Gabbay and le May, 2004; Lomas, 2007; Soubhi et al., 
2010), although learning may not be intentional.  First described by Lave and 




something they do and learn how to do it better as they interact regularly” 
(Lave and Wenger, 1991; David, 2014). They are a means of spreading 
knowledge within a group and develop when people with an interest in a 
subject or area collaborate over an extended period of time, sharing ideas and 
strategies, and finding solutions (Wenger, McDermott and Schnyder 2002; 
David, 2014).  It is defined by a shared domain of interest (e.g. GPs providing 
expert generalist practice, clinicians with an interest in paediatrics, self-care).  
Members interact and engage in shared activities, help each other, and share 
information with each other and build relationships.  Practice is developed by 
problem solving, requests for information, seeking the experiences of others, 
coordination and synergy, discussing developments, visiting other members, 
mapping knowledge and identifying gaps (Wenger, McDermott and Schnyder 
2002; David, 2014).   
Meanwhile, various studies have attempted to understand GP prescribing and 
decision-making (Armstrong, Reyburn and Jones, 1996; Ali Murshid and 
Mohaidin, 2017).  Several theoretical models of prescribing decision-making 
have also been proposed, but as these were pharmaceutical industry studies, 
it is not surprising that these theoretical models on prescribing and decision-
making were developed around the effects of pharmaceutical marketing 
factors, such as drug information availability, branding of drugs, sales, and 
medical representatives.  The main aim of these studies was to develop 
theories to try to understand what factors influence GP prescribing and they 
are summarised in a recent review (Ali Murshid and Mohaidin, 2017).  As well 
as these existing theories, the Ali Murshid (2017) review also proposed a new 
model considering pharmacy influencing factors, not previously described in 
prescribing decision models.  These pharmacy influences on prescribing 
clinicians are based on various theories, including Persuasion theory, Buyer 
Behaviour Stimulus-Response theory, Agency theory, Social Power theory and 
Planned Behaviour theory. These five theories and how they link to pharmacy 
factors are described in the new model by Ali Murshid (2017) and are briefly 





Firstly, Persuasion theory (Dainton, 2004) is based on the interaction between 
cognition and emotion and consists of four dimensions, the sender of 
information, the receiver, the exchange (interactive or active) between the 
sender and the receiver and modification in behaviour (immediate or delayed).  
While in Buyer Behaviour Stimulus-Response theory (Howard and Sheth, 
1969), the doctor i.e. the ‘buyer’, is influenced by various stimuli from drug 
marketing and other influences such as the patient and the pharmacist (Ali 
Murshid and Mohaidin, 2017). 
Next, Agency theory has been linked to decision-making (Bendickson et al., 
2016).  This theory considers the relationship between two parties, where the 
first party (the principal) relies on the second party (the agent) to perform 
certain actions e.g. doctor/patient, pharmaceutical company/doctor, 
pharmacist/doctor.  This theory also considers the patient characteristics in 
terms of requests for the medicine and patient expectations (Ali Murshid and 
Mohaidin, 2017). 
Whilst the theory of Social Power concerns the premise that an individual has 
the power to change the behaviour of another (French and Raven, 1959).  
Factors that may influence prescribing decisions are the pharmacist as an 
expert power, pharmacist-physician collaboration and trustworthiness (Ali 
Murshid and Mohaidin, 2017).  The experts in that field e.g. pharmacists about 
new medicines, may therefore be perceived by the doctor to have more 
knowledge and thus have the power to influence them (Ali Murshid and 
Mohaidin, 2017). 
Finally, Planned Behaviour theory relates to attitude (degree of like or dislike) 
for something, personal, subjective norms and perceived behaviour control 
(Ajzen, 1991).  Perceived behaviour control is based on the perception of the 
individual about whether the behaviour is easy or difficult.  This individual 
perception is thought to hinder or facilitate prescribing.  The pressure or 
expectation to perform e.g. by the patient or pharmacist, is linked to Planned 
Behaviour theory (Ali Murshid and Mohaidin, 2017).  
While the above theories have been linked to prescribing per se; within 




or signals which cause a change in prescribing behaviour (Armstrong, Reyburn 
and Jones, 1996).  The study by Armstrong et al (1996) describes three 
models of prescribing change, which the authors called the ‘accumulation 
model’, the ‘challenge model’ and the ‘continuity model’, which I now explain 
as it is relevant to my study findings.  The ‘accumulation model’ involves 
reading about something, and is particularly relevant if it is read or seen to 
come from different independent, trusted sources e.g. Drug and Therapeutics 
Bulletin® or hospital specialist clinician.  Personal experience of treating an 
illness or using a medicine also informs this model of change.  Whereas in the 
‘challenge model’, change occurs as the result of a major clinical issue or 
aversion of such.  Other challenges include changes to medicines by 
colleagues who are perceived to be more clinically up to date or via the 
unexpected success of a treatment.  Finally, changes occur in the ‘continuity 
model’ because the prescriber is willing to change as they have already seen 
information which means something to them.  For example, they have read 
about the mode of action of a new medicine, which seemed logical to treat a 
particular condition, or are prepared to change because of cost pressures.  For 
all these changes to be maintained, positive reinforcement is required from 
several directions, such as discussion with respected clinicians, or feedback 
from patients themselves.  
Prescribing decisions are complex and multifactorial (Gabbay and le May, 
2016), but despite prescribing being a core activity for GPs, prescribing 
behaviour is reportedly wide-ranging (Grant, Sullivan and Dowell, 2013).  This 
was found in a study that tried to understand how clinicians make prescribing 
decisions for complex cases (Sinnige et al., 2016).  Findings were that there 
was wide variation between clinicians in their decision-making about 
medicines.  When GPs were prescribing, initially they developed a medicines 
management strategy, which they described as deciding on prescribing goals 
and using decision support tools.  However, for each clinical vignette the 
medicines management strategy varied between GPs, with different primary 
goals based on assessing clinical value and the original reason for the 
appointment, and varying numbers of treatment goals.  GPs approached these 
goals either simultaneously or step-by-step.  Prescribing objectives identified 




for primary concern; and to adjust prescribed medicines in line with the 
primary treatment goal. They considered patient complexity in terms of the 
number of medicines they were taking, doses and multiple morbidities, and 
expressed a more pragmatic approach and less adherence to clinical practice 
guidelines if the patient was older.   
Patient factors considered by clinicians were quality of life, age, vitality, 
prognosis, life expectancy, the patient’s own views and preferences about 
their treatment (Sinnige et al., 2016).  However, GPs were unsure of the best 
approach to medication management and indecisive about making treatment 
decisions in complex patients with polypharmacy, especially when there were 
several prescribing options, and also felt unsure about stopping or changing 
medicines.  Needing to search for information and wanting to find out what 
other prescribers would do were reasons GPs gave before they were able to 
make complex prescribing decisions.  In another study by Bradley (1992), GPs 
described feeling discomfort around prescribing, particularly when they felt 
ignorant or uncertain about management of the patient and that they were not 
living up to their own expectations. They also had concerns about treatment 
appropriateness and drug toxicity (Bradley, 1992).  These factors describe the 
difficulties faced by clinicians and why there is the potential for them to seek 
advice from elsewhere, such as MI Services. 
Research about the various prescribing influencing factors, particularly those 
perceived by GPs is relatively unexplored (Grant, Sullivan and Dowell, 2013). 
However, the authors of the Grant study have developed a conceptual 
framework for prescribing decisions which showed that clinicians made ‘macro-
prescribing’ and ‘micro-prescribing’ decisions based on a combination of 
factors, and that they used prescribing ‘mindlines’ (Grant, Sullivan and Dowell, 
2013).  It was found by Grant et al (2013) that GP macro-prescribing 
decisions are informed by research evidence e.g. guidelines and the more 
subtle, ‘soft’ governance methods, which include practice pharmacists, 
formulary/ prescribing indicator reports (Sheaff et al., 2004) and practice 
values.  These can be used for the average patient with one medical condition 
only or a single medicine e.g. treatment of hypertension.  Whereas their 




views of the patient, their preferences, circumstances and their multiple 
medical conditions.  That is, they relate to person-centred care and SDM. 
Macro-decisions inform micro-decisions, whereas clinicians use their 
prescribing ‘mindlines’ to inform their micro-decisions (Gabbay and le May, 
2004; Grant, Sullivan and Dowell, 2013).  
As well as having their own individual ‘mindlines’ based on their experience, 
preferences and values, studies have found that clinicians develop ‘collective’ 
prescribing ‘mindlines’ within their ‘community of practice’ (Grant, Sullivan and 
Dowell, 2013; Gabbay and le May, 2016).  They do this via meetings with 
other GPs or pharmacists to discuss patients with complex problems, provide 
an expert check and allow exchange of ideas and information, with all these 
considered important.  This accumulated experience of having a discussion 
with other clinicians has been described as a facilitator to making prescribing 
decisions (Sinnige et al., 2016).   
In summary, prescribing is a complex decision-making process, as many 
factors need to be considered, which is compounded by the need to make 
prescribing decisions for increasingly complex patients.  Clinicians appear to 
do this by using prescribing ‘mindlines’ and micro/macro decision-making 
processes which are informed by the individual patient, prescribing guidelines 
and other clinicians.  We need to try to understand how provision of MI advice 
might help support these processes.  In the next section(s), I discuss what 
clinicians might do when faced with a prescribing dilemma, that is, how they 
answer MRQs if they cannot use their own knowledge, which means using 
digital and human resources, including the MI Service. 
How clinicians answer questions about medicines 
Clinicians field many questions about medicines and have access to a variety 
of resources to help them find answers (Clarke et al., 2013; Del Fiol, Workman 
and Gorman, 2014), but if they are unable to use their existing knowledge to 
make prescribing decisions, they may search a range of information sources, 
and in some cases have been unable, or even unwilling to access information 




answers to medicines questions, which may arise as part of the medicines 
optimisation process (RPS, 2013).   
It is inevitable that questions occur during patient consultations, with studies 
finding that clinicians tend to under estimate the number of questions raised 
(Ely et al., 2000; Dhaliwal, 2013; Del Fiol, Workman and Gorman, 2014).  A 
review about the types of questions raised by clinicians during patient care 
decision-making found that a third of questions were about medicines (Del 
Fiol, Workman and Gorman, 2014).  Overall, we think that clinicians try to 
answer about half of all the questions they are asked and of these, answer 
about three quarters (Del Fiol, Workman and Gorman, 2014).   
Besides the patient or the clinician raising questions, they may also occur via 
the clinician’s Clinical Decision Support System (CDSS).  In this case the 
clinician is alerted to a problem which they are unaware of or may be 
uncertain about how to manage; particularly if the answer cannot easily be 
found using standard resources available to them.  In fact, decision-making 
support tools with on-demand prescribing aids (e.g. linked to prescribing 
guidelines) in the electronic medication record (EMR) system were preferred to 
those that flagged issues automatically (Sinnige et al., 2016).  GPs in this 
same study also said that although they found online risk tools practical and 
valuable, they found it difficult to know which to choose because of patient 
heterogeneity e.g. CHA2DS2-VASc tool for assessing stroke risk in patients 
with atrial fibrillation or CVD risk assessment tool.  This illustrates that 
although digital information systems are useful tools for clinicians, they do not 
always provide a patient specific answer, whereas the MI Service is able to do 
this. 
To help clinicians answer questions, a wealth of digital resource is available, 
for example, First Databank® or Script-Switch®, to which clinicians can 
subscribe (Chana, 2015).  Clinicians can also readily access key reference 
texts e.g. the BNF; Monthly Index of Medical Specialities (MIMS); electronic 
Medicines Compendium (eMC), and local on-line formularies.  Other 
searchable websites are clinical guideline websites e.g. NICE, SIGN, or 
PubMed, Cochrane; NICE Evidence Search, or a subscription-based medicines 




resources for clinicians, but only if they actually choose to use them and are 
able to search them correctly.  A 2015 Cochrane review of clinician use of 
digital health information (DHI) via a range of platforms (laptop/desktop 
computer/printed information/different search interfaces/plus training) to 
improve clinical practice and patient care found that when DHI was supported 
with training, clinicians used them more often (Fiander et al., 2015). However, 
there was no evidence that it improved clinical practice or patient outcomes, 
suggesting a need to better understand why clinicians are reluctant to use DHI 
and ways to improve use.  This also highlights why we need to understand 
how they use the MI Service. 
As I have already discussed, clinical questions sometimes go unanswered, and 
there are various reasons for this (Brassil et al., 2017).  Some barriers 
reported by clinicians are lack of time, inadequate searching skills, difficulty 
keeping up to date and thinking that the answer cannot be found (Bourne, 
2007; Zwolsman, 2012; Clarke et al., 2013; Del Fiol, Workman and Gorman, 
2014).  This is unsurprising as in clinical practice, a UK GP has less than 10 
minutes per patient consultation (Irving et al., 2017), and these constraints 
mean that clinicians do not have the time to conduct in-depth, complex 
searches whilst with the patient.  Instead they may resort to doing a quick 
internet search, which may link to less reliable sources of information, look 
into providing an answer later i.e. outside surgery hours, seek additional help 
from a colleague (Clarke et al., 2013), or use a specialist clinician, community 
or practice pharmacist to help them resolve the problem (Rutter, J. and 
Rutter, 2004; Rutter, P., Warren and Rutter, 2009; Clarke et al., 2013).  
Answering complex questions is difficult and time consuming and while 
clinicians do access DHI, the information needs to be easy to find and use, 
otherwise they ask their colleagues, whose responses may not be based on 
current evidence (McGettigan et al., 2001, Clarke et al., 2013; Brassil et al., 
2017).  Some have suggested a need for someone experienced in searching 
for information to provide them with the relevant information or tailored user-
friendly summaries provided by experts (McKenna, Ashton and Keeney, 2004; 
Trevena et al., 2007; Clarke et al., 2013; Brassil et al., 2017).  This is where 




resources, are perhaps more confident using and interpreting them, and can 
help modify the data to suit the needs of the patient.  Ultimately, the MI 
Service is available to help clinicians by finding answers to their more complex 
questions which require information retrieval skills, including deciding on a 
search strategy, using their searching skills, then reviewing the information, 
while applying it to the question and the patient themselves. 
In summary, clinicians field many clinical questions, a high proportion of which 
are about medicines.  While they have access to DHI, including systems such 
as CDSS, they may be reluctant to answer their own MRQs, resulting in some 
of these going unanswered.  Clinicians seem to preference asking someone 
else for person-centred medicines advice, particularly for complex cases.  
Thus, there is a need to understand how the MI Service is used by clinicians to 
help them answer their complex questions.  Next, I discuss medicines 
information provision by pharmacy; this includes providers of pharmacy 
services in primary care and MI Services.   
Pharmacy staff working in primary care pharmacy services are obvious 
providers of medicines information and advice, with staff in community 
pharmacies easily accessible to provide advice to clinicians, patients, carers 
and members of the public (RPS, 2016).  Other pharmacists work in primary 
care as prescribing advisors, for example, in England they work for Clinical 
Commissioning Groups (CCGs) and they too provide medicines advice to other 
clinicians. Practice pharmacists, including those with prescribing rights, are 
also employed by an individual GP practice or group of practices and there are 
now pharmacists with prescribing rights working alongside GPs (NHS England, 
2015; RPS and RCGP, 2015).  
In an ideal world all practising pharmacists should be able to provide a 
consistent level of advice about medicines to help clinicians, but in reality, the 
ability of these pharmacists to provide such advice is not achievable or 
practical.  Like other clinicians, pharmacists in primary care may not have 
access to resources (Rutter, J. and Rutter, 2004; Chui and Stone, 2014), 
possess the relevant skills or expertise (Rutter, J. and Rutter, 2004; Ogunbayo 
et al., 2017) and have limited time to provide this advice (Tarn et al., 2012; 




Although, most can probably answer more straightforward questions using 
their core pharmacy knowledge and by accessing key medicines resources, 
such as the BNF (Joint Formulary Committee, 2018), due to differences in 
experience, knowledge, skills, available time and resources, pharmacists and 
their staff may provide variable advice in response to questions asked (Rutter, 
P., Warren and Rutter, 2009; Tarn et al., 2012; Elaro et al., 2015; Ogunbayo 
et al., 2017).  It is therefore not always appropriate for all pharmacists to 
answer the more complex medicines questions themselves, and they too 
might need more specialist help from other services, such as MI. 
Pharmacy-led MI Services are available as a resource for clinicians and are the 
focus of this research.  Since this study is about clinician use of MI Service 
advice, and because my review of relevant MI studies includes those 
conducted in the UK, as well as worldwide, I now explain how MI Services are 
organised to provide context for the reader.  I also relate my research 
findings, discussion and conclusions to the provision of NHS MI Services in the 
UK. 
In the UK, NHS MI Services (previously called Drug Information, but referred 
to as MI Services in this thesis) were originally developed in the 1970s to help 
clinicians in secondary care assess new medicines and to help ‘improve the 
quality of prescribing in general practice’ (Calder et al., 1981).  They were set 
up prior to the availability of the internet and located within hospital pharmacy 
departments in secondary care (Calder et al., 1981).  I mention them here 
because MI Services need to try to better understand how MI advice influences 
clinicians and the care of their patients for future service development and 
have struggled to do this over the years. 
After opening of these first centres, almost all hospital pharmacy departments 
had a dedicated MI Service, with MI recognised as a speciality within 
pharmacy, providing advice about medicines across the full range of clinical 
disciplines.  Although, primarily a service for health professionals, in some 
cases it is available to recently discharged patients and outpatients via 
dedicated helplines (Badiani et al., 2017; Bramley, Innes and Dass, 2018).  MI 
staff, who include pharmacists, pharmacy technicians and life-science 




searching specific websites and databases, literature searching, while 
interpreting and assimilating information to provide tailored advice for 
clinicians and their patients (UKMI, 2007; UKMI, 2017).   
In 2010, UK MI Services provided 300,000 responses to MRQs from primary 
and secondary care (Rehman, 2010), with a high proportion generated from 
secondary care.  This bias towards the hospital sector is largely historic as the 
majority of MI centres were, and still are, located within hospitals.  Medicines 
questions can be about a specific patient, a group of patients or about 
management of a population in a geographical location and about anything to 
do with medicines.  Ranging from ‘I have a patient with swallowing problems, 
can all their medicines be crushed and put down a feeding tube?’ to ‘I need to 
help a patient decide how she wants to manage her migraine during 
pregnancy, can you give me some advice?’  In particular, the service caters for 
complex patients and/or questions requiring difficult, time-consuming searches 
or answers that are awkward to find.  
In 2017, there was a UK network of approximately 194 local hospital-based 
centres supported by 16 regional MI centres (11 England, 1 Wales, 4 Scotland) 
providing a variety of services to primary and secondary care across the 210 
acute and mental health Trusts (NHS Confederation, 2016).  Most MI centres 
primarily provide advice to their local hospital(s), although services do extend 
beyond this, for example, drug evaluations and input into local prescribing 
committees, training other staff in MI skills and adverse event monitoring. 
Whereas regional MI Services provide support to other MI centres, and a 
medicines advice service to primary care.  The larger centres also have 
additional in-house clinical expertise and resources to offer specialist 
medicines advisory services in key clinical areas, such as complementary 
medicines, medicines in dentistry, medicines in pregnancy and lactation, 
medicines in renal failure, HIV and AIDS, oncology, psychiatry and porphyria. 
A list of regional MI specialisms can be found in the BNF. 
All these services form a virtual network called UK Medicines Information 
(UKMI), whose remit is to apply evidence-based principles in the provision of 
impartial, evaluated information.  In an attempt to respond to the needs of 




pre-emptive, active material to help clinicians answer MRQs themselves.  Most 
of these materials are now located on the Specialist Pharmacy Services 
website (UKMI, 2016), and include a range of medicines Questions and 
Answers (Q&As) (What medicines can be used to treat hypersalivation?); a 
fridge database (Our fridge has broken, is it still safe to use all the vaccines?); 
the compliance aids database (Is this medicine OK to be taken out of the 
original packaging and put in a blister pack?); omitted and delayed medicines 
tool (advice about what to do if specific doses of medicines are missed); and 
patent expiries database (to help medicines management teams plan when 
branded medicines will be superseded by cheaper generics).  Other materials 
produced by this network include the ‘Prescribing Outlook’ horizon scanning 
portfolio, which provides clinical and cost summaries of ‘pipeline’ and newly 
launched medicines likely to impact the NHS and patients; NICE Bites (concise 
monthly summaries of key NICE Guidelines) and product safety assessments 
(about safety in use of new medicines and/or formulations, primarily for use 
by Medication Safety Officers).  More recently, a new role is for regional MI 
Services to provide advice and support to the newly formed Regional 
Medicines Optimisation Committees (NHS England Medical Directorate, 2017). 
MI services are not unique to the UK, for example they have been available in 
the US since the 1960s (Rosenberg, J. et al., 2004).  However, the scope of 
provision varies from country-to-country and are described here as I discuss 
studies conducted by non-UK services in my review.  In the US, MI Services 
are provided by a range of institutions, including colleges of pharmacy and 
health care providers. In 2008, a US survey found there were 75 MI centres, 
although as in the UK, numbers are declining as clinical pharmacists are now 
required to answer questions themselves (Rosenberg, JM et al., 2009; Gabay, 
2017).  There are also academic MI centres located in colleges of pharmacy or 
university hospitals providing training for pharmacy students in MI skills 
(Brand and Kraus, 2006).   
In Finland, MI Services are provided via a call centre based within a university 
pharmacy, and operated by the School of Pharmacy (Pohjanoksa-Mäntylä et 
al., 2008).  Whereas in Canada, MI Services are described as usually hospital-




geographical area on a fee-for-service basis (McLean, 1996; The Ottawa 
Hospital Drug Information Service, 2016).  In Germany, the pharmacist run 
national MI Service was set up in 1988 by the Federal Union of German 
Associations of Pharmacists, primarily for community pharmacists but also for 
other clinicians in primary care with funding provided by the member 
organisations (Maywald et al., 2004).  As the availability of medicines has 
increased, MI Services have also been set up in developing countries, for 
example, in Khartoum State in Sudan an MI Service was set up by the 
Pharmacy Directorate on behalf of the Ministry of Health in 2000 
(Fathelrahman et al., 2008).  In short, similar services are provided in other 
countries, and although base locations, enquirer types and funding streams 
differ, they are all pharmacy-led services providing medicines advice to 
clinicians.  
In summary, when clinicians raise medicines questions, pharmacy staff can 
provide a range of medicines advice, but like other clinicians they are also 
limited by time, skills and resources.  This is why formal MI Services are 
available in the UK and worldwide to provide support to clinicians in the form 
of proactive information and reactive, person-centred advice.  In the UK 
specifically, NHS changes mean pharmacy services are changing with greater 
focus on primary care, including changes in MI Service provision.  This means 
there is an even greater need to understand the effect of MI advice on 
clinicians and their patients.  In the next section, I discuss these recent NHS 
changes, why we need to know more about the effect of MI advice, the 
problems regarding lack of clarity and consistency around terms used to 
evaluate the effects of MI advice, and finally include my review of published MI 
studies that have attempted to evaluate the effects of MI advice on clinicians 
and patients. 
Why we need to know about the effects of Medicines Information 
advice on clinicians and patients 
Health care and the NHS has and continues to evolve against changing 
economic and political landscapes, which has consequently affected MI 
Services.  This is apparent with modern-day austerity measures leading to 




services in England has changed (The Kings Fund, 2016) and is still changing. 
The move is towards decentralised commissioning of health services, either via 
local CCGs in primary care or centrally via NHS England (NHSE). The majority 
of services are commissioned via CCGs, with NHSE commissioning GP services 
and the less common, more specialist services.  The NHS Five Year Forward 
View (NHS England et al., 2014) and the Carter Report (Lord Carter of Coles, 
2016) both aim to make the NHS less focussed on the division between 
primary and secondary care, with a blurring between the two areas as patients 
are cared for in ambulatory care.  Consequently, hospitals will become more 
specialised and treat only those who need to be in an acute setting e.g. those 
requiring surgery, complex diagnoses and assessments.  This all means the 
roles of health professionals in hospitals and primary care are changing.  
The Carter Report wants all hospital pharmacists to have direct contact with 
patients and to have greater roles in medicines optimisation (Lord Carter of 
Coles, 2016).  Also, changes in Urgent and Emergency Care aim to reduce 
unnecessary visits to Accident and Emergency departments, with patients 
managed and treated closer to home without admission to hospital.  This aim 
is set to be achieved with better management of patients with LTCs, by 
development of emergency treatment plans and supply of medicines for acute 
exacerbations to avoid hospital admission, and greater utilisation of non-
medical prescriber (NMP)-led clinics (UEC Review Team and ECIST, 2015).  As 
such, the enactment of recommendations from these key documents will have 
profound effects on the delivery of patient care and the move towards greater 
provision of care out of hospital, means there will be a larger pool of health 
professionals and prescribing clinicians working in primary care.  Thus, as the 
information needs of clinicians are likely to change, the relationship MI 
Services have with their customer base, and the services and information 
offered will need to change, with a focus on provision of more services to 
primary care. 
Historically, regional MI Services in England have been funded via local 
commissioners in primary and secondary care, with additional government 
funding.  In 2012, English regional MI Services were reviewed, with funding 




NHS England (NHS England Medical Directorate, 2014) under the umbrella of 
the Specialist Pharmacy Service (SPS, 2016).  Whereas local MI Services in 
England are primarily funded by their host organisation, although this model of 
funding only looks set to continue in the short-term.  As the Carter Report 
requires more pharmacists to be patient-facing (Lord Carter of Coles, 2016), 
hospital chief pharmacists are beginning to set up service level agreements 
(SLAs) with regional MI Services to deliver specific service packages, such as 
MI skills training and enquiry answering.  This means the number of local MI 
centres are likely to decline.  Due to this changing environment, it is now even 
more important that the value of MI Services is better understood by those 
that fund the service, so that it can continue to be provided.  
However, it is not easy to evaluate the ‘impact’ i.e. the effect of MI Services 
on patients and clinicians. Generally most published studies about MI Services 
have shied away from measuring effect and concentrated on service 
evaluation, usually conducted as part of MI centre quality assurance (QA) 
requirements and almost exclusively used self-administered surveys based on 
a positivist, quantitative paradigm (Repchinsky and Masuhara, 1987; Schjøtt, 
Pomp and Gedde-Dahl, 2002; Bertsche, Hämmerlein and Schulz, 2007; 
Fathelrahman et al., 2008; Frost Widnes and SchjØtt, 2009; Hedegaard and 
Damkier, 2009; McEntee et al., 2010).  These various means of evaluating MI 
Service quality and ‘impact’ are summarised in Figure 2.1 to show the range of 
measures used and are discussed below.  Frequently, these studies have 
measured user satisfaction as it is relatively easy to define and quantify (see 
Figure 2.1).  The tendency has been to evaluate this based on the usefulness 
of the advice provided in writing or the telephone.  A variety of measures for 
determining usefulness have been used and include: speed of response 
(Maywald et al., 2004); timeliness (Melnyk, Shevchuk and Remillard, 2000; 
Schjøtt, Pomp and Gedde-Dahl, 2002; Hedegaard and Damkier, 2009); 
objectivity (Melnyk, Shevchuk and Remillard, 2000); comprehensiveness 
(Schjøtt, Pomp and Gedde-Dahl, 2002); adequacy and/or relevance of the 
answer (Maywald et al., 2004) and value of the references included with the 





Figure 2.1 MI Service advice quality assurance measures and ‘impact’ 
assessment 
 
QA= quality assurance vs=versus 
Other assessments of user satisfaction and evaluation of service quality (see 
Figure 2.1) have included questions about use of the service for future MRPs 
(Melnyk, Shevchuk and Remillard, 2000; Bramley et al., 2013) and asking 
users about actual clinical outcome compared to expected outcome (Melnyk, 
Shevchuk and Remillard, 2000).  Evaluation of non-users of the MIS has also 
been conducted, with questions asked about why they do not use the service 
and how they answer MRPs (Rutter, J. and Rutter, 2004).   
As already mentioned, it is increasingly important to try to better understand 
how MI advice influences clinicians and the care of their patients in the current 
economic, evidence-based climate.  Consequently, MI research has aimed to 
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evaluate the effect of MI advice on clinicians, patient care and patient 
outcomes (Hands, Stephens and Brown, 2002; Spinewine and Dean, 2002; 
Bertsche, Hämmerlein and Schulz, 2007; Frost Widnes and SchjØtt, 2009; 
Hedegaard and Damkier, 2009; Bramley et al., 2013; Innes, Bramley and 
Wills, 2014), and so this is the focus of my review of MI studies.  These 
various means of assessing ‘impact’ are also shown in Figure 2.1.  I am now 
going to discuss the difficulties with the terms impact, patient care and patient 
outcome, and use of these when evaluating the effects of MI advice.   
Problems evaluating the effects of Medicines Information advice  
When trying to evaluate the effects (impact) of MI advice, investigators have 
considered both patient care and patient outcome.  First, I want to clarify the 
terms ‘impact’, ‘patient care’, and ‘patient outcome’ because definitions of 
these terms are blurred. In the context of my review of MI studies, 
investigators have likewise used different interpretations of these terms, with 
regard to their meaning and what to evaluate.  
The word ‘impact’ as defined in the Oxford dictionaries is ‘a marked effect or 
influence’ (Oxford University Press, 2018).  However, as described by health 
librarians in their evaluating impact toolkit, the term ‘impact’ is vague and can 
mean different things to individuals; which makes measuring such a nebulous 
term difficult and almost impossible to define (Health Education England, 
2014).  It certainly seems popular to include the word ‘impact’ in the title of 
health care research studies, with variable measurements used.  For example, 
a pharmacist-led study entitled ‘Assessing the impact of a targeted 
pharmacist-led anticoagulant review clinic’ (Dowling et al., 2016) evaluated 
impact by checking patient satisfaction using a survey with pre-defined items, 
monitoring performance against agreed standards and calculating cost 
effectiveness.  So, in this study the measures of impact were broad and 
varying; this has also been seen in the MI studies I reviewed. 
The term ‘patient care’ is probably the easiest to define and a simple definition 
is ‘services rendered by members of the health profession and non-
professionals under their supervision’ (National Library of Medicine, 2019).  




‘patient care’ more specifically as ‘health care interventions intended to 
preserve or improve a patient’s mental or physical health’.  Certainly, it is my 
view that for a service to have an effect on patient care, it does not have to be 
as specific as an intervention having a direct effect on the patients’ health, as 
stated above.  For example, the provision of education, counselling or 
information may not preserve or improve a ‘patient’s mental or physical 
health’ as defined in Bramley (2013), but still has the potential to have a 
beneficial effect on the patient by improving patient medication adherence and 
wellbeing, providing reassurance and giving them the confidence to ask 
questions about their treatment.  
In comparison, the definition of patient outcome is more problematic.  In more 
recent MI research, ‘patient outcome’ has been described as a ‘change in the 
patient’s health status that could be a consequence of an intervention in the 
preceding health care’ (Bramley et al., 2013; Innes, Bramley and Wills, 2014), 
and this was adapted from that used in the Melnyk study (Melnyk, Shevchuk 
and Remillard, 2000).  Thus, measures used to determine patient outcome are 
wide ranging, for example, a UK patient survey used all the following terms to 
ask about patient outcome: patient understanding; patient concerns; 
information provision to patients; ability to be involved in choice, dose, care; 
ability of the clinician to explain to the patient risks/benefits; pain control and 
guideline use (Leatherman and Sutherland, 2007).  The MI study by Bramley 
(2013) actually used some of the patient outcome measures from the patient 
study above and examples of patient outcome measures used in other MI 
studies, include ‘avoidance’, e.g. avoided abortion (Bertsche, Hämmerlein and 
Schulz, 2007; Frost Widnes and SchjØtt, 2009), or a visit to their clinician 
(Joseph, Dean Franklin and James, 2004) and ‘improvement’, e.g. improved 
symptoms (Bramley et al., 2013). 
Coincidentally, a British Standard for impact assessment is now available for 
library services in the UK.  This describes ‘impact’ as the ‘influence of libraries 
and their services on individuals and/or on society’ and ‘the difference or 
change in an individual or group resulting from the contact with library 
services’ (ISO, 2014).  Moreover, these services say that changes (or impacts) 




quantify.  As I also found when reviewing published MI ‘impact’ studies, it is 
difficult to separate MI effect from other influencing factors and to prove the 
effect was due to provision of MI advice.  This means it may only be possible 
for information services to contribute to an impact (e.g. length of stay, patient 
care) rather than be solely responsible (Health Education England, 2014).  
Thus, MI Services need to be aware of the issues when designing studies to 
evaluate effect of MI advice on clinicians and patients, by clearly defining what 
they mean by impact and the measures used. 
An overview of studies evaluating the effects of Medicines Information 
Service advice 
For my research the main aim of this literature review was to identify and 
review published research evaluating the effects of MI Service advice on 
clinicians and patients, and then to identify topics for further research.  I 
conducted my review by systematically searching the literature and collating 
all relevant published MI studies.  I then summarised the aims and objectives, 
design, methodology and methods, and results of these studies. Finally, I 
thematically reviewed and critiqued these studies, identifying gaps and 
explaining the reasons for doing my study. 
 
Methods used in this review of Medicines Information studies 
The EmbaseÒ and PubMedÒ databases were searched from their respective 
start dates for original English language research articles (journals and 
conference proceedings only), spanning both primary and secondary care. 
Those papers from the two published reviews (Hands, Stephens and Brown, 
2002; Spinewine and Dean, 2002) that met the criteria for inclusion (Table 













Table 2.1 Literature search inclusion and exclusion criteria  
Inclusion criteria Exclusion criteria 
All published studies which attempted to 
evaluate the effect and outcomes of MI Service 
advice 
Unpublished studies 
(including PhD theses) 
Date range:  
PubMed 1966 to Feb 2019 
Embase 1974 to Feb 2019 
Primary research not related to 
the subject area 
Primary and secondary care 
MI studies which only evaluated 
customer satisfaction (health 
care professional and/or public) 
Any articles published as a journal article; 
congress proceedings; clinical trial and case 
reports 
Any other studies about the MI 
Service 
English language only 
Studies evaluating the effect and 
outcomes of other medicines 
information resources 
 Non-English language 
 
I have summarised the searches, search terms and number of studies 
returned in Table 2.2.  I then reviewed the abstracts of articles to decide if the 
studies were relevant to my research question, and included them if they were 
about an MI Service and evaluated the effects or outcomes of MI advice.  I 







Table 2.2: Search strategy and results 
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19 not MI  
68 MI but not 
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3 not MI 
19 MI but not 
relevant 
3 relevant MI 





















2 not MI 
23 MI but not 
relevant 
9 relevant MI 










*Indicates a thesaurus term 
Exp = term exploded 





Findings of my review of Medicines Information studies 
The literature search identified 1631 articles, of which 156 were MI papers 
with 19 eligible for inclusion (Figure 2.2). A summary of each paper is in 
Appendix 1. 
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n=22 
Other MI papers found 
in reference lists 
n= 6 
Papers excluded 
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Previously, early MI papers were subject to two reviews (Hands, Stephens and 
Brown, 2002; Spinewine and Dean, 2002).  The review by Hands el al aimed 
to establish clinical and economic impact of MI Services on patients (Hands, 
Stephens and Brown, 2002).  Seven studies were included (six published 
articles and one unpublished document), in which Hands et al concluded 
favourable impact was reported in some studies but questioned the validity of 
their findings due to methodological limitations.  The authors recognised at the 
time, that methods for assessing impact or patient outcome from MI advice 
were limited to prospective, open label cohort studies and that controlled trials 
were not possible.  They suggested using a combination of methods 
(interviews, surveys) with the patient’s clinician, the patient/carer, and 
reviewing medical notes to gather information about patient outcome.  Whilst I 
agree this approach would result in a well-designed study, it would not be 
feasible in terms of time, logistics and costs to interview the prescriber, check 
medical records and then interview the patient, particularly as in my case 
being a part-time, self-funding PhD student.  They also suggested there were 
other means of assessing impact on patient outcome, such as comparing 
desired outcome with actual outcome, which some studies have since tried to 
do.  The review by Spinewine and Dean appraised nine papers, including three 
of the same papers found by Hands, to assess impact on patient outcome of 
passive information given to clinicians (Spinewine and Dean, 2002) and they 
also included a study by Golightly et al (Golightly et al., 1988). The authors 
like Hands et al questioned the methodological rigour of the studies and 
therefore their findings. Their assessment of outcome and impact reported 
that only Stubbington et al and Melnyk et al attempted to assess actual impact 
rather than enquirer opinion of immediate patient outcome or anticipated 
outcomes (Stubbington et al., 1998; Melnyk, Shevchuk and Remillard, 2000).   
In addition, the Spinewine review helpfully discusses use of various endpoint 
measures, and explains that they are either process or outcome measures, as 
described by Donabedian (Donabedian, 1988; Spinewine and Dean, 2002).  I 
agree with their explanation that in MI terms, process measures relate to 
things that happen during the course of producing an MI answer and include 
accuracy; clarity; relevance; completeness; timeliness; adequacy; usefulness; 




measure, they do not necessarily influence the patient outcome and are really 
quality assurance indicators.  In Spinewine, the authors suggest outcome 
measures which are a result of these processes and include examples such as 
use of information, action taken, patient outcome and outcome of cases.  The 
authors suggest that outcomes should be compared before and after the 
introduction of the service, or in similar environments with and without the 
service. This is difficult to do with MI Services widely available in the UK, 
although a study has been completed comparing use of the service with non-
use of the service by finding out what non-users did instead (Rutter, J. and 
Rutter, 2004).  
In summary, both reviews were critical of the measures used and called for 
further studies to be conducted that were more robustly designed to allow 
outcome or impact to be better assessed.  Thus, MI researchers have begun to 
focus less on QA indicators and more on outcome and impact as advocated by 
the two reviews.  This review therefore attempts to assess MI research where 
outcome and/or impact has featured in the data collected, whether as the 
major objective of authors or as an element of their work.  The majority of MI 
studies I found are mostly descriptive, of variable quality and with diverse 
results.  This heterogeneity makes it difficult for me to compare studies and as 
such it was not possible to do traditional quantitative reviews, such as a meta-
analysis.   
Studies identified are non-experimental with a mostly cross-sectional survey 
design.  Unfortunately, the Critical Appraisal Skills Programme (CASP) does 
not have a specific critical appraisal tool for this type of study, in the same 
way it has for randomised controlled trials (RCTs) and systematic reviews.  
Instead, I therefore used a tool produced by the Centre for Evidence Based 
Medicine (CEBM, 2014) designed to evaluate cross-sectional studies i.e. 
surveys.  Although other checklists are also available, e.g. STROBE 
(Strengthening the Reporting of Observational research in Epidemiology), 
these are primarily designed to be used by authors writing publications rather 
than for reviewing studies, so I did not use them. 
Nineteen studies were identified, although twelve of these also included QA 




(effect).  As the focus of my review is around the effects of MI advice, I have 
not considered the QA aspects of these studies.  The tables in Appendix 1 
provide a summary of the aim and objectives, participants, design, duration, 
sampling, methods, outcome measures and findings for each study.  I 
reviewed all 19 studies using the CEBM checklist, then summarised my 
findings under five main themes based on the included participants and the 
findings of each study, with further critical discussion about strengths and 
limitations under the headings; Design and methods, and Setting and 
sampling issues.  Finally, I relate my findings to the two previously published 
reviews (Hands, Stephens and Brown, 2002; Spinewine and Dean, 2002), 
presenting my concluding thoughts concerning the need for further research 
and explain why there is a need for my study.  
As stated earlier the variability in what constitutes impact is reflected in the 19 
studies reviewed here, as all used a range of outcomes to try and gauge the 
effect of MI advice on clinicians and patients.  For clarity and to illustrate the 
range of outcomes used, I have split them into three broad groupings: those 
which relate to patients; those used with clinicians; and numerical outcomes, 
such as costs saved.  These are in Table 2.3 and Table 2.4.  The effect of MI 
advice on patients was mainly evaluated by asking the clinician (asking the 
MRQ) about the patient outcome, although in some studies they asked the 
opinion of patients (Table 2.3).  Other studies evaluated the effects of MI 
advice on clinicians themselves or used other measures (Table 2.4).  All 
papers were reviewed where data relating to descriptions around impact/effect 
and outcome were mentioned.  These were themed under five main headings, 
meaning some studies are discussed under one or more themes.   
These are: 
Ø Theme 1: views of clinicians about the effect of MI advice on patients 
Ø Theme 2: actions of clinicians after receiving MI advice 
Ø Theme 3: influence on their decision-making  
Ø Theme 4: views of patients about the effect of MI advice 








Table 2.3 Terms used to evaluate the effects of Medicines Information Service 
advice on clinicians and patients 






Positive outcome Melnyk 




Potential positive outcome Bertsche Innes 
Improved patient care/improved outcome Bramley 2013 Innes 
Affected patient outcome Cardoni 
Expected patient outcome Bramley 2009 
Improved patient care Innes Melnyk 
(No) effect on care/outcome Melnyk 
Patient understanding of medicines Innes 
Enhanced adherence  Bertsche 
Considered patient concerns Innes 
Patient reassured Innes Stubbington 
Patient able to participate in choice about 
medicines/regimen/health care Innes 
Prevented/reduced risk of treatment (defined as 
low/moderate/major) Innes 
Improved symptoms Bramley 2013 
Avoided interaction Bertsche 
Reduced ADR/ reduced risk of ADR Bramley 2013 Innes 










Avoided/resolved MRP Badiani Joseph 
Reassured Badiani Bramley 2018 





Changed medicine/how taken 
Obtained supply of medicines 
Contacted clinician 
Effect on wellbeing 
(general/physical/emotional/social) 
Avoided a visit to their clinician 
Believed they had an improved state of health  
Felt able to discuss and/or minimise uncertainties 
Maywald Gained confidence about their medicines 







Table 2.4 Other terms used to evaluate the effects of Medicines Information 
Service advice  














Changed treatment SchjØtt 



































Continued treatment Bramley 2013 Frost Widnes 










Reported ADR SchjØtt 
Stubbington 
Used with the patient  Melnyk 
Provided information to patient   Hedegaard 
Provided counselling to patient  Innes Strobach 
Referred to another clinician Melnyk 
Advised another clinician McEntee Stubbington 
Circulated to colleagues  Hedegaard Stubbington 




Based on: Effect on the patient 
Study 
(lead author) 
Used for teaching/training others McEntee Stubbington 
Used to produce guidelines/protocols/PGDs etc. McEntee Stubbington 










Used in decision-making for choice of 
treatment/to facilitate diagnosis 
Stubbington 
McEntee 
Used in decision-making for funding/formulary  Bramley 2013 
Changed clinical practice SchjØtt 
Managed risk of treatment already given 
Ability to explain risk/benefit Innes 
Risk benefit assessment Bertsche Frost Widnes 
Checked if treatment appropriate McEntee 
Checked safety of treatment Bramley 2013 Innes 
Decided best plan of action 
Confirmed change in therapy 
Confirmed safety of treatment 
Bramley 2013 




Improved advice to patient/colleague SchjØtt 
Emotional response e.g. reassured Stubbington 
Process 
measures 
Time/costs saved by using the MI Service (PHS) Marrone 
Costs saved by using the MI Service Kinky 
Number of enquiries where changed patient 
management Bramley 2009 
Opinion of MI staff about effect of advice - 
Resolved/prevented/corrected a MRP  Golightly 
 
For each theme, I discuss the main findings of the studies reviewed, along 
with some of their shortcomings. Then in the Discussion section in this 
chapter, I explain why the positive findings of some studies need to be viewed 
cautiously. 
Theme 1: Views of clinicians about the effect of Medicines Information 
advice on patients 
I found seven studies which attempted to determine clinician opinion on the 
effect of MI advice on patient care (Cardoni and Thompson, 1978; Stubbington 
et al., 1998; Melnyk, Shevchuk and Remillard, 2000; Bertsche, Hämmerlein 
and Schulz, 2007; Bramley et al., 2009; Bramley et al., 2013; Innes, Bramley 
and Wills, 2014).  Although clinician opinion is a subjective surrogate measure 




and limitations acknowledged.  Asking the clinician is a reasonable choice as 
an outcome measure, as it is difficult to directly measure patient outcome 
unless objective clinical data are available e.g. reduction in blood pressure 
which occurs as a direct result of an MI recommendation. 
In one structured (Cardoni and Thompson, 1978) and two semi-structured 
telephone interview studies (Melnyk, Shevchuk and Remillard, 2000; Bramley 
et al., 2009), clinicians were asked to assess patient outcome against pre-
defined criteria.  In the Cardoni study, clinicians (58%, n=202) thought the 
information had affected patient outcomes and had a positive effect on 
patients and their care (78%, n=157), as they started or stopped a drug.  In 
almost a third (29%) of cases clinicians selected the option ‘other’, but data 
were lacking to determine what these responses meant.  This early Cardoni 
study was retrospective and lacked clarity, making it difficult to interpret all 
the findings.  In the Melnyk study (2000), 98 enquiries generated 230 
recommendations by the MI service.  Almost three quarters of respondents 
(74%, n=72) believed the advice had a beneficial impact on the patient, with 
an expert panel agreeing that almost half (47%, n=36) had resulted in a 
positive patient outcome; ten of which were based on objective measures, e.g. 
reduction in blood pressure.  
In the small, non-peer reviewed study by Bramley et al (2009), 40 clinicians 
were asked three questions before receiving advice, one of which was centred 
on clinician expected patient outcome.  The results are unclear as responses 
were not linked to the enquiry or clinician type.  Thirty-two clinicians were 
available for follow-up, of which 59% (n=19) of patient outcomes were as 
expected, although three (9%) had improved more than expected and six 
(19%) had not improved.   
Bramley and co-workers have subsequently published other works to try and 
measure the impact of MI advice (Bramley et al., 2013; Innes, Bramley and 
Wills, 2014).  Their study in 2013 was much larger (with 179 sets of complete 
data derived from 316 initial enquiries) than the 2009 paper (Bramley et al., 
2013).  The majority of enquirers (81%, n=145) rated the impact on patient 
care or outcome as positive, 20% (n=35) said it improved patient outcome 




Only 15% (n=27) reported no impact.  No negative outcomes or cases of 
worsened patient care were reported.  An expert panel purposively reviewed 
20 cases, and found that 19 (95%) of the cases had a positive impact on 
patient care.  I will discuss the problems with the use of rating scales and 
expert panels in the section entitled ‘Design and methods’.  Although some 
clinicians (40%, n=71) agreed that MI advice resolved the therapeutic 
problem completely, almost a third (30%, n=53) said it was ‘too early to 
know’ and the rest (27%, n=48) selected ‘no/did not know/not applicable’.  
This is not surprising as follow-up time was relatively short and therefore 
potentially too soon for outcomes to be known.  Obtaining follow-up data 
about patients is problematic, particularly as their individual circumstances 
and/or time for patient response will vary according to the condition being 
treated.   
Leading on from the 2013 study, Innes et al (2014) using the same 
methodology, completed a larger (n=1450) UK multi-centre study (n=62). 
Positive findings of the impact on patient care were reported, and mirrored the 
2013 Bramley study.  For example, the majority of respondents self-reported 
that the advice had a positive impact on their patients (92%, n=597), with 
85% (n=547) considering this was positive regarding patient care or outcome.  
Furthermore, around half (53%, n=343) agreed MI advice reduced/decreased 
risk of an ADR and positively affected lowering risk/improving safety in patient 
safety/risk (58%, n=374).  Almost half felt the patient was reassured (43%, 
n=273), while a third of respondents thought that patient understanding of 
medicines was improved (33%, n=213).  Finally, just over a quarter of 
clinicians felt that patient ability to participate in choice about their medicines, 
regimen or health care was improved (28%, n=180). Even though this study 
was larger, and produced positive findings, because it used the same 
methodology as the 2013 study, it is open to the same criticisms.  
Stubbington et al mailed a questionnaire to determine the action taken by 
clinicians in response to information provided on queries centred on adverse 
effects (Stubbington et al., 1998).  In this small, non-peer reviewed study, 
almost all respondents (95%, n=125) said they found the information helped, 




patient care in at least 40 patients (30%).  A number of clinicians (n=21/117) 
thought MI advice helped them avoid a potential adverse event.  Patient 
progress after receiving MI advice was known in almost two thirds of cases 
(n=79, 60%), this included 40 responses of patient improvement, but 19 were 
under review and in 17 there was no change.  The Bertsche user satisfaction 
study (2007), also used survey methodology to sample primary care clinicians 
(n=1017), and included one question about patient outcome.  Almost half of 
the clinicians (42%, n=190) agreed there was a potentially positive outcome, 
and thematic analysis of these responses revealed that MI advice allowed a 
switch to a more suitable medicine, correct dosing, enhanced adherence or 
avoidance of an interaction.  Unfortunately, no quotes were provided to 
support these data.  In summary, findings from studies asking clinician opinion 
of the effect of MI advice on patients were positive but had methodological 
limitations. 
Theme 2: Actions of clinicians after receiving medicines information 
advice 
 
Eleven studies attempted to determine how clinicians used the information 
provided (Stubbington et al., 1998; Melnyk, Shevchuk and Remillard, 2000; 
Schjøtt, Pomp and Gedde-Dahl, 2002; Bertsche, Hämmerlein and Schulz, 
2007; Bramley et al., 2009; Frost Widnes and SchjØtt, 2009; Hedegaard and 
Damkier, 2009; McEntee et al., 2010; Bramley et al., 2013; Innes, Bramley 
and Wills, 2014; Strobach et al., 2015).  Most (n=8) were self-administered 
surveys, four of which were primarily user satisfaction surveys with 
supplementary question(s) about impact/patient outcomes (Schjøtt, Pomp and 
Gedde-Dahl, 2002; Bertsche, Hämmerlein and Schulz, 2007; Frost Widnes and 
SchjØtt, 2009; Hedegaard and Damkier, 2009).  All studies report high levels 
of clinician action subsequent to receiving the information. 
Stubbington et al (1998) found a high proportion (89%, n=117) of clinicians 
acted on the MI advice.  These were categorised as: starting (n=21) or 
stopping treatments (n=20); to modify a patient’s existing regimen (n=20); 
and to justify current therapy (n=16).  In the Bertsche study (2007), the 




medicine or to correct or optimise the dose, although these were not qualified 
with supporting quotes (Bertsche, Hämmerlein and Schulz, 2007).  
Melnyk et al (2000), also reported a high number of clinicians acting on MI 
advice (84% of 230 MI recommendations were accepted), with the greatest 
reported use (41%, n=78) being for provision of information/education, whilst 
other actions included referral to another clinician (11%, n=22), instigation of 
additional monitoring (10%, n=19) and recommending or adding a drug 
(13%, n=25).  Similarly, in the SchjØtt (2002) study more than half (61%, 
n=71) of those doctors responding stated that the information provided had 
caused a change in clinical practice, with 68 going on to describe this change.  
These were categorised as changes in pharmacotherapy (n=32), improved 
advice to patients and colleagues (n=22), stopping a medicine (n=10), 
avoidance of an abortion (n=2) and reporting an adverse drug reaction (n=2).  
According to Hedegaard (2009) most doctors (93%, n=183) used MI advice, 
for patient information (79%, n=145), whilst about half used it to change 
treatment (45%, n=82), to disseminate to colleagues (51%) and for future 
use with patients (67%, n=123). Again, many respondents (94%, n=430) in 
the McEntee et al (2010) study acted on the MI advice provided, using this 
information to manage a current patient (81%, n=350) or to plan care of 
future patients (29%, n=125), for CPD purposes (24%, n=105) and for 
training/teaching purposes (16%, n=69). Certainly, responses in all these 
studies are positive, yet these results are rather superficial as no further 
details are provided, with no sense of context as responses were not related to 
the enquiry and advice provided.  
Not surprisingly, in the Frost Widnes study (2009), looking at pregnancy 
queries, MI advice was used in some cases to avoid abortion (9%, n=11), 
although frequently it informed prescribers to either avoid/stop a medicine 
(29%, n=36), or start/continue a medicine (38%, n=47).  While these results 
are easier to realise as they relate to a specific enquiry type, it would have 
been more convincing if there were some qualitative data describing the 
effects of the advice on clinicians and their patients.   
In the 2009 Bramley paper, 30 (94%) clinicians had used the information 




administration/dosing (9%, n=3) or not to start a medicine (9%, n=3).  
Further studies involving Bramley used similar categorisation to illustrate 
actions taken.  In their 2013 study, Bramley et al found that a quarter (n=44) 
of clinicians continued the medicine, while others started a medicine or 
changed the drug regimen (21%, n=37 for each), with a quarter taking more 
than one of the listed actions (24%, n=43).  Half (54%, n=97) of the 
enquirers used advice to check medication safety, about a third (30%, n=54) 
to tell them the best plan of action and just under a quarter (22%, n=40) to 
confirm a change in therapy was needed.  A criticism of this work, was that 
the survey questions were ambiguous and poorly worded.  Similar findings 
were noted in the 2014 Innes study where about half (48%, n=311) of 
respondents used MI advice to check the safety or risks of treatment (Innes, 
Bramley and Wills, 2014).  Another more recent study by Strobach (2015), 
detailed a total of 232 clinical actions (n=113).  About half of these actions 
(49%, n=114) were considered to be due to MI advice, and included starting a 
medicine (n=34); stopping/not starting a medicine (n=21); modifying drug 
treatment (n=15); clinical monitoring (n=22); specific patient counselling 
(n=14) and modifying doses (n=6).   
To summarise, all studies report high levels of clinician action subsequent to 
receipt of MI advice.  Many used it to stop or start a medicine or to change 
treatment.  However, these responses are superficial as researchers used pre-
defined options to describe/categorise action without establishing/providing 
clinical context.  I will discuss the problem of using pre-defined options in the 
section entitled ‘Design and methods’.  
Theme 3: Influence on their decision-making 
Besides MI advice causing clinicians to take specific actions, some studies also 
reported how MI advice influenced their decision-making.  In three studies this 
was framed as a more general question.  In the Frost Widnes (2009) study 
(Frost Widnes and SchjØtt, 2009), when asked if advice was important in their 
therapeutic decision-making, the majority agreed (95%, n=111).  In the 
Bramley et al (2013) study, just under half (44%, n=79) agreed that MI 




and this was also reflected in the Innes (2014) study (40%, n=262) (Innes, 
Bramley and Wills, 2014). 
Clinicians could also be seen to use MI advice as a risk management tool; to 
reassure themselves (Stubbington et al., 1998), to allow medication safety 
checks (Bramley et al., 2013), help with their own risk/benefit assessment 
(Bertsche, Hämmerlein and Schulz, 2007; Frost Widnes and SchjØtt, 2009) or 
ability to explain risk/benefit to the patient (47%, n=306) (Innes, Bramley 
and Wills, 2014).  Other clinicians (60%, n=71) agreed that advice caused a 
change in their practice (Schjøtt, Pomp and Gedde-Dahl, 2002), which 
included being able to give more informed advice to colleagues.  
Findings from these studies suggest that MI advice does not always result in a 
direct action but can sometimes have other less obvious effects on the 
clinician. They use it in their decision-making, sometimes as a check, or to 
reassure, confirm or tell them or others what to do. 
Theme 4: Views of patients about the effect of Medicines Information 
advice 
Seeking the views of patients is an alternative to asking the clinician, 
particularly as the clinician (if not the prescriber, which was often the case) 
may not know the effect of provided information on patient outcome.  Five 
studies attempted to determine the views of patients on the impact of MI 
advice (Melnyk, Shevchuk and Remillard, 2000; Joseph, Dean Franklin and 
James, 2004; Maywald et al., 2004; Badiani et al., 2017; Bramley, Innes and 
Dass, 2018).  Joseph, Badiani and Bramley investigated the usefulness of 
advice provided to patients of a medicines helpline after hospital discharge 
(Joseph, Dean Franklin and James, 2004; Badiani et al., 2017; Bramley, Innes 
and Dass, 2018).  Joseph (2004) conducted a survey (n=87), which asked 
patients if they followed the advice given, about actions they took and how 
they felt.  Almost all the patients who replied (97%, n=58) said they followed 
the recommendations provided, and overall, two thirds (66%, n=40) said a 
MRP was avoided; three quarters (75%, n=45) also reported being less 
anxious, yet a quarter (25%, n=15) felt they were more anxious; I propose 
this may be because they were made more aware of medicine issues having 




(general, emotional, physical and social) was measured using a non-validated 
5 point Likert scale (highly positive to highly negative).  Although the well-
being scores were high, general (83%); emotional (78%); physical (74%) and 
social (74%).  In my opinion, questions about wellbeing may not be applicable 
to every MRQ asked, i.e. ’Is there a lactose-free tablet available?’  Similarly, 
findings from the study by Badiani, involving 68 patients, revealed almost all 
(96%) followed the advice to some degree.  Respondents believed advice 
received had avoided a MRP (27%) or the medicine problem had resolved 
(52%).  Almost half (45%) of the respondents stated they felt reassured after 
gaining the advice.  Lastly, the Bramley (2018) findings mirror those of 
Badiani, and of the 67 patient respondents, almost all (93%), followed the 
advice provided and felt reassured (81%) after checking about medicine safety 
and usage.  A small number (19%) reported improved health or cure following 
advice received.  
Maywald (2004) performed a much larger (n=1686) survey study, where 
patients were asked about how they used MI advice, actions they took and the 
impact this had (Maywald et al., 2004).  Of 920 respondents, over two thirds 
(68%) reported increased self-confidence in dealing with prescribed 
medicines, and others said uncertainties about medicines were reduced 
(81%).  While, over a third (38%) used the knowledge provided to discuss the 
results of MI advice with their clinician, with some reporting a better state of 
health after implementing MI advice (20%), and others felt advice prevented a 
visit to their clinician (18%). 
Finally, it must be noted that although the study by Melnyk et al (2000) 
reported data as ‘consumers’, it is not completely clear exactly who was a 
consumer.  The authors reported on 68 ‘consumer’ enquiries in which most 
(87%) recommendations were accepted and with the majority (92%) deemed 
beneficial to their care.  This study also involved clinicians and is reported in 
Theme 2.   
In summary, instead of asking the clinician, seeking patient opinion is a useful 
option to gain their perspective about the effects of MI advice.  Patients said 
they felt more confident and reassured about their medicines and were able to 




Theme 5: Process measures  
Lastly, three studies used other measures to assess impact of MI advice 
(Golightly et al., 1988; Kinky et al., 1999; Marrone and Heck, 2000).  In an 
early study by Golightly (1988), MI pharmacists assigned pre-defined potential 
outcome codes to enquiries they answered from the public.  The outcome 
codes included ADR or drug interaction prevented, corrected or explained, or 
therapeutic failure prevented.  In the opinion of MI staff, advice given to the 
public prevented or corrected about three quarters (76%, n=4333) of MRP.  
However, the results should be viewed cautiously as they were purely based 
on the subjective, retrospective opinion of the MI pharmacists.  
The two other studies considered potential cost savings by using an MI advice 
service (Marrone and Heck, 2000; Kinky et al, 1999).  In the study by Marrone 
(2000), a simple cost analysis of medicines questions (n=308) was completed 
by multiplying the time MI staff spent answering the question by the average 
salary for types of clinicians asking the question e.g. clinical pharmacist, 
hospital specialist.  This figure was called ‘Practitioner Hours Saved’ or ‘PHS’.  
A total of 266 PHS was calculated which equated to a total annual cost saving 
of $43 950 at that time.  This approach to assigning monetary value to the 
service is useful (when trying to prove ‘worth’), however their findings need to 
be interpreted with caution as time spent on an enquiry will depend on the 
experience, and therefore pay, of the MI pharmacist, which this study did not 
capture.   
In the Kinky (1999) study, investigators developed a cost avoidance model to 
determine outcome severity and potential cost savings of the enquiry 
answering service.  An expert panel (made up of the MI director, an MI 
pharmacist, an adverse event co-ordinator and a pharmacoeconomics 
specialist) reviewed just over a quarter of all enquiries (28%, n=163) by 
deciding what would have happened if the MI Service had not answered the 
question by choosing an outcome severity score from a scale of 1 to 6, where 
one was categorised as no harm through to six, which was death of the patient 
secondary to a MRP.  Although, as far as I can judge, the severity scoring 
scale used were not tested for reliability and validity.  Using this model, 




and/or additional treatment (46%, n=77).  About half the enquiries had little 
or no measurable cost impact (51%, n=83), indicating that this may not be 
the most appropriate measure for many MI questions.  Despite this, the 
authors projected potential annual cost savings of about $1.7 million.  Other 
criticisms I have of this study, are that results were about potential rather 
than actual cost savings, and could only be calculated for a small proportion 
(14%, n=77) of all MI enquiries received.   
In summary, other measures of the effects of MI advice have been used, 
including the opinion of MI pharmacists themselves.  Studies of costs saved by 
using MI advice are useful to show an element of value but also had 
limitations.  Having reviewed the studies under the five main themes they 
attempt to address, I will now discuss other strengths and limitations of the 
studies under sections, ‘Design and methods’ and ‘Setting and sampling 
issues’.  This will further highlight why there is a need for additional MI 
research, including my study. 
Design and methods  
Here, I discuss my concerns about use of prospective or retrospective surveys 
with pre-defined questions, with limited opportunity to provide additional 
information and the need for suitable response rates when quantifying data.  I 
also discuss the reliability and validity of methods used, including the location 
of participants and the use of rating scales and expert panels.  Generally, MI 
Service outcomes have mostly been collected from clinicians via surveys, with 
some attempting follow-up of patient-outcome by asking the clinician 
(Stubbington et al., 1998; Melnyk, Shevchuk and Remillard, 2000; Bertsche, 
Hämmerlein and Schulz, 2007; Bramley et al., 2009; Innes, Bramley and 
Wills, 2014), or the opinion of patients (Melnyk, Shevchuk and Remillard, 
2000; Maywald et al., 2004; Joseph, Dean Franklin and James, 2004; Badiani 
et al., 2017; Bramley, Innes and Dass, 2018).  Most studies (n=10) used self-
administered surveys (Stubbington et al., 1998; Schjøtt, Pomp and Gedde-
Dahl, 2002; Joseph, Dean Franklin and James, 2004; Maywald et al., 2004; 
Bertsche, Hämmerlein and Schulz, 2007; Frost Widnes and SchjØtt, 2009; 
Hedegaard and Damkier, 2009; McEntee et al., 2010; Bramley et al., 2013; 




way to reach a study population, it is only useful if the survey is constructed 
properly, which was not always the case, and is discussed in the next 
paragraphs.  Semi-structured telephone interviews were used in a couple of 
studies (Melnyk, Shevchuk and Remillard, 2000; Bramley et al., 2009).  This 
method should have enabled investigators to clarify respondent answers and 
probe further, but it is unclear what open questions were asked and where 
probing to elicit more information was employed.  
Studies used clinician opinion, via completion of researcher pre-defined 
outcome categories, as well as through clinician expectation of anticipated 
patient response or inference that a reported action may have had a (positive) 
effect.  Use of such measures limits the usefulness of study findings on MI 
advice influencing patient outcome because respondents were not given free 
choice in explaining outcome or were restricted to theorising outcome.   All but 
one study (n=18) used pre-defined outcome categories based on the opinion 
of the investigators and/or MI staff, and in some cases were replicated from 
previous studies.  Pre-defined categories assume the investigator knows 
exactly what categories are appropriate.  Only the Hedegaard (2009) study 
completed interviews with doctors to help inform the content of the survey 
questions, one of which explored the impact of the advice provided.  A further 
problem with pre-defined categories is that they cannot reveal the detail 
behind how clinicians use MI advice, about the specific action they take, or 
what happens to the patient afterwards.  To highlight this point, in 9 of the 10 
pre-defined impact statements in the Bramley (2013) study, at least a third 
and up to three quarters of clinicians selected ‘not applicable’, which calls in to 
question their appropriateness.  Similarly, in the Melnyk (2000) study, pre-
defined surrogate measures of outcome were used and unfortunately in a 
large number of enquiries (n value not specified) a tangible outcome was not 
found.  Also in the Bramley studies, some questions from pre-defined 
categories were vague and overlapping, e.g. those about ‘actions’, meaning 
these would yield inadequate answers.  More specifically, the question in 
Bramley 2013 about how they used MI advice, was poorly worded as it asked 
about both safety and risk in one question, which are two different things. 




complex, with some double-barrelled questions, potential for survey fatigue, 
and consequently contributing to debatable findings.  
More positively, in an attempt to obtain additional data to support the pre-
defined items, open ended questions were included in a small number of the 
surveys.  For example, Stubbington et al (1998), were able to theme 
responses about use of MI advice to provide greater context.  This use of open 
ended questions was also noted in the SchjØtt (2002) study.  However, the 
presentation of the findings from these two studies was hindered, as 
responses were quantified without any context or quotes. 
It should be noted that self-administered surveys also need to have acceptable 
clinician response rates, with 60% or higher reported as adequate (Burns et 
al., 2008); most  studies reviewed achieved this, although some studies did 
report lower rates (Bertsche, Hämmerlein and Schulz, 2007; Innes, Bramley 
and Wills, 2014).  Follow-up reminders are advocated to minimise non-
responder bias, yet this was only documented in the studies by McEntee 
(2010), Bramley (2013) and Innes (2014).  A further positive comment is that 
all surveys were anonymised, which is important as it may help improve 
response rates (Bryman, 2016).  
My next point is about time to follow-up and study duration.  It is difficult to 
know how long to wait after provision of MI advice before follow-up with a 
survey or interview.  This is because the time scale for patient outcome varies 
from one case to another.  Duration of studies ranged from 2 weeks for the 
Bramley 2009 study to the longest studies being 18 and 24 months 
respectively (Schjøtt, Pomp and Gedde-Dahl, 2002; Maywald et al., 2004).  
However, follow-up time post provision of MI advice rather than the actual 
length of study is more important in terms of enabling the clinician to 
articulate the effect advice had on patient outcome.  In studies where this was 
captured, lag time between generation of MI advice and follow-up tended to 
be short, typically two to four weeks (Melnyk, Shevchuk and Remillard, 2000; 
Bramley et al., 2009; Bramley et al., 2013; Strobach et al., 2015).  It is 
debatable if these time periods were appropriate given the high levels of 





Furthermore, for survey results to be representative an appropriate sample 
size needs to be achieved, (Bryman, 2016), which is often decided through 
use of sample size calculators (SurveyMonkey, 2019).  Survey sample size 
was only considered in two studies, McEntee (2010) and Innes (2014).  Both 
mentioned using a sample size calculation to ensure the study was sufficiently 
powered; all other survey-based studies appeared to be underpowered, with 
low participant numbers, and whilst small sample sizes using quantitative 
methods are generally acceptable for pilot or feasibility studies (Bryman, 
2016), no study reviewed explicitly stated that they were pilot or feasibility 
works.   
Despite the positive findings it has to be noted that the scales used in Bramley 
(2013) were biased toward positive reporting.  For example, the scale used to 
ask about the patient’s clinical condition was skewed to ‘unwell’ in four out of 
the five descriptors, and the scale used by the panel was skewed to positive 
impact on patient outcome in four out of the six descriptors, with only one 
neutral and one negative impact on patient outcome (See Appendix 2).  Also, 
whilst it is helpful to see a patient wellbeing score in the Joseph study as a 
measure of the impact of MI advice, it is unfortunate that the investigators did 
not use a validated quality of life tool (AQoL, 2016). Unfortunately, some 
questions in this study were poorly worded and biased towards positive 
outcomes (Joseph, Dean Franklin and James, 2004). Additionally, there was 
no option to select ‘other’ or for patients to explain their actions in their own 
words, if the options provided were not suitable.  If the investigators had used 
open-ended questions, responses could then have been analysed qualitatively, 
rather than just using a pre-determined list.   
Ideally, items or scales included in surveys should be tested for reliability and 
validity to ensure they are measuring what is intended and in a consistent way 
over time (Bryman, 2016).  Only eight studies appeared to validate their 
surveys in any way and where they did, gave brief and sometimes vague 
accounts.  At best, some studies tested their surveys for face validity.  
Investigators in the McEntee (2010) study piloted their survey for format and 
ease of completion with 27 clinicians (53 were asked), while Bramley (2013) 




respondents in the pilot.  Innes (2014) conducted their pilot in 14 MI centres, 
although they are vague about how this was done.  While Stubbington (1998) 
piloted their survey with 8 potential respondents, and Melnyk (2000) 
undertook a one-week pilot to check documentation and identify any problems 
but they do not provide any more detail.   Similarly, Maywald (2004), Bertsche 
(2007) and Hedegaard (2009) did pre-test their surveys but gave no further 
explanation.  No studies tested their survey instruments for other types of 
validity or reliability. 
Another point to mention about surveys, is that prospective surveys are 
usually preferred because they are developed with the research question in 
mind and so designed to minimise bias and confounding variables (Hands, 
Stephens and Brown, 2002; Spinewine and Dean, 2002; Bryman, 2016).  
Fortunately, most MI studies reviewed used a prospective approach (n=15) to 
evaluate the impact of MI advice.   
It is encouraging to see studies published after the reviews (Hands et al., 
2002; Spinewine & Dean, 2002) from 2002, especially publications in the last 
5 to 10 years, having a greater focus on effect and outcome and attempting to 
adopt more robust and valid ways to asses these concepts.  Recommendations 
such as the use of rating scales (Bramley et al., 2013; Innes, Bramley and 
Wills, 2014; Bramley, Innes and Dass, 2018) and independent expert clinical 
panels, have been used in some studies (Kinky et al., 1999; Melnyk, Shevchuk 
and Remillard, 2000; Joseph, Dean Franklin and James, 2004; Bramley et al., 
2013; Innes, Bramley and Wills, 2014; Bramley, Innes and Dass, 2018) and 
are to be welcomed.  However, the pharmacy rating scales originally referred 
to in the Hands (2002) review, are positively biased, with some focussed on 
one element of clinical intervention e.g. adverse drug effects or harm, and 
appear not to have undergone any testing for reliability and validity.  So, 
whilst these approaches have merit, those used suffered from potential bias, 
especially in over representing impact or outcome in a positive way.  For 
example, Bramley (2013) used a rating scale based on scales previously used 
for measuring the impact of other clinical pharmacy interventions on patient 
care and outcomes, so was not specifically developed to evaluate the effects of 




piloting and feedback to include multiple elements of both patient 
care/outcome and risk, it unclear how this was done.  The Innes (2014) study 
subsequently adapted the scale used in the Bramley (2013) study (See 
Appendix 2), but this was not tested for validity.  This used a five-point scale 
to assess multiple elements of impact, safety or risk and also patient care and 
outcomes, this use of multiple elements in one scale is inappropriate due to 
ambiguity.  In both studies these rating scales were initially included in the 
surveys sent to enquirers and then amended by the expert panel to include a 
sixth point so that the panel could differentiate ‘life-saving impact’ from ‘other 
highly positive impact’.  Although Innes et al (2014) state their scale used by 
the expert panel was based on the scale used in Bramley (2013), and that it 
was ‘developed and tested for reliability’ in the previous study, again it is not 
clear how this was done, except that the scale in Bramley was piloted with two 
‘expert’ panels.  To illustrate the differences and for reference, I have included 
a table comparing the rating scales used in Bramley 2013 and Innes 2014 in 
Appendix 2.  More recently Bramley et al (2018) reported validation of a 
modified version of their impact rating scale, however the level of detail 
reported on its validation within the paper makes it difficult to independently 
assess the authors’ conclusions (Bramley, Innes and Dass, 2018). 
Lastly, the use of expert panels can provide an objective view of patient 
outcome, with more recent MI studies utilising this methodology (Kinky et al., 
1999; Melnyk, Shevchuk and Remillard, 2000; Joseph, Dean Franklin and 
James, 2004; Bramley et al., 2013; Innes, Bramley and Wills, 2014; Bramley, 
Innes and Dass, 2018).  Melnyk (2000) used a panel to ascertain views on 
patient outcome, the views of the panel on positive outcomes were 
considerably lower compared to clinician opinion based on the survey results 
(47% n=36 vs. 73%, n=72).  This difference in personal opinion of an 
individual and the consensus of an independent panel is good.  In an attempt 
to obtain an unbiased, neutral view of the impact of MI advice, the more 
recent studies, Bramley (2013) and Innes (2014), also used a panel of 
clinicians to assess enquiries (Bramley et al., 2013; Innes, Bramley and Wills, 
2014), based on the recommendations of previous reviews (Hands, Stephens 
and Brown, 2002; Spinewine and Dean, 2002).  However, in Bramley (2013), 




and although the lead investigator also rated enquiries to see if they agreed 
with the panel rating, there were no checks for inter-rater consistency.  While, 
in Innes (2014), the expert panel only assessed 24 of 40 randomly selected MI 
answers/completed surveys, expert panel ratings were compared to clinician 
ratings using Cohens Kappa, with inter-rater consistency scores of 0.62 and 
0.4 for the patient care/outcome ratings and safety ratings, respectively (a 
score of 0.6-0.75 is regarded as good and 0.4-0.6 as fair) (Bryman, 2016).  
So consistency ratings were classed as fair, but with clinician/panel agreement 
for impact ratings better for patient care/outcome, than for risk/safety.  
Finally, the exclusion of MI pharmacists in some panels (Bramley et al., 2013; 
Innes, Bramley and Wills, 2014) is unfortunate as they should be better 
informed to explain the rationale for MI advice given.  
In summary, most published studies about the effect of MI advice have tended 
to use survey methods with findings almost exclusively being quantitative.  All 
but one study used investigator-led, pre-defined survey items, most of which 
were not tested for reliability and validity and those that did report on these 
gave minimal or poor accounts of what took place.  Some used impact rating 
scales biased towards positive outcomes, and included elements of both 
impact and outcome in the same scale.  Response rates were low for some 
studies, and sample sizes were generally small.  All these factors limit the 
usefulness of data reported.  Finally, although using a panel is a reasonable 
means of getting the consensus of a group regarding the effects of MI advice, 
the constitution of the panel, rating methods and how consensus is reached, 










Sampling and setting issues 
In this section, I review the studies in terms of the sampling methods used to 
select clinicians and enquiries, as well as the setting i.e. the location of 
participating clinicians, patients and MI centres.  With regard to sampling, 
most studies used purposive sampling, i.e. participants (clinicians/patients) 
and enquiry types were purposively selected according to the research 
question.  Most studies included in this review tended to capture the breadth 
of MI advice for all types of (patient-specific) questions, provided to a range of 
clinicians.  While this is good as it means a range of question types are 
captured, it also means that it is difficult to construct a survey that adequately 
captures data for all question and enquiry types.  Three studies restricted the 
sample to a specific type of enquiry, Stubbington et al (1998) evaluated 
adverse effect enquiries, Frost-Widnes et al (2009) included only questions 
about pregnancy, and lastly, the Strobach et al (2015) study specifically 
selected drug-drug interactions (DDI).  It is likely that targeting such specific 
question types would better enable effect or outcome to be evaluated as they 
are more likely to provide a very specific answer.  Some investigators also 
excluded simple enquiries, instead targeting more complex questions that 
potentially require greater MI input (Schjøtt, Pomp and Gedde-Dahl, 2002; 
Strobach et al., 2015), whilst others (Hedegaard and Damkier, 2009; Strobach 
et al., 2015) aimed to survey clinicians with more complex MRQs by excluding 
those where advice was provided over the telephone on the premise that 
complex information could not be communicated by telephone.  It is possible 
that focussing on the more complex MRQs may be helpful as in theory they 
may provide more data about the effect of MI advice, as these need more 
research and require a more in-depth answer. 
Obviously, the setting for recruitment of study participants defines the types 
of clinicians included.  The majority (n=15) of MI studies in this review 
included any clinician who used or had access to MI services.  This probably 
stems from MI QA studies including all types of service users and the 
predominantly positivist approach used for conducting MI surveys to date.  
Although, attempting to minimise selection bias by including all service users 




to determine patient outcome.  The problem being that in most studies a large 
proportion of enquiries were generated by pharmacists, ranging from 28% in 
the Stubbington (1998) study to 95% in the Bertsche (2007) study.  However, 
pharmacists may not be in the best position to know the effects of MI advice, 
as they are generally acting as intermediaries between the patient and 
prescribing clinician and are not prescribing.  This was recognised by Melnyk 
(2000) whose study methodology stated that if the enquirer was a pharmacist, 
then the doctor should be contacted to find out what happened.  Therefore, a 
more logical way to evaluate the effect of MI advice is with clinicians who have 
prescribing power, as they are more likely to discuss and make treatment 
decisions about medicines with the patient.  Only three studies specifically 
targeted prescribing clinicians; Frost-Widnes (2009), Hedegaard (2009) and 
Strobach (2015), although the study by SchjØtt (2002) included a high 
proportion of enquiries (about 70%, n=117) from doctors. 
Similarly, studies (n=10) have been broad in their criteria regarding clinician 
location, studying the effect of MI advice on clinicians in both primary and 
secondary care (Cardoni and Thompson, 1978; Golightly et al., 1988; Melnyk, 
Shevchuk and Remillard, 2000; Schjøtt, Pomp and Gedde-Dahl, 2002; 
Bramley et al., 2009; Frost Widnes and SchjØtt, 2009; Hedegaard and 
Damkier, 2009; McEntee et al., 2010; Bramley et al., 2013; Innes, Bramley 
and Wills, 2014), as the scope of MI Services has expanded to include primary 
as well as secondary care.  Four studies in this review focussed purely on 
clinicians in secondary care, with one a more recent publication (Stubbington 
et al., 1998; Kinky et al., 1999; Marrone and Heck, 2000; Strobach et al., 
2015), only one study looked at just primary care (Bertsche, Hämmerlein and 
Schulz, 2007).  Five other studies included either, just patients (Joseph, Dean 
Franklin and James, 2004; Maywald et al., 2004; Badiani et al., 2017; 
Bramley, Innes and Dass, 2018), or patients (consumers) as well as clinicians 
(Melnyk, Shevchuk and Remillard, 2000).  
Finally, despite studies using survey methods, only five studies used a 
multicentre design, to help aid recruitment, reduce bias and ensure a more 
representative sample (Bramley et al., 2009; Frost Widnes and SchjØtt, 2009; 
Bramley et al., 2013; Innes, Bramley and Wills, 2014; Bramley, Innes and 




Discussion of my review of Medicines Information studies 
Despite the limitations seen in current MI service research, it is recognised 
there is now a greater level of understanding on the effect MI services have on 
patient outcome compared to when the last reviews were conducted in 2002.  
An ability to show effect on patient outcome for MI services is important given 
they are under increased pressure (Gabay, 2017; NHS England, 2014).  
Overall, findings from studies asking clinician opinion about the effect MI 
advice had on patients were positive, with reported high levels of clinician 
action subsequent to receipt of MI advice.  MI advice did not always result in a 
direct action but sometimes had other less obvious effects on the clinician; 
using it in their decision-making, sometimes as a check, or to reassure, 
confirm or tell them or others what to do.  In studies seeking patient opinion 
about the effect of MI advice, they reported feeling more confident and 
reassured about their medicines, and were able to discuss their treatment with 
their clinician.  Few (and old) studies looked at impact from the perspective of 
costs saved. Given the continuing cost constraints on health care services, it is 
surprising that no recent studies have looked at costs and value for money.  
However, these positive findings for MI studies need to be interpreted with 
caution due to methodological and study limitations. Firstly, these more recent 
studies report high levels of unknown patient outcome, which seem to 
originate from problems associated with follow up times or the enquirer not 
being in a position to report on patient outcome.  Future studies should 
therefore ideally tailor follow-up time to each enquiry; this then should allow a 
higher proportion of clinicians to accurately report patient outcome.  
Frequently, the enquirer was not the prescriber, with a high proportion of 
pharmacists generating enquiries.  More recent studies may, however, be less 
prone to non-prescriber outcome uncertainty as the role of the pharmacist has 
become more patient-facing and embedded within clinical teams, and thus 
involved in decision-making on patient care.  Notwithstanding this, it is still 
the prescriber who is ultimately accountable for prescribing decisions and 
therefore best placed to describe patient outcome.  It is also likely, at times, 
that the originator of the enquiry may no longer be caring for the patient (e.g. 




views of patients is an alternative, but as yet relatively under utilised 
approach.  Additionally, they can provide insight based on patient perception 
of outcome rather than those of the clinician.  Triangulation studies using 
patient and clinician views on outcome is another, as yet untested way, of 
assessing outcome. 
 
It is understandable that studies have taken a real-world pragmatic approach 
when trying to establish effect on patients, with a variety of measures used to 
report on patient outcome, given it is almost impossible to use empirical 
measures to quantify the effect of MI advice.  Only Melnyk et al., reported 
some of their findings based on objective clinical data, e.g. reduction of blood 
pressure, as a result of MI advice to change an antihypertensive medicine 
(Melnyk, Shevchuk and Remillard, 2000).  Studies used clinician opinion, via 
completion of researcher pre-defined outcome categories, as well as through 
clinician expectation of anticipated patient response or inference that a 
reported action may have had a (positive) effect.  However, pre-defined use of 
such measures limits the usefulness of study findings on MI advice influencing 
patient outcome because respondents were not given free choice in explaining 
outcome or were restricted to theorising outcome.  
As stated previously, rating scales and expert panels have been used in recent 
research in an attempt to provide more robust data on the effect of MI advice. 
However, the way in which these tools have been developed and used needs 
to be considered.  Although work by Bramley and co-authors has used rating 
scales with descriptors of impact (Bramley et al., 2013; Innes, Bramley and 
Wills, 2014; Bramley, Innes and Dass, 2018) these works appear to use non-
validated scales that over represent the choices toward a positive response, 
thus introducing potential bias.  I acknowledge and appreciate that while MI 
advice is unlikely to increase harm, this is not known for certain, and if 
reported, what level of harm this may have caused.  Despite a recent 2018 
study by Bramley et al reporting validation of a modified version of their 
impact rating scale, the level of detail reported on its validation within the 
paper makes it difficult to independently assess the authors’ conclusions 




This review highlights it is difficult to conduct research about the effects of MI 
advice that will capture all relevant patient and clinician outcomes, particularly 
when using a survey, as every clinical situation and MI question is different.   
Thus responses to questions about the desired, perceived or actual outcomes 
will vary as each individual has a different view.  It is also difficult to fully 
determine actual patient outcome as a result of MI advice.  For instance, the 
originator of the enquiry may only see the patient for that snapshot in time 
e.g. when they are seen by a clinician as an emergency, or if they cannot get 
an appointment with their usual doctor, so they are no longer directly involved 
in the patient’s care to the point of knowing the outcome.  Additionally, the 
patient may not consult the same clinician again, or may have a change in 
personal circumstances e.g. move geographical locations. 
Additionally, for some their perception of the outcome of MI advice is often not 
easy to confirm as they may be asking the MI Service the question as an 
intermediary having been asked the question by another clinician e.g. a GP 
asks a community pharmacist or a hospital doctor, or a nurse asks a clinical 
pharmacist.  In other words, the enquirer can be remote from the patient so 
they may not know the actual patient outcome never mind the effect of MI 
advice.  
As highlighted by the Strobach (2015) study, only about half the clinical 
actions were as a result of MI advice as there were other influencing factors.  
This is because there are many other confounding factors that can potentially 
influence the final patient outcome, irrespective of MI advice given. Whilst MI 
advice can play a part in influencing the package of patient care, there are 
likely to be other factors that come into play, which means MI advice is less 
likely to be the major factor shaping patient outcome.   
A limitation of my review of MI studies is that I did not include unpublished 
studies, although it is my view that findings worthy of publication 
would/should be disseminated as such.  I also excluded non-English language 
studies, and I acknowledge this as a limitation, although historically most MI 
Services were in developed countries, so likely to be published in English 




This section has highlighted the problems around terms used to evaluate the 
effects of MI advice, then reviewed the published MI literature relating to the 
effect of MI advice on clinicians and patients, and their methodological 
limitations.  The next section discusses studies that have also attempted to 
measure the impact (effects) of Health LIS services, as they face similar 
challenges to MI services.  To justify my chosen research methods, I have also 
described some of the methods used by Health LIS services to evaluate 
service effect, in the Methodology chapter. 
An overview of studies conducted to evaluate the effects of Health 
Library Information Services 
Health LIS also provide medicines information to clinicians.  They are similar 
to MI Services, but staffed primarily by librarians and non-clinical staff.  Like 
MI Services in the UK, they are NHS funded providers of clinical and 
medicines-specific information to clinicians (Perrier et al., 2014).  Although MI 
Services have links with Health LIS, they are tenuous and there is no formal 
national collaboration.  As is the case for any service, it is essential to 
understand how the services they provide are used and valued by clinicians.  
The impact of various Health LIS has been studied, although I have not done a 
comprehensive review of these studies as it is beyond the scope of my thesis.  
However, several reviews have found, like my MI review, limited evidence of 
impact because of poor study quality (Weightman et al., 2009; Brettle et al., 
2011; Marshall, J. G. et al., 2013; Perrier et al., 2014; Brettle, Maden and 
Payne, 2016).  In the next section, I discuss some of the methodological 
issues and findings of these reviews and a recent study which are relevant to 
my research.  
A systematic review by Brettle et al (2011) considered the methods used in 
published studies to evaluate the impact of Health LIS from 2001 to 2009.  Of 
the 18 studies included, most (n=14) were undertaken in the UK and used 
surveys for data collection with some open ended questions and follow-up 
interviews.  The Brettle (2011) review highlights, as I have for MI studies, the 
difficulties of using quantitative or experimental research designs to evaluate 
the effect of providing an answer to an enquiry.  Further, the authors also 




care as other factors will also play a part, so need to be taken into account 
when interpreting the results of Health LIS studies. 
Comparable to review findings for MI studies, systematic reviews of Health LIS 
impact studies (Brettle et al., 2011; Perrier et al., 2014) also found that a 
wide range of outcome measures were used.  The difficulty in measuring 
outcomes for these services is similar to MI Services as they may not be 
‘immediate, tangible or direct’, which means that demonstrating effectiveness 
or impact is ‘likely to be difficult or complex’ (Brettle et al., 2011).  In fact, 
these reviews acknowledge that it is difficult or perhaps impossible to measure 
a direct impact of Health LIS on patient care. 
A further larger UK study of Health LIS impact by Brettle et al (2016) on 
patients and clinicians used self-administered surveys and semi-structured 
interviews to get a more in-depth understanding of service impact (Brettle, 
Maden and Payne, 2016).  Findings are reported quantitatively based on the 
survey (response rate 43%, n=340), with quotes used from interviews to 
illustrate a point.  Clinicians were asked how they used the information 
provided and the contribution and impact it had on decision-making and 
evidence-based practice.  This was done by providing a pre-defined list, with 
the option to expand their answer and they were also asked about contribution 
to patient care and health care outcomes; the choices were about quality of 
care; service development; CPD; efficiency; and financial or risk management.  
As is the case for some MI studies I reviewed, this paper also suffered from 
the pitfalls of overcomplicated and ambiguous survey design.  Twenty-four 
interviews were also completed and utilised a standard template to summarise 
interview data for each case, although the interview responses and qualitative 
analysis were not reported, apart from a mention that themes could not be 
identified. 
In summary, the impact (effect) of various Health LIS has been studied and 
highlights limited evidence of impact because of poor study quality 
(Weightman et al., 2009; Brettle et al., 2011; Marshall, J. G. et al., 2013; 
Perrier et al., 2014; Brettle, Maden and Payne, 2016).  As a result of these 
clinical librarians have now developed tools to help measure value and impact 




Conclusions and summary of this chapter 
In order to ensure MI Services are fit for purpose, it is important that we try to 
understand how they are used.  In the current economic and evidence-based 
climate showing the value of an intervention or service in the NHS is a priority, 
thus the focus of MI research has now shifted from QA studies, to studies 
specifically designed to evaluate outcomes.  Most of these studies have 
attempted to find out the effect of MI advice on patient outcomes, but as this 
review and others highlight this is unrealistic, as it is virtually impossible to 
directly link patient outcomes to the MI intervention.  Furthermore, the 
majority of studies have provided only relatively superficial findings about use 
of MI advice by clinicians and possible effects on patient care.  Therefore, 
there is plenty of scope for further MI research around the effects of MI 
advice. 
Previous suggestions for future studies, from other authors, have included 
recommendations for independent evaluation of the outcome, such as using 
patient notes or discussion with the enquirer, prescriber or the patient (Hands, 
Stephens and Brown, 2002), however this is unlikely to be practical due to 
time and cost restrictions.  The Hands review (2002) also suggested other 
options for future MI impact studies, including the need for more detailed 
economic analyses, other than costs saved (Kinky et al., 1999), such as cost 
benefit analysis using economic modelling.  However, this type of study is yet 
to be undertaken in the MI field, probably because it requires specialist 
knowledge of health economics, and is likely to be costly and time consuming.  
Further suggestions are made in the Hands review to try to ‘quantify’ the 
impact of MI advice, such as seeking the ‘enquirer’s impression of the service’, 
or asking the views of managers and other users of MI answers.  It is 
noticeable that the authors focus on ways to quantify impact and seem to 
ignore purely qualitative approaches, possibly because qualitative research 
was not as widely recognised in 2002, when these reviews were conducted. 
A limitation of many MI studies, is that a high proportion of respondents were 
pharmacists.  Previously, pharmacists have not been prescribers, so whilst 
they often asked the MI Service the question, they were not necessarily in a 




clinicians and patients.  Future evaluation and/or research could include 
pharmacists who are prescribers, but they need to be routinely recorded as 
prescribers so their use of the MI Service can be evaluated. 
Findings about how MI advice has been used by clinicians and the effect on 
patient care are scarce, which means there is a need for further research 
using appropriate methodologies.  We need to better understand how and why 
clinicians use MI advice to help us better evaluate the effect of MI advice in 
the future to help support service development.  As studies have mostly used 
survey methodology with pre-defined items, research about how MI advice 
influences clinicians in their decision-making and patient care are lacking.  
Future research needs to be well-designed with questions, methods and 
content closely linked to the original research aims and objectives, perhaps 
linked to specific enquiry types and clinicians.   
 
Suitable patient and clinician outcome measures could be better defined 
through more in-depth research, for example interviews to understand how MI 
advice is being used.  The content of self-administered surveys could then be 
appropriately developed to incorporate the findings, piloted and validated. 
Lastly, use of expert panels, rating scales and outcomes need to be further 
developed and tested for reliability and validity from those scales that already 
exist.  Methods to gain consensus regarding development of content, such as 
Delphi technique (Bryman, 2016) could be used to inform survey content. 
Health LIS have experienced similar problems to MI Services when trying to 
evaluate impact and value and suggest conducting face-to-face or telephone 
interviews to gain a deeper understanding of their service or to supplement 
data obtained via surveys with interviews as they will provide the explanation 
of “how” and “why”.  
In this background chapter, I have put into context the difficulties faced by 
primary care clinicians when they need to address a MRP, particularly for 
increasingly complex patients.  They have access to a wealth of digital 
information but limited time and skills to access it, meaning they seek help 
from specialist services.  Research from both the MI and Health LIS field has 




with limited success.  MI advice does contribute to patient outcome although 
determining to what extent is difficult due to limitations in study design and 
data capture.  From my review of MI studies, very little is known about how 
clinicians use MI advice in their decision-making and patient care.  There are 
no studies which attempt to gain a deeper insight into the effecst of MI advice.  
These studies could be used to help inform further research into the effect of 
MI service advice and the purpose of my study is to address this gap.   
The aim of my study was to better understand how primary care clinicians use 
MI advice.  More specifically the objectives were to explore how MI advice 
influences prescribing clinicians in their decision-making, and how they think 
advice subsequently affects patient care.  In the next chapter, I explain my 





Chapter 3 Methodology 
Introduction to this chapter 
This chapter explains the methodology I used to explore the aim of this 
research, which was to better understand how primary care clinicians use MI 
advice. This chapter is subdivided into sections where I provide my rationale 
and explain the research process I undertook based on my theoretical 
perspective and epistemology, including my choice of methodology and 
methods. 
The study objectives, which were to explore how MI advice influences 
prescribing clinicians in their decision-making, and how they think MI advice 
subsequently affects patient care. The research design is influenced 
deductively in the first instance based on the key concepts explored in the 
literature review. The themes then evolved during the process of analysis on 
the basis of the evidence gathered.  Taking an idealist approach and using a 
generic qualitative, interpretive exploratory methodology, I chose to do 
qualitative interviews with prescribing clinicians.  All interviews used the 
Critical Incident Technique (CIT) and explicitation, based on a specific MRQ 
they asked the MI Service.  Firstly, telephone interviews were done nationally, 
then in-depth face-to-face interviews were done in one region in England. 
Finally, in this chapter I discuss my analytical process, my ethical 
considerations and how I ensured the credibility (validity) and dependability 
(reliability) of my research. 
My choice of research paradigm  
I will now discuss my thinking and rationale for choices behind each element 
of my chosen research paradigm (Crotty, 1998).  Prior to starting this 
research I had a more ‘realist’ ontological approach, in that my belief was that 
reality exists independently, is objective and that quantitative data can be 
collected to represent it (Giacomini, 2010), and is certainly the premise for the 
design of randomised controlled trials and the evidence-based medicine 
paradigm, which has a large following in the field in which I work.  This 




However, I realised that the research position and methods used thus far to 
study the effect of MI advice on prescribers and patient care were not suited 
to understanding how MI advice is used.  Also, I was more familiar with 
applied rather than pure research, since applied research is used to address a 
practical problem and resonates with my real-world, logical approach and 
pharmacy training.   
As a pharmacist I am from a more traditionally science-based, positivist 
epistemological background, however the nature of this research required 
exploration of methodological areas that were unfamiliar to me.  As my aim 
and objectives were to explore how clinicians use MI advice in their decision-
making around prescribing and patient care, I was seeking to interpret the 
social world (Higgs, 2001) and attempting to do research that did not ‘focus 
primarily upon the identification and explanation of facts, but upon the 
illumination of peoples’ interpretations of those facts’ (Porter, 2000, p141).  In 
contrast to my previous positivist perspective, this encompasses an 
interpretive, constructivist paradigm, which uses qualitative research methods 
(Bryman, 2016).  I realised I needed to not only be aware of, but to explain 
and justify my ontological and epistemological perspective regarding how I see 
the world, my research approach and how I collected and interpreted the data. 
From an ontological perspective my views sit on the spectrum between ‘realist’ 
and ‘relativist’ (Giacomini, 2010).  As others explain, as humans we are 
situated in a reality which is constructed by our subjective experience, this 
means we are incapable of total objectivity (Crotty, 1998; Ratner, 2002).  
While, I believe that subjective meanings are crucial to gain an understanding 
of how things work in everyday life, I adopted an ‘idealist’ approach, which I 
felt was suited to my research design as this approach values subjectivity, 
particularly that of the researcher and participants, but to a lesser extent than 
a relativist one (Green and Britten, 1998; Given, 2008).  Since all clinicians 
have their own way of finding, interpreting and using information about 
medicines for and with their patients, I wanted to understand their 
perspective.   
I was aware that my background as an MI pharmacist and partial-insider 




this in more detail later in this chapter.  I also realised that as an experienced 
MI pharmacist providing advice to clinicians and their patients, there are many 
perspectives, experiences and influencing factors to consider when making 
treatment decisions and using information and knowledge to care for patients.  
This research attempts to understand how clinicians use MI advice, and 
therefore my epistemological position is that the social world is complex, 
meaning that to understand this knowledge I needed to be aware that there 
are multiple versions of reality and truth. 
Justifying my choice of methodology 
I took a pragmatic stance as my view was about getting the research done 
(Guest, MacQueen and Namey, 2012) and adopted a generic qualitative, 
interpretive exploratory approach (Clifford, 1997; Caelli, Ray and Mill, 2003; 
Kahlke, 2014; Auta, Strickland-Hodge and Maz, 2017). As my research aim 
was to understand how clinicians use MI Service advice in the clinical setting.  
my research was ethnographic in nature because I wanted to understand how 
clinicians use MI advice in practice and used interviews to collect data 
(Creswell, 2013).  
In addition, my research was aligned towards a phenomenological approach as 
I wanted to understand the subjective views of clinicians, including their 
perception and feelings about how they used MI advice (Clifford, 1997; Guest, 
MacQueen and Namey, 2012; Neubauer, Witkop and Varpio, 2019)  While this 
approach captures the ‘lived experience’ of a particular event (Gray, 2014), I 
felt it was not appropriate as the researcher needs to ‘bracket’ their own 
understandings and allow the phenomena to ‘speak for themselves’ (Gray, 
2014).  As an MI pharmacist, I was a partial-insider researcher (Costley, Elliott 
& Gibbs, 2010; Greene, 2014), doing research about how clinicians use MI 
advice as I was using my MI background to question clinicians and interpret 
their responses.   
I also needed to consider my position as an insider researcher and how this 
could affect data gathered and thus the analysis (Greene, 2014).  Although 
this was insider research, the degree of such can be considered on a 




I was not a prescribing clinician.  Nor was I employed as a practising MI 
pharmacist during the final analysis and discussion of these findings, as such 
my role was one of a partial-insider (Greene, 2014).   
Finally, my research uses elements of a modified Grounded Theory (GT) 
approach, particularly in the stage of analysing the evidence.  I used a 
constant comparative analysis which was iterative, inductive, complex and 
time-consuming, and during the evidence collection I tried to do some ongoing 
analysis to inform refinement of my interview questions (Glasser BG and 
Strauss AL., 1967; Clifford, 1997; Charmaz, 2006; Corbin and Strauss, 2008; 
Guest, MacQueen and Namey, 2012). When I set out to explore use of MI 
advice, my research question was developed after reviewing the literature, yet 
my research design was iterative in nature as I gathered evidence which I 
analysed inductively, linking my findings back to the existing literature 
(Charmaz, 2006).   
A generic qualitative, interpretive exploratory approach (Caelli, Ray and Mill, 
2003; Kahlke, 2014; Auta, Strickland-Hodge and Maz, 2017) was appropriate 
as my research question was borne out of my practice experience as an MI 
pharmacist and I wanted to understand how clinicians used MI advice in their 
decision-making and patient care (Kahlke, 2014).  As such the research 
framework links with clinician use of MI Services, decision-making and patient 
care.  I explain the boundaries of this research and the ethical implications of 
not using a specific methodology in the section ‘my reflexive approach to this 
research’ (Kahlke, 2014).  On the basis of this methodological approach, I 
justify and discuss the methods I chose to carry out this research. 
Justifying my choice of method 
I decided to select prescribing clinicians in primary care, rather than all 
clinicians as participants because government health policy has increasingly 
required patients to be managed in primary care (NHS England, Royal College 
of General Practitioners, and Health Education England, 2016).  With this 
expansion of clinical service provision in the primary care environment further 
emphasising the need to explore how these clinicians use MI advice in their 




increasing prescribing pressures, as their roles are changing to include 
management of more complex patients that historically would have been 
managed in secondary care.  For these reasons I chose primary care clinicians. 
I targeted prescribing clinicians who could be easily recruited via the MI 
Service enquiry database (MiDatabank®) (CoACS Ltd, 2014), at the time this 
study took place, which meant selecting GPs and dentists as MiDatabank® did 
not capture those other primary care professions allied to medicine with 
prescribing rights (e.g. nurses and pharmacists). I chose purposive sampling 
to enable clinician recruitment at the time they contacted the MI Service 
(Gray, 2014).  This sampling was based on the principles of maximum 
variation sampling (Bryman, 2016), as all GPs and dentists in England and 
Wales who contacted participating regional MI centres with a patient-specific 
MI enquiry were included.   
Initially, all regional MI centres in England and Wales were invited to 
participate and recruit as many potential participants as possible.  A total of 
eight (from a maximum of 12) regional MI centres in England and Wales 
agreed to participate.  MI staff were instructed to ask all GPs and dentists who 
contacted their centre with a patient-specific enquiry if they were willing to be 
involved in the study and interviewed by telephone.  Patient specific MRQs 
received and answered by all trained staff working for the MI Service, usually 
pharmacists and technicians, were eligible for inclusion.   
In addition, all types of MRQ were included, by this I mean those questions 
about administration and dose; adverse effects; availability and supply; 
pregnancy and breast feeding; choice of therapy; complementary medicines; 
identification; interaction; and pharmaceutical.  This maximum variation 
sampling also meant a diverse range of MRQs were available to help me 
identify patterns in the data (Gray, 2014).  This sampling method ensured all 
patient specific MRQs were eligible for inclusion.  Multiple MRQs from a single 
clinician were also included, as my study was about understanding how the MI 





As per usual practice, all MRQs and associated relevant details, including the 
work done by MI staff to answer the clinicians’ questions and the advice 
provided, were saved on MiDatabank®.  These MRQs were also coded with a 
complexity level by the staff member answering the question, based on the 
question asked, clinical situation, the search, critical thinking required and 
answer. All complexity levels were included. Please refer to Appendix 3 for a 
full description of UKMI Service enquiry levels 1 to 3.  
For data collection, I thought that interviews would be a possible qualitative 
method to use, as this study was about clarifying and understanding clinician 
use of MI advice and getting their perspective, and interviews are useful for 
understanding the meaning of the world in which people live (Kvale, 1996).  I 
anticipated that numbers of clinicians available for interview would be low 
compared to those who initially expressed an interest to participate.  
Therefore, for a range of clinicians and their perspectives, prescribers 
throughout England who contacted MI Services with a MRQ were recruited for 
interviews.  As clinicians were geographically spread, interviews by telephone 
were approved by the University of Wolverhampton Ethics Committee 
(Appendix 4).   
These semi-structured interviews were conducted by myself, as the research 
lead, and three final year pharmacy students from the University of 
Wolverhampton, selected by senior staff as academically able students (grades 
over 65% and on track to get a 2-1 or above). 
There has been much debate around qualitative interviews, particularly the 
pros and cons of telephone versus face-to-face (Bryman, 2016; Oltmann, 
2016).  However, qualitative interviews via telephone have become more 
common, and as Oltmann explains some authors have found they produce 
comparable results to face-to-face interviewing (Oltmann, 2016).  Yet rather 
than trying to justify that telephone interviews are comparable to face-to-face, 
I agree with others in that they have their “own unique merits” (Oltmann, 
2016; Vogl, 2013).  That is, I considered both interviewer and respondent 
contexts for telephone interviews (Oltmann, 2016) and I felt they were 




intrusive, more convenient for clinicians, and easier for all to schedule/ 
reschedule if required.  
In this study, the interviews over the telephone provided a good insight into 
how clinicians said they used MI advice, however I felt that there was potential 
to expand on the telephone interview findings and try to understand in more 
detail, how they used MI advice in their decision-making and patient care.  
Thus, I felt I needed to conduct more interviews to expand on my findings 
from the national interviews.  
Also, as the interviews by telephone included all MRQ complexity levels, the 
simpler (Level 1) MRQs were not addressing the research question in enough 
depth.  As such, the more in-depth, face-to-face interviews excluded Level 1 
questions and recruited clinicians who asked the more complex MRQs.  The 
rationale being that more complex questions potentially require more complex 
decision-making and patient care.   
I decided to do these interviews as face-to-face to allow for more in-depth 
probing, by myself as an MI practitioner.  Face-to-face interviews would also 
allow me to pick up on any non-verbal behaviour.  For these face-to-face 
interviews, I used the North West regional MI centre in Liverpool to recruit 
clinicians, as it was the MI centre where I was based and more practical for 
me to travel to do interviews within this region.   
In this study all interviews (telephone and face-to-face) used the Critical 
Incident Technique (CIT) and explicitation, as techniques to help the 
interviewee recall the MRQ and what happened when they contacted the MIS 
(Flanaghan, 1954, Urquhart et al, 2003).  Interviewees were asked to put 
themselves ‘back in the situation’ and tell the interviewer what they did 
regarding the MRQ they asked (Flanaghan, 1954). They were reminded of 
their MRQ when they called the MIS to try to get interviewees in a state of 
‘evocation’ and help them recollect what happened at the time rather than 
giving an account of what they thought the interviewer wanted to hear 
(Urquhart et al, 2003).  To do this I used ‘what’ and ‘how’ questions which 
asked about ‘the last time they sought MI advice’.  Clinicians were asked to 




specific MRQ by referring back to the question they asked and advice that was 
provided to prompt their recall. The premise behind incorporating these 
approaches in my interviews was to try to get accounts of what happened 
when they sought MI advice and how they used it.   
This methodology is now being advocated by the Health LIS for evaluating 
clinical librarian services as they explain how these techniques require ‘users 
to provide details of specific use and then answer questions relating to this 
particular instance’ (Library and Knowledge Services, 2018 – see Critical 
Incident Technique).  These techniques have also been used in other studies 
of clinician prescribing, information seeking and decision-making. (Brettle et 
al., 2011; Library and Knowledge Services, 2018).   
The CIT has been used in interviews to try and understand tasks e.g. in 
pedagogic research to understand thought processes that were considered 
impenetrable and to provide insight into learning processes, to understand 
information seeking and human-computer interaction.  The review by Brettle 
found that using ‘CIT can highlight positive impacts of the contribution of 
clinical librarian services’ (Brettle, 2011, p20). It is a technique which helps 
investigation of introspective processes and encourages the interviewer to be 
impartial and not to judge the interviewee and so I felt they would be useful in 
my interviews with clinicians. 
As part of the process of justifying my chosen method, I reviewed the 
methods used in studies that also explored clinician prescribing behaviour, 
information seeking and decision-making.  I found that studies with GPs in the 
1990s used semi-structured interviews to explore prescribing behaviour 
(Bradley, 1992; Armstrong, Reyburn and Jones, 1996).  The Bradley study 
also used CIT, which has subsequently been used to assess performance in 
professional practice, the prescribing decisions of doctors and in information 
behaviour studies in the health sector (Bradley, 1992; Sharoff, 2008).  More 
recent studies of GP prescribing have used semi-structured interviews (Grant, 
Sullivan and Dowell, 2013) and interpretive, thematic analysis (Grant, Sullivan 





When making the decision to use telephone and then face-to-face interviews, I 
considered using focus groups and clinical vignettes as they are an effective 
means of evaluating treatment decisions made by GPs (Peabody et al., 2004; 
Moen et al., 2010; Smith, O'Kelly and O'Dowd, 2010; Luijks, H. et al., 2015).  
While focus groups are useful as a means of exploring issues and collecting 
qualitative data, they are essentially group interviews, so were not suitable 
because I wanted to know about use of MI advice by a single clinician for a 
patient specific MRQ, which did not require group discussion.  A more recent 
study used focus groups with clinical vignettes to try to understand how 
doctors make prescribing decisions (Sinnige et al., 2016) and I did 
contemplate constructing clinical vignettes based on a range of MRQs but felt 
it would probably be difficult to get clinicians to spend their valuable time 
discussing hypothetical scenarios not directly relevant to their individual 
practise (Bryman, 2016).   
Finally, field study observation of clinicians using MI advice was a possible 
option, but would have necessitated being in clinical practices during 
consultations, or videoing consultations and so I decided this was not 
appropriate for my study as MRQs requiring MI advice were not likely to occur 
in every clinician-patient consultation and observation would not capture the 
non-verbal decision-making process.  Also my presence during in the 
consultation would have undoubtedly influenced clinicians to behave differently 
(McCambridge, Witton and Elbourne, 2014) and the effect of MI advice would 
not be seen immediately during the consultation.  Potentially, this method 
would be useful for another study if we wanted to understand how clinicians 
handle MRQs during consultations, rather than how they use MI advice. 
Interview questions were devised empirically to try to understand what 
clinicians did (if anything), prior to contacting the MI Service, what they did 
after getting MI advice and what happened to the patient.  I also wanted to 
understand how they used MI advice in their decision-making process and its 
influence on their decision-making, how they used it in patient care and 
whether the problem was resolved.  For the interviews by telephone, an 
introductory script and semi-structured telephone interview guide were used, 




permitted additional questioning and/or probing relevant to the research aim 
and in response to the answers given by the interviewees.  
Along with some basic participant demographics obtained during recruitment 
or at interview, clinicians were asked about their use of the MI Service by 
focusing on the MRQ asked.  The questions used, with suggested prompts are 
listed in Table 3.1 (see Appendix 5 for a full copy of the interview guide and 
introductory script).  N.B. The highlighted section in the interview guide is to 
give an example of how the questions compared with those used for the 
interview conducted face-to-face.  
These semi-structured interviews were conducted over the telephone by 
myself, as the research lead, and three final year pharmacy students. The 
students were used to improve research capacity and enable more interviews 
to be conducted and were included in the ethics approval.  The final year 
pharmacy students also needed to carry out their own final year research 
projects, which were also submitted separately for university ethics approval.  
With training, they did some of the telephone interviews with my help and 





Table 3.1 Telephone interview questions and suggested prompts 
• Before contacting the MI Service did you consult anyone else/any information sources? 
• If Yes, who did you ask?  
Researcher Note: Ask about company/other health care professionals. e.g. colleague, GP, community 
pharmacist, PCT pharmacist) 
• If Yes, what information sources did you use?  
Researcher Note: Ask about books/websites etc.  
 
• What prompted you to call the Medicines Information service?  
Researcher Note e.g. Used MI before and found it helpful/Found conflicting information and not sure 
what to do/ No time to look into, so thought I’d call you/computer warning/Someone else asked me a 
qu/No in BNF/Letter from Specialist 
 
• Did the answer provide you with enough information to make a decision about how to 
manage your patient?    
Completely/Partly/Not at all 
• If Completely, why?  • If Partly/Not at all, why not? 
• On a scale of 1 to 5, where 1 is “not very helpful” and 5 is “very helpful.”  Overall, how 
helpful was the information in deciding how to manage the patient? 
 
• What action did you take as a result of the advice provided by the Medicines 
Information service?  
Researcher Note e.g.  Choice of therapy: Started drug X/referred to specialist.   
ADRs: stopped drug X/started drug X 
Dose & Administration: Changed dose A of drug X to Dose B of drug X.  Changed drug X from route A to 
route B 
Interactions: stopped drug X and started drug Y.  Pregnancy: stopped drug X/started drug Y 
Breast feeding: stopped drug X/started drug Y 
 
• What influence did the advice provided by the Medicines Information service have on 
your decision?  
• What other issues did the Medicines Information service make you aware of (if any)?  
• What other factors did you consider to help you make your decision?  
Researcher Note e.g. drugs tried already/co-morbids/patient circumstances/patient 
discussion/colleague advice. 
 
• What happened to the patient as a result of the advice provided by the Medicines 
Information service?  
Researcher Note e.g. Choice of therapy: patient took drug & condition improved.  ADRs: resolved/still 
present/too soon to say 
Dose & Administration: Stopped/started drug X & condition improved. Interactions: Switched to drug X 
& condition improved 
Pregnancy: pregnancy ongoing & condition improved. Stopped drug X/started drug Y & pregnancy going 
well 
Breast feeding: still able to breast feed and condition improved 
 
• Overall, what effect did the MI advice have on the care of your patient? 
 
• Is the problem still ongoing? 
a. If Yes, what have you done since to manage the problem?  
b. Did you get any subsequent information/advice?  
c. Where did you get any subsequent information/advice? 
 
Researcher Note: e.g. company/books/website/colleague/GP/hospital consultant/community 
pharmacist/PCT pharmacist/website  
 
• What information/advice did you get? 








Eight regional MI centres initially agreed to participate in national recruitment 
of clinicians for interviews, one centre did not recruit any clinicians.  Of those 
clinicians, that were eligible to participate (n=181), over three quarters (78%, 
n=142) provisionally agreed to be interviewed.  Forty-three telephone 
interviews with clinicians were completed by myself (n=17) or one of the three 
final year pharmacy students (n=26), which was just under a third (30%) of 
clinicians who originally agreed to be contacted.  Although, three interviews 
were excluded (two were inaudible and one because it transpired they were 
not a prescribing clinician).   
As discussed earlier in this chapter, although findings from the telephone 
interviews provided valuable insight into how clinicians used MI advice, I felt 
that there was the potential to further understand, in more detail, how they 
used MI advice in their decision-making and patient care.   
For the more in-depth face-to-face interviews, a further semi-structured 
interview guide was developed based on my experience of conducting the 
interviews by telephone, to try to elicit additional detail about how they used 
MI advice, by focussing on the more complex (Level 2 and 3) MRQs and to 
hopefully expand on the findings and themes obtained thus far.  A protocol for 
further interviews to be conducted face-to-face was approved by the 
University of Wolverhampton Ethics Committee (April 2014) (Appendix 6). This 
enabled additional questions to be asked, according to participant responses 
and was flexible, so questions could be omitted if the clinician had already 
provided responses which a question addressed.   
The questions used in the interview guide are listed below in Table 3.2. N.B. 
The highlighted section in the interview guide is to give an example of how the 
questions compared with those used in the telephone interviews (see 
Appendix 7 for a full copy of the interview guide).  Prior to the tenth interview, 
I amended the interview guide to prompt more specifically about why they 
called MI for advice i.e. “at what point were you prompted to call?” The 
rationale for this change was because I did not feel clinicians were describing 




Table 3.2 Face-to-face interview questions and suggested prompts  
PART I: Recent medicines case and MI advice 
• Tell me what happened in this case about [insert title of MRQ here…………] 
Additional questions: 
• What prompted you to call?  
• How did you use our advice? 
•  
•  
• How did this advice affect your decision-making?  
Prompts: 
o Explain how you decided what to do next/about [……………….]?  
o What (else) did you do after getting MI advice? 
e. g. patient discussion/colleague discussion/record in patient notes 
• How did you feel after getting our advice? 
• What happened with the patient? 
Prompts: 
o Describe how you used our advice with this patient? 
N.B. Explore effect of advice on relationship with patient/use in shared decision-
making. 
• If you hadn’t called MI for advice, what would you have done? 
i.e. how do you think you would have sorted the problem out? 
PART II: Questions around key themes from phone interviews 
Risk 
• Other prescribers have described how they used UKMI advice to minimise risks to 
themselves and/or their patients. What do you think about this? 
Use of advice for reassurance/to confirm thinking 
• Other prescribers have described how MI advice reassures them and/or helps 
confirm what they were thinking when they were unsure what to do. What are 
your thoughts on this? 
Practising evidence-based medicine 
• What does EBM mean to you? (link with patient care) 
• Tell me about sources of medicines advice you use 
• Tell me how you ensure you practice EBM 
• How does MI advice fit with this? 
Practical/timely advice 
• Other prescribers have described the practical nature of MI advice. What do you 
think about this? 
• Other prescribers have described the timely nature of MI advice. What do you 
think about this? 
Clinical decision-making 
• Tell me how you generally make clinical decisions about medicines? 
Prompts: 
 o Please explain your thought processes 
 o What else do you do? 
 o What factors do you consider? (e.g. previous cases seen; experience; 
weighting; time) 
Repeat users only: Describe how MI advice fits into your clinical decision-making 
Prompts: 
o What else do you do? e. g. discussion with GP colleagues/hospital specialist 
o What happened in another case that you can remember? 
Patient care: (Repeat users only) 
• Explain how MI advice influences your patient care? 
• Tell me a bit more about how you use MI advice with your patients  
• In your opinion, how does MI advice impact on patient outcomes? 
Prompts 
o What happened in another case you can remember? 
o Give some examples of patient outcomes 
o What do you discuss with them? e g. What do you tell them about our 
service? 
MI Service 
• Repeat users: When do you tend to contact us for advice? 
• First time users: What triggered you to contact us? (if not fully explained in Part 
I) Why have you not used us before? What would happen if you couldn’t get MI 
advice? Please tell me anything else you would like to raise about this topic that 




Clinicians were recruited prospectively during the periods November 2011 and 
March 2012 (telephone interviews) and May 2014 to April 2015 (face-to-face 
interviews).  The contact details of those clinicians who agreed to participate, 
along with the MRQ asked and the advice provided, were recorded on a 
spreadsheet by the MI pharmacist who received the enquiry.  For interviews 
by telephone, details were collated by each regional MI centre (Appendix 9) 
recruiting clinicians and emailed securely by a nominated person to myself as 
the lead investigator, using NHS net to ensure participant confidentiality.  All 
spreadsheets were stored securely and only accessed by MI staff who needed 
to input the details of clinicians and their MRQ.   
All clinicians who provisionally agreed to be interviewed were then contacted 
by myself via e-mail, with details about the study, including an information 
sheet explaining the research aim and what would happen if they decided they 
were happy to do an interview and be involved in the study (See Appendix 10 
for a copy of the Information Sheet for the telephone interviews, and Appendix 
11 and Appendix 12 for a copy of the Participant Information Sheet and 
Participant covering email for the face-to-face interviews).  Clinicians were 
asked to select a suitable date and time to be interviewed and on the pre-
agreed date and time they were contacted by telephone to do the interview, 
although if it was no longer convenient another date was arranged.  For those 
interviews that were face-to-face, clinicians were reminded, by email or 
telephone, of the pre-agreed date and time and if necessary the meeting was 
rearranged. 
All interviews were done at a time and location which was convenient for the 
clinician, usually after morning or afternoon surgery in their consultation 
room, clinic or office.  Most of the face-to-face interviews were conducted in 
the GP/dental practice (n=11) after surgery hours.  One face-to-face GP 
interview was after a morning hospital dermatology clinic, as they were a GP 
with a Special Interest (GPwSI).  Another GP was interviewed early one 
morning in their home, as this was convenient for them and another at a 
prison, before they started an evening shift there.  One dentist interview took 
place at lunchtime in a local café, after they had finished for the day, as there 




For all interviews, clinicians that failed to respond to the initial e-mail 
invitation were sent up to two reminder e-mails at least 7 days apart 
(maximum time between e-mail 1 and 2 was 21 days and maximum time 
between email 2 and 3 was 26 days), then telephoned if no reply was 
received.  Non-respondents were then deemed lost to follow-up.   
Immediately before each interview (telephone and face-to-face), the identity 
of each participant was confirmed, they were reminded of the purpose of the 
study and consent verbally confirmed prior to beginning the interview.  All 
interviews were audio-recorded using a digital voice recorder (Olympus VN-
731PC). The voice recorder was switched on and checked to ensure it was 
recording (red light visible).  A telephone pickup inner ear system (Olympus 
TP7), enabled both the voice of the interviewee and interviewer to be recorded 
during the telephone interviews.  In the face-to-face interviews, the recorder 
was placed in between the interviewee and interviewer, although interviewees 
did not appear to be concerned about the presence of this device during the 
interview conversation and seemed to forget it was there (Gray, 2014; 
Oltmann, 2016; Bryman, 2016). 
All interviews were transcribed verbatim (pauses/non-verbal communication 
were not recorded), either by myself (telephone interviews) or using a 
professional transcriber (face-to-face interviews).  I checked each transcript 
against the audio to ensure each interview was correctly transcribed and to 
check technical terms.  Consistent with the processes of ATA and GT, where 
possible each interview was coded before the next interview to allow alteration 
of the interview guide and to ask clinicians about new themes.  However, 
coding each interview before the next was not always practical due to 
insufficient time before the next interview was scheduled.  As a part-time PhD 
student, interviews and preliminary analysis were done on my days off i.e. 
outside of my MI work time.   
In summary, the findings of my literature review shaped this research into 
being qualitative and exploratory in nature, where previous studies exploring 
the effects of MI advice on clinicians and patients had methodological 
limitations and minimal findings.  To better understand how primary care 




subsequent patient care, I took an interpretive, idealist perspective and used a 
generic qualitative, interpretive exploratory methodological approach.  I 
recruited prescribing clinicians nationally for interviews by telephone and then 
did more in-depth interviews as face-to-face, recruiting clinicians in one region 
in England.    
My ethical considerations during this study 
There were various ethical dilemmas which I needed to consider prior to and 
throughout my research.  Firstly, I needed to consider the effect of my 
research on all those involved; including the clinicians, the MI staff who helped 
recruit potential participants and also on myself.  I also needed to think about 
any issues regarding the involvement of the final year pharmacy students who 
physically helped me by doing some of the telephone interviews.  Secondly, I 
also needed to consider the ethics regarding the fact that as MI pharmacist, 
I was an insider researcher doing the interviews.  Finally, I needed to ensure 
the safety and confidentiality of the data once I had collected it, its storage 
and how I would use it in my analysis and within my thesis. 
For clinicians, the main issues to consider were whether there was any 
potential for causing harm or deception, making sure they could give informed 
consent and ensuring their privacy.  Although my research involved people, 
they were clinicians so I did not consider them to be vulnerable individuals, or 
that I was investigating anything that was likely to give grounds for offence or 
that it would be hazardous to the physical or psychological welfare of 
participants or myself as the researcher. 
However, there was the potential for researcher vulnerability, according to 
interview location, especially for those done face-to-face, if they were not 
conducted in a public place (Williamson and Burns, 2014).   I needed to 
ensure the interviews took place somewhere convenient for the participants 
where we could talk with minimal interruption and distraction.  In some 
instances, the interviews were in a public place e.g. coffee shop but we 
avoided discussion of any identifiers.  Although I did one interview in a GPs 
home, I felt comfortable doing this and ensured others knew where I was.  On 




starting an evening shift at a prison, however I did not feel this was 
appropriate, so this was done in a public waiting area. 
Next for consideration were the ethical issues of utilising staff from the 
regional MI centres to recruit participants.  They needed to know the 
recruitment protocol at the time they received a verbal or written answer to 
their medicines question, but to do so without coercion.  I did this by ensuring 
the MI staff were aware of the study objectives, knew what to say to clinicians 
to get their provisional verbal consent to take part, and were aware how to 
forward clinician contact details to me.  It was also necessary for me to have 
the details of the MRQ and MI advice provided, which meant the practicalities 
of transferring this information to me was also an issue.  Finally, it was 
essential to ensure both the confidentiality of the enquirer, and the anonymity 
of the MI staff receiving and/or answering the question.  To do this, eligible 
enquirers were asked to verbally consent to their details being shared with 
me.  MI staff then emailed a digital copy of the question, research and answer 
from MiDatabank®. The names of MI staff who answered the question were 
removed from this copy, as their personal information was not required. All 
this data was transferred securely via NHS email.  
To help address the ethical issues of avoiding coercion, gaining consent, 
confidentiality and data protection, MI centres were provisionally invited to 
take part via an email sent to the Director of each regional MI centre.  If they, 
in principle agreed, they were sent a copy of the information sheet about the 
study which included my contact details at the university and those of my 
supervisory team (Appendix 10).  Each Director was asked to nominate a lead 
contact at the centre to ensure continuity.  I then emailed each of these lead 
contacts and asked them to confirm they understood the study objectives, 
along with when and how to recruit participants for this national study.  They 
were asked to discuss the study with all MI staff and check all staff handling 
MRQs were able to recruit enquirers appropriately.  Each MI centre was asked 
to agree a start date for recruitment and the nominated lead to email the 
relevant data at agreed times. 
To ensure data protection and confidentiality when receiving the data from 




recorded on a spreadsheet and emailed securely to myself on a weekly basis.  
I needed the details of the MRQ to use as the basis of the interviews 
(telephone) but did not need to know the name(s) of the MI staff 
involved.  To maintain MI staff confidentiality, MI centres were asked to 
download a copy of the MRQ and answer provided from MiDatabank® and 
apart from the clinician’s details, to anonymise it and email it to me securely 
via NHS net.   
Another ethical dilemma was whether to include multiple MRQs from the same 
clinician.  As MI centres have clinicians who use the service on a regular basis, 
it was possible they would be asked to take part in my study on more than 
one occasion, with the potential of causing annoyance if they had previously 
declined.  If they were happy to be interviewed for multiple MRQs, this was 
considered appropriate as the interview was primarily based on how they used 
patient-specific MI advice provided for each MRQ, in their decision-making and 
subsequent patient care.  To keep a track of this, participating MI centres were 
asked to annotate MiDatabank® to indicate that they had asked the enquirer 
and if they had said yes or no about being a study participant; this could then 
be seen by MI staff if the same clinician subsequently contacted the service. 
The next point to consider was contacting the clinicians who had provisionally 
agreed to be interviewed.  I decided that email was the least intrusive, so they 
were contacted by email initially.  A further dilemma was then how often and 
how many times to re-email or telephone them, if there was no response.  
There needed to be a balance between trying to get them to respond without 
seeming to pursue them excessively.  In line with MI policy for contacting 
enquirers during the course of an enquiry, I decided that a further two emails, 
at a minimum of weekly intervals seemed fair.  Then if there was no email 
response, they were contacted by telephone.  If there was no reply they were 
not contacted again and recorded as lost to follow-up. 
According to ethical principles, research participants have a right to withdraw 
from a study at any time.  In my study, clinicians were treated professionally, 
as they would be if they were using the MI Service.  They were advised that I 
was doing the research as part of a PhD with the University of Wolverhampton 




deleted after the research was completed.  My contact details and the details 
of my supervisory team were included in all emails and on participant 
information sheets, in case they needed to ask questions or decided to 
withdraw from the study.  At each stage of recruitment and the interview 
process, reasons for doing the research were clearly explained and they were 
able to withdraw from the research at any time.   
Other ethical considerations were about conducting the actual interviews.  I 
needed to ensure that busy clinicians were aware how long the interview 
might take and who would be doing the interviews.  They also needed to 
consent to the interview being recorded, stored securely and transcribed, 
whilst maintaining their confidentiality.  They were informed of this in the 
emails they were sent and consent was gained verbally just before the 
interviews by telephone, or by signing a consent form just before the 
interviews done as face-to-face. 
I also had to think about the ethical issues of using the final year pharmacy 
students to help me with the interviews done by telephone, the potential risk 
to them and the participants.  They needed to know about being polite and 
professional and maintaining confidentiality.  Clinicians were told they were 
being interviewed by a pharmacy student. The final year students were trained 
(see the section on ‘Steps taken to ensure rigour in this research’) to do the 
interviews and supervised, by myself as the researcher and they had an 
introductory script to follow.  If the interview discussion became difficult they 
were able to transfer the telephone interview call to me.    
Another issue was the need for participants to know that I was an MI 
pharmacist as well as the researcher, rather than hiding the fact (see the 
section ‘My reflexive approach to this research’).  Throughout the recruitment 
and data collection for all interviews, participants were made aware of my role 
as the researcher and an MI pharmacist. 
My next concern was for the safety and confidentiality of the data once I had 
collected it.  Participant details were collated on a spreadsheet, stored securely 
and password protected.  Interview data were audio-recorded, transcribed and 




securely stored on the voice recorder, uploaded as soon as possible onto a 
password protected computer and transcribed verbatim.  Interviews were 
deleted off the recorder after uploading and checking.  All interview data were 
anonymised by assigning a unique identifier to each transcript and password 
protected in NVivo (versions 8 and 10, QSR International Pty, Warrington, 
UK).  As the researcher, only I had access to the all the data. The three 
pharmacy students had access to data for the telephone interviews only.  The 
confidentiality and anonymity of clinicians and MI centres involved were 
considered during the publication of any papers and in writing this thesis.  Any 
identifiers, such as names and places were removed, with each MI centre 
identified by a unique code, known only to myself as the researcher. 
Finally, as part of the research ethics process, it is an important requirement 
to get approval from the appropriate ethics committees to ensure all ethical 
concerns have been considered.  When I began this research (in 2010) there 
was a requirement to seek NHS research ethics committee (NREC) approval 
for research involving NHS staff.  At that time, I was unsure whether 
conducting interviews by telephone with clinicians asking a MRQ, was classed 
as service evaluation, so not subject to National Research Ethics Service 
(NRES) approval.  To clarify this, I emailed the details of my project to the 
local NREC chair and they advised that approval was not required.  For the 
face-to-face interviews, I used the Health Research Authority (HRA) checklist 
(HRA, 2019).  NREC approval was not required for face-to-face interviews as 
there was no direct patient/public involvement and NRES approval for 
conducting research with NHS staff was not required. 
All the interview guides, email invitations, participant information sheets and 
consent forms were developed by myself, and approved by the School of 
Applied Sciences, Life Sciences Ethics Committee University of 
Wolverhampton.  University ethics approval was obtained (April 2011) for the 
interviews by telephone, subject to the participant consent form being 
submitted, making it clearer to participants from the outset that interviews 
would be audio-recorded, and that the findings, but no individual data, would 




also obtained from the University of Wolverhampton for the face-to-face 
interviews (April 2014) (Appendix 6). 
My analytical framework and data analysis 
I analysed all interview transcriptions inductively using applied thematic 
analysis (ATA) and constant comparison, and within the framework of the 
research aim and objectives.  ATA is not new, it is an inductive thematic 
analysis and is described by Guest et al (Guest, MacQueen and Namey, 2012) 
as one which rejects the view that qualitative data can be compartmentalised 
and ATA can use multiple analytical techniques.  It is about trying to 
understand and explain the world in a rigorous, reliable and valid way and as 
such leans towards a positivist/interpretive approach.  ATA blends elements 
from the many analytical methods and techniques.  The view of the authors is 
that the ‘greatest strength of ATA is its pragmatic focus on using whatever 
tools might be appropriate to get the analytical job done in a transparent, 
efficient and ethical manner’ (Guest, MacQueen and Namey, 2012). 
There were forty interview transcriptions (telephone) from 37 clinicians (26 
GPs and 11 dentists), as three interviews were conducted on repeat callers 
who were GPs and a further fifteen face-to-face interview transcriptions (8 GPs 
and 7 dentists).  I immersed myself in the data by reading all the interview 
transcriptions (telephone and face-to-face) several times.  For each set of 
interview transcriptions, the text was analysed by coding each set of 
transcriptions separately. 
First, I coded the telephone interviews inductively.  To ensure a systematic 
approach while coding all interview transcripts, I used constant comparison, 
for example in the telephone interviews, I initially found 8 codes in the first 
interview transcript, the second I added 6 codes, the third a further 7, the 
fourth another 3 and so on.  After coding, I re-checked previously coded 
interview transcripts and added the new codes if appropriate.  A total of 111 
free codes (nodes) were condensed/combined into 13 themes (tree nodes) 
and 64 codes (nodes).  In total 3 full cycles of coding were completed for all 
telephone interviews, with fewer new codes added and only 1 code and no 




I did not have a pre-defined sample size, as I used inductive thematic 
analysis, so stopped data collection when thematic saturation occurred (Guest, 
Bunce and Johnson, 2006; Mason, 2010).  That is, when I thought that no 
new themes relevant to the aim of this research seemed to be appearing in 
the interview data.  For the interviews by telephone, thematic data saturation 
occurred by interview 43, as no new codes were emerging from the data.  
Copies of the codes I identified in the telephone transcriptions along with a 
summary of processes used are shown in Appendix 8: Inductive coding of the 
telephone interviews and then the face-to-face interviews.  I then refined my 
codes and themes so my analysis was focussed and aligned with my research 
aim.   
Initially, I derived the following themes from the telephone interviews; 
Advertising and publicity; Advice; Evidence; Financial; Knowledge; Medicines 
information; Patient outcome; Prescriber action; Prompts for calling MI; 
Referral; Resources; Risk Management; and Time factors. However, after 
coding and doing some analysis of the telephone interviews, I realised that 
more in-depth interviews were required to expand on my initial findings and 
further understand how clinicians use MI advice in their decision-making and 
patient care.  These initial findings were used to develop the interview guide 
for the in-depth face-to-face interviews.  
These face-to-face interviews were also inductively coded using constant 
comparison.  In total 83 free codes (nodes) were condensed/combined into 9 
themes (tree nodes) and 81 codes.  The second cycle of coding found 3 new 
codes in interviews 11 and 12 and no new codes were found in interviews 13-
15. Copies of the codes I identified in the face-to-face transcriptions, along 
with a summary of processes used are shown in Appendix 8: Inductive coding 
of the telephone interviews and then the face-to-face interviews. I then 
started to develop the themes further using the face-to-face interview codes.    
I gradually combined my themes from the telephone interviews with those 
from the face-to-face interviews, using the research aim and objectives as my 
analytical framework and developed a modified set of themes.  To illustrate 
this, copies of several documents showing the gradual process of combining 




interviews) are shown in Appendix 8b.  A transcription of an interview (face-
to-face), from NVivo with coding and themes, is shown in Appendix 8c.   
 
The final themes are shown in Table 3.3.  Themes were eventually condensed 
into wider conceptual themes (meta-themes).  As I combined the themes from 
both sets of interview transcriptions it became apparent that the interviewed 
clinicians described being influenced to seek MI advice by a wide range of 
issues (themes).  It seemed to me that these fell into two major areas, which 
I felt were ‘Domains of MI influence’ and were descriptions around ‘The 
motivating factors for clinicians deciding to seek MI advice’ and ‘The 
consequences of MI advice on clinicians’.  Across all interviews, I found 19 
themes, which I grouped into five wider conceptual meta-themes, also shown 
in Table 3.3. 
During the inductive analytical process, I realised that clinicians interviewed 
were seeking MI advice for two reasons, because they were using MI as a 
‘Safety net’ and as a ‘Medicines help desk’, so these are two of my chosen 
meta-themes.  Similarly, there appeared to be three areas relating to the 
consequences of MI advice on clinicians and I have characterised these meta-
themes as ‘Impact on prescribing’, ‘Impact on patient care’ and ‘Impact on 
feelings’.  
Each meta-theme is described and discussed and their associated themes 
illustrated with quotes taken from across all the interviews (Appendix 16: 
provides extracts from interview transcripts for selected themes).  I have 
added the letter T or F to the interview number e.g. T3 (telephone interview 
number 3) or F5 (face-to-face interview number 5) to enable the reader to 
differentiate between quotes best representing the themes from interviews by 
telephone or face-to-face, from a range of clinicians.  I have also added 
whether the quote was from a GP or a dentist with a brief enquiry title as 





Table 3.3 Inductive interpretation of themes, meta-themes and domains 
identified in the interview data 
The process of induction " The process of induction " The process of induction 
Theme Meta-theme Domain of MI 
influence 
Providing a decision 
Safety net 
The motivating 
factors for clinicians 
deciding to seek 
Medicines 
Information advice 
Confirming a decision  
Shaping a decision 
Clinical knowledge issues 
Technical knowledge issues 
Information resource issues 
Risk and medico-legal back-up 
Expert service 
Medicines ‘help desk’ Trusted service 
Convenience 
Immediate change in prescribing 
Impact on prescribing 





Shift in prescribing practice 
Improving the clinician-patient 
relationship 
Impact on patient care Reassuring patients 
Empowering patients 
Clinical effect  
Feeling reassured  
Impact on feelings 
Feeling empowered 
Finally, I want to explain my rationale for inclusion/exclusion of some of the 
questions from the telephone interviews in this analysis.  To re-iterate, these 
interviews included mostly open questions (Q2-4, 6, 7, 9-14, 16, and 18), 
designed to enable the clinicians to describe how they used MI advice in their 
decision-making and patient care.  Although, some questions asked in these 
interviews are not specifically reported (Q1, 5, 15, 17), they were included to 
help open-up further description of the MRP clinicians were faced with, why 
they decided to contact MI and how they used MI advice in their prescribing 




did you consult anyone else?” was included to help understand their decisions 
and actions prior to using the service and at what point they subsequently 
contacted MI.  Others, i.e. Q8 “How helpful was the information in deciding 
how to manage the patient?”, Q21, 22 are not specifically reported, as these 
were Likert scale questions which with hindsight were really about user 
satisfaction so not wholly relevant to the objectives of this research.  Whereas, 
Question 19 “Did you record the Medicines Information advice in the patient 
notes?” is discussed in the theme: Risk and medico-legal back-up, along with 
supporting quotes from the face-to-face interviews. 
Steps taken to ensure rigour in this research 
It is important in all research to describe the steps taken to ensure rigour and 
trustworthiness regarding validity (credibility) and reliability (dependability).  
Although I found it somewhat confusing as to what guidance I should follow, 
as there has been a great deal of debate over the years and a lack of 
agreement regarding what this should entail for qualitative research. 
In terms of validity (credibility), I needed to ensure internal validity i.e. how 
my research findings match reality, and external validity i.e. the extent to 
which my findings could be replicated to other environments (Bryman, 2016). 
This is perhaps more straightforward in survey research as validity is about 
ensuring the survey instrument measures what was intended.  Whilst in 
qualitative research, validity has been termed ‘credibility’ or ‘truth value’ and 
is about being confident in the truth of study findings and being able to 
understand the context (Lincoln and Guba, 1985; Ulin, Robinson and Tolley, 
2005; Charmaz, 2006).  In doing this research, I have tried to ensure 
credibility by considering each of the questions suggested by Ulin et al (2005) 
as listed below and discuss these next: 
w Has your research achieved intimate familiarity with the setting topic? 
w Are the data sufficient to merit your claims? (Consider the range, number, 
and depth of observations in the data.) 
w Have you made systematic comparisons between observations and 
between categories? 
w Do the categories cover a wide range of empirical observations? 
w Are there strong links between the gathered data and your argument and 
analysis? 
w Has your research provided enough evidence for your claims to allow the 





In the same way as that of quantitative research, where the researcher needs 
to make sure the results are reliable i.e. they are consistent and can be 
reproduced, this also needs to be ensured in qualitative research and is called 
‘dependability’ (Bryman, 2016).  I did this by making sure my research was 
consistent and carried out according to standards of qualitative methodology 
(Lincoln and Guba, 1985; Ulin, Robinson and Tolley, 2005).  I have tried to 
ensure credibility and dependability at each stage of my research by referring 
to the Standards for Reporting Qualitative Research (SRQR) published by 
O’Brien et al (2014) by discussing all methodological aspects of this study 
adequately, appropriately and in a transparent manner.  These main points 
are summarised in Table 3.4 and also discussed in the text after the table. 
The techniques I used to help enhance credibility and dependability are listed 
in Table 3.4.  As part of the research design stage and data collection, for the 
interviews by telephone I explained the research aim and discussed the 
interview questions with the three pharmacy students.  These students also 
visited a local MI centre to help them understand the service.  As the lead 
researcher I completed interview skills training as part of a qualitative 
research methods course (Qualitative interviews skills course 2013, Oxford).  I 
then trained the pharmacy students so they could help conduct the interviews 
by telephone appropriately and they understood the questions in the interview 
guide.  Each of us (myself and the three pharmacy students) did five practice 
interviews over the telephone with academic pharmacy staff (University of 
Wolverhampton), based on example MI questions. This was to ensure we were 
familiar with introducing ourselves, introducing the study to participants, 
gaining consent, the questions, using the audio recorder and ending the 
interview.   I also completed two study days about NVivo (versions 8/10, QSR 
International Pty, Warrington, UK) to familiarise myself with the software, 
which I used to facilitate and organise my inductive analysis of all the 
interview transcripts. 
  






Table 3.4 Techniques used in this study to enhance credibility and 
dependability  














Used interviews by telephone and 
then face-to-face  
Allowed comparison of results for convergence or 
divergence 
Pre-tested telephone interview 
guide with academic staff and the 3 
final year pharmacy students who 
helped me with the telephone 
interviews 
Ensured questions made sense to all doing the 
interviews by telephone, and clinicians 
Reviewed interview guides after 1st 













Trained the three pharmacy 
students in data collection using 
practice scenarios 
Training on purpose of the questions and probing 
techniques improves dependability 
Both semi-structured interview 
guides were designed in-line with 
the study aim and objectives 
 
The guide for face-to-face 
interviews was less structured as I 
was the only data collector 
Increasing the structure of the data collection 
instrument increases ability to compare across 
data collectors i.e. for interviews by telephone 
 
Less structured instruments are good if 
exploratory research with one data collector i.e. 












Developed and used a clear 
codebook during my analysis The codebook helped me find themes in the data  
Created an audit trail Documenting steps in analysis and codebook revisions ensures transparency 
Triangulated data sources i.e. all 
interviews by telephone and face-
to-face  
Convergent data helps validate findings.  This 
was achieved by similar and expanded findings 
across the telephone and face-to-face interviews 
Looked for negative or deviant 
cases during my analysis 
This made me look for findings differing from the 
main findings 
Supported themes and 
interpretations with quotes across 
all the interviews (telephone and 
face-to-face) 
Used verbatim quotes to connect my 
interpretations with what clinicians actually said 
(Adapted from Guest et al 2012 pp99-101) 
For all interviews, protocols were used during data collection, and when the 
final year pharmacy students did their interviews I was present, they were 
able to pause during the interview to ask me questions if necessary and I was 
able to intervene if needed.  We also listened to each other during the 
interview, listened to the audio recording afterwards and then discussed any 
good points and areas for improvement.  No questions were changed for the 
interviews by telephone, but there was flexibility to ask questions based on 
responses and to probe clinicians for more information.   
As previously mentioned, all interviews were digitally recorded, transcribed 




face interview recordings were transcribed verbatim by a professional external 
transcriber (SL Typing Services, March 2019), I then listened to each audio 
and checked the transcribing was correct.  The external transcriber was not 
familiar with all the medical and pharmaceutical terms used, so these were 
corrected by myself, along with anything else that had been misheard or 
misunderstood.  
As I have already explained, both sets of interview transcriptions were 
inductively coded and systematically analysed.   I developed a codebook using 
NVivo 8/10 software to organise the data and assigned codes (See Appendix 
8).  Code descriptions were added for clarity and recall if required.  I also used 
a constant comparative process for coding each transcription and as new 
codes were added I then re-visited the earlier interview transcriptions and 
coded these with the new codes if appropriate.  Then I combined and 
compared findings across all interviews, which was a means of triangulation, 
providing further support for the findings of my research. 
I also revisited my coding and themes after 6 months to see if I agreed with 
my own initial findings.  Coding was reviewed for four of the interviews done 
by telephone, by two of my supervisors, any differences discussed and codes 
amended as needed.  During my analysis I also tried to look for negative or 
deviant cases to minimise data selection bias and the variety within various 
themes (Guest et al 2012).  As previously explained, themes derived from 
clinician descriptions are also supported with quotes from a range of clinicians 
across all the interviews, to help provide a sense of context. 
Nevertheless, I do recognise that there were limitations in my analysis.  In 
some instances, another way to help ensure credibility in qualitative research 
is to carry out ‘member checks’ i.e. a copy of the interview transcript is sent to 
the interviewee for comment.  In this study, it was not realistic to ask 
clinicians to also review transcriptions as they had already given up valuable 
time to take part in the interviews and it was highly unlikely they would do 
this as well.  Finally, while some peer review of my coding of the interviews by 
telephone was done, this was not the case for the other interviews which were 
face-to-face due to supervisory team changes, lack of a suitably experienced 




My reflexive approach to this research 
For this study I used a generic qualitative, interpretive exploratory approach 
(Caelli, Ray and Mill, 2003; Kahlke, 2014; Auta, Strickland-Hodge and Maz, 
2017) and here I explain my reflexive approach throughout this study, the 
boundaries of this research and the ethical implications of not using a specific 
methodology (Kahlke, 2014).  I knew that to practise reflexivity, I needed to 
be critically aware, acknowledge and question the ways my own attitudes or 
beliefs might shape the data collection, analysis and interpretation (Guest et al 
2012).  As such it is important for me to clarify how my qualities, assumptions 
and my role and relationship with participants may have influenced the 
research process (O'Brien et al., 2014).  I will now discuss each of these in 
turn. 
I now realise that it is not possible to be completely objective in qualitative 
research and that subjectivity is embraced (Koch 2004).  Firstly, I 
acknowledge and appreciate that as pharmacist who qualified in 1992, with 15 
years MI experience, including five years as a manager of MI Services, my 
own ontological assumptions and experiences will have inevitably influenced 
the data collection and analysis.  Yet this was helpful in trying to understand 
clinician responses to the questions asked, as I felt able to probe more 
effectively being a fellow clinician conducting the interviews.  This was one 
reason for conducting the in-depth face-to-face interviews myself, as in the 
telephone interviews the pharmacy students sometimes found it difficult to 
gain a rapport with clinicians over the telephone due to their limited 
experience of clinical discussions.  
Secondly, all clinicians who were interviewed were made aware that the 
researcher was an MI pharmacist and for the face-to-face interviews they 
knew that I worked at the North West MI centre, although MRQs I answered 
were excluded.  Thirdly, although the names of some clinicians were familiar 
to me as some of them had used the service for previous MRQs, I did not 
know any of them professionally.  In reality, the relationship between MI staff 
and clinicians was invaluable in recruiting participants who were willing to be 




Next, as stated in my introduction to this thesis, my motivation for this 
research was based on the circumstances I found myself in around the time I 
embarked on this study.  As a senior MI pharmacist I had a role as research 
lead, locally and nationally and I was acutely aware of MI ‘impact’ studies that 
had been completed using unsuitable methodology, with subsequent 
questionable findings.  Also, an element of my research role was to try and 
inspire others to do research, so leading by example was important to me and 
having completed an MSc research project about MI, I wanted to do further MI 
research. 
To further explain my reflexivity during the data collection and analysis 
process, I noted my thoughts, about how I may have influenced interviewee 
responses and/or have been influenced by interviewees themselves and their 
responses.  Although inductive coding is subjective, my analysis was grounded 
in the data and while interviewee responses are also subjective, I conducted a 
systematic constant comparative analysis with development of themes 
supported by relevant, direct quotes from the data. 
As a generic qualitative, interpretive exploratory approach was taken, this 
research was not aligned to a specific methodology.  However, I have been 
transparent by clearly describing how this research was conducted and 
analysed and provided supporting quotes to illustrate the themes and enable 
the reader to review the findings and discussion themselves. 
Finally, it was also inevitable that during the years of doing this part-time 
research, that my supervisory team would change.  In fact the team has 
changed several times which has been rather challenging and disruptive.  My 
first two Directors of Studies (DoS), based in the Faculty of Science and 
Engineering (FSE), both left the team due to retirement.  When my first DoS 
retired, an academic nurse with qualitative research experience from the 
Faculty of Education, Health and Wellbeing (FEHW) joined the supervisory 
team and subsequently became my third DoS in 2015, as there was no 
suitable candidate in the FSE. During this time, the Professor of Pharmacy 
Practice who had been on the team since the outset, moved to another 




Since there was no one with suitable pharmacy academic experience in FSE to 
supervise, I was transferred across to FEHW.  At this time, a further nurse 
researcher joined the team, but left due to illness in July 2017, so now 
another experienced member of FEHW staff, with an education and qualitative 
research background is part of my supervisory team.  Also, as is the nature of 
research, I found doing this study difficult and was perhaps initially somewhat 
naïve in my approach.  This was a qualitative study, although I never set out 
to do a purely qualitative research project, so much of my study design (and 
data collection) was completed before supervisory team members with more 
extensive qualitative research experience were appointed.  Although 
invaluable, this meant they were only really able to advise during final analysis 
and writing up. 
Summary of this chapter 
In this chapter, I have explained my philosophical position regarding my 
knowledge and understanding of the world, as well as why I chose a generic 
qualitative approach.  I explain my use of interviews as my method, how they 
were conducted and my analytical approach using constant comparison for 
coding, and then finding themes in the data.  As a partial-insider researcher, 
to try and ensure rigour and trustworthiness i.e. credibility and dependability 
throughout the research process, I adopted a reflexive, transparent and 
systematic approach throughout the study and during my analysis.  The 
findings of my constant comparative, thematic analysis across all these 





Chapter 4 Findings and discussion  
Introduction to this chapter 
My findings are related to the aim and objectives of this research, which were 
to better understand how primary care clinicians use MI advice; how MI advice 
influences prescribing clinicians in their decision-making; and how they think 
advice subsequently affects patient care.  This chapter begins with an 
explanation of the main characteristics of clinicians interviewed, either by 
telephone or face-to-face; the MRQs which initiated each interview; and the 
interviews themselves.  I then describe and discuss the combined interview 
findings from my inductive thematic analysis (as mentioned in Table 3.3).  I 
have structured this around the meta-themes and domains.  As previously 
mentioned, quotes are referenced with ‘T’ or ‘F’ to indicate whether they relate 
to a telephone or face-to-face interview. 
Characteristics of clinicians, enquiries, and the interviews  
A total of 55 interviews with 51 different clinicians were included in my 
analysis.  Thirty-three were GPs and 18 were dentists.  Thirty were female, of 
these 21 were GPs and 9 were dentists.  Almost all clinicians (n=44, 86%) 
interviewed had used the service previously. This is a potential indicator of 
their prior satisfaction with the service (see telephone interview tool question 
20 / face-to face interviews: pre-interview data collection form Appendix 15), 
although user satisfaction was not an objective of this study, it is perhaps 
reflected in their descriptions of MI Service use.  
There was a broad range of experience regarding number of years qualified, 
ranging from 2 to 40 years, and as such clinician descriptions were not solely 
from those who were less experienced.  Each MRQ asked by clinicians was 
categorised according to the enquiry type(s) based on standard UKMI enquiry 
codes used in MiDatabank®, for example ‘choice of therapy’, ‘adverse effects’, 
‘interaction’ and shows the breadth of MRPs described across all interviews.  
Telephone interview times ranged from 4 - 16 minutes (mean time JR 9 min 9 
sec, students 8 min 43 sec).  However, all clinicians described how they used 
the service, and while a few were brief, the telephone interviews provided 




interview times were longer and ranged from 19 minutes to an hour; nine 
interviews were 30 minutes or more (mean 30 min 45 sec).  Appendix 17 
summarises demographic data from telephone interviews and the medicines 
questions asked.  The same data from the face-to-face interviews are also 
shown in Appendix 18.   
The motivating factors for clinicians deciding to seek MI advice and 
consequences of MI advice on clinicians  
I have structured the findings and discussion around the themes and meta-
themes described earlier (See Table 3.3) and they are now shown in Table 4.1 
Motivating factors for clinicians deciding to seek MI advice and the 
consequences of MI advice on clinicians. Although this table contains the same 
information as Table 3.3, it is included here to show the reader the Domains of 
MI influence, Meta-themes and Themes in the order I discuss them. 
As some of the themes are interlinked, I am going to discuss my findings 
around the framework of answering a MRQ, that is under various 
circumstances clinicians described how they sought MI advice, then how they 
used it to make a clinical/prescribing decision to enable patient care, as 
clinicians described seeking MI advice and using it as a safety net to provide, 






Table 4.1 Motivating factors for clinicians deciding to seek MI advice and 
consequences of MI advice on clinicians  
Domain of Medicines 
Information influence Meta-theme Theme 
The motivating factors for 
clinicians deciding to seek 
Medicines Information advice 
Safety net 
Providing a decision 
Confirming a decision  
Shaping a decision 
The consequences of 




Immediate change in 
prescribing 
Enhancing prescribing  













The motivating factors for 
clinicians deciding to seek 
Medicines Information advice 
Safety net 














Next, I discuss the findings in Table 4.1 that relate to the consequences of MI 
advice on clinicians regarding their descriptions around impact on their 
prescribing i.e. to make immediate changes in prescribing, by enhancing 
prescribing and/or shifting prescribing practice (see Table 4.1).  Finally, I 
discuss my findings based on their descriptions of impact on patient care (i.e. 
improving the clinician-patient relationship, reassuring patients, empowering 
patients and/or clinical effect) (see Table 4.1); which is why I have called the 
next section ‘The place of Medicines Information advice in clinician decision-




After the section mentioned above, I then describe and discuss my findings 
relating to clinician descriptions of MI advice on their feelings, i.e. ‘impact on 
feelings’ (feeling reassured and/or empowered) (see Table 4.1).  The other 
findings from Table 4.1, around their expressions regarding using the MI 
Service as a ‘safety net’ because of clinical and/or technical knowledge issues, 
and/or information resources issues, or for risk and medico-legal back-up, are 
described and discussed later in a separate section.  Finally, their views of the 
MI Service as an expert, trusted, convenient service i.e. a ‘medicines help 
desk’ are described and discussed.   
The place of Medicines Information advice in clinician decision-
making, prescribing and patient care 
I have extracted all the themes from Table 4.1 which are relevant here and 
these are shown below in Table 4.2.  
Table 4.2 Domains, meta-themes and themes about clinician decision-
making, prescribing and patient care 
Domain of Medicines 
Information influence Meta-theme Theme 
The motivating factors for 
clinicians deciding to seek 
Medicines Information advice 
Safety net 
Providing a decision 
Confirming a decision  
Shaping a decision 
The consequences of Medicines 
Information advice on clinicians 
Impact on 
prescribing 
Immediate change in 
prescribing 
Enhancing prescribing 
Shift in prescribing practice 
Impact on 
patient care 




Clinical effect  
There were various factors which saw clinicians deciding to seek MI advice 
because they needed to make a prescribing decision about a patient.  There 
appeared to be a ‘trigger point’, at which stage they contacted the MI Service, 
because for some reason they were unable to answer the medicines question 
themselves.  I am now going to discuss the meta-themes, ‘Safety net’, 
‘Impact on prescribing’ and ‘Impact on patient care’ in three sections entitled; 
‘Medicines Information advice as a safety net for clinician decision-making’, 
‘The effects of Medicines Information advice on clinicians and their prescribing’ 





Medicines Information advice as a safety net for clinician decision-
making  
In the findings of my research, I have used the term ‘Safety net’ to describe 
how clinicians wanted support, security and back-up in their clinical decision-
making so they felt able to prescribe safely and appropriately, and in case of 
patient complaint.  Although not the same, this is analogous to ‘safety-netting’ 
used by clinicians during patient consultations which was first described by 
Neighbour to help ensure patients know what to do if their condition 
subsequently changes (Neighbour, 2004; Silverston, 2014).  As exemplified in 
these extracts, clinicians were using MI advice as a security blanket to check 
and defend their decision-making when they were prescribing;  
“I'm happy to take advice off someone, it's nice to have a safety backdrop, 
just to give you kind of more of a certainty on what you're doing...” (F5 
Dentist)  
“…you want to know what you're prescribing is safe and been used before” 
(F3 GP).  
The motivating factors for clinicians seeking and using MI advice as a ‘Safety 
net’ were broadly about them wanting support for their decision-making, 
although some expressed this more specifically as MI providing them with a 
decision, or confirming, or shaping a decision.  Clinical decision-making is a 
complex process which takes place when clinicians make diagnostic and 
treatment decisions.  As stated in Chapter 2, it is thought that clinicians make 
their decisions using the ‘dual process’ theory of decision-making.   Clinicians 
mostly use System 1 processes which are based on their existing ‘tacit 
knowledge’ and ‘mindlines’, only switching to System 2 decision-making when 
they consciously override System 1 (Bate et al., 2012; Gabbay and le May, 
2016; Wieringa and Greenhalgh, 2015).  System 1 processing is quick and 
intuitive and enables them to make a patient-centred diagnostic or treatment 
decision without needing to consult more widely (Bate et al., 2012).  I have 
linked my findings to the different elements of decision-making and these are 
further explained in line with the ‘dual process’ theory of decision-making. 





Clinicians mainly sought MI advice about medicines when they had a clinical 
dilemma and did not know what to do and were running out of options, 
particularly for complex or high risk cases.  Although a high risk case may not 
be as multifactorial as a complex case, they were classed as such by clinicians 
because the question was about use of medicines in pregnancy, breast feeding, 
paediatrics, medicine choice in a history of allergy or severe adverse effects. 
These question types are often difficult to answer because the medicine is not 
licensed for use in those circumstances, data are lacking, not easy to find, or 
require clinical interpretation. 
 
Providing a decision: MI advice certainly had a positive influence on clinician 
decision-making as MI staff sometimes made the decision for them.   This was 
expressed by clinicians when they said they used MI advice exactly i.e. did 
what MI said with statements such as “…made my decision for me” (T4 GP); 
“…told me what to do” (T1 Dentist).  They valued the fact that MI answered 
their question “fully basically, gave me all the information I needed” (T4 GP) 
(Use of mirtazapine in a patient on warfarin).  Doing what MI said was 
particularly important for another GP who asked about how to restart 
lamotrigine in a vulnerable patient who had decided to stop their medicine a 
few weeks before;  
“They [MI] gave me some information about how I was going to manage 
it, logistically they told me how I was going to manage it. […] so it wasn’t 
just a just a vague answer – I did what they said” (T37).  
This illustrates that when making prescribing decisions, clinicians had already 
made a conscious decision to seek MI advice for their System 2 decision-
making.  When the MI Service were providing a decision, clinicians did not 
want and/or need to interpret the advice further and were able to use it 
directly.  In other words, the MI Service were doing System 2 decision-making 
for the clinician.   
It is not surprising that clinicians sometimes need to check elsewhere, 
particularly for advice about management of uncommon conditions with 
unfamiliar medicines.  When clinicians did not know what to do next, they 
used the MI Service to provide them with a decision.  That is, they felt the 




they had at the time without having to do anything else.  They have limited 
additional capacity and do not necessarily have time to consider all the 
variables when they need to prescribe another medicine (Zwolsman, 2012; Del 
Fiol, Workman and Gorman, 2014; Baird et al., 2016).  As GPs are ‘expert 
generalists’, they know about the management of a wide range of common 
clinical conditions, with limited specialist knowledge (Reeve et al., 2013; 
Reeve, 2015).  Similarly, although dentists should be familiar with a more 
restricted range of medicines they prescribe e.g. antibiotics used for spreading 
dental infections, such as amoxicillin or metronidazole, or analgesics for pain 
relief, they generally do not know much about the numerous medicines 
patients take for conditions not associated with dental care.  Whilst they may 
be happy to answer simple questions using texts such as the BNF, they may 
not have the time, resources, expertise or skills to handle complex medicines 
questions.   
Sometimes clinicians had tried to do their own research i.e. to use their 
System 2 decision-making, but they contacted MI because they were 
struggling to know what to do and wanted to discuss the problem with 
someone else.  This dentist explains the pressures they are under when they 
cannot do a dental intervention and have other patients waiting.  The patient 
in question was complex and presented with a worsening infection, the dentist 
needed to prescribe an antibiotic and needed ’just in time’ advice without 
having to wait; 
“…in a, ‘an emergency situation’ is probably a bit strong a word, but it is in 
the situation where everything else has failed me, right, well what, what 
are we doing now, you know, he’s allergic so I've got to give this, or she's 
taking that but I want her to take this, and you need to take it, I want you 
to take it now to get you out of discomfort…[…]…antibiotics really was 
going to be our last, it was our last port of call really, so I needed to 
prescribe it 'cause the others hadn't worked, our other measures we didn’t 
feel were working…’ (F9) (Amoxicillin with dabigatran). 
 
The management of patient’s taking medicines new to the market caused 
clinical uncertainty for clinicians, with MI providing them with a decision.  For 




of patients taking a new anticoagulant medicine, dabigatran, which they knew 
little about.  Several dentists described having a clinical dilemma when they 
needed to do a tooth extraction and did not know if they had to stop the 
medicine before this procedure; 
“…so we were in a little bit of limbo situation […] we weren't quite sure 
which way to go with it” (F11). 
Provision of definitive advice to GPs for their complex patients, such as 
prescribing medicines in older, nursing home patients was useful, as this GP 
explains,  
“The thing with polypharmacy, where it comes in is when nursing home 
patients, some elderly, some patients with a complex past medical history, 
a lot of medications and then you're adding in a new substance, or 
changing the dose where you haven't got much experience with it 
(JR:Yeah)… or the information, you can't find in, then it's quite useful” 
(F13). 
Another GP had a ‘tricky patient’ who had chronic kidney disease and needed 
more analgesia to manage their neuropathic pain.  Specific MI advice about 
using higher doses of gabapentin helped them with their dilemma and was 
appreciated as they could do what the patient wanted; 
“…because of the CKD [chronic kidney disease], the dose was restricted, 
she asked if she could have more, her current medication now, she's on 
Matrifen [Fentanyl patch] which somehow or other managed to get 
bumped up to, I think it's 100mcg …(JR: Right)…and a little bit of codeine 
at night if she woke up with pain …(JR: Yeah)… and gabapentin, she 
couldn’t tolerate tricyclics at all, so upping her Gabapentin was a good 
option really” (F15) (High dose gabapentin in CKD). 
These examples illustrate the difficulties primary care clinicians face, 
particularly as patients are becoming increasingly complex due to ageing and 
frailty, concomitant diseases and multiple medicines (NHS England, Royal 
College of General Practitioners, and Health Education England, 2016).  With 
the focus on treating the patient closer to home, the number and complexity 
of consultations in general practice has risen dramatically in the last 10 years 




This study found that MI Service advice enabled GPs and dentists to make 
prescribing decisions about patients who were difficult to manage, whether 
because of long term health conditions or complex medicines regimes, and in 
some instances allowed them to manage the patient rather than refer them to 
secondary care. A clinician felt MI advice about use of amitriptyline for pain in 
early pregnancy was “crucial”.  They were not sure if it was better to wait for 
the patient to see the pain team or just help her because it was going to be a 
few days before she was going to be seen (T38 GP).  Asking MI for advice 
therefore stopped the clinician referring to a clinical specialist and meant they 
could decide what to do without the patient having to wait.  Another clinician 
described using the MI Service when they did not know what to do because 
they wanted to know which medicine they could prescribe for a mental health 
problem in pregnancy and their patient did not meet the threshold for a 
mental health referral;  
“…those sort of things where you're not, you know sure what medication 
to prescribe; I mean normally we’ll go through the psychiatrist for that 
but…(JR: right)…occasionally there’ll be patients that aren't at a level 
where they need psychiatric intervention” (F12 GP). 
 
Contraindications to medicines also caused clinical uncertainty when 
prescribing in high risk situations.  Clinicians valued definitive advice when the 
patient had already taken a potentially harmful medicine, such as avoiding a 
‘statin’ in early pregnancy;  
“When it said in the BNF, you know, not to be prescribed in pregnancy, 
that's when you know I thought I need to get a bit more information” (F14 
GP) (Simvastatin in early pregnancy). 
They also wanted to be told what to do before prescribing a medicine that was 
contraindicated in a high risk case, for example when prescribing an antifungal 
to a woman who was breast feeding a neonate;  
“I think it was… either six or eight weeks where they were sort of saying, 
you know, it was either stressing avoid, or using caution, so I thought 
that's why I’d ask for some advice” (F12 GP). 
Confirming a decision: Rather than relying on what they had found in a core 




thing”, sometimes clinicians still wanted MI advice.  Even though they said 
they had already made a prescribing decision i.e. they had made a decision 
but then decided to check their thinking by getting a second opinion. In other 
words clinicians used MI as a safety net to check their own ‘mindlines’ or 
System 2 decision-making, particularly when they began to have self-doubts 
or were worried about prescribing certain medicines.  A dentist described this 
prescribing uncertainty as having the “occasional niggle” and one GP as; 
“…sometimes you've got an idea about what you might, or might not, do, 
and I think it's helpful to get a more, you know, more expert opinion about 
that to confirm what, you know, which hopefully confirm what you were 
thinking already” (F14). 
This is an important finding as despite clinicians having a plethora of 
information resources available to them, ranging from their prescribing 
systems to utilising a range of human resource options, they were still using 
MI as a safety net to confirm their next course of action.  This thinking was 
expressed by clinicians verbalising that they were seeking confirmation for 
what they had already tentatively decided.  The interview extracts certainly 
show that some sought MI advice to verify their own thinking, particularly for 
difficult cases.  This is illustrated by one GP who had a question about a 
complex patient who needed treatment for depression.  The patient had a 
history of coronary artery bypass graft (CABG) and myocardial infarction a few 
years ago, plus diabetes and gout, managed with multiple medicines.  The GP 
thought they knew what to do but wanted to confirm that sertraline was the 
best option from the range of antidepressants. They had an;  
“inkling that it was going to be sertraline”…”it’s not uncommon that one 
ends up treating patients for depression with cardiovascular disease and I 
had an incident before where I inherited a patient who was on a tricyclic 
which I didn’t think was going to be the right drug and I remembered that 
it was likely to be an SSRI and I wanted to check that it was still going to 
be sertraline” (T15 GP).   
The MI Service verbally advised that tricyclic antidepressants and venlafaxine 
were not suitable and confirmed that sertraline was the best option post 




Medicines optimisation issues also challenged clinician decision-making.  One 
clinician needed to know how to switch from one antidepressant to another 
(citalopram to sertraline) and was concerned about the risk of serotonin 
syndrome; specific MI advice about a potential patient safety issue was 
described as having; 
“a big influence in terms of confirming that it was the correct thing 
pharmacologically to do” (T23 GP). 
 
As is the case for GPs, dentists are also under increasing workload pressures.  
Not surprisingly dentists also wanted a second check when they had a complex 
patient in the dental chair or waiting room, on an extensive medication list;  
“Sometimes someone will come in with a whole 20, 25 tablets, and to 
manually check it, it’s going to be a bit difficult even though I, you know 
you, there may be very little effects, say from amoxicillin I still would 
probably get it and have a look, just maybe more as a reassurance than 
anything else” (F4).  
Dentists sometimes wanted to double-check or confirm their thinking about 
antibiotic prescribing when they had run out of dental treatment options;  
“I think realistically it's usually for something that I'll know is going to be 
all right but I just want that, that bit o' back-up, so clinically I suppose I've 
already made the decision because that's in the [dental treatment] 
pathway,[…] usually in dentistry it's going to be antibiotic prescribing and 
that's going to be your last option anyway, if your local [dental] measures 
haven't worked ” (F9). 
Shaping a decision: It was apparent that sometimes clinicians were unable 
to make a decision themselves, and needed MI advice to help them shape 
their decision.  During the interviews, clinicians described how they needed 
advice to help them formulate or shape their own decision.  By asking MI, 
clinicians were able to make an informed decision about choice of therapy 
using the advice they received.  A GP was unsure what to do in an 11-year old 
as they could not use a tetracycline because NICE guidance about acne 




“to make an informed decision basically I guess, so that the patient was 
happy getting some treatment that was evidence-based” (T35 GP).  
This shaping of a decision was apparent as the MI pharmacist advised that the 
GP could prescribe Zineryt®, a topical erythromycin containing product 
instead, as this could be used in children; and confirmed the avoidance of 
tetracyclines because of detrimental effects on the teeth and bones.   
A more complex case required MI advice to help the clinician formulate a 
person-centred clinical plan.  A GP needed to make a treatment choice about 
post herpetic neuralgia for a 91-year old nursing home patient who was taking 
phenytoin for epilepsy, as well as co-codamol for pain relief.  They were 
considering prescribing amitriptyline and were struggling as NICE guidance on 
treatment of neuropathic pain does not specifically consider what to do in a 
patient with epilepsy.  MI advised avoiding amitriptyline as this can lower the 
seizure threshold.  Instead they suggested using a licensed medicine, 
pregabalin as per NICE guidance.  When the GP asked about gabapentin 
because it was cheaper and also licensed for pain, although not in the NICE 
guidance, MI agreed this was another option. Here the GP describes what 
happened after getting MI advice; 
“Read advice and prescribed gabapentin for this lady…..I didn’t prescribe 
amitriptyline which I was thinking about with the phenytoin. I was 
informed by [the MI Pharmacist] that amitriptyline is not licensed for 
neuropathic pain and the dose is much lower than antidepressant. 
Basically we looked at pregabalin and gabapentin and because of the cost 
of pregabalin decided to go for gabapentin” (T20).  
As this patient was older with renal impairment (CKD stage 3) and at risk of 
central nervous system effects, MI also advised to start at a low dose and 
increase the dose slowly.  To add to the complex nature of this case, there 
was the potential for interactions with epilepsy medicines, some of which can 
be used for neuropathic pain as well.   
It is notable that prior to asking MI, this GP very nearly decided to rely on 
their own ‘mindlines’;  
“…potentially I could of, which hopefully I wouldn’t have done, prescribed 




Had they not spoken to MI, they might have prescribed amitriptyline, which is 
not appropriate in epilepsy and this could have put the patient at risk of 
having a seizure.   
It is understandable that they wanted advice to shape their decisions as there 
are lots of elements to consider when making complex medicines decisions.  
Such as, if there are interactions with other medicines (prescribed, over-the-
counter (OTC) and complementary); dose adjustments based on current renal 
and hepatic function, both of which decline with age; contraindications with 
underlying medical conditions and any previous allergies.  This is in addition to 
the actual practicalities of adding a medicine to an already complex medicines 
regimen. For example, if the medicine requires additional monitoring, this may 
mean frequent visits to a clinic.  Finally, making a prescribing decision should 
also involve reviewing existing medication and deciding if any can be stopped 
or doses reduced.   
Clinicians also sought MI advice to help them shape decisions for their high 
risk cases, particularly when they needed to weigh-up the range of treatment 
options before deciding what to do.  In this case, the clinician described their 
dilemma about choosing analgesic treatment in pregnancy and contacted the 
MI pharmacist for help;  
“I had a feeling that low dose codeine, 8/500 was probably going to be 
OK, but I thought 30/500 is definitely out, […] I thought OK I’ll ring you 
guys and see what you can help me with” (F6 GP).   
The MI Service checked all the major drugs in pregnancy resources, then 
searched the literature.  They then advised that if paracetamol was not 
sufficient, codeine, even at higher 30mg doses, and non-steroidal anti-
inflammatory drugs could also be used outside the first trimester.  
Finding answers to difficult prescribing situations is complicated, as practical, 
person-centred information is often lacking.  When selecting a medicine, there 
are a variety of factors to consider, including whether the medicine is likely to 
be of sufficient clinical benefit to the patient (Marshall, M. and Bibby, 2011).  
Use of medicines in pregnancy is undoubtedly a high risk area of prescribing, 
as the clinician needs to consider the potential risk to the unborn baby as well 




cannot do clinical trials in pregnant women, which means first-line medicines 
reference sources, such as the BNF and eMC tend to just say the medicine 
should not be used in pregnancy or at best provide minimal, cautious 
information.  Clinicians are sometimes more cautious and avoid prescribing 
medicines in pregnancy, which may mean the woman is potentially denied 
suitable medical treatment (Pharmacy Humber NHS Foundation Trust, 2013).  
To summarise, primary care clinicians used MI advice as a safety net for their 
decision-making, that is when they consciously switch to System 2 decision-
making thought processes.  However, this more deductive and analytical 
approach is slower, requires research into the problem and is not easy to do, 
and on these occasions they seek MI advice.  As I have already explained, the 
premise of the dual process theory of decision-making means that when 
clinicians do not know the answer, they are unable to use their own knowledge 
(System 1) and so switch to System 2 decision-making.  This dual process 
theory can be linked to a cycle of learning, where clinicians switch from being 
‘unconsciously competent’ (i.e. using System 1) to ‘consciously incompetent’ 
(needing to use System 2) (Croskerry and Norman, 2008; Croskerry and 
Nimmo, 2011; Bate et al., 2012).  The result being the need to acquire new 
knowledge, either by doing their own research or by asking someone else to 
help them with their complex decision-making.   Although, if they think their 
own knowledge is correct, they will not switch to System 2 and are thus 
‘unconsciously incompetent’.   
In both the telephone and face-to-face interviews, primary care clinicians were 
describing how they were sometimes unable to make prescribing decisions, 
particularly for complex or high risk cases and/or those where the answer was 
difficult to find, so they used MI as a safety net.  Sometimes, MI staff told 
them what to do and then they acted on it, or MI helped shape their thought 
processes so they were able to make a decision.  In some cases, MI advice 
was so specific e.g. about an interaction or use of a medicine in pregnancy, 
the clinician knew what to do and acted on it, so did not need to find any other 
information to make their decision.  In short, making prescribing choices about 
complex and/or high risk cases requires intensive System 2 research and 




with which clinicians need support.  The MI Service therefore plays a key role 
in decision-making for the clinician by taking over their System 2 decision-
making.  Sometimes, clinicians used MI advice to get a second opinion and to 
confirm what they were thinking.  In these cases, it is proposed that they were 
using MI advice to ‘calibrate’ their System 1 thinking and to update their tacit 
knowledge and ‘mindlines’ (Croskerry and Nimmo, 2011).  It is my view that 
clinicians valued using MI for joint decision-making, they were using the MI 
Service as a ‘knowledge broker’ and as such the service forms part of their 
‘community of practice’ (Gabbay and le May, 2004; Lomas, 2007; Soubhi et 
al., 2010).  In the next section I will describe and discuss the effect of MI 
advice on clinicians, their prescribing and patient care. 
 
The effects of Medicines Information advice on clinicians and their 
prescribing 
In the previous section I described and discussed the elements around 
clinicians seeking MI advice when they were making decisions about 
prescribing medicines.   Although decision-making and prescribing are closely 
linked, this section is subtly different as it is more specifically around 
descriptions of the effect of MI advice on clinicians in terms of their prescribing 
for the patient in question, and its effect on their subsequent prescribing 
practice with future patients.  (Themes about prescribing and patient care are 
listed in Table 4.2). 
Immediate change in prescribing: After making a decision, clinicians then 
described how they used MI advice to make a prescribing change for the 
patient.  Fundamentally, MI advice was patient specific and/or detailed enough 
to enable clinicians to make an immediate, clear-cut prescribing change 
without having to consider or do anything else.  For some the advice was 
followed ‘to the letter’ and particularly important to ensure best care was 
given.  For example, for one dentist, advice enabled local anaesthetic 
prescribing and avoided the patient being labelled as having an allergy to a 




“so I contacted [name of MI pharmacist] to ask her advice and she replied 
with a very considered response, which was, no, she felt this was a 
reaction with the adrenalin in the local, and the outcome of it is that we've 
now used adrenalin-free local with the guy and not had a repeat of the 
same problem” (F2 Dentist).   
Clinicians acted upon the information provided as it directly informed how they 
managed their patients.  This was also a recurring issue identified in almost all 
telephone interviews, and is exemplified by this GP who said;  
“they just gave me the information about how I was going to manage it, 
logistically they told me how I was going to manage it…” (T37). 
Enhancing prescribing: Besides clinicians immediately being able to make a 
prescribing change for the patient after getting MI advice, most described how 
their prescribing was enhanced or improved, either because they felt the 
evidence-base was improved and/or their prescribing was safer.  When asked 
about safer prescribing (in the face-to-face interviews), clinicians felt their 
prescribing was safer by receiving evidence-based MI advice;  
“Whenever I've had problems previously, […..] I've felt then confident to 
use that information that you've given to you know, then to take forward 
with the patient and you know hopefully…treat them in a fairly safe 
manner” (F11 Dentist). 
A GP also expressed the issue of safer prescribing as; 
“…rather than taking an educated guess and then taking a risk sort of 
thing and not being very sure, I think it's always a good idea [to contact 
MI]…” (F13).   
That is, they were using MI advice to help inform their micro-prescribing 
decisions (Gabbay and le May, 2004; Grant, Sullivan and Dowell, 2013; 
Wieringa and Greenhalgh, 2015). 
This dentist explained how a safety issue was raised by the MI Service when 
he contacted them with an enquiry. The patient was taking two beta-blockers 
when they should have only been taking one and because they were made 
aware of a medication error, they were then able to clarify it with the patient 




“…I asked the patient and she said “oh yeah, I'm taking both of those,” 
and then we had to check with the doctor, and the doctor said ‘oh no the 
atenolol was dropped,’ so I was made aware of things [by the MI Service] 
which I wouldn’t have picked up on” (F4).   
MI staff were able to alert clinicians to other clinical issues they were unware 
of and thus change their prescribing or the prescribing of others.  It is the role 
of all pharmacists, including those in MI, to be aware of all the medicines the 
patient is taking or using and anything that may impact on this, (e.g. mobility 
problems, living alone), and to highlight all relevant medicines concerns to 
other clinicians.  
Shift in prescribing practice: A shift in prescribing practice was portrayed 
by clinicians, as they explained how they could reapply MI advice with future 
patients to help them prescribe safely, as in this example from a dentist;  
“In future I know if I’m in a similar situation that I can give it and now I 
know that metronidazole is safe” (in a patient with a history of stomach 
ulcers) (T27 Dentist).  
Further examples of this shift in prescribing were also noted, with a different 
dentist, changing his practice about antibiotic interactions;  
“…so you change your practice in terms of what you know, this is, I'm fine 
with this and you can prescribe it, so the information I suppose gets 
reinforced in your sort of own knowledge of what you can and what you 
can't prescribe, what interacts, what doesn't interact”;  
also selecting the safest antihistamines based on central nervous system 
effects; 
“it does affect my decisions that I make in the future for patients taking 
antihistamines, I know which one’s drowsy, and which one’s not going to 
be drowsy…” (F4). 
Similarly, advice about use of analgesia in pregnancy enabled a change in a 
GPs prescribing practice by updating their clinical knowledge and giving them 
the confidence to prescribe safely in pregnancy.  In this instance, the GP was 





“… now I understand that you know I can prescribe codeine and non-
steroidals; […] I thought they [NSAIDs] were a complete no-no in 
pregnancy. […] Since then I have seen other patients who have had pain 
in pregnancy, and it's given me like more confidence to advise them, and 
even […] last week I was actually speaking to a staff member who’s 
pregnant and she's asked me about analgesia in pregnancy and I knew the 
advice to give her …” (F6). 
Changes in prescribing practice were also described by GPs through reusing 
previous advice with other patients.  Here a GP explained how MI gave them; 
“…some advice about using high dose fluconazole [in pregnancy] and 
things like that, and that was an email I got, and then whenever this issue 
arises I […] re-use it” (F6).   
Some described this further as they mentioned storing copies of MI advice 
which they could quickly retrieve and re-use, by keeping this; ‘useful 
information’ on their email system or even in their desk drawer so they could 
easily access it; 
 “..I've used it in repeat consultations […] I still use the information I got 
even a year or two ago with patients to talk about some alternatives” (with 
respect to HRT) (F7 GP).  
This re-use of MI advice describes how clinicians used it not only for the 
original patient enquiry but to update and inform their own clinical knowledge 
and future practice.  That is they were using MI advice to inform their micro, 
and macro-prescribing decisions (Gabbay and le May, 2004; Grant, Sullivan 
and Dowell, 2013; Wieringa and Greenhalgh, 2015).  A non-MI study looked at 
how clinicians make prescribing decisions and what influences them (Grant, 
Sullivan and Dowell, 2013), but did not find any major effects on improved 
prescribing per se.  However, this study illustrates how clinicians used MI 
advice to develop their prescribing practice for subsequent patients.  This 
appears to be by instilling confidence, incorporating it into their existing 
knowledge and storing information so they could refer to it.  This is an 
important finding as no other MI studies have shown how MI advice has been 
used to inform prescribing for future patients (Hedegaard and Damkier, 2009; 




A further key finding from my interviews was that clinicians shared their newly 
acquired medicines knowledge with their colleagues to potentially improve 
prescribing within their wider ‘community of practice’.  Multiple examples of 
this sharing of good practice were noted and are exemplified with the following 
interview extracts; dentist (F9) stated they incorporated the latest advice 
about new anticoagulants into “practising life”, and this GP (T9) quote about 
obtaining a special paediatric product, i.e. a licensed melatonin preparation; 
“Able to share it [MI advice] with my partners, the other doctors, so they 
were aware of it”.  
The MI advice was shared in a variety of ways.  For example, the advice 
provided to one dentist about the management of patients taking 
bisphosphonates for osteoporosis and the practicalities of dental treatment, 
due to the risk of osteonecrosis of the jaw, was shared with their colleagues; 
“Once again the bisphosphonates, we’ve just adapted that as, as time’s 
gone on, so em yeah, it's eh, yeah we've, it's certainly something we do 
use” (F11 Dentist).   
Some described sharing MI advice with others via email, IT networks or 
meetings, as these extracts illustrate; 
”…so I’ll put it on that resource there [shared network]…and email round 
saying “I had this issue today, this is the advice I was given, if you want 
further advice so people know where to go…”  (F12 GP) (8 GPs in the 
practice). 
“…we have a server that runs all the computers in the surgery, […..]…so I 
said to the…, told all other the clinicians, you know, this document [about 
new anticoagulants and bleeding risk] might be helpful, and it's on our 
server, so that's accessible …” (F9 Dentist) (6 dental staff in the practice). 
Sharing MI advice at practice meetings or study groups was also described 
and valued by others;  
“I've shared it [MI advice] with colleagues as well, you know we have a 
very, we have a regular meeting, so sometimes if I find out some new 
information, I can't think of specifically whether I've done it recently, but 




“…this is something that I share at the study group and say “now I've used 
this and it's absolutely brilliant…” (F15 GP). 
Other shifts in prescribing practice described were when MI advice was 
subsequently applied to a group of patients.  This GP described using the 
advice provided for patient-specific questions (about taking a tricyclic 
antidepressant for pain) to review other patients in the practice who were on a 
similar combination of medicines;  
“Actually not just one patient, it’s several patients. So we looked through 
all the patients that we’d got in the practice on citalopram and each 
individual doctor went through to see whether they were also on tricyclics 
in particular, but also other drugs that may affect the QT interval” (T32).  
In this case, clinicians in the practice used MI advice to manage the risk of a 
serious cardiovascular problem in a sub-group of patients who were taking 
citalopram with other antidepressants.  This reveals how individual patient 
advice has the potential to be used for other patients which may then have a 
broader impact on patient care. 
This is the first MI study to describe how clinicians actively share MI advice 
with their colleagues and how this effects subsequent practice of the individual 
and the wider health care team.  Other MI studies have found that sometimes 
the advice provided was shared with another clinician (Stubbington et al., 
1998; McEntee et al., 2010) or circulated to colleagues (Stubbington et al., 
1998; Hedegaard and Damkier, 2009), but they did not provide any 
description of the way this information was utilised to change individual 
prescribing decisions or how it was applied to whole practice populations.  
Only in the SchjØtt study did clinicians agree that MI advice caused a change 
in their practice (Schjøtt, Pomp and Gedde-Dahl, 2002).  However, like other 
MI studies, the level of detail reported in this study was lacking and only 
reported that the enquirer was able to give more informed advice to 
colleagues.   
My study is the first MI study to describe how MI advice was used to change 
the future practice of prescribing clinicians and their colleagues.  This finding is 




also being used for future patients and shared with clinical colleagues has not 
been fully appreciated by those who commission MI Services and previous MI 
studies have failed to describe this (Stubbington et al., 1998; Schjøtt, Pomp 
and Gedde-Dahl, 2002; Bertsche, Hämmerlein and Schulz, 2007; Frost Widnes 
and SchjØtt, 2009; Hedegaard and Damkier, 2009; McEntee et al., 2010; 
Bramley et al., 2013; Innes, Bramley and Wills, 2014; Strobach et al., 2015).  
This use of MI advice is synonymous with clinicians using their wider 
‘community of practice’ (Wenger, McDermott and Schnyder 2002, David 2014) 
and the potential for MI advice to change the practice of prescribing clinicians 
asking the question, but also of other clinicians.  Further, sharing of this 
advice is analogous with findings in the ethnographic study by Grant (2013), 
where information sharing at meetings, the coffee room and one-to-one in 
consulting rooms was seen as one factor to influence prescribing, and deemed 
to be an important factor for a practice to have high quality prescribing. 
To summarise the effects of MI advice on prescribing, clinicians thought it was 
improved as they used MI advice to inform their prescribing especially for 
those complex or high risk cases.  Additionally, they used MI advice for their 
challenging questions, which they felt were difficult to answer themselves for a 
variety of reasons, including those about drug interactions, adverse effects 
and prescribing/obtaining unlicensed or unusual products.  They then felt able 
to make an immediate prescribing change for the patient based on the MI 
advice.  Some also thought their prescribing was better and/or safer in some 
way because they knew their prescribing was informed by reliable evidence.   
In addition to being able to act on MI advice and prescribing for their patients, 
clinicians also explained how they used advice to update their own knowledge 
i.e. using it then helped improve their ‘mindlines’ at the micro-prescribing 
level.  In some cases, clinicians appeared to integrate MI advice into their 
System 1 decision-making as they changed their prescribing practice for 
subsequent patients i.e. they altered their prescribing practice.  They were 
then able to use this new knowledge to shift their prescribing practice, and to 
subsequently use it with future patients. Importantly, they also described use 
of patient-specific advice to review the prescribing of similar patient groups 




avoiding similar problems for other patients.  Equally important, they also said 
they used MI advice not only for their own patients and CPD but also shared it 
with their colleagues to inform their wider ‘community of practice’ and 
potentially improve the prescribing of other clinicians.   
In this section, I have discussed and summarised my findings about the 
influence of MI advice on clinicians and their prescribing.  In the next section I 
will describe and discuss the effects of MI advice on clinicians and patient care. 
The effects of Medicines Information advice on clinicians and their 
patient care 
With ‘person-centred’ care being advocated, clinicians need to consider the 
care of their patient, or rather the person, as a whole when making a 
prescribing decision (Barnett, 2018).  Other MI studies have tried to evaluate 
the impact of MI advice on patient care (Cardoni and Thompson, 1978; 
Stubbington et al., 1998; Melnyk, Shevchuk and Remillard, 2000; Bertsche, 
Hämmerlein and Schulz, 2007; Frost Widnes and SchjØtt, 2009; Bramley et 
al., 2013; Innes, Bramley and Wills, 2014), but as mentioned in my review in 
Chapter 2, it is difficult to elucidate the effect(s) of MI advice on patients per 
se, as there are many other confounding factors.  The findings of previous 
studies were based almost exclusively on pre-defined options, such as 
avoiding an ADR, termination of pregnancy or interaction (Stubbington et al., 
1998; Bertsche, Hämmerlein and Schulz, 2007; Frost Widnes and SchjØtt, 
2009), and so artificially limit our understanding of what effect MI advice may 
have had. Through my work, as shown in table 4.2, the themes inductively 
coded and derived from clinician descriptions in the telephone and face-to-face 
interviews about the impact of MI advice on patient care, were about 
improving the clinician-patient relationship, reassuring patients, empowering 
patients and clinical effect. I will discuss each of these findings in turn. 
Improving the clinician/patient relationship: While some patients may be 
happy to follow the clinician’s advice with a traditional ‘Doctor knows best’ 
approach, others are now expecting a more equal relationship.  Clinicians are 
now encouraged to practise SDM, with campaigns like Choosing Wisely 
(Choosing Wisely, 2019) providing support for patients and clinicians.  The aim 




risks and benefits and for a decision to be reached jointly (NICE, 2017).  An 
important element of SDM is good communication between the patient and the 
clinician.  This type of relationship was observed in the interviews regarding 
enquiries generated by some clinicians, as they said they had already 
discussed the issue with the patient before contacting MI; 
“I already talked to the patient and said I was going to ask the drug info 
people” (about an interaction with warfarin and mirtazapine) (T4 GP).   
Being transparent with patients about things they were unsure of and checking 
with someone else was also apparent, as this GP explained;  
“…think patients are always actually quite happy if you say to them I don't 
know the answer to your query” (F7). 
Several clinicians felt that because they made the effort to look into the 
problem it appeared to have a beneficial effect on their relationship with the 
patient, especially if the patient knew the clinician was contacting MI prior to 
making a decision; 
“…definitely discussed it [switching from citalopram to sertraline], I discuss 
all changes with the patient and negotiate any drug changes with the 
patient and they were happy for me to discuss it with [MI] and get a 
balanced view” (T24 GP). 
Others felt that patients were unconcerned about them checking with someone 
else, particularly for unfamiliar medicines and thought patients did not mind 
them checking elsewhere and appreciated the clinician taking the time to 
check; 
“If I'm giving somebody amoxicillin for a chest infection I'm not too 
worried about that, but if it's giving something I'm less familiar with I will 
often look it up […?], I don't think patients mind it generally …” (F15 GP). 
After getting MI advice, they believed their relationship with the patient was 
improved because they were able to use it in a discussion with them about 
further treatment options; 
“…was quite, quite happy (JR: M-mmm)… em, I wouldn’t say ‘impressed,’ 
but you know oh great, yeah you can ring somebody and, and […] it 
wasn’t a barrier,[…] I was quite upfront and said “look, it's changing all the 




A different dentist felt able to have a patient discussion about something they 
were previously unsure of; 
“…I could share it with eh, with the patient as well and discuss it 'cause it 
wasn’t clear…” (Use of miconazole oral gel with simvastatin, risk of 
interaction and adverse effects) (F10).  
Clinicians also expressed that patients appreciated their efforts to resolve 
specific problems. In this example, a dentist contacted the MI Service around 
foetal exposure in pregnancy, and felt the patient appreciated what they had 
done as the advice helped allay concerns about risk to her unborn baby; 
“she was really pleased that I'd taken time out to like look into it further, 
and just made sure we weren't giving her something [High strength 
fluoride toothpaste] that may have like done damage to the baby” (F1 
Dentist). 
These examples highlight how MI advice was used to support and facilitate 
clinician/patient SDM.  
Reassuring patients: Clinicians also felt patients were reassured by the 
advice they were able to give after speaking with MI, as well as improving 
their overall relationship with patients.  This has previously been found in 
other MI studies, although findings reported tended to be superficial 
(Stubbington et al., 1998; Bertsche, Hämmerlein and Schulz, 2007).  In my 
study, the data derived allowed for greater context and meaning around the 
concept of reassurance.  For example, clinicians felt able to have a more 
confident medicines conversation with the patient; 
“…when the patient [is] aware [they are] being prescribed something 
which is safe for them — or presumed to be safe — and the doctor has 
more clinical confidence, they feel more confident” (F13 GP).   
Or that they felt able to articulate to patients no further actions were required 
in cases which could be seen as high risk (use of medicines in pregnancy, 
breastfeeding and children) For example, foetal exposure to an antibiotic;  
“She was reassured, she felt reassured and just continued with her 
pregnancy as normal” (Inadvertent exposure to metronidazole in the first 




Or as in the case of a mother who needed to take an antifungal for mastitis 
when she was breastfeeding a very young baby; 
“I think mum felt reassured as well, em that was the main thing really” 
(Antifungal in breastfeeding) (F12 GP). 
Finally, a GP was able to reassure a worried parent, where their 2 year-old 
child had mistakenly been given an aspirin derivative (adult dental gel) and 
the parent had read on the label that it was contraindicated; 
“It helped me to sort of reassure the mother and clarify that there was 
nothing else really to be done” (T39 GP). 
These examples illustrate how MI advice about unplanned use of medicines in 
the first trimester of pregnancy, appropriate use of a therapeutic dose of an 
anti-infective medicine in breastfeeding, and mistaken use of an adult 
medicine in a child all provided reassurance to both clinicians and their 
patients.  
Empowering patients: Clinicians also spoke about how MI advice helped 
them discuss a treatment plan with the patient and perceived this as enabling 
SDM by empowering their patients.  They spoke about using/showing the 
written MI advice provided with the patient to help inform decisions.   
In this next case, where there was no definitive answer about a patient with a 
history of allergy to local anaesthetic, the dentist contacted MI for advice.  The 
clinician was advised that the patient needed allergy testing to check for cross-
sensitivity and considered the advice empowering for the patient, as it gave 
them the confidence to ask their GP for a referral to a specialist for tests; 
“They also said it would still be advisable to get these allergies checked 
anyway […..], rather than potentially end up with a medical emergency on 
my hands and the patient was completely understanding about that and it 
also gave her the clout to go back to her GP and demand tests as well.” 
(T29 Dentist). 
Similarly, for the MRQ about use of analgesia in pregnancy, although the 
patient did not actually take the combined codeine/paracetamol, the GP felt MI 





“She knew that there was a fall back, so it empowered her to, you know to 
understand that if she wasn’t able to control the pain with whatever way 
she was controlling it — with paracetamol and the hot water bottle — then 
she could always come back and I'd have something for her, to fall back 
on (F6 GP). 
Clinical effect: Previous MI studies have ascertained that clinicians do act on 
MI advice, such as continuing or discontinuing, not starting or starting 
medicines.  Unfortunately, they have not provided specific details about how 
medicines were changed or what actually happened to the patient clinically as 
a possible effect of MI advice (Stubbington et al., 1998; Schjøtt, Pomp and 
Gedde-Dahl, 2002; Bertsche, Hämmerlein and Schulz, 2007; Bramley et al., 
2009; Frost Widnes and SchjØtt, 2009; Hedegaard and Damkier, 2009; 
Bramley et al., 2013; Innes, Bramley and Wills, 2014; Strobach et al., 2015).  
However, in my study several patient treatment outcomes were known, and 
explained during the interviews.  My research, unlike previous MI studies, has 
been able to provide further description about how clinicians used MI advice in 
their clinical care and treatment.  For some, MI advice had an important effect 
on the management of the medical condition and/or treatment.  Descriptions 
of resolution or stabilisation of their patient’s condition were articulated after 
taking advice about how to safely switch from one medicine to another, as 
exemplified by this GP quote regarding switching antidepressants;  
“They’re having on-going treatment. It’s early days at the moment, he’s 
just on sertraline now and he’s come off his citalopram and he’s mentally 
stable” (T23). 
Avoidance of a potential allergic reaction was an effect of MI advice when MI 
staff advised that it was safer to not use a local anaesthetic, as this dentist 
explains;  
“The advice they gave me was that although the risk was fairly minimal, 
that there could have been potential cross interaction […], rather than 
potentially end up with a medical emergency on my hands…” (T29). 
For those clinicians that knew what had happened to the patient after 
receiving MI advice, they were able to describe the effects MI advice had on 




safely manage patients by providing practical advice over a variety of clinical 
dilemmas, whether that be switching medicines in chronic clinical conditions, 
such as depression, avoidance of a possible allergic reaction, the correct 
therapeutic dose in pregnancy, or when the clinician was using a sub-
therapeutic dose. 
MI advice also saw medicines being stopped or started and as such aligns with 
other MI work, although as interviews were used in my study, I was able to 
get a better understanding as to how and why.  The below example highlights 
where a patient was prevented starting a medicine, as advice to the GP was to 
increase the dose of their existing treatment (for pain), rather than adding in a 
new antidepressant; 
“What we did was not start a new antidepressant and work with the 
nortriptyline and have the scope for increasing that if necessary” (T32). 
 
Likewise, for another patient, on a long term medicine (aminophylline), MI 
advice resulted in the medicine being stopped and reviewed according to 
symptoms, rather than what the GP had been considering, which was 
switching them to theophylline and may not have been necessary;  
“Because she’s been on it for quite a long time we decided in the first 
instance to stop it rather than change it” (T34). 
A further example found that MI advice allowed the patient to be treated 
successfully for an infection.  They advised the clinician to prescribe an 
antifungal pessary for a longer period of time (than recommended in non-
pregnant women) for treatment of recurrent vaginal thrush during pregnancy.  
Then because the clinician knew what to do, they explained how they were 
able to treat the patient again when it recurred;  
“it was a two week course of pessaries, which, you know at first thought 
you wouldn’t think that would be great in a pregnant woman, but it 
worked really well and it was safe and we’ve used it again since” (F3 GP). 
Sometimes, MI advice helped prioritise the clinical treatment for multiple 
conditions and aided SDM.  In this case, a husband asked the GP about his 
wife taking St John’s wort with topiramate and they contacted MI.  Controlling 




she stopped taking the St John’s wort as there was the potential for it to 
reduce her topiramate serum levels and migraine control, as; 
“...it was more important for them at that moment in time to treat the 
migraine than to start the new medication…” (F13 GP).  
This study shows how clinicians perceived the role of MI Services in directly 
contributing to the medicines optimisation agenda by having an effect on 
patient care through managing polypharmacy and, at times, helping with 
deprescribing (RPS, 2013; Drenth-van Maanen et al., 2018; NICE, 2015).  
Clinicians described this as titrating rather than adding medicines and 
reviewing clinical need for continuing chronic treatments. 
To summarise the effects of MI advice on clinicians and their patient care, 
clinicians explained how they thought it was better to be honest with patients 
when they did not know what to do, and communicated to the patient that 
they were going to ask a specialist service for medicines advice, particularly 
for their complex or high risk cases, or for answers that were difficult to find. 
Their view was that patients seemed to appreciate this fact, and they used MI 
advice implicitly in SDM discussions with their patients.  Therefore, clinicians’ 
thoughts were that because patients were aware they were contacting the MI 
Service, their relationship with the patient improved, and felt their advice 
provided reassurance and empowerment to patients.  Some prescribers knew 
how MI advice had had a clinical effect on the patient, and enabled continuity 
of care.  
Clinician feelings 
The next theme I want to discuss is about clinicians and their feelings.  The 
relevant themes extracted from Table 4.1 are shown below in Table 4.3.  
Earlier I discussed the themes of ‘reassuring’ and ‘empowering’ patients, see 
Table 4.2.  Here, MI advice seemed to have an emotional effect on prescribing 
clinicians themselves and their frame of mind, as they described feeling 






Table 4.3 Domains, meta-themes and themes about clinicians and their 
feelings 
Domain of Medicines 
Information influence  
Meta-theme Theme 
The consequences of 







Feeling reassured: It was clear that when clinicians had to make decisions, 
they thought the advice they received had a positive effect on how they 
handled the problem as they found it reassuring.  They described this as 
enabling them to make decisions that appeared to confer greater clinical 
confidence in managing patient problems, as these GPs explained;  
“Gave me the confidence to do it when there are known interactions” 
(Amoxicillin with methotrexate) (T22); 
“Given me the confidence to move forward to help the patient manage 
what is in effect a tricky area of decision-making, without having to refer 
further” (Venlafaxine in pregnancy) (T9). 
 
Similarly, the value of discussing a question with the MI Service about the 
risks of using Bio-Oss® bone substitute material prior to a dental implant, was 
described by this dentist; 
“…I was looking for reassurance that there was no BSE risk here, no prion 
disease risk here, … you know I couldn’t have had a better response that 
completely reassured me that this was a material that was safe to use…” 
(F2). 
Feeling reassured and confident to have a patient discussion, after speaking 
with the MI pharmacist, was described by another GP;  
“I use it [MI advice] to discuss with the patients, you know, we've done 
this, I've done this information gathering and database use, and all the 
rest of it, and it reassures me and them that the information’s up to 
date…[…..]…also I think it helps, it makes you - as a doctor- you feel well-
reassured” (F3). 
Reassurance was further expressed by a GP who needed help to make a 
prescribing decision, as they started to doubt themselves when they found 




“you're pretty sure it's the right thing to do but because you've not being 
doing it all the time you've, […], it often is reassurance that it is the right 
thing to do… ” (F12). 
This reassurance was further described as feeling more confident i.e. they 
were reassured about a complex case, as a result of being able to discuss and 
share the decision-making.  Discussing a medicines interaction dilemma, or a 
pregnancy question with the MI pharmacist was valued;  
“I was more confident that eh, it wasn’t going to be my own decision…” 
(F10 Dentist) (Miconazole oral gel with simvastatin); 
“So once I got the advice that it's OK to prescribe non-steroidals and 
codeine in the first two trimesters then that gave me confidence” (F6 GP). 
More specifically, other GPs expressed feeling more confident and comfortable 
about their prescribing; 
“…so it gives a lot more confidence when you're giving a prescription or 
prescribing or advising something” (F13 GP); 
“…I felt very much more comfortable that…(JR:OK)…the risks that we were 
taking by doing that were actually…worth it…” (F15 GP). 
Feeling empowered: Another sentiment expressed by clinicians was feeling 
empowered.  Some described how they felt enabled to manage the patient; “It 
empowers the patient, it empowers me” (T15 GP), sometimes as a result of 
feeling reassured and gaining confidence;  
“I had a game plan of you know what the fall back was and what the next 
step was and it gave me more confidence in this regard” (F6 GP). 
In certain circumstances, clinicians felt able to question other clinicians, 
explaining how they used MI advice as the impetus to help them challenge a 
specialist about why they had prescribed something controversial;  
“…and drugs you're not familiar with…you know, when you get a letter 
from the hospital, you know, “do this… prescribe this and… if it's 
reasonable and something you’ve sort of heard of, but if it isn't I do 
sometimes write back and say “no, can you explain what we're doing 




To summarise the effect of MI advice on clinicians and their feelings, they 
described feeling reassured and even empowered by MI advice when they 
were better informed.  If someone is uncertain about what to do, they need to 
move from feeling uncertain to being more certain, by providing reassurance 
MI advice gave clinicians the confidence to move to being more certain, thus 
helping them to make a decision.  They then felt better able to make 
prescribing decisions for their patients, or to question a decision made by 
those perceived as more powerful, e.g. a hospital specialist.  My findings build 
on previous MI studies, which have, to a limited extent shown elements of 
reassurance, for example findings by Stubbington et al (1998).  In addition, 
the concept of empowerment has not been reported previously.  
Other reasons for using Medicines Information as a safety net      
At the beginning of this chapter, I discussed my findings about clinicians using 
MI advice as a safety net for their decision-making.  Here, I discuss how they 
used MI advice as a safety net because of a range of problems to do with 
knowledge, resources, risk and/or medico-legal concerns.  I have extracted 
these themes from Table 4.1 for ease of reference and they are shown in 
Table 4.4.  Descriptions of issues around clinical knowledge, technical 
knowledge and information resources, all relate to impeding prescribing and 
patient care.  In other words, they were using MI advice to fill the gaps in their 
knowledge.  Also apparent were their explanations linked to MI Service use to 
minimise risk to themselves and for medico-legal back-up.  I will describe and 
discuss each of these in turn, starting with clinical knowledge issues.   
Table 4.4 Domains, meta-themes and themes about knowledge, resources 
and risk 
Domain of Medicines 
Information influence  
Meta-theme Theme 
The motivating factors for 
clinicians deciding to seek 
Medicines Information advice 
Safety net 












Clinical knowledge issues: A key issue for clinicians was trying to keep up 
to date. Clinicians need to keep up to date to practise safely and effectively; 
mandatory CPD and revalidation is one mechanism by which regulators 
enforce this.  Yet it is impossible to keep up to date about everything.  Lone 
working or being in a small practice was felt to be particularly challenging 
when trying to keep up to date about clinical changes relating to medicines.  
As this dentist, who did their dental degree over 25 years ago (and relied on 
their joint partner in the practice) explains;  
“…you do find as a dentist you are quite isolated really, and eh….I 
subscribe to the dental updates […], and then generally I liaise with [my 
colleague] as well, 'cause he talks to other dentists, and things along those 
lines, which you know you don’t really get, […] you didn’t get taught at 
dental school” (F11 Dentist). 
Clinicians mostly used their colleagues and their wider ‘community of practice’ 
to help keep themselves updated.  One coping strategy for keeping up to date, 
was to identify what secondary care specialists were prescribing.  A GP 
explained; 
“as new medications come on they’re often used in secondary care more, 
so we get to know what's being used, say in the diabetic clinics and stuff, 
so we would see what our secondary, our expert colleagues are starting to 
use and as patients come out of hospital and those we become more 
familiar with” (F7). 
Clinicians described a range of information available to help them keep up to 
date, but articulated they struggled to manage the high volume of 
information; 
“…there's a huge amount, a wealth of information out there, and how that 
gets disseminated to us as practitioners is a bit of an issue, when you're 
trying to fit in your continuing development and keeping up with 
everything” (F7 GP).  
“up to date with all those zillions of guidelines that drown you on a weekly 




Given the high volume of new and changing information on medicines it is not 
surprising clinicians felt this way.  This is compounded by the overwhelming 
array of online information available via a range of digital portals, all of which 
require appropriate training, skills and knowledge for clinicians to use them 
correctly, effectively and efficiently.  The concepts of not knowing everything 
and difficulty in keeping up to date with constantly changing information about 
medicines were described by this GP who discussed antibiotic prescribing 
changes;  
“a lot of the time the trends are changing, so in the past I would be 
prescribing more antibiotics, now because of the old PCT’s [Primary Care 
Trust] guidance on trying to decrease antibiotic prescribing, those levels 
have fallen…” (F6).   
Similarly, a dentist described amoxicillin and paracetamol dose changes in 
children and then checking this with the MI Service; 
“…if there's any changes in the doses, 'cause they've changed the 
amoxicillin for instance from 250-500 [mg], I'd double check that with 
them [MI].  Also, if it's the Children’s Formulary [BNF], the paediatric one, 
I would phone Medicines Information for any specific information about the 
dosage of paracetamol” (F4). 
Inevitably, clinicians are bound to have limitations in their clinical knowledge, 
as it is impossible for them to know everything there is to know, as 
highlighted by responses from clinicians interviewed in this study; 
“I don't think anybody can be expected to know the answers to 
everything“, and “I […] don’t see how you can know everything about it 
[all the medicines patients take], it's constantly changing …” (F14 GP, F4 
Dentist).   
Typically, clinicians explained that they called MI for advice because they knew 
their own knowledge was out of date. They appeared to value MI advice as it 
gave them confidence in what they were doing, as this GP explained; 
“I’ll be asking them things I can’t remember because I don’t use it 
frequently enough and also I need the confidence to know what I’m doing 




Help from the MI Service was sought where MRQs arose because of infrequent 
prescribing of a medicine, as this GP described; 
“so that might be a prescription request from secondary care, or from a 
patient that’s come from abroad on medication that is less often 
prescribed here or is not prescribed here at all” (F7).   
Similarly, a dentist also highlighted unfamiliar medicines as a reason for using 
the MI Service; 
“…when a new patient comes in — we get a list of their medication and if 
there's something that we're not familiar with then that would generally 
tend to be a trigger to, to look at getting in contact with the [MI] service 
just to see if there is any sort of dental implications” (F11). 
It was encouraging to see (and good practice) that clinicians recognised when 
they were not clinically up to date, and were aware of their limitations i.e. they 
knew they were not competent to answer a question.  Although, it was 
observed that a few clinicians believed their knowledge was up to date; 
”cause, I've not been qualified too long, it's only four years, so I'm like up 
to date with a lot of things” (F1 Dentist).   
While more recently qualified clinicians may feel their knowledge is current, 
this feeling of confidence about being up to date because of being recently 
qualified may be a fallacy (a type of bias) and could potentially be due to 
overconfidence in their own knowledge or unconscious incompetence 
(Croskerry and Nimmo, 2011; Bate et al., 2012).  Although, findings from this 
study suggest that that even when clinicians did their best to keep up to date, 
they still sought MI advice, especially for information that might be difficult to 
find, as this GP described; 
“…just simple things you know that it's difficult to get, to gather evidence 
or things that are less common, and they haven't done the trials” (F7). 
Being up to date about medicines is challenging for generalist primary care 
clinicians who perhaps, compared to specialist clinicians, seldom know with 
what clinical condition the patient will present.  Also with more patients having 
multiple morbidities, it is inevitable they will already be taking medicines, 




knowledge gaps were also exposed when dealing with complex and high risk 
medicines in clinical areas where they were not ‘expert’.  Unlike those who 
specialise in a clinical area e.g. cardiology, neurology, obstetrics or psychiatry, 
where there is a narrower field on which to focus ones’ attention, many 
primary care clinicians need to know a little bit about everything.  For 
example, choosing the safest antidepressant in a patient with epilepsy, or 
choice of treatment in pregnancy or breastfeeding; 
“it's usually in pregnancy, you know where the data changes quite 
frequently, the database changes … antidepressants in pregnancy is 
another one I've used you for … use of antidepressants in epileptics is 
coming to mind now,, which was, you know the one with the lowest 
incidence of reducing the seizure threshold …” (F3). 
GPs need to be expert generalists (Reeve, 2015), and MI Services provide 
them with support by helping them manage their complex patients.  Likewise, 
although the range of conditions dentists manage is less diverse than GPs, 
they do not know with what dental complaint the patient will present.  Also 
problematic for dentists with knowledge of a narrow range of medicines, is 
that they provide an emergency dental service to unfamiliar patients, who can 
be on a huge list of medications for conditions they may know little about.  
One dentist explained they needed help with a dental emergency for a 
housebound patient as they were unfamiliar with their anticoagulation therapy 
and instigation of antibiotics; 
“..the reason I contacted you was going on a domiciliary visit, so limited 
amount I could do, thought antibiotics might be needed,[……] was unsure 
when I'd looked in the BNF” (F5) (Amoxicillin with acenocoumarol). 
A major clinical knowledge gap was apparent for dentists around the time of 
this study, when a new oral anticoagulant medicine (dabigatran) was 
launched, as an alternative to warfarin.  As a new medicine seen infrequently 
in primary care, dentists had limited clinical experience about how to manage 
the potential for increased bleeding risk with dental treatment e.g. tooth 
extractions or fillings.  Difficulty and concern were expressed by several 
dentists who wanted a range of practical advice about adverse effects and 




clarity amongst clinical specialists about patient management and there was 
no national guidance available.  A dentist described their uncertainty about 
this new medicine as; 
”.... she'd not been on it [dabigatran] too long, and with it being a bit 
unpredictable, […], so people don’t really know how it's reacting, so I 
thought right…“ and asked MI (F9).   
The same dentist was understandably worried, as a specialist had previously 
advised caution because of the risk of bleeding during dental surgical 
treatment;  
“...my lack of knowledge …(JR: Right) … on the drug and the lack of 
perceived knowledge of it as well, you know amongst eh colleagues […] 
not long before that that I’d spoken to the Consultant in oral surgery and 
he had, he'd made it quite clear that, do not take one of these teeth out in 
the practice” (F9). 
In the last 10 years there have been some important clinical issues around the 
use of medicines in dentistry, with subsequent guidance issued.  For example, 
changes to dental use of antibiotics to prevent infective endocarditis, (NICE, 
2016); a safety issue about bisphosphonates causing necrosis of the jaw 
(MHRA, 2009); and managing the bleeding risks of dental treatment for those 
on new oral anticoagulants (SDCEP, 2015).  However, the lag time between 
guidance issued and use in practice meant that dentists did seek MI Service 
advice to fill this information void, and thus update their knowledge.  
The challenge for dentists knowing about new medicines and their relevance to 
dentistry is described by this dentist who explained how they struggled to 
keep up with their CPD about medicines, especially as available CPD training 
for dentists did not include medicines; 
“…we do Continuing Professional Development, but not specifically on 
current medications,…[…]… bisphosphonates and these new anticoagulants 
in the last few years that I think have been a stumbling block to us or 
something that we've had to kind of learn on our feet as we go along.  And 
obviously the change in em antibiotic prophylaxis as well and probably 




we've had to kinda sit back and start doing a bit of reviewing around it” 
(F9). 
Managing patients on new medicines poses challenges for GPs too, not only 
because they are unfamiliar, but also because they are often initiated by 
specialists in secondary care, and there may be no SCG agreement in place. 
(East Lancashire Medicines Management Board, 2018).  Exacerbating the 
difficulties of clinicians prescribing in primary care is that trial data on usage is 
not drawn from primary care patients, this means evidence is not aligned to 
the patient population seen in practice (Galbraith, Ward and Heneghan, 2017).  
This makes it more difficult to answer MRQs for these patients and thus 
provide person-centred evidence-based care and is where the MI Service is 
able to help. 
Besides new or unfamiliar medicines proving a challenge for them, clinicians 
sometimes lacked medicines knowledge to be able to advise colleagues 
appropriately, or make a treatment choice in an unfamiliar situation.  This GP 
had been asked by a practice nurse about switching a patient from one long 
acting prostate cancer medicine to another; 
“I was asked to swap a patient from one [medicine] to the other […] asked 
if there will be any problems and I didn’t know the answer” (T5 GP) 
(Switching from leuprorelin implant [Zoladex] to gosarelin injection 
[Prostap] for prostate cancer).   
 
Another GP was unsure about use of an antifungal medicine in breastfeeding;  
“…perhaps you don’t deal with it all the time like I, you know I may have 
prescribed that six months ago, two years ago and then you're, you're 
pretty sure it's the right thing to do but because you've not being doing it 
all the time you've, you've forgotten or you've, you know, or you're not 
too sure,” (F12 GP). 
In both instances, contacting MI Services, when they realised they did not 
know the answer, was well founded, as based on the MI enquiry record, the 
answers to both of these questions were not easily found by the MI 




The MI Service also provided support for clinicians when patients asked them 
something they had insufficient knowledge about.  A well-informed patient 
questioned this GP about use of St John’s wort with an antiepileptic medicine, 
which was being used for migraine; 
“…then the wife said “’oh yeah, you talked to me before,’ so they threw 
that question [about St John’s wort with topiramate] onto me and I 
obviously didn’t know the answer” (F13).  
This illustrates the importance of clinicians recognising their own knowledge 
limitations and understand the concept of conscious incompetence, which was 
exemplified by this GP who went on to say it was better to ask someone else, 
i.e. the MI Service, if they did not know the answer to a question they were 
asked; 
“… we feel sort of like someone is there to help.  I mean people often think 
of the GP sitting there, is an encyclopaedia of knowledge, but that is 
actually not true … … we've got limitations…” (F13). 
Clinicians interviewed were using MI advice to update their knowledge and 
support their CPD about medicines, with the advice they received being an 
opportune way for them to update their own knowledge; as this dentist 
explained; 
“Generally with … with local anaesthetics, I mean when it, I mean when I 
go back to dental school 25 years ago you know, we were always told to 
avoid using adrenalin containing local anaesthetics with certain 
antidepressants and things like that, so…(JR:Yeah)… generally I have rung 
up previously just to find out what the current opinion was on that, 
because you know things do change over 25 years…” (F11).   
A GP said about advice regarding venlafaxine in pregnancy;  
“plus points are I learn a lot, it empowers me and the patient to feel 







Moreover, use of MI advice in CPD for appraisal purposes was described by 
this GP;  
“…at our appraisals we’re always asked to show evidence […], …so it's 
useful for the appraisal process…to be able to show” copies of written MI 
advice (F14). 
To summarise my findings about clinical knowledge issues, the MI Service 
plays a part in filling gaps in clinician knowledge when they have MRQs they 
are unable to answer.  Sometimes it was apparent that clinicians did not have 
the embedded knowledge and experience about how to manage a particular 
clinical scenario because it was something they had not been asked about 
before, or that they dealt with infrequently, so contacted MI.  Consequently, 
gaps in knowledge were instrumental to clinicians using the MI Service as a 
safety net.  They can then use this to update their own knowledge and for 
CPD.  
Technical knowledge issues: Clinicians also need the technical skills to be 
able to effectively and critically search online portals/websites and the wider 
literature so they can answer clinical questions themselves without referral to 
MI Services.  However, it was apparent that clinicians contacted MI because of 
technical knowledge limitations.  Some were unable to find the answer to their 
question because they did not know where to look; as these GPs describe; 
“If you can't find it, […] but if we don’t and it's not written information, 
something new comes across…(JR:Yeah)…I think at that stage we think we 
need some advice and…(JR: OK) …we’ll get hold of you girls” (F13). 
“…you've got a prescribing question or query, something that's out of the 
ordinary, something that you just don’t, can't access the information, it's 
somewhere else …” (F14). 
Yet even if they had access to appropriate resources, they were unable to 
search them properly; “they're quite tricky to navigate sometimes” (F1 
Dentist) (About searching the British Dental Journal website and PubMed). 
They did try internet searches, but if this failed, utilised MI Services; 
“…I will just use the, the Internet, em obviously you can, you can type it 
into Google obviously you can make a judgement whether it's a reputable 




good, em and then beyond that it would be often first port of call would be 
Medicines Management…” (In this instance the GP meant the MI Service) 
(F12). 
This highlights that clinicians found searching for information to be 
challenging, finding it easier to ask someone else they could rely on, such as 
MI staff; 
“…that's the quickest way you can get an answer off someone who’s 
trained in that, to give, you know, that you can trust (JR: OK)… without 
going on a search engine.” (F5 Dentist). 
Of course, these research findings about technical knowledge only relate to 
those clinicians that understood their searching skills limitations, and who 
were aware they could ask the MI Service to help them answer their question 
due to greater technical ability.  What is not known is how those clinicians that 
do not use the MI Service answer their MRQs.  One presumes these clinicians 
feel sufficiently competent to look for information themselves, and are able to 
search specific websites and online databases correctly to find answers to their 
own MRQs.  What is worrying, given the research evidence on clinician ability, 
is that they may do so but poorly.  For example, it is possible that these 
clinicians are ‘satisficing’; this happens if clinicians use the first piece of 
information they find even though it may not be the correct or the most up to 
date evidence (Bate et al., 2012; Croskerry, 2013).   
Information resource issues:  For some MRQs, clinicians may know where 
to look and how to search various resources, but sometimes the resources 
themselves cause issues.  For example, GP prescribing systems and CDSS play 
a major role in the provision of prescribing information and alerting clinicians 
to potential clinical problems, such as contraindications and medicine 
interactions.  To help minimise the risk of using incorrect, inappropriate 
information, CDSS are linked to GP prescribing systems to help the busy, 
time-poor GP; although they do have their own limitations that can cause 
additional clinical uncertainty.  This GP highlights how prescribing system 
alerts can be unhelpful;  
“when you actually … (JR: prescribe something)…try to prescribe 




system] flags it up, I mean that [erythromycin and simvastatin 
interaction] I would know but there are others that are flagged up that I 
don't know the interactions” (F14). 
In other words, GPs used MI when their prescribing system and CDSS were 
unhelpful.  This problem with CDSS has also been reported by other authors 
(Hayward et al., 2013; Chana, 2015), as while these systems provide alerts, 
they do not provide practical advice about how best to manage the issue in an 
individual patient.  This issue is further illustrated by another GP explaining 
how they contacted MI after their prescribing system flagged an unfamiliar 
interaction warning, stating that a medicine should not be prescribed and the 
BNF was also unclear;  
“It might be where perhaps the computer’s flashed up an interaction, and 
it's something I really want to give, and it's saying ‘no’, but it often says 
no …(JR: Computer says no) … computer says no, and then I check the 
BNF and it's sort of half-heartedly mentioned in there, or something in the 
same drug group, but not the specific drug that I want to give, and then I 
might phone you then and say what's the chances of this, what kind of 
interaction level is this, do I have to really worry about it?” (F15). 
Information in first-line resources, such as the BNF, can be ambiguous as 
highlighted in the example above, or sometimes the information listed raises 
further concerns for the clinician about how to manage the patient, which was 
why they then contacted MI Services.  Several clinicians sought MI advice due 
to a lack of clarity with information in the BNF itself;  
“the BNF wasn’t clear whether it [terbinafine cream] could be used in 
neonates” (T18 GP).   
Another sought MI advice when BNF information about choice of 
antidepressant post myocardial infarction/CABG, was unhelpful; 
“the BNF […] that didn’t help that much, so I think these are the people 
[MI] to help me” (T15 GP).   
Some dentists specifically highlighted that when the drug interaction 
information in the back of the BNF did not enable them to make a prescribing 




“In the back of the BNF, like I sometimes think it's a bit vague, it's not 
very specific on that so, I think it's essentially easier probably quicker to 
phone and just get that sort of, get those checked out, any unusual ones” 
(F4). 
“…sometimes the BNF, it just doesn't quite say the exact wording you 
want, even if it's just kind of a very similar drug, unless you, sometimes 
you just want someone to say ‘yeah, 100%, that's right’…” (F5). 
This is interesting as although the BNF is a key reference for clinicians, the 
content about interactions tends to be minimal, so it is no surprise that they 
expressed a tendency for calling MI Services.  For example, based on my 
experience as an MI pharmacist, the use of pharmaceutical terms in the BNF 
can cause confusion regarding interactions, even for clinicians, by use of poor 
nomenclature, such as using the term relating to a class of medicines, such as 
‘macrolide’ for erythromycin; or ‘quinolone’ instead of ciprofloxacin.  This may 
cause further uncertainty for some clinicians e.g. dentists with limited 
medicines training.  
To help clinicians answer their MRQs about interactions, MI Services have 
access to some subscription-based resources, usually unavailable to primary 
care clinicians, for example Stockley’s Drug Interactions® and Micromedex 
DrugDex®.  These provide much more in-depth information through details of 
case reports, mechanism of the interaction if known and associated practical 
advice.  These additional resources enable MI staff to give clinicians more 
evidence-based, person-centred advice.  This was seen on a number of 
occasions, including advice being sought for herbal medicine interaction 
information, as described by this GP; 
“...questions around herbal remedies or natural remedies or things that 
maybe I wouldn’t be able to find in the BNF, or interactions with those sort 
of things...” (F7).   
The GP, quite rightly, identifies that unfortunately the BNF is not helpful for 
answering questions about interactions with complementary medicines.  This 
poses a dilemma for clinicians who really have nowhere else to look, other 
than perhaps a Google search, which obviously calls in to question the veracity 




Further content limitations of available resources were seen when clinicians 
tried to use the BNF to answer questions involving patients on multiple 
medicines with renal impairment.  Necessarily, the BNF only contains basic 
information about prescribing in renal impairment and more detailed specialist 
resources are lacking in primary care.  This GP needed to prescribe gabapentin 
for chronic pain, so called MI for advice; as the extract highlights; 
 “….the BNF clearly states that you shouldn’t increase the dose of 
gabapentin beyond 900mg when the eGFR is, I think it was less than 
45…(JR:Yeah) I can't remember, that's what the BNF states, but actually 
when you ask, when I asked [name of the MI pharmacist] and she got all 
this additional evidence from other people, some of it anecdotal from the 
renal unit” (F15).  
As such, even though the BNF does include some information to help clinicians 
answer questions about complex patients, the content is limited to very brief 
advice without any context, making the BNF less useful for answering these 
questions.  Thus, there is a tendency for the BNF to state that the medicine 
should not be used or that data are limited, which is not necessarily helpful to 
clinicians.   
It was also apparent during interviews that some clinicians had a tendency for 
using the hard copy BNF, so they would check with the MI Service when they 
thought it to be out of date; 
“like I say I think because of the, the nature of the BNF and it's annual, 
you know you don’t know if it's, it's never going to be up to date, it's 
always going to be out of date you know a couple of months after it's 
published, isn't it?” (F9 Dentist).  
Although the BNF is an invaluable core resource containing key information 
about medicines and is the ‘gold standard’ medicines reference for clinicians in 
the UK, it cannot be comprehensive.  However, the online version has regular 
updates and is more current than the bi-annually published paper copy.  Yet it 
is a concern that they may use out of date information, if they do not refer to 
the online version, or use alternative resources available to them such as the 





The eMC is a digital resource providing Summaries of Product Characteristics 
and Patient Information Leaflets for licensed UK medicines (OTC and 
Prescription Only).  It is a valuable resource listing all the key information 
about the medicine from clinical trials and post marketing data collated by the 
pharmaceutical companies, such as interactions with other medicines and 
foods, contraindications and adverse effects.  Still, this research did not 
highlight accounts of eMC use by clinicians interviewed, possibly because of a 
lack of awareness, or because it is not easy to search e.g. for an interaction 
and the risk is the user may miss or misunderstand information, so it is 
quicker to ask MI.  Content from both the BNF and eMC is accessible via the 
NICE Evidence Search portal (NICE, 2019) and has the potential to be a highly 
useful resource, as it acts as a ‘one-stop shop’ for clinicians.  This website 
combines evidence on health, drugs and technologies, public health, social 
care, and health care management and commissioning in one place, including 
guidance, systematic reviews, evidence summaries and patient information, 
but again no clinician mentioned knowing about or using this resource. 
Additionally, clinicians can also use clinical guidelines to manage their patients.  
However, most guidelines are usually about treatment of an individual clinical 
condition and do not consider the practicalities of treating patients with 
multiple morbidities, where one medicine may exacerbate another clinical 
condition or interact with other medicines.  In this study, clinicians wanted MI 
advice for their complex cases as their management did not ‘fit’ the guideline, 
given the patient’s clinical situation and personal circumstances, as these GPs 
described; 
“…I don’t suppose there’ll be NICE Guidance to cover those awkward 
situations when I phone you, that's probably where you come in …” (F3). 
“....if you want information on how to treat something that's out there and 
quite easily accessible through the guidelines, but when you're trying to 
weigh up risk, you know, whether that be your, you know, using an 
unlicensed medication, or ore tailored, doesn't it? […] it's that, it's 
prescribing out of guidelines, that, you need to speak to … […] what I'm 
talking about, about the sort of looking at your guidelines and the situation 




When they needed help to consider the options and disregard guidelines to 
manage a complex patient they sought MI advice.  Here, a GP needed to 
control pain in an older patient, already on multiple treatments with renal 
impairment, as noted in the following interview extract; 
“… she couldn’t tolerate tricyclics at all, so upping her Gabapentin was a 
good option really, and I just decided to ring the drug information 
pharmacist and see how much of a risk I was taking, because I am of that 
generation of doctors that the guidelines are there, but at, I think 
sometimes now we do tend to have this ‘perfect’ approach to prescribing 
[…] but it leaves the patient struggling, and I am prepared to talk to 
people I know about the risks we're taking with different sorts of 
medication, and if it seems reasonable slightly step outside…” (F15).  
This use of MI Services, when patients do not fit guidelines, seems appropriate 
as MI are ideally placed to help clinicians manage their complex cases where 
conflicting treatment dilemmas exist that require medicines optimisation.  
Besides Health LIS, there is no other freely available service in the UK able to 
provide this level of medicines support and advice to primary care clinicians.  
Under the theme of Information Resource Issues, clinicians also have the 
option of using a human resource i.e. asking another person, as well as digital 
information.  For this they have several options, including discussion within 
their immediate ‘community of practice’ i.e. other dentists or GPs within their 
practice or local community, who may have come across a similar problem; 
clinical pharmacists based in the practice or CCG, or community pharmacists.  
They can also ask specialist clinicians in a secondary or tertiary care setting.  
Other choices include, asking a clinical librarian, pharmaceutical company or 
as in this study, the MI Service.  For some clinicians interviewed, MI was being 
used as a last resort after asking colleagues.  Initially they would discuss a 
medicines question with their colleagues and were more likely to seek MI 
advice if they too were also unsure of the answer, as explained by this dentist; 
“…, maybe you would discuss it with a colleague, the other way round, do 
that first and if everyone’s unsure then it's probably time to call” (F5). 
Although clinicians can ask pharmacists MRQs, findings from my research 




pharmacists, or thought they did not have the time to help them.  Community 
and practice pharmacists are an obvious choice to field some medicines 
questions, however clinicians in this study had reservations about using them. 
This may be historical, in that pharmacists in primary care have had restricted 
access to resources and limited training in handling complex MRQs, i.e. about 
those patients with multiple medicines and conditions.  GPs in particular, 
explained that while they could use their local practice or community 
pharmacist, they had concerns about their level of knowledge, ability and their 
willingness to help.  For example, this GP was referred to the MI Service by 
the practice pharmacist for a complex case about choice of treatment for 
neuralgia in a patient with epilepsy and renal impairment;  
“I spoke to our pharmacist here [practice pharmacist], regarding the 
combination of the two and lowering the seizure threshold for amitriptyline 
and phenytoin. He said coming up the same on his computer and he 
advised me to phone yourselves” (T20 GP).   
It is reasonable, however, that the pharmacist decided to defer to the MI 
Service as this was about managing a complex patient which involved 
checking for interactions, considering possible adverse effects and choosing 
the most appropriate medicine. 
Another GP described a community pharmacist as checking the BNF, but not 
doing much more than the GP had already done; 
“Done that before and not always that helpful [contacted the community 
pharmacist] – tell you what they know and look in the BNF which you’ve 
already done and won’t go any further” (T35). 
Additionally, they described difficulty contacting busy practice pharmacists;  
“…I don’t tend to contact them for these sorts of queries […], but just 
because I feel like, you know, you won't always get through to them 
(JR: No) they've got other calls on their time” (F14 GP) (relating to 
simvastatin in early pregnancy).  
GPs were also uncertain about the level of clinical experience of pharmacists 
based in their practice and this affected their confidence in getting a response, 




“…it depends, at one time there are one or two pharmacists, it's quite a 
big pharmacy here, sometimes as well and obviously it depends [on] their 
clinical experience as well, what background they've got, what clinical 
confidence they've got, so sometimes we do get an answer, other times 
we don’t…” (F13). 
Community pharmacists are, like GPs and dentists, time poor to take on other 
activities as they are busy checking prescriptions, counselling patients, 
conducting medicines use reviews and advising on treatment of minor 
ailments.  This premise is supported as MI Services do receive MRQs from 
practice and community pharmacists, as they too have the same constraints 
for handling difficult MRQs or in complex cases, as GPs and dentists.  This may 
go some way to explaining why GPs held negative opinions about using them 
for MRQs. However, this situation may change with the development of 
pharmacists working in primary care, including clinical pharmacists in GP 
practices and nursing homes (NHS England, 2015), as they receive further 
training on searching medicines resources and answering MRQs (CPPE, 2019).  
Primary care clinicians can also contact secondary care staff and pharmacists 
in this sector were an option, although some clinicians expressed a reluctance 
to speak with them due to prior poor experience, and so tended to discount 
them as viable; 
“… pharmaceutical people, wherever pharmacists are not, to get them is 
hard…(JR: OK)… it’s difficult to access them and then they’re not there or 
they’re on wards…(JR: Yeah)… it's a nuisance and they have to ring you 
back…” (F8 GP).   
Alternatively, a specialist clinician can be contacted, but as in this thesis, see 
‘Providing a decision’, and based on published evidence, they may be difficult 
to contact, slow in responding and less inclined to provide person-centred 
advice (Baird et al., 2016).   
Besides other clinicians or MI Services, another possibility is to ask a clinical 
librarian based in a Health LIS.  Clinical librarians are skilled in searching the 
literature (Brettle et al., 2011; Davies, 2011; Perrier et al., 2014), but 




and provide medicines optimisation to individual patients.  Use of Health LIS 
was not specifically mentioned by clinicians interviewed. 
Risk and medico-legal back-up:  Clinicians also used MI as a safety net 
when they had concerns about risk and wanted medico-legal back-up.  Some 
of those interviewed valued the fact that MI advice was recorded on a 
database, which could be used as evidence, should they need it in the future; 
 “It's one of the big advantages as well, I mean as you would know with 
the current atmosphere and the way the litigation side of things as 
well.”……“…. that I've spoken to Medicines Information advice line and 
been advised to do this, this, this …(JR: M-mmm)… so it becomes for audit 
purposes as well, for clinical awareness purposes that we do know who 
we're taking advice from” (F13 GP).   
On the subject of using MI as back-up, another GP said; 
“…I feel I've been following good advice that you know if, even if 
something did go wrong we can say faithfully that we're following best 
practice, and medico/legally, I know you guys are logging things at your 
end” (F6). 
Most clinicians in the UK use a digital patient record system e.g. EMIS Health® 
and SystmOne®, to keep notes of patient consultations and can also record 
other interventions in the patient’s (electronic) health record.  Clinicians also 
explained that they made a note of their communication with the MI Service in 
the patient notes, indicating that they keep a record to corroborate their 
prescribing.  When specifically asked in the telephone interviews, clinicians 
said they documented MI advice in the patient’s notes in all cases except one.   
Some clinicians interviewed also added a copy of the MI email response to the 
patient’s health record, and looked for a referenced written reply, as this 
enabled them to verify and reassure themselves about the reliability of the 
information provided; 
“..think it [written reply] was better because you can, you can check the 
reference on the article as well, and check how it was based and how it 
was done, if it's credible or not” (F10 Dentist).  This GP valued the fact 




references if you wanted to, you know chase it up and look into it more 
deeply” (F3). 
To help protect themselves against negligence claims, clinicians subscribe to 
indemnity insurance, through the Medical Protection Society/Medical Defence 
Union for GPs, and the Dental Protection Society for dentists.  This 
experienced overseas dentist, more recently working in the UK, mentioned 
getting MI advice as well as asking their indemnity provider, to help minimise 
risk should they have any negligence claims made against them; 
“…it is important to have the reference, isn't it, it is, 'cause they say in the 
Dental Protection Agency if it is not written, it's not given so you always 
write any conversation”......“I think when, I think when they [medicines 
questions] come about it's always just for, to see if somebody else have a 
different information that you're not aware, and then you can take better 
decisions, and sometimes we'll do the Medical Protection as well” (F10).  
As a society we have become more aware about litigation and lawyers actively 
encourage us to make claims against others when things go wrong (Schepers 
S, 2017).  Clinicians voiced the issue of being sued and were minimising the 
risks to themselves by not relying on their own ability, their prescribing 
systems, other people or other information sources, as this dentist explained; 
“I thought I'd check …(JR: … yeah)… just to be safe, so it's just probably 
covering my own back as well [……]… and you don’t want to do anything 
that you could get sued for, or in trouble for …” (F5).    
Clinical practice is inevitably prone to litigation as evidence-based practice 
consists of three components which include, balancing the best available 
evidence, clinical expertise, and patient values and preferences (Sackett et al., 
1996).  Full-time doctors and dentists can expect to receive two clinical 
negligence claims during the course of their career (Dental Protection, 2017; 
Medical Protection Society, 2018).  Of course nothing in life is risk free, we all 
take calculated risks every day e.g. driving a car or crossing the road. 
Similarly, no aspect of medical or dental care is risk free and it is the job of 
clinicians to take measured risks.  In this study, clinicians did not want to rely 




get a second opinion.  Clinicians said they sought MI advice to help them 
weigh up the risks for difficult cases,  
“…I suppose I wasn’t, I wasn’t, I wasn’t trying to minimise I was more 
trying to establish the risk really…” (F12 GP). 
This dentist was understandably risk averse when a specialist had previously 
highlighted the lack of data about bleeding risk in dental patients with a new 
oral anticoagulant medicine and wanted back-up from the MI Service;  
“…I’d spoken to the Consultant in oral surgery and he had, he'd made it 
quite clear that, do not take one of these teeth out in the 
practice…[.....]…you must send them in, because he’d had 50/50, some 
were fine, others were really big bleeds and he said it's just so 
unpredictable, so I just thought from a, from a point of view of prescribing 
as well, I wanted to be safe” (F9). 
The dilemma of managing risk in a complex patient with CKD was described by 
this GP, as they were running out of options to treat the patient’s neuropathic 
pain.  As guidelines were not relevant, they needed to weigh up the risk 
versus the benefits and found it helpful to discuss options with the MI 
pharmacist; 
“…I just decided to ring the drug information pharmacist and see how 
much of a risk I was taking…” (F15).   
They also wanted back-up from MI as they needed to prescribe higher doses 
of medicines than listed in the BNF or eMC; as is described here; 
“…it's still my responsibility if I write the prescription.  […] because I was 
worried about the consequences, or increasing it anyway, but probably 
being a little bit more anxious about it, because these aren't easy 
decisions to make…” (F15).  
Problems with use of general reference sources for high risk questions were 
also an issue highlighted by some as a risk-related reason for consulting the 
MI Service.  For example, the BNF only has limited information about use of 




“…the information in the BNF is not always that extensive I think, yeah, to 
minimise the risk to yourself as a professional it's about getting other 
sources of information…” (Simvastatin in pregnancy) (F14).   
Another GP was unsure because the BNF advised caution when using an 
antifungal in breastfeeding; 
“I'd seen the, there was a little section saying about the, the age of the 
child and, and, and em advising a caution that's, that's when I sort of 
thought well perhaps I better just ask some advice before I prescribe” 
(F12).  
Prescribing analgesia, other than paracetamol, in pregnancy was also a 
concern, especially as the BNF information was alarming; 
“I had seen codeine prescribed in pregnancy floating around, I know they 
would give pethidine in the end stage of pregnancy and things like that, 
but you know the BNF, if you look at it, it just talks about decreased 
neonatal movements and things like that, and you're thinking you know, 
that sounds a bit scary to me, I don't think I'd want to suppress anyone’s 
respiratory … (JR: No)… centre in the baby, and obviously they're more 
sensitive to medications than adults, so I always veer away from 
prescribing” (F6 GP). 
When a patient wanted to continue an antidepressant that they felt was 
effective after they found they were pregnant, concerns about managing this 
case were given by this GP as a reason for contacting MI; 
“Usually, you know the patient’s already pregnant and is on an 
antidepressant and you're worried that it might not be safe and the patient 
doesn't want to stop, and it's sort of then trying to gather together some 
evidence…” (F3). 
Clinicians even described that if they didn’t get MI advice, they would avoid 
prescribing some medicines; 
“I'd err on the side of caution, I'd just, you know I wouldn’t, if I wasn’t 





This practise was also expressed by a GP; 
“I would have probably just given her paracetamol and said just stick with 
that, that’s as far as I would have gone. […] “I've seen many women and 
I've always advised them, look, you know things aren't safe, best just to 
stick to paracetamol, hot water bottle, and then just, you know let nature 
take its course” (F6). 
This tendency to do little or nothing in a more litigious society is unsurprising 
with clinicians becoming more risk averse (Medical Protection Society, 2018; 
Dental Protection, 2018).  It has been found that those subjected to clinical 
negligence claims may subsequently practise more defensively; for example 
by ordering more tests than necessary (O'Dowd, 2015).  Although it was not 
clear if any clinicians interviewed in my study had been subjected to these 
types of claims, this type of practice is concerning as a patient may be denied 
potentially helpful treatment and possibly have inadequately managed 
symptoms.   
Conversely, an experienced GP, qualified for many years, talked about feeling 
that they should be more risk averse in their practice, as the working climate 
was different compared to when they first qualified; 
“…really you can't do that now [prescribe outside guidelines], […..], so a 
little bit of science behind supporting the decision you're making is actually 
helpful” (F15).   
They also found it frustrating that their younger colleagues were more risk 
averse than they were, and felt they should behave in the same way; 
“…I work with a lot of younger doctors and we, we actually have a study 
group…(JR: OK, yeah)…but if you read any of their notes, it's all 
“guidelines say can't prescribe” (F15).   
This GP felt that their younger colleagues would benefit from using the MI 
Service for support and explained how a younger GP had referred a patient to 





“…you can't use antidepressants in liver disease …well, you can […] and 
explain what the difficulties are, but this younger doctor didn’t feel 
comfortable doing that…” (F15). 
Ideally, GPs as expert generalists, should practise person-centred care rather 
than protocol driven care, although this is a skill that comes with experience 
and training (Reeve et al., 2013; Reeve, 2015).  The role of the expert 
generalist clinician is to be flexible about guidelines if they do not fit what the 
patient needs and/or wants, but potentially leaves the clinician open to 
criticism, unless they can back up their decision.  Complex cases carry greater 
risk as there are more confounding and competing variables to weigh up, with 
clinicians trying to use interpretive practice rather than protocol driven care.  
Risks can be managed by discussion of complex cases with the wider clinical 
team, to gather their knowledge and perspective about the clinical problem, 
and also with the patient themselves.  In this study, the MI Service was able 
to help clinicians practise patient-centred care whilst minimising risk as by 
using MI to allay any concerns, clinicians felt able to prescribe appropriately 
and safely, backed-up by the fact they are using an expert service. 
To summarise these findings about clinicians using MI advice as a safety net 
for knowledge and/or resource issues, as well as risk and/or medico-legal 
concerns.  Interview extracts describe how they used it to fill in the gaps in 
their clinical knowledge, but also when they lacked technical ability, or there 
was insufficient information from those resources consulted, and if they had 
concerns about risk to themselves over perceived litigation possibilities.   
This use of the MI Service as a safety net was apparent when clinicians moved 
from their usual decision-making processes to making decisions that exceeded 
their competency boundaries.  Despite doing CPD, they knew it was impossible 
to keep up to date about everything, especially when unfamiliar medicines 
were initiated by specialist clinicians in the hospital sector.  This is 
compounded by the fact that there is too much information to access, which is 
also constantly changing.  Clinicians used MI advice to fill in gaps in their 




Although some clinicians tried to find the answer themselves, especially for 
simpler questions; others described difficulties when their prescribing system 
flagged a problem, particularly if the answer was not in their usual reference 
sources, like the BNF; or if it was in the BNF, the information they found was 
unclear, insufficient or worrying.  These problems were particularly apparent 
for challenging questions for which they did not know where to find the 
answer, including those complex or high-risk cases less likely to be covered in 
a clinical guideline.  When the clinician was unable to use their own 
knowledge, resources, or their wider ‘community of practice’ to answer a MRQ, 
tapping into human resources was an option and previous positive use of MI 
meant that clinicians would often use MI Services preferentially.   
Past poor experiences utilising pharmacists, and slow replies from secondary 
care clinicians also resulted in them using MI Services.  In some instances, 
prescribing clinicians were unsure of the ability of some pharmacists to be able 
to answer the more complex, high risk questions and if they could, whether 
they would have the time.  
Finally, clinicians also contacted MI when they wanted back-up and support to 
minimise risk to themselves and their patient care.  They valued the fact that 
the MI Service sometimes provided a written, referenced response which they 
could keep with the patient’s medical notes.  Also they appreciated the fact 
that the MI Service kept a record of their enquiry and the advice provided, 
should they need to provide evidence for possible medical negligence claims in 
the future.   
In the next section I will describe and discuss how clinicians used the MI 








Medicines Information as a medicines ‘help desk’ 
The relevant themes extracted from Table 4.1 are in Table 4.5 below. 
 
Table 4.5 Domains, meta-themes and themes for Medicines Information        
as a ‘help desk’ 
Domain of Medicines 
Information influence  
Meta-theme Theme 
The motivating factors for 
clinicians deciding to seek 






A ‘help desk’ or ‘customer service centre’ is a central point that people can 
contact when they have something they need support about.  They are 
particularly well known in the IT setting as a resource people use when they 
need technical support.  Similarly, ‘call centres’ or ‘contact centres’ are 
provided by organisations to support customers or service users.  In the NHS, 
111 (formerly NHS Direct) is a dedicated public contact centre for urgent 
medical concerns in England and Scotland (NHS 111, 2019) yet there is no 
nationally recognised contact centre for NHS clinicians with MRQs. 
Clinicians interviewed used a variety of expressions related to them viewing 
the MI Service as a medicines ‘help desk’ or ‘contact centre’, with expressions 
such as; 
“…it's more like a live help desk sort of a situation thing, where somebody 
is sitting just ring them and they’ll look into it straightaway and get back in 
to us” (F13 GP).” 
Others expressed this as being able to go directly to someone that could help; 
particularly when the person at the end of the phone could use their database 
to access a similar MRQ; 
“It was really nice going one route and very quickly getting a definite 
decision” (T36 GP). 
“It was very helpful practical advice, they’d [MI] had a similar query 
recently and they’d already looked up a lot of the information and it 
seemed that the advice was that it (sodium cromoglicate eye drops) was 




Nowadays, most commercial organisations have contact centres and within 
these, as well as the traditional method of telephone contact, they have 
increasingly been expanding their use of multichannel technologies, such as 
online FAQs, Facebook, Twitter and live webchat to provide customer service, 
while reducing costs and ensuring accessibility.  They do this by providing 
customers with digital self-service options first e.g. online FAQs, moving 
towards ‘live assistance’ if the user cannot find an answer.  This type of 
service provision is something the MI Service does in a small way via FAQs, 
although this requires further development to be more intuitive, interactive 
and user-friendly.  However, human contact was highly desired by 
interviewees in this study; clinicians valued and preferred to speak to a 
person; 
“you know I [..] just, I want to pick up the phone and speak to 
somebody…” (F8 GP); 
“…sometimes you want to hear someone at the other end of the line say 
‘actually, I've had a look and there's nothing’ ” (F9 Dentist); 
“My perception is that you phone, give the query, if it's a straightforward 
answer that you can give over the phone then you give the answer at the 
time” (F14 GP). 
The findings in this study about clinician preference for human contact, align 
with the fact that despite the increasing use of digital options in commercial 
organisations, customers still want ‘live assistance’, to experience the human 
connection, and prefer to speak to a technical expert for more difficult 
problems (Call Centre Helper, 2017).  Although perhaps, as practising 
clinicians become more familiar with various clinical/medical digital platforms 
at undergraduate level and their use becomes embedded into practice, 
preference to speak to the MI Service may change in the long term.  While it is 
inevitable that those call handlers in centres who follow strict algorithms are 
likely to be replaced with digital options, until artificial intelligence is able to 
handle complex problems, contact centres will need people to answer more 
difficult customer questions, either by telephone or other digital media, such 
as web chat (Call Centre Helper, 2017).  Similarly, it is unlikely that digital 




required for MRQs involving complex cases, which are only going to increase.  
Although, as those with more digital experience filter into practice, the 
challenge for MI Services will be to develop digital platforms, to allow users to 
answer their own MRQs if they prefer.  The main themes identified within this 
medicines helpdesk meta-theme with regard to clinicians using the MI Service 
as a medicines ‘help desk’ were around provision of an expert, trusted service 
and convenience, these are described and discussed next. 
Expert service: Clinicians described how they perceived MI advice as 
provided by an expert, specialist qualified service able to check the 
appropriate resources;  
“…it's [advice is] only as good as the person on the end of the phone, isn't 
it, they [other clinicians] don’t have the access to the databases that you 
have, where you are” (F3 GP). 
A similar view was expressed by this GP; 
“so the information we've got is from a qualified pharmacist who are 
looking into the appropriate website and databases.  I think for me 
personally that, that gives me a lot more confidence” (F13). 
They also wanted detailed pharmaceutical advice, which they felt could only be 
provided by a specialist service like MI, rather than from another specialist 
clinician; 
“You can go to a clinician but they won’t really, they know about handling 
the drug in everyday work which is very useful but you want to know 
something specifically about this drug, does the drug company say this or 
that, what does the pharmacopoeia say, if psychiatric drug or neurological 
drug and go to Maudsley [psychiatry] Guidelines and they [MI] have 
access to so much, think they are a fantastic service” (T15 GP) (Choice of 
antidepressant post myocardial infarction/CABG).   
In fact, the specific, practical nature of information provided by an MI expert 
was valued by this GP; 
“…it was very, you know, good detailed information about how to prescribe 




These findings support the MI remit where services are provided by ‘expert’ 
pharmacists, who use their critical thinking skills to clarify the MRQ with the 
clinician in order to obtain as much relevant patient and clinical information as 
possible. Additionally, staff have training and experience of searching 
evidence-based medical and pharmaceutical resources, and the wider medical 
literature; ultimately providing a person-centred evidence-based response, by 
using their MI skills and pharmacy knowledge to interpret the information. 
Trusted service: For people to become repeat users of a ‘help desk’, they 
need to be able to trust the advice provided.  This trust was exemplified by the 
fact that many clinicians interviewed were repeat service users and agrees 
with the wealth of previously published MI studies with positive findings for 
user satisfaction. Their trust in MI was expressed as a specialist service, 
providing evidence-based advice they could rely on; 
“I take their advice as being really the best advice I can get as a GP in the 
UK” (T10); 
“…we can never know as much as a service like yours is, so I think we 
kinda put that trust on you, that you're giving out evidence-based 
advice…” (F9 Dentist); 
“…whatever advice I will give them is going to be you know tried and 
trusted advice, 'cause it's been coming from a specialist service...” (F6 
GP). 
Others thought that because MI staff were skilled in searching for and 
evaluating up to date, evidence-based information, this instilled in them 
confidence and trust; 
“I always find that you know the, it's good current information that I 
receive, it's, it's information that I can be confident with to use […], and 
take into practice with, without any, any worries at all, …[…]…I trust in 
your expertise…[…]…you guys know what you're doing…” (F11 Dentist); 
“…you're probably aware of a lot more websites and databases where you 
can get evidence-based first hand appropriate information there and then 
straightaway, so I think that that gives a lot of confidence to us as well, 
that this information which has come out is not just from Google or 




Convenience: A key feature of the ideal ‘help desk’ is that it should be 
convenient to use.  For a service to be convenient for the end-user it needs to 
be accessible, ideally quicker than doing their own research and provided at an 
appropriate time i.e. a response provided according to the individual 
requirements of the customer.  The accessibility and timeliness of the MI 
Service was described by clinicians as getting answers straight away; 
“somebody there to help me then and there” (T21 GP);  
 “.. the good thing about your service is that it's, you know it's easily 
accessible, and you can get an instant answer all the time” (F6 GP); 
“Every time I ring up I've just found the service really, really good, 
because it's really quick, and it's really clear” (F1 Dentist). 
Ideally, MI Services aim to provide responses at a time convenient for the 
clinician, as this GP states;  
“It’s a very convenient way of getting up to date information most easily” 
(T10).  
The balance being that not every question is answered immediately, as 
responsiveness has to be weighed against clinical urgency, complexity of the 
question and enquiry service workload.  
Clinicians also found the service convenient because they could pick up the 
telephone, speak to someone and get advice whilst the patient was waiting, 
meaning treatment for patients was not delayed, for example as this dentist 
described; 
“…it's really easy accessible, you know I've em … many a time if 
something’s arisen I've asked the patient to wait in the Waiting Room, I've 
just said “do you fancy sitting outside with a magazine for five minutes?,” 
I've been on the phone, sorted it out, got them back in, all within the 
appointment” (F9 dentist). 
The timely nature of MI advice was also valued by GPs as they too could 
quickly make decisions about patient treatment; 
“I needed to know on that day. She was not well and we needed an 




 “…this guy, I phoned you within quite a short time I could phone him [the 
patient] back…(JR: OK) … … it’s sorted…(JR: … yeah)… you know happy 
guy, doctor sorted…Imagine if I had to phone him back in 2 days’ time” 
(F8 GP). 
Using the MI Service was viewed in some cases as more convenient than 
asking other people for advice.  When clinicians were asked about alternative 
sources of information, they explained that if they asked a GP or specialist 
they might have to wait for a reply.  They felt they got a quicker response and 
could treat the patient straight away, compared to contacting another 
clinician.  
Ideally, busy clinicians do not want to wait for an answer to their more urgent 
treatment dilemmas and using MI avoided them having to contact another 
clinician.  This dentist avoided having to ring the GP and wait for an answer; 
“…you can deliver the [dental] treatment that you need to in good time, 
there isn't any stalling […..] I think you can probably provide pain relief 
and something that's going to alleviate your [the patient’s] symptoms 
quicker, you can deliver it faster when you've got that advice at your 
fingertips […..] [the] alternative would be to ring the GP…” (F9). 
Although they could ask someone else, clinicians also stated it was not always 
easy to know who to ask, and that it might be more difficult to get an answer 
from a specialist due to their availability and workload; 
“…may be asking eh one of the, I don't know, specialists at the hospital it 
probably would be…(JR: M-mmm)…but em whether it would be someone 
at the breast clinic or one of the you know obstetricians, …[…]…some 
consultants it, it depends,…[…]…when you've called them […], it may be at 
a time when they're doing admin work it's quite easy, other times 
obviously they're busy…” (F12 GP).   
Fundamentally, by preferentially using the MI Service over hospital physicians, 
the service was invaluable for clinicians, and their patients, because it could be 




“is it safe to continue, or not, while you're waiting for their appointment to 
come up at psychiatry, you know through an antenatal clinic, which might 
be some weeks away …” (F3 GP).  
Whilst speed of response was appreciated, sometimes this was seen as less of 
an issue for some clinicians, as their MRQ was non-urgent but complex, thus 
requiring a more detailed search.  This GP thought it was understandable that 
it might take time to get a response; 
“…quite often [the answer does not seem to be straightforward], so you go 
away and look at your resources, which I presume you're looking at the 
literature and then come back with the answer based on that…[…]…so I 
would have thought it's entirely reasonable and appropriate that there is a 
bit of a time delay whilst you look at the evidence …(JR: OK)… that you've 
got, you know literature that you've got,” (F14 GP). 
Other interviewees expressed convenience, not as getting an immediate 
answer, but as contacting the MI Service at a time convenient to them, such 
as prior to the patient’s pre-arranged appointment, or after surgery hours 
when they have more time to telephone MI and discuss the MRQ; 
“…it's generally been a case that, as in with the case of the guy with the 
extraction, you know it’s something that we're planning to do in the future, 
so it gives me time to, to give you a ring and then get back to the patient 
after that…” (F11 Dentist); 
“I don’t tend to use the service while the patient is there, just because of 
time constraints during surgery, but I will ring after surgery and very 
quickly […..], you know usually within a day I would get an answer, which 
is really helpful, I can feedback to the patient very quickly then” (F7 GP). 
Another element of convenience, as well as accessibility and timeliness, 
conveyed by clinicians, was saving them time.  They did not have to spend 
time trying to find an answer themselves, as these clinicians described;  
“...I've always found yourselves really helpful in answering those questions 
where it's, it would be more difficult, it would take me more time maybe to 




…it's just more time-consuming really, I'd rather like ring yourselves, it's 
just a lot quicker, 'cause you seem to have like the evidence to-hand…” 
(F1 Dentist). 
Particularly when the patient was taking multiple medicines;  
“…because I think when you're confronted with 21 medications, unless you 
specifically know the interaction with all of them, or check it manually, 
which I think will take a really long time - 'cause I have done it before” (F4 
Dentist); 
“It is quite useful for me as well, it saved my time as well …(JR: Yeah)… of 
sending them away, then getting in contact with you people…” (F13 GP). 
A recurring type of MRQ, mentioned as time consuming by several clinicians, 
was that of complementary therapies, which are very popular with patients 
(James, 2017).  They needed to find answers to herbal medicine questions but 
were unsure about reputable information sources.  This GP described 
contacting MI because of time constraints and a lack of easily accessible, 
reliable information sources about interactions with complementary medicines; 
“…I've a, you know, lots of demands and I may not have been as quick to 
find out the information, and it's difficult to know what to trust 
…(JR: Yeah)… as well out there, because if you put anything, particularly 
about natural herbal remedies, there's unsubstantiated claims about lots of 
them, so to sift through that would be time-consuming, […..], but it 
wouldn’t have been as easy for me…” (F7 GP) (Barley grass powder with 
other medicines). 
This difficulty of searching for answers to herbal medicine questions was 
expressed by another clinician.  Whilst they believed they would have found 
the answer (St John’s wort with topiramate), it would have taken them far too 
long and potentially left the patient without any treatment for their 
depression; 
“I think somehow I could have still got the information…(JR: Yeah)… not 
necessarily sort of same day or next day, maybe within a week, that may 




medication, I think that's happened in the past before I started to use this 
service (F13 GP). 
Whilst it might be safer for clinicians to encourage patients to avoid 
complementary therapies due to lack of efficacy or possible risks, the reality is 
this is not likely to happen, due to their popularity.  This means that primary 
care clinicians need to make informed decisions about complementary 
therapies, but unfortunately the availability of accessible, reliable resources 
they can access to answer these questions is minimal.  Although there are 
some UKMI Q&As, EMA monographs and Cochrane reviews, there is little else 
and it is debatable as to whether clinicians are even aware of such resources.  
Instead, they can contact MI Services, who subscribe to well-recognised 
resources e.g. the US produced Natural Medicines Database (Natural 
Medicines, 2019) and who have the skills to answer the more time-consuming, 
complex complementary therapy questions.  That is, considering the 
interaction risk with their other medicines, as well as the effect on the 
patient’s other conditions, by taking into account the pharmacology of the 
complementary medicine and possible liver enzyme effects (Schjott and Erdal, 
2014; Gregory et al., 2015; Day and Snowden, 2016). 
A final element of convenience regarded time saved when the clinician did not 
have to send the patient away with an unanswered question, so could get on 
with other work without having to re-see or contact the patient, thus saving 
both themselves, and the patient, time; “… you're not sending the patient 
away to then come back at a later date to do something, you, you can crack 
on and do it straightaway” (F9 Dentist);  
“I think that was quite good in that sense, it was done…(JR: Doing it at the 
time?) …there and then” (F13 GP). 
Although other MI studies have documented MI Services as convenient by 
providing an accessible, timely service from a quality assurance perspective, 
they did not give any detail about how this was achieved (Melnyk, Shevchuk 
and Remillard, 2000; Schjøtt, Pomp and Gedde-Dahl, 2002; Hedegaard and 
Damkier, 2009).  This study is the first study to describe how clinicians value 
the MI Service as a ‘help desk’ for their MRQs.  They found it convenient as 




telephone advice about medicines treatment, often whilst the patient was 
there, which avoided delays in treatment or them having to wait for a referral 
to a specialist clinician.  For non-urgent, complex questions they knew they 
might have to wait but preferred to do this than wait for a hospital clinician to 
respond, especially if they did not know who to ask or if they would be free to 
discuss the problem.  Timeliness was also about being able to contact MI at 
their own convenience, i.e. in advance of a patient consultation so they were 
prepared for discussion with the patient or after surgery hours when they had 
more time to discuss their MRQ with the MI Service.  
While the study by Marrone previously described time savings that MI Services 
could make as PHS, this was more theoretical than actually documented 
(Marrone and Heck, 2000).  My study is the first to describe how the MI 
Service saves clinician time by answering their MRQs whilst the patient was 
with them, as they did not have to send the patient away and either, call them 
back or book another consultation.  The MI Service saved clinicians spending 
time trying to answer their difficult questions, especially those where 
resources are lacking, e.g. MRQs about complementary therapies, or for 
complex cases where they thought the information would be awkward to find, 
or take them longer to search for. 
As this study found, the MI service acts as a ‘help desk’ because it is viewed 
as a trusted, convenient, expert service, although it is unfortunate that not all 
primary care clinicians know about MI Services in the UK (Rutter, J. and 
Rutter, 2004).  This is a concern, as non-MI studies have found that GPs have 
to prioritise questions as best they can and do not answer them all (Del Fiol, 
Workman and Gorman, 2014), particularly as very little is known about what 
clinicians do to answer MRQs if they do not use the MI Service (Rutter, J. and 
Rutter, 2004).  In my research the problem of not being able to answer their 
own MRQs at that moment in time was described by a GP as a reason for 
seeking MI advice; 
“…sometimes it’s just pressure of time to look it up and when am I going 
to be able to look that up and the moment’s passed and I think am I going 




Prior to knowing about the MI Service, this GP explained how they would try to 
answer questions they had jotted down after surgery, as this was what other 
prescribers did in the practice; 
“…a lot of queries do come in from day-to-day, and somehow we do get to 
the bottom of it and do find the answer of it, […..], some people write it 
down and that is part of the thing I used to do before as well, […..] we 
have, every GP has got their own sort of like small notebook, or, and we 
jot things down” (F13 GP). 
Once they knew about the MI Service, instead of doing what their colleagues 
did, this GP was able to contact MI directly with their more awkward 
questions, rather than answering themselves after surgery;  
“At the end of the surgery they’re looking through it [the list of questions], 
like any queries to do that they need to check, go back and do, take some 
more information or find out something, and that used to be part of that 
list for me as well […..], either ask a senior colleague, ask a local 
pharmacist, ask a friend, Google it, different portals …” (F13 GP). 
This illustrates how prior knowledge of the MI Service, enabled this GP to use 
MI for future MRQs, and is consistent with findings of the MI study where 
primary care clinicians did not use MI because they did not know about it 
(Rutter, J. and Rutter, 2004).   
The time saving element of the MI Service being viewed as convenient is 
important.  GPs and dentists are under increasing workload pressure and time 
constraints, as such various means of reducing pressure and saving GP time 
are being introduced (NHS England, Royal College of General Practitioners, 
and Health Education England, 2016; Baird et al., 2016), including the 
development of the role of clinical pharmacists in primary care.  Although 
these clinicians, including practice pharmacists, have access to websites and 
various CDSS, they too are also restricted by time and may not have sufficient 
skills to answer those difficult MRQs, certainly those involving complex 
patients.  Therefore, clinicians accessing the MI Services saw it as a ‘one-stop-
shop’ because it was accessible, convenient, and provided real-world advice.  
The varied awareness of the MI Service as a ‘help-desk’ is compounded by the 




promotion is achieved through centres listed in the inside front cover of the 
paper BNF, and furthermore, although some digital information is provided, 
via the SPS website, this has had limited formal publicity since its launch in 
August 2016.   
To summarise my findings about clinician descriptions of use of the MI Service 
as a medicines ‘help desk’, it acted as such by providing trusted, expert, 
convenient advice.  They used the service to provide person-centred, 
evidence-based advice, which sometimes required specialist resources they 
could not access. Clinicians interviewed found discussing the case via 
telephone invaluable, particularly if they got immediate advice whilst the 
patient was there.  Finally, they found the MI Service convenient because as 
well as being accessible, it also saved them time.  In fact, the immediacy of 
some of the advice potentially saved time for patients and clinicians alike, as 
there was no need to book a follow-up consultation to discuss the outcome of 
the MRQ.  
Summary of this chapter 
This study describes how clinicians used MI advice as a safety net in their 
decision-making, as well as the effects of advice on their prescribing and 
patient care, and effects on their feelings.  They also used the service as a 
safety net when they had knowledge or information resource issues, and 
wanted risk and/or medico-legal back-up; and viewed the service as a 
medicines ‘help desk’.  These findings are summarised below. 
Decision-making: Clinicians were using MI advice as a safety net for their 
decision-making, especially for complex or high risk cases and/or those where 
the answer was difficult to find.  MI staff often told them what to do and then 
they acted on it, or it helped shape their thought processes so they were able 
to make a decision.  The MI Service therefore plays a key role in clinician 
decision-making by taking over the difficult, time-consuming research and 
System 2 decision-making directly processes.  They were also using MI advice 





Prescribing:  Clinicians thought their prescribing was improved when they 
used MI advice to inform their prescribing for complex or high risk cases.  
Additionally, they used the MI Service for other challenging questions, which 
they found difficult to answer themselves, allowing them to make an 
immediate prescribing change for the patient.  They also felt their prescribing 
was better and/or safer because they knew their prescribing was informed by 
reliable, trusted evidence.  They also described how they used advice to 
update their own knowledge i.e. it helped improve their ‘mindlines’.  They are 
also able to integrate MI advice into their System 1 decision-making, 
illustrated by how they changed their prescribing practice and subsequently 
used it with future patients.  Importantly, they also used patient-specific 
advice to review prescribing of similar patient groups within their practice, 
thus avoiding potential problems for other patients. Equally important, they 
also said they used MI advice not only for their own patients and CPD, but also 
shared it with their colleagues, that is their ‘community of practice’ 
Patient care: MI advice was viewed as improving the clinician patient 
relationship, as well as reassuring or empowering patients and having a 
clinical effect.  Clinicians thought it was better to be honest with patients when 
they did not know what to do, and explained to the patient that they were 
going to ask a specialist service for medicines advice.  They thought patients 
seemed to appreciate this fact, and described how they were able to use MI 
advice in SDM discussions.  They also felt their relationship with the patient 
was improved.  Some felt that MI advice had a beneficial clinical effect on the 
patient, thus enabling continuity of care.   
Clinician feelings:  Clinicians were better informed, as such they described 
feeling reassured and even empowered by MI advice, to make improved 
prescribing decisions for their patients, or to question a decision by others 
whom they perceived as expert.   
Knowledge or information resource issues, and risk and/or medico-
legal concerns: Clinicians used the MI Service as a safety net to fill in the 
gaps in their clinical knowledge, but also when they had technical or 
information resource issues, or concerns about risk and wanted medico-legal 




everything, especially when unfamiliar medicines were initiated by specialist 
clinicians in the hospital sector or there was too much information to access, 
and were using MI advice to update their knowledge for future use.  When 
their prescribing system flagged a problem, the answer was not in the BNF, or 
if the information was unclear, insufficient or worrying, or for challenging 
questions for which they did not know where to find the answer, such as for 
those complex or high risk cases less likely to be covered in a guideline, they 
sought MI advice. This was sometimes in preference to others, due to previous 
positive use of the service.  Finally, clinicians explained how they contacted MI 
when they wanted back-up and support to minimise risk to themselves and 
their patient.  Additionally, they valued the fact that MI provided a response 
which they could incorporate into the patient record, refer to for future 
patients and for possible medical negligence claims in the future.   
Medicines ‘help desk’: Clinicians in this study viewed the MI Service as ‘help 
desk’ because it provided them with trusted, expert, convenient person-
centred evidence-based advice.  They also valued ‘human’ contact and the 
immediacy of advice, as potentially saving time for patients and clinicians 
alike. 
In the next chapter, I discuss my findings further by relating them to the 






Chapter 5 Overall discussion and conclusion 
In the previous chapter, I described, discussed and summarised my findings, 
including those about how clinicians described their use of MI advice in their 
decision-making and prescribing.  In this chapter, I expand on these findings 
by linking them with the decision-making and prescribing models I 
introduced in Chapter 2, and discuss the contribution these findings make to 
the MI Service, clinicians and the wider NHS, along with my overall 
conclusions and recommendations. 
Clinician use of MI advice to make prescribing decisions 
As already mentioned, clinical decision-making and prescribing are complex, 
multifactorial processes, and have been linked to the dual process theory of 
decision-making (Bate et al., 2012).  Figure 5.1 on the next page shows an 
adapted model of the dual process theory of decision-making, with boxes 
added in green to indicate where I think MI advice correlates with the dual 
process theory of decision-making; these are discussed below. 
Findings from my study show how clinicians contacted MI when they were 
unable to use their usual decision-making processes; that is their System 1 
decision-making processes for which they rely on their existing tacit 
knowledge, ‘rules of thumb’ or ‘mindlines’. In other words, the MRQ was not 
recognised via their ‘pattern processor’, for example when they had unfamiliar, 
challenging, complex and/or high risk cases, and switched from being 
unconsciously competent to consciously incompetent, so wanted someone 
whom they perceived as ‘more expert’, to do their System 2 thinking for them.  
As Figure 5.1 shows, System 2 decision-making is not easy as it requires 
intellectual ability, education and training, critical thinking and logical 
processes, and while clinicians are capable of doing some or all of this, they do 
not necessarily have the time, skills or experience to do this for unfamiliar, 
complex and/or high risk cases.  My findings show how that advice from MI 
either provided the clinician with a decision i.e. did their System 2 research 
and thinking for them, or helped them with their System 2 decision-making, 
and thus enabled them to make an informed decision so they could ‘rationally 
override’ System 2  i.e. use MI advice, and revert back to System 1 thinking.
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Figure 5.1 Dual process theory of decision-making - adapted to recognise the influence of MI advice 
 
Note: Green MI Advice boxes are additions to the original model and (GREEN arrows) show how these relate to it. All other text and arrows are in 








































Also, as shown in Figure 5.1, clinicians described how they used the MI Service 
as they wanted advice to check their thinking was correct i.e. they wanted to 
‘calibrate’ their System 1, by using the MI Service as a safety net to confirm a 
decision and then felt reassured, or even empowered, to prescribe safely.  The 
green ‘MI advice’ boxes have been added to indicate where MI advice fits in 
this model.  Original text and arrows from the model has been changed to red 
to indicate the influence of MI advice.  Sometimes they used MI for an MRQ 
because of prior past experience of asking MI, which is why I have added a 
box directly above the one that starts with ‘Clinical problem (MRQ)’, to show 
how sometimes they sought MI advice without doing anything first.  
Furthermore, the box and text in red on this decision-making model referring 
to ‘context’, ‘task difficulty, task ambiguity and ‘affective state’ correlate with 
my findings where they viewed the MI Service as a medicines ‘help desk’ they 
trusted, which was able to provide convenient, expert advice.  
Additionally, findings about clinician use of MI advice for future patients 
explain how they incorporated their new knowledge and advice into their 
System 1 decision-making process, so they knew what to do subsequently 
i.e. informed their ‘pattern recognition’, thereby minimising their need to use 
their more time consuming System 2 processes for similar future problems.  
MI advice was able to help improve their knowledge base so they became 
consciously, then potentially unconsciously competent, once the MI advice 
had been embedded in their System 1 processing.  Finally, the box and text 
in red on this decision-making model referring to skills required for System 2 
decision-making, ‘intellectual ability’, ‘education & training’, ‘critical thinking’ 
and ‘logical competence’, correlate with my findings around clinicians seeking 
MI advice as support for System 2 decision-making. 
Next, I want to discuss the model of doctor prescribing decisions, proposed by 
Ali Murshid et al, that I introduced in Chapter 2 of this thesis (Ali Murshid and 
Mohaidin, 2017).  Figure 5.2 shows this theoretical model, and I have added 
the green ‘MI advice’ boxes to indicate, based on my findings, where MI advice 
fits in this model and the influence of MI advice.  All other text and arrows 
were in the original model.  This model proposed that several pharmacist 
factors, derived from Social Power theory, were relevant to doctors making 




expert power and pharmacist-doctor collaboration, with trustworthiness being 
an additional factor.  Conversely, my findings also help support the pharmacist 
elements that were proposed by the authors of this model, that is, of the 
pharmacist providing expert power and trustworthiness. The pharmacist 
elements align with the findings of my study, in that prescribing clinicians 
described how they valued the MI Service as a ‘help desk’ because they felt it 
was a trusted service, provided by expert pharmacists.  
As well as the MI Service influencing prescribers on the premise of Social 
Power theory, I propose that findings about clinician use of the MI Service can 
also be linked to Persuasion theory, Agency theory and Buyer Behaviour 
Stimulus Response theory.  By enabling clinicians to change their prescribing 
for an individual, and then subsequent patients, this indicates MI as having a 
role in Persuasion theory, where the sender of information (MI) modifies the 
behaviour of the receiver (clinician), which can be immediate or delayed. 
Then, when clinicians sought MI advice because they viewed it as a ‘help 
desk’, the clinician, acting as the principal was relying on the MI Service, as 
the agent to do the work for them and is the premise for Agency theory.  
Furthermore, the basis for Buyer Behaviour Stimulus Response theory is that 
various stimuli influence the ‘customer’, in this case the clinician, and produce 
certain responses.  In other words, MI advice influences clinicians, as 
interaction with MI stimulates ’buying behaviour’ i.e. them to change their 
prescribing. 
Next, the Grant prescribing model for practices, introduced in Chapter 2, found 
that well performing practices continually made both macro, and micro-
prescribing decisions and produced macro-prescribing policies for staff (Grant, 
Sullivan and Dowell, 2013).  The conceptual prescribing model produced by 
the authors is shown in Figure 5.3 and I have added the green ‘MI advice’ 
boxes to show where MI advice fits in this model.  Original text from the 
model has been changed to red to indicate where I think MI advice 
complements this model, based on my findings. 
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Figure 5.2 Ali Murshid model of doctor prescribing decisions - adapted to recognise the influence of MI advice  
 
Note: MI Advice boxes (GREEN) are additions to the original model and (GREEN arrows) show how these relate to it. All other text and 
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Figure 5.3 Grant prescribing model for practices – adapted to recognise the influence of MI advice  
 
Note: MI Advice boxes (GREEN) are additions to the original model and (GREEN arrows) show how these relate to it.  All other text and 























In my study clinicians described how they sought MI advice when they were 
unable to use their ‘mindlines’ to make micro-prescribing decisions i.e. for 
individual patients.  They viewed it as a more accessible alternative to asking 
other clinicians in secondary care, when their colleagues were unable to help, 
or when they were also unsure what to do.  They then used MI advice to 
update their own ‘mindlines’, sometimes sharing it within their wider 
‘community of practice’, members of which also used it to update their own 
‘mindlines’.  Linking my findings to the Grant model shows how MI advice 
played a role in influencing not only macro-prescribing policy, but also micro-
prescribing decisions, which was not a pharmacy-related finding in the Grant 
study, as pharmacy (through practice pharmacists) had a role at the macro-
level only (Grant, Sullivan and Dowell, 2013).  The authors found that practice 
pharmacists were necessary to inform macro-prescribing policies by filtering 
research, interpreting and applying evidence to the local population, and 
leading on prescribing practice.  However, in my study, MI Services played a 
part in filtering, interpreting and applying the evidence, either to the wider 
population or for individual patients.  
Finally, my findings illustrate how MI advice was able to influence prescribing 
change through a variety of routes and also correlate to the three models of 
prescribing change suggested by Armstrong, introduced in Chapter 2 
(Armstrong, Reyburn and Jones, 1996).  This study describes how MI advice 
influenced prescribing change via the Accumulation model by acting as an 
independent, trusted source of advice; via the Challenge model by averting an 
actual or potential prescribing error, i.e. by acting as a safety net for clinician 
decision-making and enhancing prescribing, or being seen as providers of up 
to date advice i.e. a ‘help desk’; and via the Continuity model by providing 
advice and information that clinicians are able to assimilate, which means they 
are willing to make prescribing changes, which can then lead to a shift in their 
prescribing practice. 
This is the first study to link MI advice to theoretical models of decision-
making and prescribing, which is important as this shows how the MI Service 
plays a key role in influencing prescribing decisions and its value as a non-




In the next section, I discuss the limitations of this research and finally 
present my conclusions. 
Research limitations 
This study inevitably has a number of limitations.  Some features of the 
research design and problems that arose during the research itself may have 
affected the quality of the findings.  I acknowledge the various issues and 
explain them below. 
Due to the limitations of part-time doctoral study, part-time work and time 
available for the pharmacy students to do interviews.  Doing the telephone 
interviews meant that the time for data collection was limited.  Ideally 
interviews should have been transcribed and analysed before the next, but I 
had to take a pragmatic approach, so some were not done until after data 
collection was complete. Time available for data collection was also a 
restriction for the face-to-face interviews as they took place at times 
convenient to the clinicians but also needed to be convenient for myself as the 
interviewer.  I tried to be as flexible as possible, sometimes altering my 
working pattern or hours to enable an interview.  
I was fortunate the face-to-face interviews were sent to a professional, 
external transcriber, however the turnaround time was dependent on 
transcriber workload.  As a result I was not always able to immerse myself in 
or reflect on the data from individual interviews until after completing further 
interviews.  Consequently, I was not able to amend the interview questions 
based on formal analysis. Although, as the sole interviewer I was able to 
reflect on how I felt each face-to-face interview had progressed. 
A number of interviewees could not recall the case when first being spoken to, 
however, all did so when prompted with the MI question and answer.  Memory 
recall in these cases may have affected the quality of responses, especially 
those with greater time between the answer and interview.  However, using 
the CIT and explicitation techniques helped with recall, whereby clinicians 
were reminded of their MRQ, the time and date and the advice provided by the 




first emailed, again when the interview date was agreed and at the start of the 
interview.  Additionally, in some cases the outcome for the patient was 
unknown as the interview took place too early for the clinician to comment on 
this aspect.  Although, postponing and rescheduling the interview was a 
possibility, this was not pursued to due to rescheduling with busy clinicians 
and the fear of loss to the study.  
Occasionally during the course of an interview, I was drawn into general 
discussion about the MI Service. Where possible I asked if their questions 
about service provision, or a new MRQ they had, could be addressed at the 
end of the interview and interviewees were happy to do this. 
Determining thematic (data) saturation for the telephone interviews was 
problematic; firstly despite training, the pharmacy students lacked practice 
experience and found gaining rapport with clinicians difficult, which on 
occasion, hindered the quality of answers received; secondly, I acknowledge 
that the telephone interviews were short; although this was not unexpected, 
as recruiting primary care doctors and dentists was anticipated to be difficult.  
The possibility of researcher bias exists, as an MI pharmacist, I was working 
as an insider researcher (Costley, Elliott & Gibbs, 2010). However, questions I 
answered as an MI pharmacist were excluded, also I have been transparent 
throughout regarding my role as an insider researcher and I believe the 
findings speak for themselves, as exemplified by the interview extracts 
provided.  Although I may have influenced some of the findings, coding and 
theme development were analysed inductively for all data sets and checked by 
non-MI pharmacists during analysis of the telephone interviews.  Rather, my 
role as an insider researcher was invaluable as I had could understand context 
and had a sense of the situation, regarding the MRQs asked, MI advice 
provided, and the ability to probe clinicians to expand on their responses. 
Additionally, responder bias may have confounded the findings. Those with a 
more positive opinion (i.e. repeat users of the service made up the majority of 
the sample) may have been more likely to participate in the study (self-
selection bias) and be inclined to provide answers (social desirability bias) that 




represented that organisation.  In fact, as clinicians were satisfied with the 
service, they wanted to help with the research, so were willing to be 
interviewed. They may not have been as amenable with an outsider 
researcher, and for my analysis I was able to consider their responses based 
on their medicines question and the advice provided, which an outsider 
researcher may not have done. 
While the telephone interviews did provide some valuable qualitative 
responses, they did not reveal as much detail about how clinicians used MI 
advice in their decision-making and patient care as I hoped.  This was 
probably hampered by the use of final-year pharmacy students to help 
conduct some of the telephone interviews.  Although, they were selected as 
academically able students (grades over 65% and on track to get a 2-1 or 
above), were doing the research module of their MPharm degree, and received 
training and support (about research, the work of the MI Service and interview 
skills), they were lacking real-life experience of speaking to clinicians, as well 
as the experience and confidence of applying their clinical knowledge to 
discuss the MI question and probing to get them to elaborate on a particular 
issue.  However, the telephone interview responses enabled development of 
themes which were further expanded in the face-to-face interviews. 
I felt that interviews were an appropriate means of understanding the 
perceptions of clinicians, regarding MRQs and their use of MI advice.  This 
study initially gathered a wider, perspective of clinician use of MI advice by 
national recruitment of clinicians and so interviews were by telephone.  
Additional in-depth interviews as face-to-face were then used to expand on 
findings to further understand how clinicians used MI advice.  However, this 
study only included prescribing clinicians in primary care that were recorded 
as such on MiDatabank®, at the time.  Although, other prescribers e.g. nurses, 
pharmacists, also contact MI Services, they were not specifically recorded as 
prescribers.  This could be considered for further research, if other prescribers 






Conclusions of this research 
The aim of my research was to understand how primary care clinicians use MI 
advice and the findings show this.  We now have a better understanding about 
how MI advice influences primary care clinicians in their prescribing decision-
making.  When they had gaps in their existing knowledge, they described how 
they used MI advice as a safety net to shape, support or even make their 
prescribing decisions for them.  Fundamentally, they wanted MI advice to 
support, or complete their complex, and/or time consuming (System 2) 
research. 
Clinicians tend to use tacit knowledge, ‘rules of thumb’ and ‘mindlines’ to 
make prescribing decisions.  This study describes how MI advice was 
incorporated it into clinician ‘mindlines’ for future use, thus contributing to 
their (System 1) decision-making for subsequent patients.  They were also 
able to share MI advice within their ‘community of practice’, which had the 
potential to develop the ‘collective mindlines’ of other clinicians, and so be 
assimilated into the individual prescribing ‘mindlines’ of others. 
We also have a greater appreciation of how clinicians think MI advice affects 
patient care, in that they described how they found the provision of person-
centred evidence-based MI advice empowering, as they felt able to make 
prescribing changes for their patients confidently and safely.  They said how 
they used MI advice to reassure themselves and their patients; and to support 
SDM, and perceived their relationship with the patient was improved, 
especially when they were viewed as taking the time to ask a specialist 
service.   
When they could not sort the problem themselves, ask a colleague or another 
clinician, they explained how they valued that person-centred evidence-based 
advice was provided by a pharmacy, MI expert, via an accessible ‘help desk’ 
service they could trust.  They also described this value in that they could call 
the service whilst the patient was with them, which avoided the inconvenience 
of referrals for clinicians and patients, in terms of time spent making, and 
waiting for, the referral and associated costs.  For urgent cases, advice was 




advice about complex cases, if it saved them time, was quicker than or 
avoided referral, and minimised risk to themselves and their patients. 
Anything which has a positive influence on prescribing is beneficial for 
clinicians, patients and the NHS alike.  This is the first MI study to show how 
MI advice is incorporated into the ‘mindlines’ of clinicians and their colleagues 
to effect subsequent prescribing decision-making and future patient care.  It is 
also the first study to describe where the MI Service fits into the dual process 
theory of decision-making (Bate et al., 2012) to effect prescribing; to show 
how MI advice influences prescribers at both the micro (patient) level and 
wider macro level (Grant, Sullivan and Dowell, 2013).  Finally, it is also the 
first MI study to find that, after getting MI Service advice, clinicians updated 
their knowledge and adapted this for subsequent patients.  This links to the 
Armstrong model of prescribing change, where consulting a trusted authority 
about something brings about change (Armstrong, Reyburn and Jones, 1996). 
In the next section, I present my recommendations for MI Services, 
stakeholders and clinicians, and for further research. 
Recommendations for practice, policy and further research 
Recommendations for practice: 
• Clinicians valued the MI Service as a medicines ‘helpdesk’ which they used 
in their prescribing decision-making.  MI Services need to share the 
findings of this study with NHS England and other stakeholders, with a view 
to agreeing funding to develop a nationally recognised, co-ordinated 
medicines ‘help desk’ with a central number that is accessible to all 
prescribing clinicians in primary care.  
• MI Services need to focus on answering complex, high risk MRQs from 
prescribing clinicians in primary care.  This means they need to prioritise 
the development of resources and training so non-MI pharmacists can 
answer other MRQs. 
• The service needs to work with NHS England and other stakeholders to 
ensure equitable access to key resources that would enable prescribing 




Services.  For example, enabling access to key resources to identify foreign 
medicines, and for complementary medicine interactions.  
• The MI Service should proactively review MRQs and collate data to inform 
providers of core resources about usage and content problems experienced 
by clinicians.  For example, the BNF or providers of CDSS when they flag 
medicines interactions.  MI staff could offer a service to providers of these 
resources to improve content and usability. 
• A further recommendation is to develop and agree clear definitions of 
impact, patient care and outcome, which are specific to the provision of MI 
Service advice, and separately defined for clinicians and patients.  These 
could be based on those already defined, by other services such as Health 
LIS, and then used for future service evaluation and research. 
Recommendations for policy: 
• Clinicians valued a ‘help-desk’ service they could access easily, at a time 
convenient to them.  As such, prescribing clinicians should have access to a 
co-ordinated, support service for their complex and/or high risk medicines 
questions.  Stakeholders need to provide funding to develop a recognised, 
co-ordinated medicines ‘help desk’ with a central contact number. 
• Clinicians acknowledged technical and resource limitations and valued 
human contact via a ‘help desk’ for complex, high risk scenarios.  Although, 
as the NHS becomes more digital and clinicians are more familiar with 
using technology, stakeholders should invest in alternative options for 
human contact, such as online webchat.  
 
Recommendations for further research: 
• MI Services need to collaborate with Health LIS, as other providers of 
health and medicines information, and as these services have also 
struggled to evaluate the effects of their service on clinicians and patients.  
Collaboration will help minimise duplication of effort and enable sharing of 
best practice.  As Health LIS have already begun to develop a range of 
tools, which use a range of methods to help them describe their impact and 





• It would be useful to compare the MI Service with Health LIS, as these are 
currently separate NHS funded services, for example by comparing 
answers to MRQs.  
• We need to know how non-users of the MI Service answer MRQs and if 
they answer them correctly, these answers could be compared to those 
provided by the MI Service. 
• Specific outcomes for evaluation of service effectiveness could be 
developed, agreed using the findings of this study and incorporated into 
existing tools to evaluate the effects of the MI Service on clinicians and 
patient care.  For example, the themes and meta-themes found in this 
study could be used to inform further development of robust, properly 
validated tools.  To enable MI Services to contextualise clinician responses, 
these tools, their content and their findings may need to be linked to the 
MRQ, enquiry type and answer provided. 
• MI Services and Health LIS could collaborate to develop existing ‘impact’ 
rating scales, such as those produced by Bramley and colleagues, by using 
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US To investigate 
the use of MI 
answers and the 


















• Specific outcome(s) of medicines 
related problems 
• Effect on patient outcome 
 
58% of clinicians (n=202) thought the 
information had affected patient 
outcomes, and had a positive effect on 
patients and their care (78%, n=157) as 




US To document the 
activity and 
effectiveness of 








12 months All enquiries 
received 
In-house review  
 
Enquiries were 











related to MRP 
were coded 
 
Potential outcome codes for public 
enquiries: 
• ADR prevented/corrected/explained 
• Compliance improved/reinforced 
•  Drug interaction 
prevented/corrected/ explained 
• Therapeutic failure prevented 
• Medical problem referred 
• Drug misuse prevented/corrected 
 
In the opinion of MI staff, answers given 
to the public prevented or corrected about 





































US To develop a 
cost avoidance 
model  to 
determine 
potential cost 


























• Optimal results 
• Treatment failure 
• New medical problem 
• Treatment failure and new medical 
problem 
• Costs avoided 
 
Using this model, potential cost savings 
were mostly due to prevention of 
increased monitoring and/or additional 
treatment (46%, n=77), although about 
half the enquiries had little or no 
measurable cost impact (51%, n=83). 
Despite this the projected potential 
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• Action taken as result of MI answer 
• Effect on subsequent patient 
progress 
• Effect on CPD 
 
Almost all respondents (95%, n=125) 
said they found the information helped, 
with the authors concluding that the MI 
service had a favourable impact on 
patient care in at least 40 patients (30%). 
The patient progress after the MI advice 
was known in 79 cases (60%); this 
included 40 responses of patient 
improvement 
 
A high proportion (89%, n=117) of 
clinicians acted on the MI advice. These 
were categorised as: starting new 
treatments (n=21); stopping treatments 
(n=20); avoidance of a potential adverse 
event (n=21) to modify a patient’s 
existing treatment (n=20); to stop an 
adverse event from getting worse (n=7); 




US To determine the 
economic impact 











12 weeks All enquiries Cost analysis 
PHS calculated by 
multiplying time 
to find answer 
and give a 
response by 
average salary for 






• PHS by use of the MI enquiry 
service 
• Potential costs saved by using the 
MI enquiry service 
 
A total of 266 PHS was calculated, which 
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after 1-2 days, 
then up to 6 













• Desired outcome 
• Actual patient outcome 
• Enquirer opinion of impact on 
patient outcome 
• Views of a clinical panel on 
impact on patient outcome  
 
Seventy-two clinicians (74%) believed 
the advice had a beneficial impact on 
the patient, with an expert panel 
agreeing that 36 (46.8%) had resulted 
in a positive patient outcome; ten of 
which were based on objective 
measures, e.g. reduction in blood 
pressure.  
 
A high number of clinicians acted on 
MI advice (84% of 230 MI 
recommendations were accepted) with 
the highest reported use (41%, n=78) 
being for provision of 
information/education, whilst other 
actions included referral to another 
clinician (13%), instigation of 
additional monitoring (10%) and 
recommending or adding a drug 
(13%) 
 
Of 68 consumer enquiries, 87% of 
recommendations were accepted and 
92% of these were deemed as 
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18 months All 
enquiries 
answered 















• Change in clinical practice 
• Use of MI answer with patients 
 
More than half (61%, n=71) of 
respondents stated that the information 
provided had caused a change in clinical 
practice, with 68 going on to describe 
this change. Categorised as changes in 
pharmacotherapy (n=32), improved 
advice to patients and colleagues (n=22), 
stopping a medicine (n=10), avoidance 
of abortion (n=2), and reporting an 
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• Use of MI answer 
• Action taken 
• Impact on the patient 
 
Over a third (38%) used the knowledge 
provided to discuss the results of MI 
advice with their clinician. Over two thirds 
(68%) respondents reported increased 
confidence in dealing with prescribed 
medicines and others said uncertainties 
about medicines were reduced (81%). 
Some reported a better state of health 
after implementing MI advice (20%) and 
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• Advice followed 
• Action taken 
• Impact on wellbeing 
 
Almost all patients who replied (97%, 
n=58) said they followed the 
recommendations provided, and overall, 
two thirds (66%, n=40) said a medicine-
related problem was avoided; three 





Germany To explore the 
impact of the 



















• Potential positive patient outcomes  
 
Almost half of the clinicians (42%, 
n=190) agreed there was a potential 
positive outcome, and thematic analysis 
of these responses revealed that MI 
advice allowed a switch to more suitable 
medicine, correct/optimum dosing, 
enhanced adherence or avoided an 
interaction 
 
Clinicians could also be seen to use MI 
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• Importance of answer on therapeutic 
decision  
• Use in decision making: 
• Asked if agreed with the statement: 
• “the answer from the [MIS] was 
important for my therapeutic 
decision”  
 
MI advice was used to avoid termination 
(9%, n=11), although frequently it 
informed them to either avoid/stop a 
medicine (29%, n=36) or start/continue 
a medicine (38%, n=47) 
 
The majority agreed (95%, n=111) 
advice was important in their therapeutic 
decision making 
Clinicians could also be seen to use MI 





Denmark To evaluate the 






















• How MI answer was used  
 
Most doctors (93%) used the MI answer, 
with many using the answer for patient 
information (79%), to change treatment 
(45%), to disseminate to colleagues 





































UK To find out: 
Proportion of 
enquiries where 
MI advice was 


















uptake of MI 
answers 


















interviews at 7 to 





• Number of enquiries used 
answer/followed advice 
• Number of enquiries answer 
changed patient management 
• Action taken as a result of MI 
answer 
• Number of enquiries were waiting 
for MI answer before going ahead 
• Number of patients whose clinical 
outcome differed compared to 
expected 
 
Thirty-two clinicians were available for 
follow-up, of which 59% (n=19) of 
patient outcomes were as expected, 
three (9%) had improved further than 
expected, although six (19%) had not 
improved compared to what had been 
anticipated 
 
30 (94%) clinicians had used the 
information provided, most frequently to 
start a medicine (25%, n=8), to change 
administration/dosing (9%, n=3) or not 




UK To assess how 
MI answers 
were used by 
clinicians and 
usefulness in 















(68% response  
rate) 
• How MI advice was used  
• Use in patient care  
 
Many respondents (81%, n=430) acted 
on the MI answer provided. They used 
this information to manage a current 
patient or to plan care of future patients 
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with a 5-point 
rating scale 
about impact of 
MI advice on 
patient care & 
outcomes 
1st questionnaire 
completed by MI 
centre at the 










(24/40) using a 6 





• Use of MI answer 
• Impact of MI answer on patient 
specific measures using a rating 
scale i.e. ADRs; Safety/risk; Patient 
concerns; Information provided; 
Patient understanding; Choice of 
medicines 
• Ability to explain risks/benefits to 
patient 
• Overall impact of MI answer on 
patient care and outcomes 
 
The majority of respondents self-reported 
that the advice had a positive impact on 
their patients (92%, n=597/647), with 
85% (n=547) considering this was 
positive regarding patient care or 
outcome. Furthermore, around half 
(53%, n=343) agreed MI advice 
reduced/decreased risk of an ADR and 
positively affected lowering 
risk/improving safety (58%, n=374) 
 
48%, n=311 of respondents stated they 
used it to check the safety or risks of 
treatment 
44%, (n=79) agreed that the MI advice 
played a part in their decision-making 
process  
They felt MI advice helped their ability to 




































UK To determine 
the impact of MI 

























weeks apart from 
generation of 
enquiry. Survey 
included a 5-point 
rating scale about 
impact of MI 







answers using a 6 




answers using the 
















• Were they waiting for MI advice 
before going ahead 
• Planned action after had MI answer 
• Action taken after MI answer 
• Rating scale to measure impact on 
patient care and outcomes 
 
The majority of enquirers (81%, n=145) 
rated the impact on patient care or 
outcome as positive: 20% (n=35) said it 
improved patient outcome and 62% 
(n=110) replied that their patients’ care 
was improved. Only 15% (n=27) reported 
no impact. No negative outcomes or 
cases of worsened patient care were 
reported. An expert panel purposively 
reviewed 20 cases, and found that 19 
(95%) of cases had a positive impact on 
patient care 
 
A quarter (n=44) continued the medicine, 
while others started a medicine or 
changed the drug regimen (21%, n=37 
for each), with a quarter taking more than 
one of the listed actions (24%, n=43).  
Half (54%, n=97) used advice to check 
medication safety, 30% to tell them the 
best plan of action and 22% to confirm a 
change in therapy was needed. 
 
44% (n=79) agreed MI advice played a 
part in their decision-making process 
Clinicians could also be seen to use MI 
advice as a risk management tool, to 
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Interviewed 3 to 






• All actions taken after MI answer 
 
About half of 232 clinical actions (49%, 
n=114) were considered to be due to MI 
advice, and included starting a medicine 
(n=34); stopping/not starting a medicine 
(n=21); modifying drug treatment 
(n=15); clinical monitoring (n=22); 
specific patient counselling (n=14) and 




UK Did patients 
follow advice 
given after 

















• Patient outcome after using helpline 
 
68 patients, Almost all (96%) followed the 
advice to some degree. Respondents 
believed advice received had avoided a 
medicine related problem (27%) or the 
medicine problem had resolved (52%). 
Almost half (45%) of the respondents 
stated they felt reassured after gaining 
the advice 
Bramley  
et al  
(2018) 










4 to 6 
weeks 









medicines safety  
 
Delphi technique 
with focus groups 
to validate scales 
 
67/111 
       
(60% 
response rate) 
• Patient outcome after using helpline 
• Development and validation of 
impact rating scale 
 
Almost all (93%) respondents followed 
the advice provided and felt reassured 
(81%) after checking about medicine 
safety and usage. A small number (19%) 
reported improved health or cure 




Note: The rating scale has subsequently been updated in Bramley 2018  
Appendix 2 Rating scales used by expert panels 




Descriptor Impact on  Descriptor 
1 Adverse 
impact 
Detrimental effect on patient care or 
outcome 
AND/OR 





The advice from MI increased the risk to the 
patient 
The advice from MI had a detrimental effect on 
patient care or outcome 
2 No 
impact 
No effect on patient care or outcome 
AND/OR 





The advice from MI had no effect on the risk to 
the patient 





Positive effect on patient care but no 
apparent improvement in patient 
outcome 
AND/OR 





The advice from MI meant that a low risk to the 
patient was avoided 
The advice from MI improved the care of the 
patient but was unlikely to lead to an 
improvement in patient outcome 
4 Positive 
impact 
Positive effect on patient care likely to 
lead to an improvement in patient 
outcome 
But no improvement in patient outcome 
apparent 
AND/OR 





The advice from MI meant that a moderate risk 
to the patient was avoided 
The advice from MI improved the care of the 
patient and this was likely to lead to an 
improvement in patient outcome (no 




Positive effect on patient outcome 
AND/OR a very positive effect on patient 
care 
AND/OR 





The advice from MI meant that a major risk to 
the patient was avoided 
The advice from MI improved the patient 





Potentially life saving 
AND/OR 





The advice from MI meant that an extreme risk 
to the patient was avoided 




Appendix 3: UK MI Service enquiry levels 
Level 
description 





• Requests for information 
which any pharmacist or 
accredited pharmacy 
technician would be expected 
to deal with using readily 
available sources.   
• Enquiries answered solely 
using sources such as local 
formulary/guidelines, 
paediatric formularies, or 
electronic databases such as 
Drugdex.  
• Information from such 
sources passed on to the 
enquirer without further 
evaluation or interpretation.  
• Requests for standard dosing 
information and/or administration 
instructions for licensed, or commonly 
accepted unlicensed indications.  
• Basic information about well-
documented adverse effects.  
• Identification of foreign drugs.  
• Tablet identification using TICTAC 
(either directly or by contact with the 
regional MI centre) where further 
advice not required.  
• ‘Librarian services’ such as finding a 
particular reference on Medline for 
which some details are known. 
• Requests to contact the 
pharmaceutical industry for basic 







• Enquiries that require the use 
of more specialist resources 
and/or the interrogation of 
multiple sources.  
• Enquiries where application 
of medicines information 
skills and knowledge is 
needed, but sources provide 
a reasonably clear answer or 
course of action to offer the 
enquirer. 
• Dosing information for unlicensed 
indications. 
• Intravenous drug compatibilities not 
found in standard sources e.g. 
admixtures or Y-site compatibilities.  
• Dosing adjustments for commonly-
used drugs in organ failure.  
• Information about previous case 
reports of an adverse drug reaction. 
• Safety of drugs in pregnancy/lactation 
where published reviews give clear 






• Enquiries where the answer 
relies on the knowledge, 
experience and skill of the MI 
practitioner. 
• Core concepts of 
therapeutics, risk 
management and literature 
evaluation are applied. 
• Complex enquiries that cover 
situations where individual 
patients have unusual co-
morbidities or drug 
combinations. 
• Identifying the most likely causative 
agent of an adverse drug reaction and 
advising how to manage the patient. 
• Offering advice on an appropriate 
therapeutic regimen when standard 
options have failed and there is no 
literature consensus. 
• Evaluating the safest and most 
effective treatment where there are 
multiple contra-indications or 
cautions. 
• Calculating drug doses using the first 
principles of pharmacokinetics or 
therapeutic drug monitoring. 
• Assessing the appropriateness of 
new/experimental treatments for a 
patient by appraising published clinical 
data.  
• Advising on the safest injectable 
medicines to mix when mixing is 
unavoidable but there is no directly 





Guidance notes for ranking enquiries 
Level is independent of the time taken to complete the enquiry.  
Level is independent of the method used to communicate the answer. 
There is a degree of subjectivity when assessing levels; no system can completely remove this.  
The way an enquiry is received may partly determine its level. The questioning skills of 
experienced MI staff may turn an apparently straightforward level 1 enquiry into a level 2 or 3 
once the full clinical implications have been teased out. 
Examples are for guidance only; some categories of enquiry may sometimes fit better into 
another. E.g. enquiries about drugs in pregnancy and lactation (listed as levels 2 and 3) may 
















Appendix 4:  Ethics approval (telephone interviews) 
RES20A Jill Rutter 
R Morgan  
P Rutter 
What effect do 
medicine information 
(MI) answers provided 
to primary care 
prescribers have on 
patient care? 
8/04/11   
  
1. Procedures seem to be satisfactory, but the consent form appears to 
be missing 
 
2. The investigator mentions that the interviews will be audio-recorded, 
but this should be made more explicit to the participants at the 
outset 
 
3. Data should be held for 5 years prior to disposal, and should be 
accessible to both the research supervisor and any potential 
examiners. 
 
4. The information sheet states that “a copy of the results will be sent 
to participants”. The investigator needs to state that results will be 
made available upon request (perhaps ask participants at point of 
phone-in), and that no individual results will be made available. 
  
 
04/11 – once amendments had been made this was APPROVED via 











Impact of Medicines Information Answers: an evaluation of 
Primary Care Prescriber Decision-making 
 
Section A: Background Information (To be populated by Principal Investigator) 
 
Call taken by (UKMi Centre):________________________________________________ 
 









Enquirer Details  
































BEFORE ASKING ANY QUESTIONS:  
 
a. Introduce yourself; 
b. State the purpose of the call;  
c. Ask them if they still want to continue with the survey;  
d. Determine if now is a good time or the need to call back later;  
e. If appropriate, talk them through the key ‘participant information’;  
f. Confirm they still want to take part (verbal consent). 
See sheet: verbal information for potential participants 
 
IF THEY AGREE TO TAKE PART, REMIND THEM OF THE QUERY THEY ASKED & THE ANSWER 
GIVEN  
 
Section B: Evaluation of Impact of Medicines Information Answers: an 
evaluation of Primary Care Prescriber Decision-making 
 
1. Before contacting the MI service did you consult 
anyone else/any information sources? 
  






2. If Yes, who did you ask?  
Researcher Note: Ask about company/other health care professionals. e.g. colleague, GP, community 







3. If Yes, what information sources did you use?  
Researcher Note: Ask about books/websites etc.  
 
 
4. What prompted you to call the Medicines Information service?  
Researcher Note e.g. Used MI before and found it helpful/Found conflicting information and not sure 
what to do 
No time to look into, so thought I’d call you/computer warning/Someone else asked me a qu/No in 




5. Did the answer provide you with enough 
information to make a decision about how 








Go to Qu 7 
Not at all 
 
¨ 
Go to Qu 7 
 










8. On a scale of 1 to 5, where 1 is “not very helpful” and 5 is “very helpful” 
Overall, how helpful was the information in deciding how to manage the patient? 
 Not very helpful Very helpful 
 1 2 3 4 5 
9. What action did you take as a result of the advice provided by the Medicines 
Information service?  
Researcher Note  
e.g.  Choice of therapy: Started drug X/referred to specialist.  ADRs: stopped drug X/started drug X 
Dose & Administration: Changed dose A of drug X to Dose B of drug X.  Changed drug X from route A to 
route B 
Interactions: stopped drug X and started drug Y.  Pregnancy: stopped drug X/started drug Y 




10. What influence did the advice provided by the Medicines Information service have 
on your decision?  
 
 




12. What other factors did you consider to help you make your decision?  





13. What happened to the patient as a result of the advice provided by the Medicines 
Information service?  
Researcher Note e.g. Choice of therapy: patient took drug & condition improved.  ADRs: resolved/still 
present/too soon to say 
Dose & Administration: Stopped &/started drug X & condition improved. Interactions: Switched to 
drug X & condition improved 
Pregnancy: pregnancy ongoing & condition improved. Stopped drug X/started drug Y & pregnancy 
going well 
Breast feeding: still able to breast feed and condition improved 
 
 




15. Is the problem still 
ongoing? 
Yes ¨ No 
 














17. Did you get any 
subsequent 
information/advice 









18. (If Yes), Where did you get any subsequent information/advice? 
Researcher Note: e.g. company/books/website/colleague/GP/hospital consultant/community 
pharmacist/PCT pharmacist/website  
 
What information/advice did you get? 
 
19. Did you record the Medicines Information advice 











Section C:  
“Now I am just going to ask you a few general questions” 
 












21. On a scale of 1 to 5, where 1 is “not very likely” and 5 is “very likely”, 
will you use the Medicines Information service again? 
 Not very likely  Very likely  
 1 2 3 4 5 
  
22. On a scale of 1 to 5, where 1 is “not very likely” and 5 is “very likely”, 
how likely are you to recommend the Medicines Information service to colleagues? 
 Not very likely Very likely 
 1 2 3 4 5 
 






24. And finally, would you like to receive a copy of 















Verbal information for potential participants 
 
a. Introduce yourself; 
 
b. State the purpose of the call;  
 
c. Ask them if they still want to continue with the survey;  
 
d. Determine if now is a good time or the need to call back later;  
 
Phoning to arrange telephone interview 
If get reception/someone else: 
 
Hello, can I speak to Dr/Mr/Mrs [insert title]. I’m calling about an NHS medicines 
information survey.  Dr/Mr/Mrs [insert title] said they were happy to be contacted to 
arrange a suitable time.  
Are they available? 
 
If No – When is the best time to call back? 
If Yes & they transfer you – introduce yourself as below* 
 
If speak directly to the enquirer: 
Hello, am I speaking to Dr/Mr/Mrs [insert title]?  I’m calling about an NHS medicines 
information survey.  You recently contacted the medicines information service with an enquiry 
about [XXXXXXX] and indicated that you would be happy to be contacted to discuss how you 
used the advice provided. 
 
If Yes – Is now a good time?  
If No – When is the best time to call back? 
 
If No – thank them for their time and apologise for taking up their time: 
 
That’s fine, thank you for your time. 
 
If No, not now - try to arrange a convenient time to call back: 
 
I’m happy to call you back later today when it’s more convenient. When would be the 
best time?  
 
If No, not today: 
 
I’m happy to call you back another day when it’s more convenient. When would be the 












Phoning to do telephone interview 
If get reception/someone else: 
 
Hello, my name is [XXXXXXX], I’m a pharmacy student from Wolverhampton University 
calling about an NHS medicines information survey, Dr/Mr/Mrs [insert title] is expecting my 
call.  
They recently contacted the medicines information service with an enquiry about [XXXXXXX] 
and indicated that you would be happy to be contacted TODAY. 
 
If speak directly to the enquirer: * 
 
Hello, my name is [XXXX], I’m a pharmacy student from Wolverhampton University calling 
about an NHS medicines information survey, am I speaking to Dr/Mr/Mrs [insert title].  
You recently contacted the medicines information service with an enquiry about [XXXXXXX] 
and indicated that you would be happy to be contacted [TODAY/This Morning/This 
afternoon] to discuss how you used the advice provided. Is that correct? 
 
If No – thank them for their time and apologise for taking up their time: 
 
That’s fine, thank you for your time. 
 
If No, not now - try to arrange a convenient time to call back: 
 
I’m happy to call you back later today when it’s more convenient. When would be the 
best time?  
 
If No, not today: 
 
I’m happy to call you back another day when it’s more convenient. When would be the 
best time?  
 
If Yes, continue with script below.  
 
 Do you have 10-15 minutes for me to ask you a few questions? 
 
If Yes, then continue. 
 
 Before I can ask you any questions can you confirm you read the emailed information about the 
 study, including the information sheet.  
 
If Yes, skip script below and move to confirmatory questions. 
 
If No not read the emailed information, then continue with script below. 
 
e. Talk them through the key ‘participant information’;  
 
f. Confirm they still want to take part (verbal consent) 
 
You are invited to complete a telephone interview as part of an evaluation of the UK Medicines 
Information Service, which you recently contacted. The purpose of the study is to see how 





You do not have to participate and we will ask you to verbally agree to take part after I have 
provided you with this information. Even, after you agree to take part you can still withdraw 
at any time, without a given reason even after you have answered all the questions. It is 
possible that you may not wish to answer one or more of the questions, please just let me 
know.  
 
Any information you provide will be kept confidential and not be shared with a third party. It 
will only be seen by the investigators. Any information that relates directly to you will be 
made unidentifiable and all paper and electronic records will be destroyed after 5 years.  
 






Would you like to ask any questions? 
 
If No,  
 
Let’s begin the survey? 
 
 
IF THEY AGREE TO TAKE PART, REMIND THEM OF THE QUERY THEY ASKED & THE ANSWER 
GIVEN  
 
At the end of the survey, 
 










What influence does 
medicine information 
(MI) advice have on 
prescriber decision 
making? 
26/3/14   Not Approved - Defer to next meeting  
Amendments: Concern regarding project title which is not the same 
throughout document.  Student needs to provide evidence that those 
contacted have given their consent to be contacted via the database e.g. 
whether there is a tick box on the database stating that GPs using the 
service have agreed to be contacted.  If not, evidence that the student is 
following UKMI data protection guidelines should be provided.  If this is 
not possible, alternative routes of contact should be considered.   
 
 
Student to be aware that the project will be approved as a pilot study 
and as such, a completion date should be provided. A follow-on study 
would need a new submission detailing changes for approval by the Life 










Appendix 7: Face-to-face Interview topic guide (schedule) 
 
Before asking any questions 
 
p Introduce yourself;  
p State the purpose of the interview;  
p Ask them if they have read the participant information sheet;  
p If not, talk them through the participant information;  
p Confirm they still want to take part (signed consent form). 




Interview topic guide (schedule) 
Interviewer answers any participant questions, ensures participant has had an 
opportunity to read the information leaflet and has signed the consent form 
Introduction: 
You asked the MI service about [insert question here] on [insert date here]. 
I’d like you to describe what happened, from the initial patient encounter right through 
to receiving our advice and subsequently what happened afterwards?   
I will then ask some questions to follow up on any specific issues that crop up during 
our conversation? 
PART I: Recent medicines case & MI advice: 
• Tell me what happened in this case about [……………….] 
 
Additional questions: 
• What prompted you to call?  
• How did you use our advice? 
• How did this advice affect your decision-making?  
Prompts: 
o Explain how you decided what to do next/about [……………….]?  
o What (else) did you do after getting MI advice? 
e. g. patient discussion/colleague discussion/record in patient notes 
 
• How did you feel after getting our advice? 
• What happened with the patient? 
Prompts 
o Describe how you used our advice with this patient? 
N.B.  
Explore effect of advice on relationship with patient. 
Explore use in shared decision-making 
 
• If you hadn’t called MI for advice, what would you have done? 











PART II: General 
Questions around key themes from phone interviews: 
Risk 
• Other prescribers have described how they used UKMI advice to minimise risks to 
themselves and/or their patients. What do you think about this? 
Use of advice for reassurance/to confirm thinking 
• Other prescribers have described how MI advice reassures them and/or helps 
confirm what they were thinking when they were unsure what to do. What are 
your thoughts on this? 
 
Practising evidence-based medicine 
• What does EBM mean to you? (link with patient care) 
• Tell me about sources of medicines advice you use 
• Tell me how you ensure you practice EBM 
• How does MI advice fit with this? 
 
Practical/timely advice 
• Other prescribers have described the practical nature of MI advice. What do you 
think about this? 
• Other prescribers have described the timely nature of MI advice. What do you 
think about this? 
 
Clinical decision-making: 
• Tell me how you generally make clinical decisions about medicines? 
Prompts:  
o Please explain your thought processes 
o What factors do you consider?  
(e.g. previous cases seen; experience; weighting; time)  
o What else do you do? 
 
Repeat users only: 
• Describe how MI advice fits into your clinical decision-making  
Prompts 
o What else do you do?  
e. g. discussion with GP colleagues/hospital specialist) 
o What happened in another case that you can remember? 
 
Patient care: (Repeat users only) 
• Explain how MI advice influences your patient care? 
• Tell me a bit more about how you use MI advice with your patients  
• In your opinion, how does MI advice impact on patient outcomes? 
Prompts 
o What happened in another case you can remember? 
o Give some examples of patient outcomes 
o What do you discuss with them? 
e g. What do you tell them about our service? 
 
MI Service: 
• Repeat users:  




• First time users:  
o What triggered you to contact us? (if not fully explained in Part I) 
o Why have you not used us before? 
• What would happen if you couldn’t get MI advice? 
 
Please tell me anything else you would like to raise about this topic that we 
haven’t already discussed. 




Appendix 8a: Inductive coding of the telephone and then the face-to-face 
interviews 
Process of coding the telephone interviews  
• Constant comparison was used, for example, 
o 1st interview =8 codes 
o 2nd interview +6 codes 
o 3rd interview +7 codes 
o 4th interview +3 codes 
o After each cycle I re-checked previously coded interview transcripts for new 
codes 
• 111 free nodes (codes) were condensed/combined into 13 Tree nodes and 64 
nodes 
• In total 3 full cycles of coding were completed for all telephone interviews, with 
fewer new codes added and only 1 code and no new codes added in the third cycle 
Codes for Telephone Interviews 





Number of references to 
code 
Advertising & Publicity 10 12 
Advice   
Answer appropriate 11 11 
Confirmed Prescriber Thinking 14 16 
Consultants Advice 8 11 
Degree of influence 17 18 
Detailed advice 4 5 
Difficulty recalling the advice 4 4 
Other Issues Made Aware  of 4 4 
Practical advice 19 24 
Evidence   
Changing prescribing habits 1 1 
Evidence base changed 1 1 
Evidence based 11 20 
Financial 1 1 
Cost 2 2 
Knowledge   
CPD 9 15 
Updated knowledge of others 2 2 
Medicines Information   
Helpful 9 12 
MI Service 6 9 
Professional service 2 2 
Role of MI 2 2 
Trusted Source 7 8 
Useful Service 11 13 
Value of Medicines Information 5 9 
Patient Outcome   









Number of references to 
code 
Outcome Unclear or Too Soon 14 17 
Positive Patient Outcome 25 31 
Prescriber Action   
Changed management of patient 4 6 
Deferred responsibility 5 11 
Empowerment 20 27 
Information sharing 3 3 
Other Factors Considered 21 25 
Patient circumstances 15 24 
Patient Discussion 23 32 
Prescriber Discussion 5 5 
Procedure performed 2 2 
Use of Advice in Patient Care 39 59 
Prompts for calling MI 41 45 
Complex Queries 14 18 
Positive Prior Experience 25 27 
Recommendation by someone else 9 9 
Another HCP 1 1 
Colleague 5 5 
Professional body 1 1 
Trainer 2 2 
Used MI Before 31 32 
Referral 4 6 
Resources   
Information Difficult to Find 9 10 
Information Sources after MI - not people 2 3 
Information Sources after MI - People 10 11 
Information Sources B4 MI - not people 35 37 
BNF B4 MI 31 31 
Information Sources B4 MI - people 19 21 
Colleague B4 MI 11 12 
Specialist B4 MI 5 5 
Information sources unhelpful 21 29 
BNF Unclear or didn't help 15 19 
Colleague didn't know 2 2 
Community pharmacist could not help 5 7 
Risk Management   
Record of MI advice 15 16 
No Record 3 3 
Safe Prescribing 18 21 
Second opinion 13 15 









Number of references to 
code 
Seeking clarification 23 29 
Seeking Evidence 4 5 
Seeking Reassurance 18 31 
Time Factors   
Convenient 9 13 
Time Constraints 4 7 
 
Process of coding the face-to-face interviews  
• Constant comparison was used, as described above 
• The second cycle of coding found 3 new codes in interviews 11 and 12 
• No new codes were found in interviews 13-15 
• 83 free nodes (codes) were condensed/combined into 9 Tree Nodes and 81 codes 
Codes for Face to Face Interviews 





Number of references 
to code 
Decision making   
Correct diagnosis 3 4 
Future decision making 7 13 
Intuition 3 7 
Judgement 5 14 
Other Specialist Advice 4 8 
Patient or carer decision-making 5 10 
Place of MI advice in prescriber decision 
making 
15 87 
Practicalities of medicine or medical treatment 6 8 
Prior knowledge of scenario 13 46 
Running out of options 6 16 
Safety & Efficacy of medicines (in practice) 11 27 
Shared-decision making 12 32 
Type of procedure 2 2 
Evidence based practice 1 1 
Description of EBM 11 17 
Keeping up to date 14 59 
Online searching skills 10 21 
Postgraduate training 6 9 
Practising EBM 11 36 
Information sources: other 1 1 
Alternative sources of information and advice 15 159 
Community pharmacy response 2 2 




Perception of community dental service by 
secondary care 
1 1 
Ref source unhelpful 13 35 
MI Advice   
Acts on MI advice 14 34 
Clarified available evidence 4 7 
Emailed advice 12 21 
Immediacy of response 14 43 
MI service logs query 3 5 
Opinion of MI response 13 37 
Passes on MI advice 9 19 
Provided answer to unknown question 10 13 
Referral to specialist 2 9 
Refers back to MI advice 8 22 
Signposting 1 1 
User friendly answer 7 17 
MI as an Information source   
Contacting the MI service 13 33 
Prior use of MI service 12 20 
Rapport with MI staff 4 6 
Refers colleagues to MI service 6 6 
Telephone discussion with MI 10 23 
Third party enquiry 2 4 
MI Training 1 2 
Patient care 1 1 
Better patient follow-up 5 7 
Care of future patients 9 16 
Complex patient 13 31 
Minimising patient risk 15 57 
Patient aware consulting MI 12 29 
Patient circumstance 14 44 
Patient education 6 14 
Patient factors considered 13 40 
Patient or carer advice 8 10 
Patient outcome 14 43 
Patient prescriber relationship 15 66 
Patient reassured 12 21 
Phoned patient or carer 9 14 
Referral of Patients 5 12 
Specific patient-centred advice 1 5 
Prescriber feelings   
Confirmation when unsure 11 31 
Don't know everything 11 43 
Isolated or lonely 1 1 




Risk averse 4 12 
Risk minimisation 12 42 
Seeking reassurance 9 23 
Prescribing 1 1 
Appropriate prescribing 11 22 
Change to prescriber practice 8 28 
Factors considered about prescribing 
medicines 
15 44 
Not considered risk 1 1 
Safe prescribing 12 44 
Questioned by others   
Asked a question by another HC 
professional 
2 3 
Asked a question by the patient 5 9 
View of MI service   
BNF information service 3 6 
Enquirer perception of MI 13 31 
Evidence based response 11 22 
Knowing about the service 12 28 
Known MI contact 1 3 
Opinion of MI service 14 38 
Reasons for using MI service 9 28 
Time saved by enquirer 6 15 
Unfamiliar medicine(s) 7 21 
Unfamiliar patient 3 8 
Unsure what to do 12 30 
Record of MI advice 6 16 
Specialist service 9 26 






Appendix 8b: The process of combining and developing themes across both 








The process of combining and developing themes across both data sets: 
telephone and face-to-face interviews: 




The process of combining and developing themes across both data sets:  
face-to-face interview theme development 
 




The process of combining and developing themes across both data sets:  







The process of combining and developing themes and meta-themes 





Appendix 8c: Transcription extract of a face-to-face interview with coding 
Note: Codes have been deleted to only show the coding (codes with stripes) relevant to this transcript.  
However, some codes are still visible due to formatting issues, as deleting these would have deleted codes I wanted to show in this document 
TOPIRAMATE & INTERACTION WITH ST JOHN’S WORT 
JR: Yeah. So yeah, so if we can move onto, if you want to ask me at the end anything about the service. So you asked us 
about St John's Wort and Topiramate, and I don't know if you can describe what happened, if you can remember anything 
about the incident …? 
 
I: I think, I've not had further clinical encounter with the same 
patient afterwards … JR: No 
I: … but I remember when I spoke to you and I think it was looked into through your manuals and you got back to me saying … 
just recall… 
 
JR:   It's a long 
time ago, isn't 
it? I: Mmm 




JR:   … about St John's Wort decreasing Topiramate levels 
…  I: Yes there was … 
JR: Yeah 
 
I: … yeah … 
 
JR:   … but that was all, so … I:
 … that's true 
JR:   … I don't know what, the pharmacist that did the query has written a little bit on the enquiry, 'cause we record 
them all electronically    and she put something about, it sounded like you were talking to the patient at the 
time … 
 
I: That's true … JR: … yeah, so … 
I: … yeah, I think what we did is, because I think her headaches were getting worse …  
 
J R: Yeah  
 quite a lengthy consultation, she asked quite a few questions and in the end asked this as well, so I thought rather than, because I  





I: … she was advised to carry on taking Topiramate, now they were present in the consultation when she asked this question, it was 
Theme: 
information 
resource issues  
  
 235 
J R: No  
 
J R:     Right  
 
 
JR:     Yeah 
 
I: … and I've actually put the speaker on …  
 
J R: Oh OK, yeah …  
 
 
J R: … sometimes that's a good idea…  
 
 
J R: … yeah  
 
J R: Right  
 
I : … and the fact that they found out straightaway there and then  
JR: M-mmm … 
I: … em … 
JR: … what, the patient themselves … 
I: … the patient, 
yeah  
JR: … right, OK 
 
 
J R:     Yeah  
 sense, it was done …  
 
J R:     Doing it at the time …  
 
 
J R: … rather than …  
 
 
J R: … by email  
 
JR: Yeah. So did the patient, I don't know if you can remember, was the patient already on St John's Wort, or were they just 
thinking about taking it? 
 
I: I think they were already on St John's Wort, they were taking on and off  
J R: Right  
 
 switched to Amitriptyline …  
 
I: … then I think I had your number handy as well, so … 
I: It is quite useful for me as well, it saved my time as well … 
I: … there and then … 
I: … yeah … 
I: … during the consultation 
I: … the information advice line, so I rang in on the speaker there and then and spoke to your people … 
I: … so they … 
I: … could hear it … 







relationship   
  
 236 
J R:     Yeah  
 
 
J R:     Yeah  
 
 
J R:     Right, OK  
 
 
J R:     No, yeah  
 
I : … but it was actually the husband who brought it 
up … JR: Oh OK 
I: … and asked me the question 
… JR: Right 
I: … and then … 
 
JR:   And he was there as well 
… I: He was there … 
JR: Right … 
 
I: … as well … 
 
JR: … yeah 
 
I: … and then the wife said “oh yeah, you talked to me before,” so they threw that question onto me and I obviously didn’t know the  
 answer [slight laugh] 
JR: No [slight laugh] 
I: … yeah, so it was useful 
 
JR: Yeah. So where did you look then when you initially were asked that question? 
 
I: Yeah, I mean the first portal is obviously BNF, we look to that. I tend to use electronic BNF a lot more, I don’t use the paper copy of it,  
 
 down the list and see 
it … JR: Yeah 
I: … and if I find the information there that's good enough for me, if not then normally if, if flexible sometimes like an out-of-hours,  
 evenings or late, Friday afternoon I've got a very close pharmacist 
friend … JR: Right 
I: … so I must say that, I mean he is working most of the time…  
J R: Yeah  
 
J R:     Yeah  
 
 
J R: OK  
I: …sometimes I informally send him a message as well, if it's like a non-urgent type query … 
I: … and which wasn’t effective and at that stage they were asked to go onto Propranolol, sorry Topiramate … 
I: … and I think it was her husband who looked on Internet somehow … 
I: … and he found out somehow, I don’t entirely remember … 
I: … and ask him … 
 Theme: clinical 
knowledge issues  
Theme: clinical 








I: …many times if we've got a query, we can't deal with people look at the BNF first, some people look at MIMS first …  




I: … where they're going to go next, some people have just a little bit more experience, they deal with it, sometimes they make it as like a  
 different query, ask the patient to go home and check it. Some people ring in, we've got an in-house pharmacy 
here … JR: Yeah 
I: … there's a pharmacist here … 
JR: Yeah 
 
I: … but obviously it depends, at one time there are one or two pharmacists, it's quite a big pharmacy here, sometimes as 
well and obviously it depends [on?] their clinical experience as well, what background they've got, what clinical 
confidence they've got, so 
 sometimes we do get an answer, other times we don’t, so that's what I used to do before as well … 
 
JR:    OK I: 
JR: No 
 
I: … obviously he’s more experienced than me, he probably knows the answer to 
everything … JR: Right [slight laugh] … 
I: … [?] … 
 
JR: … I don't think anyone knows the answer to everythin 
 
I: … no, so he probably ring in as well to this local pharmacy, if they can't get answers then people looked around MIMS, I don't know  
 what they do afterwards 
… JR: Right … 
I: … yeah … 
 
JR: … OK, is there anywhere else you look on the Internet at all after BNF, or …? 
 
I: I think I tend, there is a website, I've got that on my own desktop … I've got a bookmark made … I don't know off the top off my head,  
 it's quite a large medication database … 
JR: OK 
 
I: … I’ll just see if I can bring it up here 
 
JR:   Do you use NHS Evidence at all?  Is that one you 
use? I: Do you mean things like … 
JR: The NICE Evidence search or NHS Evidence it's called? I wonder if that might be what you meant 
 
I: I think, yes of course we do, use it for guidelines and things quite a lot, I use Patient Summaries, I use NICE, I use the Website, we use  




I: … I don't know if you're aware that 
that's … JR: I've heard of it … 
I: … good as well? 
JR:   … I've never seen it, 
I: … if they can’t find the answer then there's no standard protocol … 
Theme: 
information 
resource issues  
Theme: clinical 






I: … emm … 
 
JR: Do you Google? 
 
I: I Google as well …  
 
J R: Yeah  
 
 
J R: We all do, yeah  
 




I: And it's just clinic, what's the word 
… JR: Clinical knowledge summary? 
I: Clinical knowledge … JR: Yeah … 
I: … CKS, yeah 
 
JR:   … it used to be Prodigy … I: … 
clinical know, yeah …  
JR: … yeah we use … 
I: … so that's that one …  
JR: M-mmmI: … so we use 
them. There is another thing in this 
Website …  
 
J R:   Oh yeah Medicine’s CompleteI:
 … [?] … 
 
JR:     … yeah 
 
I: … so when you put in here, so you can look into other publications as well, eh …  
 
J R: Depends on what you've got subscription … so does this organisation subscribe to it then, or is it …?  
JR:   'Cause the problem with searching in the main search box is we always think you don’t know what you're going to go to do you …  
I: Yeah 
JR:   … we would always go into the particular resource we wanted on MedicinesComplete  
I: Yeah 
JR: Yeah, OK 
 
I: So if we can't get through, obviously people are looking online on these portals first and if they can't get enough information then they  
 ring the  local pharmacist.   I think, I must say our  pharmacist, one or two  of them  have  been working here for a  period  of  time  and  
 they're quite good, very helpful, they take details …  
 
J R: Yeah  
I: … to be honest … 
I: … it depends what sort of a link it comes out with, I may or may not take advice, I may not take it as definite but I do Google, so 
I: … and feedback to us later on, it may not be the same day, it may be the next day depending how busy they are… 
Theme: 
information 




JR: Yeah, get someone else, OK. So if we just go back to the case, and just talk a bit about the actual case that, when you 




JR:  … so when you, you've maybe explained it already, how you used our advice, so the patient was there, the patient and her 




JR:     Yeah 
 
I: I think … 
 
JR:   I just want you to describe to me more what happened, 'cause this is 
qualitative, so … I: Yeah 
JR:   … what happened and how you felt about it after you got our advice as well 
really 
 I: I think it was just … 
JR:   These are just prompts for me on 
here 
 I: OK 
JR: Yeah 
 
I: It was very useful to have, to know at the back of the mind that there is a sort of a qualified expert pharmacy service is there 
to advise you, I was able to get into that straightaway, and they took my details, they looked through, gave me advice and it 
was first-hand information there and then I passed it on …  
J R: Yeah  
 
I : … to the patient.  I knew it was reliable evidence-based information, it was safe, so I'm, I mean I felt quite confident as well.  
And in fact  to an extent that when I knew I was talking to another professional, and then I actually turned the speaker on and they 
could hear it as  well …  
JR:    Yeah [?], OK yeah.  So at what point, I'm trying to get into peoples’ heads about at what point makes you 
decide oh I don't know what   to do next, I need to phone, I need to contact … this service, so thinking … 
I: Yeah 
 
JR:   … about maybe that case and other times that you've used the service, at what point … 
I: Yeah 
JR: … in your thinking process, or in the consultation, does it, do you decide to contact the service? 
 
I: I think the practical bits of interaction when we come across in day-to-day things, sometimes things are very straightforward, obvious,  
 few things are written or documented, part of the BNF written guidance, most of them we do find is fine …  
 
J R:     Yeah  
 
J R:     Mmm  
 
J R:     Yeah  
 
I: … if you can't find it, if you've got previous experience of it, like I know about Topiramate and St John's Wort now … 
I: … so we utilise it, but if we don’t and it's not written information, something new comes across … 
I: … I think at that stage we think we need some advice and … 
Theme: clinician 
patient relationship  
Theme: clinical 
knowledge issues  






Theme: Expert  
service  
Theme: clinical 





J R: OK …  
 
 
JR:   … so if it's something you're not 
familiar … I: Yeah 
JR:  … familiar with, OK.  You've already said what happened with the patient … did she decide to continue with the St 
John's Wort, you're  not sure what happened with …? 
 
I: I think they stopped it …  
 
J R:     Right  
 
 
J R:     Yeah  
 
 





I: … so they stopped it 
 
JR:   OK.  Right so if you hadn't, you've maybe talked about some of this already but just in case there's anything else you’ve 
not mentioned, is if you hadn't called Medicines Information for advice, what would you have done then, how else would 
you have sorted the problem out? 
 
 
J R: Yeah  
 
 of that list for me as well …  
 
J R: Mmm  
 
 friend, Google it, different portals …  
 
J R: OK  
 
 
J R: Yeah  
 
 have to wait for it. I think with this service is that it, it's more like a live helpdesk sort of a situation thing, where somebody is sitting just  
 ring them and they’ll look into it straightaway and get back in to us  
 
JR: OK, yeah.  I try not to say too much because obviously it's for you to talk to me really, so that's fine, that's great.  So what 
about, when  I've done some other interviews, I have done some phone interviews as well as doing these face-to-face 
ones, the phone interviews, some of the things that came up was about using Medicines Information advice to minimise 
risk to themselves and/or patients … 
I: … we’ll get hold of you girls? 
I: … as far as I remember … 
I: … based on the advice they were given 
I: Because it was more important for them at that moment in time to treat the migraine than to start the new medication … 
Theme: clinician 
patient relationship   
I: … and find out then ring back the patient … 
I: … or book a follow-up appointment and talk to them. Other things, somehow I will find the answer but they you wait, yeah, the people 
Theme: clinician 





I: I think somehow I could have still got the information … 











JR: … I just wonder if you've got anything, what do you think about that? 
 
I: I think yeah, certainly it's one of the big advantages as well, I mean as you would know with the current atmosphere and 
the way the  
 litigation side of things as well, and obviously in terms of the patient perspective, they want to know more and more, and the 
patients  
 know a lot more as well these days …  
JR: Yeah 
I: … 
 very good safe prescribing record, so it gives a lot more confidence when you're giving a prescription or prescribing or advising  




I: … if you find the advice, I mean the BNF as you know is like a bible sort of thing, as most of the things are blind trust in, pass it 
on, but 
 if we don’t then rather than taking an educated guess and then taking a risk sort of thing and not being very sure, I think it's 
always a  good idea, you feel a lot more confident as well …  
 
J R: Right  
 
 
J R: OK  
 
JR: You document it in?… 
 
 
J R: M-mmm  
 
I : … so it becomes for audit purposes as well, for clinical awareness purposes that we do know who we're taking advice 
from …  
JR: Yeah 
I: … so that information is auditable 
 
JR:   OK, yeah.  And when we've sent you, have we sent you emails and things before now as 
well?  
I: Yeah 
JR:     Yeah 
 
I: Yeah, I mean I've received a few emails, there were, two or three of the main enquiries I've recently asked, one was … 
it was to do with Creons … 
 
JR:     Right, OK 
 
I: … and, I don't know if it was yourself or one of your 
colleagues … JR: I don't think it would … 
I: … I'm not sure … 
 
JR:   … yeah I'm part-time, so quite often it's not 
me … I: Yeah 
JR: … you you're alright [slight laugh], and it's all confidential anyway, but I haven't looked at what you'd asked more recently 'cause … 
they want to be absolutely and we want to be very safe in our prescribing as well, but we're actually in a practice where we have a 
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JR: … I wanted you to tell me 
 
I: I've actually been using it quite frequently, 
your … J R: Yeah  
I : … service 
JR:   Well, yeah that's fine, that's what we're 
there for I: So that's tru , 
 which is actually evidence-based, is …  
 
J R: Yeah  
 
 
JR: OK, so yeah, so it's kinda of getting to the point of, obviously you've never met us before and we're on the phone, how 
do you, what is your perception of the service, how does it give you confidence, that's something that's …? 
 
I: Yeah I think we were told firstly, somehow the information got into the Practice Manager I think …  
 
J R: Right, OK  
 
I : … and we were told that this information advice line is available. We also have got, actually a clinical pharmacist works in our practice  
 …  
J R: Yeah  
 
 
I:   prescribing, cost-effectiveness, efficacy and all that, some people go and take advice from them as 
well … JR: Mmm 
I: … speak to them. So that's how we got the information, and since then, I mean I've been using it, I find it … 
JR: Mmm 
I: … sorry if I’ve … 
 
JR: No, no … 
 
I: … forgotten … 
 
JR: … no, no it's fine … 
 
I: … to answer the question. 
 
JR: … no it's quite difficult to ask you the right question to kind of get you to tell me a bit more about it, I'm trying to work out 




JR:   … we're qualified pharmacists and…  
I: Yeah 
JR:   … maybe we, it's slightly different than using the community 
pharmacist 
I:  Yeah I think we feel quite supported 
JR: Yeah  
 
I:    but that is actually not true 
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… JR: [slight laugh] 
I: … we've got limitations, we are asked so many, a ton of questions every single day …  
 
J R: Yeah  
 
 different things, they bring in actually print-outs from the paper cutting, newspapers, from all different components and things a lot  
 more, so it's not easy to know everything.  In the past we used to take it from them, take the information and go back and often we  
 were looking at different portals, but not obviously, I mean you being a pharmacist and you being part of the service as well, you're   
 probably aware of a lot more websites and databases where you can get evidence-based first hand appropriate information there and  
 then straightaway, so I think that that gives a lot of confidence to us as well, that this information which has come out is not just from  
 Google or anything, cos of course people like yourself, you're part of this PhD course and, so the information we've got is from a  
 qualified pharmacist who are looking into the appropriate Website and databases.  I think for me personally that, that gives me a lot  





 lot more clinical-orientate …  
 
J R:   Mmm, m-mmm  
 
  
JR: OK … 
 
I: … so 
 
JR:  … yeah, OK.  So practising evidence-based medicine, we've probably talked about sources of evidence-based medicine 
that you use, but what does evidence-based medicine mean to you? 
 
I: I think anything we advise, prescribe, we give information, is appropriate, is looked into, has got research-backing, is recommended for  
 that person, for that indication, is appropriate, safe and advisable, I mean that's what …I'm conscious of the time 
JR:  M-mmm, OK.  A few other questions just to ask you … I think maybe, when I've done other interviews it's been mentioned 
about practical advice that we give, you've mentioned that it's timely because you can get an answer more or less 




JR: … have you got anything to say about it from  a  practical point of view, or is that not  something you've really,  it depends 
on the  questions you've asked, it might not really have come up? Say when we've emailed you with information has it, 
how has it been in terms of telling you what to do? 
 
I: I think it's quite good, I was given, on numerous occasions, I was given this option twice when I rang, and I was asked that, is that  




I: I think on a couple of occasions because it wasn’t something I wanted to know straightaway there and then, 'cause somebody asked  
 me  just not long  ago, if the  Creons they take for  their chronic pancreatitis, because  they're  very like  strict  vegetarian,  for religious  
 reason they won't take sort of like any pork gelatine in it …  
 
J R: Yeah  
 
I: … not pharmacologically-orientated … 
'cause I may take information and we go back and do homework, but we're probably looking at the Websites which give, which are a 
I: … and more and more people are coming in, and they do a lot of their homework, they know about medications, they're looking at 
I: … so there was no urgency for that, I said … 
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J R: No  
 
I : … “OK if you can look into it then get back to me 
later on” JR: M-mmm 
I: Similarly the situation with some vitamin D preparation, I didn’t need to know there and then and I said “OK fine, you can take my email  
 address and let me know later on”  
 
J R: Yeah  
 
 appropriately according to the urgency …  
 
J R: Yeah  
 
 
J R:     M-mmm  
 
I : … the person on the other end of the phone they sort of sensed it quite appropriately then got 
back to me. JR: Yeah … 
I: … if they needed to. 
 
JR:   … I guess if they knew the patient was there …  
I: Yeah 
JR: … yeah.  So how do you make, forget about our service, but how do you tend to make decisions about medicines, 
about prescribing  them, how does it fit in your clinical decision-making thought processes? These questions get 
harder as … [slight laugh] … 
 
I:   Ooh … [slight pause] … obviously we are driven mainly by the clinical indication.  Patient choices, the past history, there are 
numerous  factors and I think there are, there were like a longs what all GPs would do for that condition, which is pretty much 
standardised, but  slight variation in terms of … it's a very quick sort of, you can say like a browsing in the head we have to go 
through, looking at someone while they're sitting there looking at their history, looking at the condition, so many things just pass through 




I: … so many things 
 
JR:   And how do you think that happens, that process, is 
that…?  
 
I: I think it happens naturally … 
JR: Mmm 
 
I: … yeah sometimes we just don’t have a control on it …  
 
J R: No  
 
I : … because you’ve done something so many times … 
JR: Yeah 
JR: … OK, all right 
I: But on this occasion Topiramate, St John's Wort, I think I, they got back to me straightaway there and then, so I think it was dealt with 








JR:   Yeah, OK, so are you kind of ruling out 
certain things and then … I: Mmm 
 
JR: … moving onto … OK, and how does the Medicines Information advice fit into the process, at what point do you tend to use …? 
of prescribing, if someone has come in with a long list of medication, multiple co-morbidities, or they've got like an unusual syndrome,  
something different in their past medical history …  
 
J R:     Yeah  
 





JR:   Yeah, 'cause it's all right when you've got a patient who’s got one 
thing going on … I: Yeah 
JR: … but that's not normally the case is it 
I: The thing with polypharmacy, where it comes in is when nursing home 
patients, some elderly, some patients with a complex past medical history, a lot of 
medications and then you're adding in a new substance, or changing the dose where 
you haven't got much experience with it …  
JR: Yeah  
 
 
JR: OK.  So in terms of your, the care of your patients and advice that Medicines Information 
have given you, how do you think it influences the care of your patients when you have 
used it? 
 
I: I think it has a positive effect … 
JR: OK 
I: … em we, em, when the patient get aware being prescribed something which is safe for them — or presumed to be safe — and the  
 doctor has more clinical confidence, they feel more confident, I think it helps with the patient/doctor relationship as well, sometimes  
 involving like a third person or expert into the equation and …  
 
J R: Yeah  
 
 pharmacist and there's no interaction,” so they feel like I listened to, they feel, sort of not just one, but a few experts working together  
 and trying to help them 
JR: OK  
I: It's like a second reflex, so you just do it 
I: … or the information, you can't find in, then it's quite useful 
I: Yeah I think at times it would take a decision which is not part of the routine, something you havent' got more experience with in terms 
I: … so we don't know how this is going to go in … 
I: … it's always useful to have information taken from the pharmacist … 
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Table used by Medicines Information centres to collate participant and enquiry details 
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Appendix 10: Participant information sheet (telephone interviews) 
 
Impact of Medicines Information Answers: an evaluation of Primary Care Prescriber 
Decision-making 
 
Reasons for conducting the study 
 
UK Medicines Information (UKMi) is an NHS funded service which is provided to health care 
professionals in primary and secondary care. Service evaluation has traditionally involved quality 
assurance of the service, however little is known about the effect of the information and advice 
provided on patient care.  This study aims to find out how answers to MI enquiries influence 
prescribers in their decision-making and what impact these answers have on patient care. 
 
Why should I become involved? 
 
This study is being conducted with primary care prescribers in England and Wales who request an 
answer from their medicines information centre (UKMi) about a patient in their care. You have been 
recognised as a potential candidate for the study. This will provide us with the opportunity for you 
to help us understand how medicines information answers are used by the prescriber to inform 
patient care and demonstrate the potential benefits of the service. 
 
Do I have to be involved? 
 
It is your decision whether you want to be involved in the study. You are free to withdraw at any 
time, without giving reason.  
 
Benefits of taking part or benefits of the study 
 
For those prescribers taking part in the study there are no intended benefits. The information 
obtained will however help to determine the effect the UKMi service has on prescribers and patient 
care and help to make the UKMi service more responsive to prescriber need. 
 
What will happen if I decide to take part? 
 
If you decide to take part you will be asked to take part in a telephone survey that will last 
approximately 10-15 minutes. The survey will take place on a date and time that it is suitable for 
you. The interview will consist of a series of questions relating to how you used the medicines 
information answer. The survey will be recorded to ensure accuracy.  
 
What will happen if I decide not to take part? 
 
We thank you for taking the time to read this information. To ensure we do not contact you again 
please could you email or and in the message box simply 
state ‘NONE PARTICIPATION’.   
 
What will happen to the comments I provide and confidentiality? 
 
The survey will be confidential and any information/comments provided may be used in reports 









Results of the study 
 
The results will be included in the researcher’s PhD project thesis. The results may be made 
available for a peer reviewed journal. No individual results will be made available, however a copy 
of the final results can be sent out to participants upon request. 
Authorisation from School Ethics Committee 
 
Ethics approval has been granted by The Behavioural Sciences Ethics Committee, School of Applied 
Sciences, University of Wolverhampton. 
 
What should I do now if I want to take part? 
 
If you would like to take part in the study please complete the section 
below and email it to  or . The 
investigator will then contact you by email to confirm the date and 
time for the telephone interview to take place. 
 
Contact for Further Information 
 
If you have any questions about this study before deciding to take part, please contact the lead 
investigator, Jill Rutter or the university supervisors, who will be pleased to help you: 
 
Jill Rutter Professor Rae Morgan/Dr Paul Rutter (Supervisors) 
Pharmacy Practice Division Pharmacy Practice Division 
Department of Pharmacy  Department of Pharmacy 
School of Applied Sciences  School of Applied Sciences 
University of Wolverhampton University of Wolverhampton 
Wulfruna Street, WV1 1LY  Wulfruna Street, WV1 1LY 
United Kingdom  United Kingdom  
Mobile:   Tel:  
Email:  or  Email: /  
  
 
Please  complete  and email to or   
 
§ We will contact you approximately 2 weeks after you received your medicines information 
answer.  
§ If you are happy to take part in this study, please indicate below any suitable dates and times 
when you will be available. 
  
Suitable Date(s) and Times for you to contact me by telephone are:   









AM AM AM AM 
PM PM PM PM 
 
The best telephone number to contact me on is: _________________________________ 
   
Name:                               Date:              











Use of medicines information advice in primary care: 
An exploration of effect on prescriber decision-making and patient care 
 
Dear  _________________ 
   
You recently contacted the medicines information (MI) service with a patient query about: 
________________________________________________________________________________ 
 
I would like to invite you to take part in a study, which I am carrying out as part of my PhD 
research programme at the University of Wolverhampton.  
 
We would like to find out what happens after you receive our advice. 
The main objective of this study is to find out how MI answers are used in prescriber decision-
making and what effect they have on patient care. Participation in this study will involve you 
taking part in a face-to-face interview that will last no longer than an hour. 
 
The information you provide will only be identifiable by the investigator and her supervisors. No 
data you provide will be identifiable in any reports or publications.  Attached is an information 
sheet that gives more details of the study. Once you have read this and if you are willing to 
discuss your use of the advice received, please complete the attached form and email to 
  I will then telephone you to arrange a date and time for the informal face-to-
face interview to take place. 
If you require any further assistance, do not hesitate to contact either myself or my supervisors 
(Professor Ray Fitzpatrick, Dr Hilary Paniagua and Professor Paul Rutter) via email or telephone. 
Contact details have been stated in the information sheet.  
 







MI Pharmacist/PhD Researcher 
Pharmacy Practice Division 
Department of Pharmacy 
School of Applied Sciences 
University of Wolverhampton 
Wulfruna Street,  
WV1 1LY  
United Kingdom 





Appendix 12: Participant information sheet (face-to-face) 
 
Use of medicines information advice in primary care: 
An exploration of effect on prescriber decision-making and patient care 
 
Reasons for conducting the study 
 
UK Medicines Information (UKMi) is an NHS funded service which is provided to health care 
professionals in primary and secondary care. Service evaluation has traditionally involved quality 
assurance of the service, however little is known about the effect the advice has on prescribers and 
patient care.  This qualitative study aims to find out how answers to MI enquiries are used by 
prescribers in their decision-making and what effect these answers have on patient care. 
 
Why should I become involved? 
 
This study is being conducted with primary care prescribers who request advice from their 
medicines information centre (UKMi) about a patient in their care. You have been recognised as a 
potential candidate for the study. Your involvement will help us understand how medicines 
information answers are used by prescribers to inform patient care. 
 
Do I have to be involved? 
 
It is your decision whether you want to be involved in the study. You are free to withdraw at any 
time, without giving reason.  
 
Benefits of taking part or benefits of the study 
 
For prescribers taking part in the study there are no intended benefits. The information obtained 
will however help to determine the effect the UKMi service has on prescribers and patient care and 
hopefully help to make the UKMi service more responsive to prescriber need. 
 
What will happen if I decide to take part? 
 
If you are interested in being involved, you will be asked to take part in an informal face-to-face 
interview that will last no longer than an hour.  The interview will take place on a date and time 
that it is suitable for you. The interview will consist of a series of open questions relating to how 
you use medicines information answers in your decision-making and management of your patients. 
The interview will be recorded to allow transcription and analysis.  
 
What will happen if I decide not to take part? 
 
We thank you for taking the time to read this information. To ensure we do not contact you again 
please could you email  and in the message box simply state ‘NO THANK YOU’.   
 
What will happen to the comments I provide and confidentiality? 
 
The interview data will be confidential and any information/comments provided may be used in 
reports but it will be anonymous and all data will be stored confidentially and destroyed after 5 





Results of the study 
 
The results will be included in the researcher’s PhD project thesis. The results may be made 
available for a peer reviewed journal. No individual results will be made available, however a copy 
of the final results can be sent out to participants upon request. 
 
Authorisation from School Ethics Committee 
 
Ethics approval has been granted by the Life Sciences Ethics Committee, Faculty of Science and 
Engineering, University of Wolverhampton. NHS Ethics approval was not required as this study is 
classed as service evaluation. 
 
What should I do now if I want to take part? 
 
If you would like to take part in the study please reply to  The investigator will 
then contact you by telephone to confirm the date and time for the interview to take place. 
 
Contact for Further Information 
 
If you have any questions about this study before deciding to take part, please contact the lead 
investigator, Jill Rutter or the university supervisors, who will be pleased to help you: 
 
Jill Rutter Dr Hilary Paniagua/ 
Pharmacy Practice Division Professor Paul Rutter (Supervisors) 
Department of Pharmacy Pharmacy Practice Division 
School of Applied Sciences Department of Pharmacy 
University of Wolverhampton School of Applied Sciences 
Wulfruna Street, WV1 1LY University of Wolverhampton 
United Kingdom Wulfruna Street, WV1 1LY 
Mobile:  United Kingdom  




Please  complete  the box below & email to  
 
  
Yes, I am happy to take part in an interview about how I use medicines information advice. 
The best telephone number to contact me on is:  
Name:                         Date:                                      





Appendix 13: Participant consent form 
 
Use of medicines information advice in primary care: 
An exploration of effect on prescriber decision-making and patient care 
 
This will involve talking to the investigator for up to 1 hour on how you go about using 
Medicines information advice in your decision-making. Please read the information below 
and tick each box if you wish to participate in the study. 
 Please tick each box 
I have read and understood the information sheet for the study  
I have had the opportunity to ask questions about the study and have had 
them answered satisfactorily 
 
I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason 
 
I understand that any information I give as part of the study, including patient 
details, will be treated with strict confidentiality and that I will be anonymous 
in any written reports from the research 
 
 























Appendix 14: Pre/post interview information and checklist 
 
Initial telephone call: 
 
Hello, can I speak to [Insert Title]? 
 
You recently contacted the medicines information service with an enquiry and responded to 
an email saying that you would be happy to take part in a face-to-face interview about how 
you use our advice in your decision-making and patient care. Is that right? 
 
If at this point the person says No – thank them for their time and apologise for taking up their 
time 
 
If Yes, continue with script below.  
 
I’m phoning to arrange a suitable date and time to meet up and do the interview. Is now a 
good time to sort this out? 
 
If at this point the person says No – try to arrange a convenient time to call back. 
 
If Yes, ask pre-interview questions, and agree a suitable date & time. Confirm address & room 
(quiet without interruptions). 
 
Thank you, I look forward to meeting you on [Insert Date], I will call you the day before to 
confirm everything? 
 
p Pre-interview Checklist 
p Completed participant details form 
p Signed consent form 
p Checked recording device 
p Confirmed time available 
p Explained about recording and making additional notes  
p Interruptions likely/phones diverted/on silent? 
 
Before/after the interview: 
 
Before we start please can you confirm you read the emailed information about the study, 
including the information sheet.  
 
If Yes, skip below script and move to confirmatory questions. 
 
If No, then continue with script below. 
 
You are invited to take part in an interview as part of an evaluation of the UK Medicines 
Information Service, which you recently contacted. The purpose of the study is to see how the 
advice provided was used. The interview will be recorded to allow transcription and qualitative 
analysis. 
 
You do not have to participate and we will ask you to verbally agree to take part after I have 
provided you with this information. Even, after you agree to take part you can still withdraw 




possible that you may not wish to answer one or more of the questions, please just let me 
know.  
 
Any information you provide will be kept confidential and not be shared with a third party. It 
will only be seen by the investigators. Any information that relates directly to you will be made 
unidentifiable and all paper and electronic records will be destroyed after 5 years.  
 
Finally, this study has also been approved by the University of Wolverhampton Ethics 
Committee. 
 
Would you like to ask any questions? 
 
If Yes,  
 
What questions would you like to ask? 
 
If No,  
 
Can we start the interview? 
 
If Yes,  
 
Start voice recorder and begin interview. 
 
At the end of the interview, 
 
Thank you for your time. Do you want me to email you a copy of the final results of this study? 
 


















Appendix 15: Form with participant and enquiry details 
 
Use of medicines information advice in primary care: 
An exploration of effect on prescriber decision-making and patient care 
 
Participant/enquiry details form  
 
Section 1: Data obtained from MiDatabank (To be populated by JR) 
Enquiry Details Enq No: Agreed to be contacted 
for research purposes: 
 
MI Centre:  
Date Enquiry 
received: 
 Date Enquiry answered:  
Enquiry 
Complexity  Level 
1/2/3 
(exclude level 1) 







Complex patient  
e.g. multiple meds/morbidities 







 Possibly:  

















Section 2: Data obtained from MiDatabank/Phase 1 of PhD/Phase 2  











Previously interviewed: Phase 1:  Phase 2:   
 
Section 3: Participant recruitment tracker (To be populated by JR) 
Interview invitation    
Date email/letter sent  Reply received Yes/No 
    
Agreed to interview Yes/No Date/time re-
confirmed 
Yes/No 







Section 4: Data obtained from investigator phone call with prescriber    (To be 
populated by JR) 
Pre-interview data    
Repeat user:  First time user:  
No. of GPs/dentists in 
the practice 
(Internet search) 
   
Years qualified:  
(ask when see prescriber 
after consent) 
   
Seen patient since received 
MI answer: 
Yes  No  If no when 
likely?:  
 
Patient outcome known: Yes  No  If no when 
likely?: 
 
Prescriber can access patient 
notes:  
Yes  No   











Appendix 16: Extracts from interview transcripts for selected themes 
Safety Net Meta-theme:  
All Interview extracts relating to decision-making 
Providing a decision 
 
T1 Dentist 
…told me what to do   
 
T2 GP 
well perindopril doesn’t (cause psoriasis) so just used that information in treating the patient. 
Patient still on perindopril. Not looked for other causes. 
 
T4 GP 
…made my decision for me 
…basically, gave me all the information I needed. 
 
T36 GP 
I think it would have just taken me a lot longer to find out. It was really nice going one route 
and very quickly getting a definite decision, when I have had to do an online search & check 




They [MI] gave me some information about how I was going to manage it, logistically they told 
me how I was going to manage it. […] so it wasn’t just a just a vague answer – I did what they 
said” 
 
T38 GP    
I’ve got the patient sitting with me and it’s something really crucial and I need to know today 
or this morning.  
F2 Dentist 
I'd say it has quite a significant part… 
I’ll listen to what you say and I’ll act accordingly 
F9 Dentist  
…in a, ‘an emergency situation’ is probably a bit strong a word, but it is in the situation where 
everything else has failed me, right, well what, what are we doing now, you know, he’s allergic 
so I've got to give this, or she's taking that but I want her to take this, and you need to take it, I 
want you to take it now to get you out of discomfort…[…]…antibiotics really was going to be 
our last, it was our last port of call really, so I needed to prescribe it 'cause the others hadn't 
worked, our other measures we didn’t feel were working… 
 
F11 Dentist 








those sort of things where you're not, you know sure what medication to prescribe; I mean 
normally we’ll go through the psychiatrist for that but…(JR: right)…occasionally there’ll be 
patients that aren't at a level where they need psychiatric intervention… 
 
I think it was… either six or eight weeks where they were sort of saying, you know, it was 
either stressing avoid, or using caution, so I thought that's why I’d ask for some advice 
 
I basically rang the patient … rang the patient and prescribed the, the medication 
I explained that the, you know that, that medication at that dose had been, had been used 
…you know eh previously, em and that you know I felt it was a, a, you know safe for her and 
for, and for the …… for the baby.  Em and em that you know that I'd taken your, taken some 
advice on it and that was the recommendation 
F13 GP 
The thing with polypharmacy, where it comes in is when nursing home patients, some elderly, 
some patients with a complex past medical history, a lot of medications and then you're 
adding in a new substance, or changing the dose where you haven't got much experience with 
it (JR:Yeah)… or the information, you can't find in, then it's quite useful 
 
F14 GP   
When it said in the BNF, you know, not to be prescribed in pregnancy, that's when you know I 
thought I need to get a bit more information 
 
F15 GP 
 …because of the CKD [chronic kidney disease], the dose was restricted, she asked if she could 
have more, her current medication now, she's on Matrifen [Fentanyl patch] which somehow or 
other managed to get bumped up to, I think it's 100mcg …(JR: Right)…and a little bit of codeine 
at night if she woke up with pain …(JR: Yeah)… and gabapentin, she couldn’t tolerate tricyclics 
at all, so upping her Gabapentin was a good option really 
 
Confirming a decision 
 
T1 Dentist  
Essentially the advice that I was given is that no evidence to state that antibiotic cover is 
required for renal transplant patients. 
 
I already knew that there was no evidence in the literature to suggest that antibiotic cover was 
require for renal transplant patients but I needed to have an opinion from a well-respected 
body and that was provided by the people who called me from the BNF 
 
T6 GP 
I already had idea but without name and the information from MI confirmed my suspicion 
 
T7 GP 




It confirmed what I suspected but wasn’t 100% sure about. I probably would have prescribed, 
well I was thinking about prescribing it in any case, and it confirmed that would be the right 




uncertainty about it. 
 
T14 GP 
I was able to take the decision knowing that I’ve asked experts with access to extra specialist 
information and I now know that what I’m doing for my patient is absolutely right 
 
T15 GP 
Had an inkling that it was going to be sertraline– I mean it’s not uncommon that one ends up 
treating patients for depression with cardiovascular disease, & I had an incident before where I 
inherited a patient who was on a tricyclic which I didn’t think was going to be the right drug & I 
remembered that it was likely to be an SSRI and I wanted to check that it was still going to be 
sertraline.  
 
Confirmed it  
 
T23 GP 
It had a big influence in terms of confirming that it was the correct thing pharmacologically to 
do  
 
It’s nice just to have someone’s opinion; a pharmacological, professional opinion really to 
confirm that what I’m doing is the correct thing. 
 
T26 GP 
It confirmed my suspicions and it convinced me to go ahead rather than take a chance because 
he’d been taking a chance and using medication not stored correctly 
 
T27 Dentist 
I always cross reference myself, I make sure before I prescribe something if I’m unsure to 
always ring that number cos it’s in the BNF, that number for the dentists.  
 
T28 Dentist 
It confirmed what I’d decided 
 
I just wanted to be sure that what I was doing was the best treatment for the patient because 
it’s quite a difficult case 
 
T29 Dentist 
I’d probably say it clarified what I was already feeling myself anyway, that I didn’t want to do 
anything until I had allergy tests completed. 
 
T35 GP 
confirmed what I thought I already knew from looking in BNF that not lot choice for under 12s, 
basically the topicals really 
 
T36 GP 
I think it also gives a bit more power to the decision making within the practice and when 
giving information to patients. When you say, I have mentioned that I have checked with the 
prescribing team at the [MI Centre] and they confirmed that we shouldn’t be doing this even 
though it’s only low  
dose. 
T39 GP 
basically I was wanting to confirm really that there wasn’t anything other than that to be 
concerned about and as mum had only used it the once, I didn’t think it was going to be a 




are things you might not have thought about, some other reason and that was fine. 
 
T40 GP 
I think the information that you gave us had some sort of comments about that it was not 
known to be unsafe but use as little as possible and try not to use it if possible, that sort of 
thing which is fine, I mean you can’t always have exact figures on these things.  It was the 
same information I think that basically that was in the BNF, I just wanted to make sure there 
was not any other information 
 
It just confirmed my concerns that I had helped back up what I already thought.  
 
F4 Dentist 
Sometimes someone will come in with a whole 20, 25 tablets, and to manually check it, it’s 
going to be a bit difficult even though I, you know you, there may be very little effects, say 
from amoxicillin I still would probably get it and have a look, just maybe more as a reassurance 
than anything else. 
F9 Dentist 
I think realistically it's usually for something that I'll know is going to be all right but I just want 
that, that bit o' back-up, so clinically I suppose I've already made the decision because that's in 
the [dental treatment] pathway,[…] usually in dentistry it's going to be antibiotic prescribing 
and that's going to be your last option anyway, if your local [dental] measures haven't worked. 
 
F10 Dentist  
I don't think I would have taken the chance in prescribing the miconazole, even if she’d had it 
before,  
I think when they come about it's always just for, to see if somebody else have a different 
information that you're not aware, and then you can take better decisions,  
F14 GP  
when it said in the BNF, you know, not to be prescribed in pregnancy, that's when you know I 
thought I need to get a bit more information because it was, it would have been, had we 
discovered that she was on Simvastatin and she wasn’t pregnant at the time, then the process 
might yeah, I imagine the process would have been to say look, pretty much stop Simvastatin 
now, but I wouldn’t have contacted your service, 'cause I wouldn’t have been … 
… concerned about the risk …[JR: Yeah]: … to the pregnancy surely I mean I suppose it didn’t 
alter my decision that she should stop the medication …[JR: No]…there wasn’t any question 
…at any stage …[ JR: … yeah …]… that she should continue her Simvastatin, particularly as she 
was on it for a primary prevention rather than a secondary prevention, but even so, it wouldn’t 
have altered my decision to stop it … 
you don’t want patients to be, continue with medications that, you know may 'cause harm, so 
[I suppose that's about patient risk?] in this situation it was more for the, like I say for the 
advice and counselling rather than you know what to do about the medication per se, 'cause 
that was already stopped. 
I mean, yeah, that's it, I can think of at least two or three that have related to pregnancy and 
breastfeeding, because I think the information in the BNF is not that extensive in those areas … 
I think yeah, sometimes you've got an idea about what you might, or might not, do, and I think 
it's helpful to get a more, you know, more expert opinion about that to confirm what, you 




F5 Dentist  
the reason I contacted you was going on a domiciliary visit, so limited amount I could do, 
thought antibiotics might be needed, was unsure when I'd looked in the BNF, so I just wanted 
confirmation 
I'd err on the side of caution, I'd just, you know I wouldn’t, if I wasn’t 100% on something I'd 
just not do it rather than take the gamble 
If it's there in black and white in the BNF then you're happy, but sometimes the BNF, it just 
doesn't quite say the exact wording you want, even if it's just kind of a very similar drug, unless 
you, sometimes you just want someone to say “yeah, 100%, that's right,” but then I'd probably 
only do it if I'm really unsure because I probably don’t have enough time in the day to, you 
know.. 
Shaping a decision 
 
T12 GP  
The concern was that the patient had been treated with metronidazole for bacterial vaginosis.  
She then came back that she was pregnant and looking at her dates she probably would 
conceived have been the first week or so of pregnancy that she had taken the dose of 
metronidazole.  So the first thing I wanted to know was what actually is high dose of 
metronidazole and I think that it’s the 2g stat dose which dose is not what she had.  Then the 
next thing was whether there was concern about teratogenesis 
 
T13 GP 




Had Neurologist writing back anyway with a specialist recommendation and I looked at BNF 
which gave me some concerns about renal impairment and valproate and then I thought that 
as  the GP I have to write the prescription although the consultant has given the advice, It’s my 
responsibility, I’m writing the legal document and I’m taking the clinical risk so at that point 
has the consultant really taken on board the degree of the patients renal impairment which 
was significant and the BNF gives me some advice. So that‘s the sort of situation that’s starting 
to be tricky so I thought actually this is where I am going to the XXX Medicines Information 
Service because you want something that’s a little bit more in depth. I’ve already got 2 sources 
of information, the BNF and the consultant Neurologist and none of them are writing the 
prescription so in that situation I thought – and they gave me very clear advice, have you got it 
there? 
 
that would have been really hard for me to get & that really helped me because I was able to 
take the decision knowing that I’ve asked experts with access to extra specialist information 
and I now know that what I’m doing for my patient is absolutely right.  
 
T15 GP 
I use them whenever there is something tricky and I need just another level of insight that isn’t 
in the BNF, that isn’t in the drug interactions there. The tricky multiple drug interaction 
situation or a very tricky patient with multiple allergies or multiple pathology and lots of 
morbidity, I have a lot of patients like that and they are really good.  
 
its really when you write to the psychiatrist and you’ve worked it up and you can say I’ve been 
in touch with the [MI Service] ..errm ..this is their view and this is where I’m going it’s useful, 





Sometimes I don’t, it’s out of hours and they’re closed and I have to make a decision, I had a 
man last week with advanced renal failure with gout, that’s a very. Pre-dialysis with an eGFR of 
12, can’t have NSAIDs, he’s on a tiny dose of allopurinol which is a bit questionable anyway, I 
need treat him he’s in terrible pain and I look at colchicine and the BNF says don’t give. I would 
have gone at that point to the medicines people and said look the BNF is saying don’t, I’m 
probably going to have to give him steroids, is colchicine really contraindicated. So I thought at 
this point, this is where you do need a clinician, so I discussed it with a renal physician and they 
said don’t worry about the BNF in practice we do use but in very reduced doses even when the 
BNF says you can’t so at that point, it was at night I needed to make a decision straight away I 
gave him colchicine on the basis of my conversation, ignoring the BNF and the man is better. 
Sometimes I do it without  the [Regional] medicines but in the daytime I might have said you 
what do the manufacturers says because the BNF says this and the renal team say this. I might 
have done that but actually I’m not so sure because the clinical expertise of a renal physician 
treating patients like this all time its invaluable 
 
T18 GP  
Because the more I had concerns about the patient then you reassured me that it was alright 
 
T20 GP 
Read advice and prescribed gabapentin for this lady…..I didn’t prescribe amitriptyline which I 
was thinking about with the phenytoin. I was informed by [the MI Pharmacist] that 
amitriptyline is not licensed for neuropathic pain and the dose is much lower than 
antidepressant. Basically we looked at pregabalin and gabapentin and because of the cost of 
pregabalin decided to go for gabapentin. 
 
T23 GP 
It was triggered by citalopram, the drug manufacturer saying that levels above I think it was 
above 40mg put an increased risk of QT interval prolongation and that was exacerbated by the 
concomitant use of quetiapine, as quetiapine also is known to have a problem. So the reason 
for talking to them was to find out if we needed a wash in /wash out period or if we could just 
start the sertraline at the same time as stopping or cutting down the citalopram really. I had a 
couple of patient that were in the same position 
 
T24 Dentist 
Patient seemed to have had it impressed upon her by the surgeon that she would need 
antibiotic cover.  I’d spoken to her about it then having looked it up, I think she was allergic to 
amoxicillin so then I was thinking of what else to give her and looked up clindamycin which 
would have been my second choice. It said something there about it possibly causing some 
other problems particularly in elderly patients or those who’d recently had joint replacements.  
This is off the top of my head now - there seemed to be a number of contradictory things, 
particularly in high risk groups or potential complications in those on big doses of clindamycin.  
 
T30 Dentist 
Didn’t really have any concrete information (BNF) so I was a little bit concerned the patient 
had come from secondary care from the dental hospital, orthodontic department to have this 
elective procedure in a sense. The difficulty was that the family weren’t good historians 
because there was a language problem and it was the older sister that was doing all the talking 
so we couldn’t even get information like who is GP was or who the specialist was that dealt 
with this condition so the only thing that she knew was that he couldn’t take aspirin so that’s 
what actually prompted me to ring yourself because I thought I’m not happy doing this. He’d 
come from the dental hospital and they’d obviously overlooked the issues that possibly 






to make an informed decision basically I guess, so that the patient was happy getting some 
treatment that was evidence-based. 
 
T36 GP 
Had information from the PCT which was what led to the enquiry in the first place. 
(What information did you have from the PCT?) It was that citalopram does increase the QT 
interval and shouldn’t be co-prescribed with other drugs that did, including the tricyclics. What 
I wasn’t sure about was cos they said it was dose dependent was whether that meant that 
definite no no to small dose amitriptyline or whether if on a lower dose citalopram with low 
dose amitriptyline it was OK? 
 
I think it would have just taken me a lot longer to find out. It was really nice going one route 
and very quickly getting a definite decision, when I have had to do an online search & check 




so  if I've … I was going to say if I've been doing something wrong, but if I haven't been like 
following the correct guidelines, they’ve like changed so I'm following the up-to-date 
guidelines, I don't think I've ever like not done that really, I've always been in line with what 
you've suggested… 
F3 GP 
it's usually in pregnancy, you know where the data changes quite frequently, the database 
changes … antidepressants in pregnancy is another one I've used you for … use of 
antidepressants in epileptics is coming to mind now,, which was, you know the one with the 
lowest incidence of reducing the seizure threshold … 
I suppose I use it as … in, well, I don’t suppose there’ll be NICE Guidance to cover those 
awkward situations when I phone you, that's probably where you come in … 
it's good to sort of like have a bank of stuff that I can refer back to, you know in slightly 
different clinical scenarios I can use the same guidance I suppose 
I mean you're not normally specific to one drug, you'll give a choice, won't you, of two or three 
different scenarios, and I guess I choose the one that’s … if it was an antihistamine I suppose, 
the first [line, or one?] here is Cetirizine, isn't it, it's our cheapest one … 
I can phone you and get the information I need straightaway to make a decision 
Usually, you know the patient’s already pregnant and is on an antidepressant and you're 
worried that it might not be safe and the patient doesn't want to stop, and it's sort of then 
trying to gather together some evidence; is it safe to continue, or not, while you're waiting for 
their appointment to come up at psychiatry, you know through an antenatal clinic, which 
might be some weeks away … 
F4 Dentist 
Well, No I thought, because of the, I'm not sure what this drug’s going to do and there was, 
obviously and it was checked that there wasn’t anything specific that I didn’t act on that, I 
thought well, if there's no evidence that it's bad or good then I wouldn’t do it, so in terms of 




I weighed it up and I thought well, I'd rather not just in case there is an adverse effect, even 
though there's nothing reported, but there's nothing specific that actually said that it couldn’t 
do damage to foetus or baby, so I thought well, if there's an alternative option, which was 
Chlorhexidine, that was fine … 
I would have just prescribed the Chlorhexidine, and then did what I did, so it wouldn’t have 
changed the management, but knowing that, the thing about the Peroxyl now I probably 
wouldn’t have prescribed that, or if a patient asks, you know what about this mouthwash 
Peroxyl, then I would explain to them what I've been told by Medicines Information and then 
sort of say well it might be worth just using the Chlorhex instead 
to be honest Medicines Information is pretty much my first port of call 
F5 Dentist  
… I'd probably make a judgement on, like on that case, I just wasn’t sure, so it was definitely 
worth the call, but if you, you know you’re happy, maybe you would discuss it with a 
colleague, the other way round, do that first and if everyone’s unsure then it's probably time 
to call 
F6 GP 
I wasn’t sure whether and how you can prescribe that, so I thought it was good but I wasn’t 
sure much about it, so I've never up to this point prescribed codeine in pregnancy.  I had a 
feeling that low dose codeine, 8/500 was probably going to be OK, but I thought 30/500 is 
definitely out, [?] I thought OK I’ll ring you guys and see what you can help me with 
So then once I got that, I did query also you know the strength of the codeine, and they said 
you know, it doesn't make a difference to the strength of the codeine, in this regard, so I spoke 
to the lady, I said you know let’s, it's fine to take some co-codamol, I elected for the 8/500 
dose then and thought we could titrate upwards if necessary. 
It's the first time I've ever prescribed anything apart from paracetamol in pregnancy, and I've 
been a GP since 2006, I've seen many women and I've always advised them, look, you know 
things aren't safe, best just to stick to paracetamol, hot water bottle, and then just, you know 
let nature take its course, and so yes I, and now I understand that you know I can prescribe 
codeine and non-steroidals; that was quite interesting about non-steroidals, I thought they 
were a complete no-no in pregnancy and you know I got the advice, that was really helpful, 
made sense as well 
I put it high at the top because I'd say that, you know you guys are specialists in your field, 
you're experienced pharmacists, you've got a, I was actually going to ask you about what kind 
of databases you have, you know I can hear typing in the background … 
 mean I, if there was a, you know general advice, like NICE Guidelines or something 
straightforward then I wouldn’t be ringing you … 
… because you know it's there, in plain sight, I would only contact you whenever there's a 
complicated case …… where specialist advice is required and then whatever you gave to me I 
probably would just take that advice 
before I think of asking for your advice I probably would try and get a general feel for you 
know what the patient wanted; both the cases I've spoken to you about are related to either 
being pregnant or breastfeeding, so if a patient said to me “whatever happens I'm not going to 
take any tablets or any medication,” then there would be no point in me ringing you, so I 
would probably ascertain that they, you know they would be happy to take some treatment, 





for my decision-making really it didn’t make any difference to my particular management,  
I think the difficulty often as a GP is that when you're asked to prescribe a medication that 
you're unfamiliar with, so that might be a prescription request from secondary care, or from a 
patient that’s come from abroad on medication that is less often prescribed here or is not 
prescribed here at all, and I suppose I haven't actually used the service in that way but I may 
do 
if you are not comfortable that you have a sufficient knowledge about a medication before you 
prescribe it, ultimately you are taking responsibility by signing the prescription that you have 
to justify that you've got enough knowledge about that medication and in that condition to be 
able to safely prescribe it, errm…so I think it could be really useful if I was put in that position 
Whenever I've had some interaction with Medicines Information, it's always presented in 
terms of evidence-based, some information that I got a couple of years ago about natural 
therapies for symptoms of the menopause, and that was presented really excellently with 
evidence: was there evidence for it, and was it effective and was it safe, in that format, and 
that's really helpful, because it's visual and then I can talk to patients about it – it's likely to be 
safe, we're not sure about the evidence, but it always, well my experience, I get very good 
feedback from Medicines Information about the level of evidence there is for each of the bits 
of advice that's been given … 
… and that's helpful in helping me to make a decision on acting on that or not 
Sometimes it's really useful if I've got it written down, if a patient comes back, to say this is 
what I've done and to actually, we can make a decision together and actually it's a shared 
decision-making often, if it's not clear cut, if it's not you know, it's not ‘you've got 
hyperthyroidism, you need thyroxine,’ if there's more leeway in making a decision about 
whether or not to prescribe, and often you know we can come to a shared decision, so I've 
used it for that. 
F8 GP 
if I phone about black tongue, I don’t want you guessing, so you have to do your homework. 
That's one area called evidence-based medicine. 
why shouldn’t you know something more than I do? 
F9 Dentist 
I think it's cos we're aware of it because we run the oral surgery service, but we're also aware 
that they're quite unpredictable as well, so em, whereas with Warfarin we kinda know where 
we stand and in prescribing, we usually get in touch with the phlebotomist and ask them to, to 
do a check afterwards, but with that yeah, it was a lady, she'd not been on it too long, and with 
it being a bit unpredictable, and from what I can gather it's very new to medicine anyway, so 
people don’t really know how it's reacting, so I thought right, I’ll give you a ring just to make 
sure that there aren't any new interactions that I might have, might not be aware of.  
Obviously I looked in the BNF but because obviously that's an annual, or bi-annual publication 
then my concern was there might be something come up that I wouldn’t know about, so … 
generally speaking a lot of what I use your service for is the interactions, and as I say we’ll look 
at the BNF first, but if there's any doubt in our minds we’ll give you a ring.  And we eh, we, I'd 
spoken to our local oral surgeon actually regarding Pradaxa and those kind of drugs, and his 
immediate thing was if they need any extractions or anything like that send them straight to 




safely — or as safely as possible — because I understand that they're not monitored as well, 
like warfarin … 
We’d done everything we could with regards to treating the patient to drain the infection and 
treat it in that manner, so antibiotics really was going to be our last, it was our last port of call 
really, so I needed to prescribe it 'cause the others hadn't worked, our other measures we 
didn’t feel were working, you know, so … 
I rang on that occasion as well, and it was agreed between kind of the three of us that actually 
it wasn’t an allergy, that it was more a, you know, it was the side-effects of it, however, just for 
that short period of a three day course, we were giving, perhaps you know, maybe just get 
through it or say, take a paracetamol or two eh, and, and that was kind of made between the 
three of us then and I think the patient was kinda, he was happy that it was, it was a group, 
almost a group decision, 
In all honestly usually when I've used you it is in a, ‘an emergency situation’ is probably a bit 
strong a word, but it is in the situation where everything else has failed me, right, well what, 
what are we doing now, you know, he’s allergic so I've got to give this, or she's taking that but I 
want her to take this, and you need to take it, I want you to take it now to get you out of 
discomfort, so yeah, it's always done really quickly.  
I think that patient we talked about wi' the anticoagulant, you know she was in before lunch, I 
kinda sent, sent her off said yeah you know this is what we're going to be doing, I'm 100% sure 
it's going to be right, but I'm going to take further advice on it, so there we go, I’ll give you a 
shout after lunch, keep your mobile on … 
… you know, it was great, rang her up, ten minutes later reception rang her and said “yeah, go 
for it …,” you know “you can get this prescription” 
so clinically I suppose I've already made the decision because that's in the pathway, and with it 
being, usually in dentistry it's going to be antibiotic prescribing and that's going to be your last 
option anyway, if your local measures haven't worked, so I suppose clinical decision-making, it 
doesn't bear a huge impact on it but it's more allowing that final stage to go ahead if it's 
suitable 
so I wouldn’t say it's sent me one way than another, if that makes sense, you know, I mean 
we've already got to that end point … 
so … rather than it being a, here’s your antibiotic, oh I’ll try and drain it later, sort of thing, so 
we tend to follow that pathway of using it as a last option, so the decision is already kind of in 
the pathway, it's just to make sure we can do it, you know … 
helps us to deliver safe treatment I think, eh yeah, 'cause it, generally you know you're down 
to a decision where you need to know if you can prescribe something or you need to know you 
can go ahead with something, 
F11 Dentist 
as soon as I realised we need to do the extraction and there were going to be, possibly some 
issues with it being a new drug …  
… I thought, we just needed as much information then to, to proceed with the extraction 
generally [sighs] em yeah, if it's a, a drug-related issue then I'd generally use you as the first 




we had the initial advice on the Bisphosphonates so we were probably quite uptight about 
that, probably last year and a few years ago as regards extractions, but I think we're becoming 
a bit more relaxed about doing it, I think we worry too much about doing the extractions on 
the oral Bisphosphonates, but obviously we're very careful with the intravenous and probably 
wouldn’t do any extractions on anybody with intravenous Bisphosphonates, and always look at 
referring those to a specialist centre, so em we do use that information that you give us to, you 
know then incorporate into, you know the sort of practising life and things like that, so… 
I think it’s, yeah it's, as I say with the pathway you gave us on, on, on the patients with cancer, 
you know that's influenced, you know how we would deal with you know patients who come 
through the door now, you know who are unfortunate to, you know, to have cancer,  
it gave us further ideas, eh well further avenues which we could explore to try and get some 
more information so that worked quite well.  Once again the Bisphosphonates, we’ve just 
adapted that as, as time’s gone on, so em yeah, it's eh, yeah we've, it's certainly something we 
do use, well I’ll certainly use a lot and, and value the service  
F13 GP 
…it was quite a lengthy consultation, she asked quite a few questions and in the end asked this 
as well, so I thought rather than, because I looked through the BNF straightaway and I couldn’t 
find any potential interaction there … 
… then I think I had your number handy as well, so … 
… the information advice line, so I rang in on the speaker there and then and spoke to your 
people … 
 if you can't find it, if you've got previous experience of it, like I know about Topiramate and St 
John's Wort now … 
… so we utilise it, but if we don’t and it's not written information, something new comes across 
…I think at that stage we think we need some advice and … we’ll get hold of you girls? 
I think at times it would take a decision which is not part of the routine, something you 
haven’t' got more experience with in terms of prescribing, if someone has come in with a long 
list of medication, multiple co-morbidities, or they've got like an unusual syndrome, something 
different in their past medical history … 
The thing with polypharmacy, where it comes in is when nursing home patients, some elderly, 
some patients with a complex past medical history, a lot of medications and then you're 
adding in a new substance, or changing the dose where you haven't got much experience with 
it …or the information, you can't find in, then it's quite useful 
I think it helps with the patient/doctor relationship as well, sometimes involving like a third 
person or expert into the equation and … 
… and telling them that “look, I've taken …,” just like in this particular situation, but you know, 
“look I've taken advice from the expert pharmacist and there's no interaction,” so they feel like 
I listened to, they feel, sort of not just one, but a few experts working together and trying to 
help them 
F14 GP 
I can't think of an occasion where it didn’t give me the answer or didn’t enable me to make a 
management decision, where I was kind of left thinking well I've got this information but I 




I suppose the decision to ask for advice is when you've got a prescribing question or query, 
something that's out of the ordinary, something that you just don’t, can't access the 
information, it's somewhere else … 
… and something where you potentially have got time, because if you need to make a decision 
there and then, you need to make a decision there and then, you have to sort of balance the 
level of risk on that, but where you've got a bit of time to delay your decision … 
it's the unusual and the new, unusual …sort of scenarios …about medications which don’t arise 
every day, if, and I'd say time comes in to it as well, I think it's a, you know you can't be 
phoning somebody … 
 As far as the question about when would I contact your service and when would I contact a 
specialist at the hospital, I think if the question, if the patient I think can be managed within 
primary care … but I need some specific prescribing advice, then that's when I'd contact your… 
service. 
F15 GP 
… and Gabapentin, she couldn’t tolerate tricyclics at all, so upping her Gabapentin was a good 
option really, and I just decided to ring the drug information pharmacist and see how much of 
a risk I was taking, because I am of that generation of doctors that the guidelines are there, but 
at, I think sometimes now we do tend to have this ‘perfect’ approach to prescribing —  which 
is good — but it leaves the patient struggling, and I am prepared to talk to people I know about 
the risks we're taking with different sorts of medication, and if it seems reasonable slightly 
step outside, but then I thought I'd speak to the drug information pharmacist …And she got 
back really quickly and said actually it's fine … so I upped it, so she's now on 1200mgs… 
but really you can't do that now, I don't think, so a little bit of science behind supporting the 
decision you're making is actually helpful 
so you know just sort of try and get to that point, and if I feel I'm doing something that really I 
shouldn’t then I will look for advice, but I haven't …… used this service before 
A little bit …more information to make the … decision …'cause I'd have then been reduced to 
taking the consultant’s advice, but it's still my responsibility if I write the prescription.  Not 
doing it, because I was worried about the consequences, or increasing it anyway, but probably 
being a little bit more anxious about it, because these aren't easy decisions to make when … 
… you're treating people with either unlicensed medication sometimes, or you are stepping 
outside the guidelines, potentially with significant consequences …… so I'd have felt a lot more 
anxious about doing it 
I think that, that's usually probably why you look for that sort of information, because if you 
want information on how to treat something that's out there and quite easily accessible 
through the guidelines, but when you're trying to weigh up risk, you know, whether that be 
your, you know, using an unlicensed medication, or prescribing out of guidelines, that, you 
need to speak to … it has to be more tailored, doesn't it? 
The advice has to be more tailored…quite neatly in that case actually, 'cause the … the BNF 
clearly states that you shouldn’t increase the dose of Gabapentin beyond 900mg when the 
eGFR is, I think it was less than 45 … 
.. I can't remember, that's what the BNF states, but actually when you ask, when I asked J and 





… they'd actually suggested it was safe, so that made it easy to make that decision 
As I say I, I don’t really know why I haven't used it before, and actually as I said to you in my 
email, I will use it now when I've got …got queries … 
… because I think that … it's very helpful and it's … that's a really good word ‘practical’ … 
… it's that, it's what I'm talking about, about the sort of looking at your guidelines and the 
situation and blending them together and coming [out?] with the right solution 
I, I think what I found so helpful about speaking to J was that it was helping me come to a 
conclusion of what to do, whereas perhaps speaking to the Drug Information Pharmacist 
associated with drug companies, it is actually giving you, you know, all the different risks and 
the numerical risks and that sort of thing, and then ‘handing it over’ if you like …… so you get 
more information that you can make your decision on 
… and is it worth taking that risk or are you going to 'cause somebody more problems than 
you're solving; that's definitely … I'm just trying to think … and that is definitely a reason 
…reason to phone 
the black and white stuff is really the, you can find the information, it's the grey areas that you 





Impact on Prescribing Meta-theme:  
All interview extracts relating to prescribing themes 
 
Immediate change in prescribing 
 
T1 Dentist 
Essentially the advice that I was given is that no evidence to state that antibiotic cover is 
required for renal transplant patients. 
As an advisory body there was enough evidence to use that as a basis for not providing 
antibiotic cover despite the consultants wish to prescribe the antibiotics for the patient. So I 
actually got the consultant to issue the antibiotics for the patient so I didn’t play a role in it. 
From my point of view there was no evidence from any advisory bodies (i.e.. the phone No in 
BNF) to suggest that antibiotics are necessary. 
 
T3 Dentist  
So it did really impact being able to check that what I was doing was correct & therefore give it 
to him straight away 
..enabled me to give the dose required there and then which I actually I believe helped with 
the healing. Basically not been able to take out tooth and had been operating on the site for a 
while. I perceived he would have quite a lot of pain and swelling as a result of it so that’s why I 
wanted to give antibiotics that day. So it did really impact being able to check that what I was 
doing was correct  
 
T9 GP 
Well, I knew what the protocol was, which I wasn’t aware of before, I know where to find more 
information if I wanted it and I was comfortable prescribing it for the patient because I felt 
comfortable that I had enough knowledge to do so. 
 
T12 GP 
I supposed it changed my management in that I didn’t have to do anything else. 
 
T20 GP  
I didn’t prescribe amitriptyline which I was thinking about with the phenytoin. 
It can only be good, can’t it really because I needed some advice & I got it so potentially I could 
of, which hopefully I wouldn’t have done, Rx the amitriptyline anyway & hoped for the best. 
 
T37 GP 
they just gave me the information about how I was going to manage it, logistically they told me 
how I was going to manage it… 
F1 Dentist 
changed the prescription that I'd given to the patient, I gave her a lower dose of the toothpaste 
 
F2 Dentist 
she felt this was a reaction with the adrenalin in the local, and the outcome of it is that we've 














I’ll be asking them things that I can’t remember because I don’t use it frequently enough & I 




They gave me as much information as exists at the moment but I think the drug is a relatively 
new drug and no longer term studies available, so they’ve given me as much as is out there. 
 
T20 GP 
Whoever I spoke to was very thorough and talked me thru looking at gabapentin & pregnancy 
& stuff. Obviously, we decided that amitriptyline wasn’t the way forward 
 
I was informed by her that amitriptyline not licensed for neuropathic pain & dose is much 
lower than antidepressant. Basically, we looked at pregabalin & gabapentin & because of the 
cost of pregabalin decided to go for gabapentin. Aware of cost, more expensive, so gabapentin 
seemed to tick all the boxes really 
 
T36 GP 
my gut feeling is that if their a young person that‘s only on 20mg, probably having 10mg of 
amitriptyline is probably fine but when it’s clearly stated that you can’t do it, you can’t do it. 
 
T39 GP 
The main problem often is that there are things you might not have thought about, some other 
reason and that was fine. 
 
F1 Dentist 
I had a patient taking oral Bisphosphonates and I did an extraction and the guidelines were to 
follow up like in two to four weeks, so I brought the patient back just to make sure everything 
was healing fine and everything was, and I've seen them like for a few more check-ups since 
and everything’s been fine, so I probably wouldn’t have done like the three to four week 
check-up if I hadn't have known about it through the guidelines, I would have just seen her at 
the next like check-up appointment in six months … 
 
F4 Dentist 
but knowing that, the thing about the Peroxyl now I probably wouldn’t have prescribed that, 
or if a patient asks, you know what about this mouthwash Peroxyl, then I would explain to 
them what I've been told by Medicines Information and then sort of say well it might be worth 
just using the Chlorhex instead 
 
In fact yesterday, a few days ago I was giving a list of patient drugs to the Medicines 
Information and they said, noted an error that the patient’s taking Propranolol and Atenolol, 
they said they can't be doing that, can you just double check that, I asked the patient and she 
said “oh yeah, I'm taking both of those,” and then we had to check with the doctor, and the 
doctor said “oh no the atenolol was dropped,” so I was made aware of things which I wouldn’t 
have picked up on 
 
F11 Dentist 
Whenever I've had problems previously, […..] I've felt then confident to use that information 
that you've given to you know, then to take forward with the patient and you know 





rather than taking an educated guess and then taking a risk sort of thing and not being very 
sure, I think it's always a good idea [to contact MI]…  
 
Shift in prescribing practice 
 
T9 GP 
was able to share it with my partners, the other doctors, so they were aware of it.  
 
T11 GP  
If I now know these things are around, I will be very curious & I will try & find out thru [name 
of PCT] prescribing 
 
having come across the Synvisc, I now realise that there might be other ways of exploring what 
this could be about. Means that I’ve got to learn more about it. 
 
T27 Dentist 
In future I know that if I’m in a similar situation that I can give it and now I know that 
metronidazole is safe  
 
T32 GP 
Actually not just one patient, it’s several patients. So we looked through all the patients that 
we’d got in the practice on citalopram and each individual doctor went through to see whether 
they were also on tricyclics in particular, but also other drugs that may affect the QT interval.  
 
T36 GP 
I’ve already changed quite a few patients usually to sertraline if they wanted to carry on with 
the amitriptyline. 
errm… some patients on a higher dose as well so we were contacting them,… well probably at 
least 10. 
Actually not just one patient, it’s several patients. So we looked through all the patients that 
we’d got in the practice on citalopram and each individual doctor went through to see whether 
also on tricyclics in particular, but also other drugs that may also affect the QT interval  
 
F2 Dentist 
dependent on the response I get from your service, I will modify my practice to take account of 
what you guys say and advise 
 
I was concerned we, you know, got guidance, modified our practice, good result 
 
F3 GP 
I find when you send me the information on email I’ll print it off, it's in my drawer and I refer 
back to it again and again.   
 
I think I've approached you about switching antidepressants as well, I've got some information 
that I use quite regularly for that, from the, I think, is it from the Maudsley Hospital, was it, there 
was a protocol I got from you there, that was a few years ago, but I still refer to that … … if you 
let me check my drawer … 
 
it's good to sort of like have a bank of stuff that I can refer back to, you know in slightly 




it's usually in pregnancy, you know where the data changes quite frequently, the database 
changes … antidepressants in pregnancy is another one I've used you for … use of 
antidepressants in epileptics is coming to mind now,, which was, you know the one with the 
lowest incidence of reducing the seizure threshold … 
 
F4 Dentist 
so I got an email sent and then we sort of printed that out and put it on our noticeboard, so we 
do that as routine now, if there's anything sort of specific 
 
so you change your practice in terms of what you know, this is, I'm fine with this and you can 
prescribe it, so the information I suppose gets reinforced in your sort of own knowledge of what 
you can and what you can't prescribe, what interacts, what doesn't interact 
 
if it's a particular big one like the latex in anaesthetics, we’ll tell everyone else that as well you 
know we receive the emails, from medicines information saying these are the anaesthetics that 
are latex-free, you can use them but watch out for these.  Then we’ll put that up on the 
noticeboard and everyone will know that and then that's becomes part of our sort of, so yeah 
in terms of that it's quite, it's yeah it's invaluable 
 
it does affect my decisions that I make in the future for patients taking antihistamines, I know 
which one’s drowsy, and which one’s not going to be drowsy, rather than having to read a book 
and just sort of do it that way, which would maybe look a bit unprofessional when the patient’s 
sort of sitting in the chair, yeah. 
 
F6 GP 
Since then I have seen other patients who have had pain in pregnancy, and it's given me like 
more confidence to advise them, and even few last week I was actually speaking to a staff 
member who’s pregnant and she's asked me about analgesia in pregnancy and I knew the advice 
to give her … 
 
they gave me some advice about using high dose fluconazole and things like that, and that was 
an email I got, and then whenever this issue arises I just do a search of my emails and find that 
advice again and re-use it,  
 
It's the first time I've ever prescribed anything apart from paracetamol in pregnancy, and I've 
been a GP since 2006, I've seen many women and I've always advised them, look, you know 
things aren't safe, best just to stick to paracetamol, hot water bottle, and then just, you know 
let nature take its course, and so yes I, and now I understand that you know I can prescribe 
codeine and non-steroidals; that was quite interesting about non-steroidals, I thought they were 
a complete no-no in pregnancy and you know I got the advice, that was really helpful, made 
sense as well 
 
F7 GP 
I've used it in repeat consultations, I keep some of that information here in surgery and I can 
bring it out, because, I've mentioned the HRT one, or alternatives to the HRT, I still use the 
information I got even a year or two ago with patients to talk about some alternatives, 
 
F9 Dentist 
We have a server that runs all the computers in the surgery, […..]…so I said to the, told all 
other the clinicians, you know, this document [about new anticoagulants and bleeding risk] 
might be helpful, and it's on our server, so that's accessible … 
almost solved the wider problem as well, that we have access to something that we hadn't had 





We had a bisphosphonate sheet, like the one that you sent us, on the server as well that we all 
access…I'm sure I've got that one.  
 
F11 Dentist 
so em we do use that information that you give us to, you know then incorporate into, you know 
the sort of practising life 
 
it gave us further ideas, eh well further avenues which we could explore to try and get some 
more information so that worked quite well.  Once again the Bisphosphonates, we’ve just 
adapted that as, as time’s gone on, so em yeah, it's eh, yeah we've, it's certainly something we 
do use, well I’ll certainly use a lot and, and value the service  
 
I think the more patients that you see, I mean the more extractions you do on, on, in patients 
on Bisphosphonates, the more confident you become that it, it's not as big an issue as we 
possibly thought it was … 
 
I think it’s, yeah it's, as I say with the pathway you gave us on, on, on the patients with cancer, 
you know that's influenced, you know how we would deal with you know patients who come 
through the door now, you know who are unfortunate to, you know, to have cancer, 
 
you [you're a specialist service who, you know are able to give further advice to, to dentists on 
certain aspects of, of their treatment which will enable us to, you know treat them in a safer 
manner in future … 
 
then I can just stick it in a file and it's always good for reference at a later date 
 
F12 GP 
…so I’ll put it on that resource there [shared network]…and email round saying “I had this issue 
today, this is the advice I was given, if you want further advice so people know where to go… 
 
F13 GP 
if you've got previous experience of it, like I know about Topiramate and St John's Wort now… 






















 08/11/11 T1 (MIA) What antibiotic can I use for dental prophylaxis (root canal treatment) in a kidney transplant patient? 2 
Choice of therapy 
Admin & dose 
Renal 
Dentist (F) Student 1 
29/11/11 T2 (MIA)  (1 of 2) Can perindopril (ACE inhibitors) exacerbate psoriasis? 2 Adverse effects 
GP (M) 
 JR 
24/11/11 T3 (MIA) What is the correct dose of amoxicillin in a 16 year old? 1 Admin & dose Dentist (F) JR 
13/01/12 T4 (MIA) Can I prescribe mirtazapine if the patient is on warfarin? 2 Interaction GP (M) JR 
27/01/12 T5 (MIA) How do I convert a patient from Zoladex (leuprorelin) implant to Prostap (gosarelin) injection? 2 Admin & dose GP (F)  Student 3 
27/01/12 T6 (MIA) What is Aprax? It is from Turkey 2 Identification GP (F) Student 1 
29/11/11 T7 (MIA)  (2 of 2) How do I treat psoriasis in pregnancy? (1
st trimester) 3 
Pregnancy 




03/02/12 T8 (MIA) Can I prescribe sodium cromoglicate eye drops for a 1 year old child? 1 Admin & Dose GP (M) Student 2 
30/01/12 T9 (MIB) What melatonin preparation is available for a child? 2 Availability and supply GP (M) Student 3 
25/11/11 T10 (MIB)  (1 of 2) Can I prescribe venlafaxine throughout pregnancy? 2 
Pregnancy 
Choice of therapy GP (F) JR 
25/11/11 T11 (MIB) (2 of 2) 
Can I have some information about efficacy & cost for 
Durolane injection for OA knee? 3 Choice of therapy GP (F)  JR 
03/02/12 T12 (MIB) Are there likely to be any problems if a patient has had metronidazole in pregnancy (1st trimester?) 2 
Pregnancy 
Choice of therapy GP (F) 
Student 1 
 



















16/02/12 T14 (MIB) (1 of 2) 
What is the maximum dose of sodium valproate in a 
patient with renal impairment? 2 




16/02/12 T15 (MIB) (2 of 2) 
What antidepressant can I prescribe for a patient post 
myocardial infarction/CABG? 2 
Choice if therapy 
Adverse effects GP (M JR 
06/02/12 T16 (MIC) What is the correct dose of enoxaparin for DVT treatment? 2 Admin & dose GP (F) 
Student 2 
 




GP (F) Student 1 
13/11/11 T18 (MID) Can I use terbinafine cream in a 1 year old?  1 Adverse effects GP (M) JR 
02/02/12 T19 (MID)  What level of activity will pamidronate still have 3 years after it has been stopped? 2 Pharmacokinetics Dentist (M) Student 1 
25/11/11 T20 (MIE) What can I prescribe for post herpetic neuralgia in a patient with epilepsy and kidney impairment? 3 
Choice of therapy 
Interaction 
Adverse effects 
GP (F) JR 
5/01/12 T21 (MIE) Can I do root canal treatment in a patient with recent heart valve replacement? 2 
Choice of therapy 
Adverse effects Dentist (F) JR 






16/01/12 T23 (MIE) How do I switch a patient from citalopram to sertraline? 2 Adverse effects Interaction GP (F) Student 2 
24/11//11 T24 (MIE) Do I need to give antibiotic prophylaxis for dental treatment in a patient with a knee replacement?  2 Adverse effects Dentist (M) Student 1 
06/02/12 T25 (MIE) What is the correct dose of metronidazole in a 16 year old? 1 Admin & Dose Dentist (F) Student 3 
27/01/12 T26 (MIE) Is it ok to use Exenatide if it has been out of the fridge for 6 weeks? 2 Pharmaceutical GP (M) Student 3 



















13/02/12 T28 (MIE) Does amoxicillin interact with allopurinol?  3 Interaction Dentist (F) Student 3 
06/02/12 T29 (MIE) Which local anaesthetic can I use in a patient with allergy to some anaesthetics? 2 Choice of therapy Dentist (F) Student 3 
16/02/12 T30 (MIE) Which local anaesthetic can I use in a patient with G6PD deficiency? 2 Choice of therapy Dentist (F) JR 
10/02/12 T31 (MIE)  Can I prescribe metronidazole with the patient’s other medicines? 2 
Admin & dose 
Interaction Dentist (M) Student 1 
21/02/12 T32 (MIF) Can I prescribe citalopram if the patient is on nortriptyline for pain? 2 
Admin & dose 
Interaction GP (F) JR 
27/03/12 T33 (MIF) Is there a lactose free formulation of desmopressin for child with severe cow’s milk/lactose allergy? 1 Pharmaceutical GP (F) JR 
13/02/12 T34 (MIF) How do I convert a dose of aminophylline to theophylline? 2 Admin & Dose GP (F) Student 2 
22/12/11 T35 (MIG) What antibiotic can I use for moderate acne in an 11 year old? 2 Choice of therapy GP (F) JR 
26/01/12 T36 (MIG) Can I prescribe citalopram in a patient on low dose amitriptyline? 2 
Choice of therapy 
Interactions GP (F) JR 
17/02/12) T37 (MIG) Do I have to restart lamotrigine at low doses if the patient has not had it for 2 weeks? 3 
Admin & dose 
Pharmacokinetics GP (F) Student 3 
16/02/12 T38 (MIG) Can I prescribe low dose amitriptyline in pregnancy (1
st 
trimester)? 3 
Admin & dose 
Pregnancy GP (M) JR 
12/02/12 T39 (MIG) Are there likely to be any problems if a 1 year old child has had adult Bonjela (choline salicylate)? 2 Adverse effects GP (F) Student 3 






Appendix 18: Summary of medicines questions asked, demographics of clinicians and face-to-face interviews 
Interview 
code 





























Can I prescribe Duraphat 
5000ppm (high strength fluoride 











26 min 4 s 
F2 
Can I prescribe fluoride 
toothpaste/saliva substitute in a 












44 min 3 s 
F3 
How do I treat recurrent vaginal 






GP (F) 21 years Yes 41 days 
16:00 after 
PM surgery 
Drs office  
20 min 44 s 
F4 
Can I prescribe chlorhexidine or 
hydrogen peroxide mouthwash 












/few staff in 
& out)  
54 min 7 s 
F5 
Can I prescribe amoxicillin for 
dental infection in a housebound 










18 min 55 s 
F6 
What analgesics can I prescribe 















































Can a patient take barley grass 












23 min 25 s 
F8 Can ciprofloxacin cause black tongue, what should I do? 3 
Adverse effects 





32 min 41 s 
F9 
Can I prescribe amoxicillin for a 















Can I prescribe miconazole oral 

















F11 Do I need to stop dabigatran (for AF) before an extraction? 2 
Admin & Dose 






36 min 40 s 
F12 
What antifungal can I prescribe 










~ 30 min 
(recorder 
failed at 23 
min) 
F13 
Can my patient take St John’s 
wort if they are taking 















































What do I need to do if a patient 
has taken simvastatin 40mg in 
early pregnancy? 




33 min 16 s 
F15 
What is the highest dose of 
gabapentin I can prescribe in a 
patient with chronic kidney 
disease (CKD)? 
3 Admin & Dose Renal GP (F) 32 years No 96 days 





59 min 33 s 
 
 
 
